Pregnancy Medicine — MCQs

Q: A 37-year-old woman at 28 weeks gestation presents with sudden onset dyspnea and chest pain. She has a history of previous DVT. D-dimer is elevated. What is the most appropriate anticoagulant if PE is confirmed?

Low molecular weight heparin. ***Low molecular weight heparin*** - **Low molecular weight heparin (LMWH)** is the preferred anticoagulant for treating **pulmonary embolism (PE)** during pregnancy because it **does not cross the placenta**, minimizing risk to the fetus. - It is effective, has a predictable dose-response, and requires less monitoring than unfractionated heparin. *Warfarin* - **Warfarin** is a **teratogen** (Category X) and is strictly contraindicated during the first trimester due to the risk of **fetal warfarin syndrome**. - It carries a risk of fetal hemorrhage and central nervous system abnormalities even in later trimesters, making it generally avoided in pregnancy. *Dabigatran* - **Dabigatran** is a direct thrombin inhibitor (DOAC) with limited data on safety during pregnancy, and its molecular weight suggests some placental transfer is possible. - Due to lack of robust safety data, **DOACs** are generally not recommended for use in pregnant women for treating VTE. *Rivaroxaban* - **Rivaroxaban** is a Factor Xa inhibitor (DOAC) also generally avoided in pregnancy due to insufficient data on fetal safety and potential placental transfer. - There is a theoretical risk of fetal bleeding, and **LMWH** remains the standard of care. *Unfractionated heparin* - **Unfractionated heparin (UFH)** is safe in pregnancy as it does not cross the placenta, similar to LMWH. - However, **LMWH** is preferred due to its greater bioavailability, longer half-life, and lower risk of **heparin-induced thrombocytopenia (HIT)** and **osteoporosis** with long-term use.

Q: A 33-year-old woman at 36 weeks gestation presents with severe abdominal pain and vaginal bleeding. Her previous pregnancy was delivered by cesarean section. Fetal heart rate shows bradycardia. What is the most likely diagnosis?

Uterine rupture. ***Uterine rupture*** - The combination of acute, severe abdominal pain, vaginal bleeding, and profound fetal **bradycardia** in a woman with a history of a previous **Cesarean section** is highly indicative of uterine rupture. - A prior uterine scar is a significant risk factor for rupture, which leads to immediate fetal compromise due to placental detachment or expulsion into the abdomen, along with maternal hemorrhage. *Placental abruption* - While placental abruption can present with vaginal bleeding, abdominal pain, and fetal distress, the pain is often described as constant with a **board-like abdomen**, and the primary cause is typically not a prior uterine incision leading to mechanical failure. - Although fetal bradycardia is common, the patient's history of a Cesarean section points to a mechanical failure of the uterus rather than primary abruption. *Placenta previa* - Placenta previa characteristically causes **painless vaginal bleeding**, often recurrent, and usually does not present with severe acute abdominal pain. - Fetal distress in previa is typically due to significant maternal blood loss, not a sudden uterine catastrophe. *Preterm labor* - Preterm labor involves rhythmic, painful uterine **contractions** leading to cervical changes, not the constant, severe, tearing-like pain indicative of a uterine tear. - While severe pain and fetal bradycardia can occur in complicated labor, the underlying cause in this scenario is specifically suggested by the previous **uterine scar** and the acute, severe presentation. *Vasa previa* - Vasa previa involves the rupture of **fetal blood vessels** within the membranes over the cervix, causing **painless vaginal bleeding** of fetal origin and rapid fetal distress. - It does not explain the severe maternal abdominal pain associated with a major uterine insult and is not directly related to a prior Cesarean scar.

Q: A 37-year-old woman at 30 weeks gestation presents with sudden onset dyspnea and pleuritic chest pain. She has a swollen left calf. What is the most appropriate initial investigation?

Compression ultrasound of leg. ***Compression ultrasound of leg*** - In a pregnant patient with symptomatic DVT/PE suspicion, identifying a **proximal DVT** via CUS is crucial as it confirms venous thromboembolism (VTE) and often allows **anticoagulation initiation** without further imaging that involves radiation (CTPA or V/Q scan). - CUS is **non-invasive**, readily available, and carries **no risk of fetal radiation**, making it the safest and most appropriate initial diagnostic test for VTE in pregnancy in this clinical context. *D-dimer* - The **D-dimer** test is unreliable in pregnancy because levels naturally increase throughout gestation, especially in the third trimester (30 weeks here), leading to **high false-positive rates** and poor diagnostic specificity. - While useful in low-risk non-pregnant patients (PERC rule), its lack of negative predictive value in this high-risk scenario makes it an inappropriate *initial* diagnostic step. *Chest X-ray* - A **Chest X-ray (CXR)** is primarily used to exclude alternative diagnoses, such as **pneumonia** or **pneumothorax**, that could mimic PE symptoms. - It is generally **not diagnostic** for PE itself, as findings are often non-specific or normal, and therefore does not confirm the need for anticoagulation. *V/Q scan* - A **V/Q scan** involves ionizing radiation and is typically considered for confirming PE only if the CUS is negative and clinical suspicion remains high. - While it has **lower fetal radiation exposure** compared to CTPA, it is deferred until non-invasive CUS results are known. *CTPA* - **CT Pulmonary Angiography (CTPA)** is highly sensitive for PE but exposes the mother (especially the breasts) to higher radiation doses compared to a V/Q scan. - It is usually reserved for cases where the **CXR is abnormal** or when the V/Q scan is **non-diagnostic**, following an initial assessment with CUS.

Q: A 28-year-old woman at 34 weeks gestation presents with sudden onset severe headache and seizures. Her BP is 180/120 mmHg. What is the most appropriate immediate treatment?

Magnesium sulfate IV. ***Magnesium sulfate IV***- **Magnesium sulfate** is the first-line and definitive treatment for the prevention and cessation of seizures in women with **eclampsia**.- It acts by stabilizing neuronal membranes and reducing neuromuscular irritability, providing effective seizure control superior to traditional *anticonvulsants*.*Labetalol IV*- Labetalol is an **antihypertensive** used to manage severe *hypertension* (BP 160/110 mmHg) in preeclampsia/eclampsia, but it does not treat or prevent the underlying seizures.- Control of blood pressure is secondary to achieving **seizure cessation** and prevention with magnesium sulfate in the immediate management protocol.*Immediate cesarean section*- Delivery is the definitive cure for eclampsia and severe preeclampsia, but immediate **maternal stabilization**, including seizure control (MgSO4) and blood pressure management, must precede delivery unless other emergent obstetric indications exist.- A planned delivery is necessary once the patient is stable, but the *seizures* must be controlled first, making MgSO4 the most **immediate** necessary step.*Diazepam IV*- While an effective general anticonvulsant, **diazepam** is generally reserved as a *second-line agent* if seizures persist despite adequate administration of magnesium sulfate.- Magnesium sulfate is preferred because it is more effective for eclamptic seizures and carries a lower risk of fetal respiratory depression and **neonatal hypotonia** compared to benzodiazepines.*Mannitol IV*- **Mannitol** is an osmotic diuretic primarily used to reduce increased *intracranial pressure* (ICP) or treat cerebral edema.- It is not the primary immediate agent for *seizure control* in eclampsia, which requires **magnesium sulfate**.

Q: A 34-year-old woman at 32 weeks gestation presents with severe headache and visual disturbances. BP is $165/105\mathrm{mmHg}$. Proteinuria is $3+$. Blood tests show normal platelets and liver enzymes. What is the most likely diagnosis?

Severe pre-eclampsia. ***Severe pre-eclampsia*** - The presence of **hypertension** ($165/105\mathrm{mmHg}$) and significant **proteinuria ($3+$)** in a woman at 32 weeks gestation (after 20 weeks) indicates pre-eclampsia. - The additional presence of **severe symptoms** like **headache** and **visual disturbances**, along with **severe-range blood pressure** ($\geq 160/110\mathrm{mmHg}$), confirms the diagnosis of **severe pre-eclampsia**. *Gestational hypertension* - *Gestational hypertension* is characterized by new-onset **hypertension** after 20 weeks gestation in the absence of **proteinuria** or any **severe features**. - The patient's **$3+$ proteinuria** and **severe symptoms** (headache, visual disturbances) directly exclude this diagnosis. *HELLP syndrome* - **HELLP syndrome** is a severe form of pre-eclampsia defined by **Hemolysis**, **Elevated Liver enzymes**, and **Low Platelets** (thrombocytopenia). - The clinical vignette explicitly states that the patient's **platelets and liver enzymes are normal**, thereby ruling out HELLP syndrome. *Eclampsia* - **Eclampsia** is diagnosed by the occurrence of **generalized tonic-clonic seizures** or unexplained coma in a patient with pre-eclampsia. - While the patient has severe pre-eclampsia, the absence of **seizures** in the presentation means she has not yet progressed to eclampsia. *Chronic hypertension* - **Chronic hypertension** is hypertension diagnosed before pregnancy or before **20 weeks gestation**, or hypertension that persists beyond 12 weeks postpartum. - The **new-onset proteinuria** and severe symptoms arising after 20 weeks gestation are characteristic of a pregnancy-specific hypertensive disorder, specifically **pre-eclampsia**, rather than isolated chronic hypertension.

Q: A 37-year-old woman presents with fatigue, joint pain, and a photosensitive rash. She is anti-Ro positive and planning pregnancy. What is the recommended fetal monitoring?

Serial fetal echocardiograms. ***Serial fetal echocardiograms***- Anti-Ro (SSA) antibodies cross the placenta and target the **fetal cardiac conduction system**, causing **congenital heart block (CHB)**, a serious complication.- Serial monitoring with fetal echocardiograms (starting around 16–18 weeks gestation) is crucial to detect early signs of CHB, allowing for timely treatment with maternal **fluorinated steroids**.*Monthly ultrasounds*- Standard monthly ultrasounds primarily monitor fetal growth and amniotic fluid volume but are often insufficient to reliably detect subtle changes in **fetal heart rhythm** characteristic of early CHB.- A dedicated **fetal echocardiogram** uses specialized techniques to visualize cardiac structures and assess the conduction system comprehensively.*Amniocentesis*- This is an invasive procedure used for **prenatal diagnosis of genetic and chromosomal disorders** by analyzing amniotic fluid, not for routine monitoring of cardiac function or rhythm.- The primary goal in an anti-Ro positive pregnancy is surveillance for development of CHB, which does not require genetic testing.*Chorionic villus sampling*- CVS is an invasive procedure typically performed in the first trimester (10–13 weeks) for **genetic and chromosomal analysis**.- It is not indicated for the surveillance or diagnosis of **fetal conduction abnormalities** caused by maternal autoantibodies, which usually manifest later in the second trimester (16–26 weeks).*No additional monitoring*- This approach is dangerous because **Anti-Ro antibodies** confer a 1–2% risk of the fetus developing **congenital heart block**, requiring specialized cardiac surveillance to prevent adverse outcomes.- Lack of appropriate surveillance can lead to late diagnosis of CHB, potentially resulting in **fetal hydrops** or the need for an immediate **pacemaker** after birth.

Q: A 34-year-old woman at 28 weeks gestation presents with severe itching, particularly on palms and soles. Bile acids are elevated. What is the most likely diagnosis?

Intrahepatic cholestasis of pregnancy. ***Intrahepatic cholestasis of pregnancy*** - The presentation of severe, generalized **pruritus**, especially on the **palms and soles**, during the third trimester is highly characteristic of this condition. - The definitive diagnosis relies on elevated serum **bile acids** (>10 µmol/L) in the absence of other primary liver pathology.*Atopic dermatitis* - This condition is characterized by an **eczematous rash** (papules, plaques) and is generally not localized solely to the palms and soles as isolated, severe pruritus. - It is a primary dermatological condition and does not result in the diagnostic elevation of serum **bile acids** seen in cholestasis.*HELLP syndrome* - HELLP is a life-threatening complication characterized by **H**emolysis, **E**levated **L**iver enzymes, and **L**ow **P**latelets, causing severe systemic illness (e.g., abdominal pain, nausea). - While it involves liver pathology, severe isolated pruritus and elevated bile acids are defining features of ICP, not **HELLP**.*Acute fatty liver of pregnancy* - AFLP is a fulminant process presenting with nausea, vomiting, **hypoglycemia**, coagulopathy, and **hepatic failure** (often requiring intensive care). - The clinical picture here is limited to isolated pruritus and elevated bile acids, which does not fit the severe systemic compromise or **acute liver failure** seen in AFLP.*Scabies* - Scabies is a skin infestation resulting in intensely pruritic papules and **burrows**, typically found in the finger web spaces, wrists, and belt line. - This diagnosis would not account for the significant elevation of **bile acids** found on laboratory testing, which indicates a hepatobiliary issue.

Pregnancy Medicine UK Medical PG Practice Questions and MCQs

Question 1: A 37-year-old woman at 28 weeks gestation presents with sudden onset dyspnea and chest pain. She has a history of previous DVT. D-dimer is elevated. What is the most appropriate anticoagulant if PE is confirmed?

A. Warfarin
B. Dabigatran
C. Rivaroxaban
D. Low molecular weight heparin (Correct Answer)
E. Unfractionated heparin

Explanation: ***Low molecular weight heparin*** - **Low molecular weight heparin (LMWH)** is the preferred anticoagulant for treating **pulmonary embolism (PE)** during pregnancy because it **does not cross the placenta**, minimizing risk to the fetus. - It is effective, has a predictable dose-response, and requires less monitoring than unfractionated heparin. *Warfarin* - **Warfarin** is a **teratogen** (Category X) and is strictly contraindicated during the first trimester due to the risk of **fetal warfarin syndrome**. - It carries a risk of fetal hemorrhage and central nervous system abnormalities even in later trimesters, making it generally avoided in pregnancy. *Dabigatran* - **Dabigatran** is a direct thrombin inhibitor (DOAC) with limited data on safety during pregnancy, and its molecular weight suggests some placental transfer is possible. - Due to lack of robust safety data, **DOACs** are generally not recommended for use in pregnant women for treating VTE. *Rivaroxaban* - **Rivaroxaban** is a Factor Xa inhibitor (DOAC) also generally avoided in pregnancy due to insufficient data on fetal safety and potential placental transfer. - There is a theoretical risk of fetal bleeding, and **LMWH** remains the standard of care. *Unfractionated heparin* - **Unfractionated heparin (UFH)** is safe in pregnancy as it does not cross the placenta, similar to LMWH. - However, **LMWH** is preferred due to its greater bioavailability, longer half-life, and lower risk of **heparin-induced thrombocytopenia (HIT)** and **osteoporosis** with long-term use.

Question 2: A 35-year-old woman at 32 weeks gestation presents with severe headache, visual changes, and RUQ pain. BP is 175/110 mmHg. Blood tests show AST 200 U/L, platelets 70,000/μL. What is the most appropriate management?

A. Antihypertensive treatment
B. Magnesium sulfate
C. Immediate delivery (Correct Answer)
D. Corticosteroids
E. Observation

Explanation: ***Immediate delivery*** - The patient's symptoms (severe headache, visual changes, RUQ pain, BP 175/110 mmHg) and lab results (**AST 200 U/L**, **platelets 70,000/μL**) meet the criteria for **HELLP syndrome**, a severe manifestation of preeclampsia. - **Immediate delivery** is the definitive management for **HELLP syndrome**, as removing the placenta resolves the underlying pathology and prevents life-threatening maternal complications like stroke, DIC, and liver rupture, especially given the severe presentation at 32 weeks gestation. *Antihypertensive treatment* - While crucial for preventing **hemorrhagic stroke** by managing the severe hypertension (BP 175/110 mmHg), antihypertensive treatment (e.g., **labetalol**, **hydralazine**) only addresses a symptom. - It is a supportive measure and not the definitive treatment for the underlying pathophysiology of **HELLP syndrome**, which requires removal of the placenta. *Magnesium sulfate* - **Magnesium sulfate** is essential for **seizure prophylaxis** to prevent **eclampsia** in patients with severe preeclampsia and HELLP syndrome, addressing a critical maternal complication. - However, it does not resolve the underlying liver dysfunction or hematological abnormalities of **HELLP syndrome**; therefore, it is an important stabilizing measure but not the primary definitive management. *Corticosteroids* - Corticosteroids like **betamethasone** are primarily administered before 34 weeks for **fetal lung maturity**, but they require 24-48 hours to be effective. - In severe maternal conditions like **HELLP syndrome**, delaying delivery for corticosteroid administration can pose significant risks to the mother and is often contraindicated when immediate delivery is indicated. *Observation* - **Observation** is dangerous and contraindicated in cases of severe preeclampsia with **HELLP syndrome** due to the imminent risk of life-threatening maternal complications, including **eclampsia**, **placental abruption**, and **maternal stroke**. - This clinical scenario requires **active management**, which includes stabilization and **definitive delivery**, rather than passive monitoring.

Question 3: A 33-year-old woman at 36 weeks gestation presents with severe abdominal pain and vaginal bleeding. Her previous pregnancy was delivered by cesarean section. Fetal heart rate shows bradycardia. What is the most likely diagnosis?

A. Placental abruption
B. Uterine rupture (Correct Answer)
C. Placenta previa
D. Preterm labor
E. Vasa previa

Explanation: ***Uterine rupture*** - The combination of acute, severe abdominal pain, vaginal bleeding, and profound fetal **bradycardia** in a woman with a history of a previous **Cesarean section** is highly indicative of uterine rupture. - A prior uterine scar is a significant risk factor for rupture, which leads to immediate fetal compromise due to placental detachment or expulsion into the abdomen, along with maternal hemorrhage. *Placental abruption* - While placental abruption can present with vaginal bleeding, abdominal pain, and fetal distress, the pain is often described as constant with a **board-like abdomen**, and the primary cause is typically not a prior uterine incision leading to mechanical failure. - Although fetal bradycardia is common, the patient's history of a Cesarean section points to a mechanical failure of the uterus rather than primary abruption. *Placenta previa* - Placenta previa characteristically causes **painless vaginal bleeding**, often recurrent, and usually does not present with severe acute abdominal pain. - Fetal distress in previa is typically due to significant maternal blood loss, not a sudden uterine catastrophe. *Preterm labor* - Preterm labor involves rhythmic, painful uterine **contractions** leading to cervical changes, not the constant, severe, tearing-like pain indicative of a uterine tear. - While severe pain and fetal bradycardia can occur in complicated labor, the underlying cause in this scenario is specifically suggested by the previous **uterine scar** and the acute, severe presentation. *Vasa previa* - Vasa previa involves the rupture of **fetal blood vessels** within the membranes over the cervix, causing **painless vaginal bleeding** of fetal origin and rapid fetal distress. - It does not explain the severe maternal abdominal pain associated with a major uterine insult and is not directly related to a prior Cesarean scar.

Question 4: A 37-year-old woman at 30 weeks gestation presents with sudden onset dyspnea and pleuritic chest pain. She has a swollen left calf. What is the most appropriate initial investigation?

A. D-dimer
B. Chest X-ray
C. Compression ultrasound of leg (Correct Answer)
D. V/Q scan
E. CTPA

Explanation: ***Compression ultrasound of leg*** - In a pregnant patient with symptomatic DVT/PE suspicion, identifying a **proximal DVT** via CUS is crucial as it confirms venous thromboembolism (VTE) and often allows **anticoagulation initiation** without further imaging that involves radiation (CTPA or V/Q scan). - CUS is **non-invasive**, readily available, and carries **no risk of fetal radiation**, making it the safest and most appropriate initial diagnostic test for VTE in pregnancy in this clinical context. *D-dimer* - The **D-dimer** test is unreliable in pregnancy because levels naturally increase throughout gestation, especially in the third trimester (30 weeks here), leading to **high false-positive rates** and poor diagnostic specificity. - While useful in low-risk non-pregnant patients (PERC rule), its lack of negative predictive value in this high-risk scenario makes it an inappropriate *initial* diagnostic step. *Chest X-ray* - A **Chest X-ray (CXR)** is primarily used to exclude alternative diagnoses, such as **pneumonia** or **pneumothorax**, that could mimic PE symptoms. - It is generally **not diagnostic** for PE itself, as findings are often non-specific or normal, and therefore does not confirm the need for anticoagulation. *V/Q scan* - A **V/Q scan** involves ionizing radiation and is typically considered for confirming PE only if the CUS is negative and clinical suspicion remains high. - While it has **lower fetal radiation exposure** compared to CTPA, it is deferred until non-invasive CUS results are known. *CTPA* - **CT Pulmonary Angiography (CTPA)** is highly sensitive for PE but exposes the mother (especially the breasts) to higher radiation doses compared to a V/Q scan. - It is usually reserved for cases where the **CXR is abnormal** or when the V/Q scan is **non-diagnostic**, following an initial assessment with CUS.

Question 5: A 28-year-old woman at 34 weeks gestation presents with sudden onset severe headache and seizures. Her BP is 180/120 mmHg. What is the most appropriate immediate treatment?

A. Labetalol IV
B. Magnesium sulfate IV (Correct Answer)
C. Immediate cesarean section
D. Diazepam IV
E. Mannitol IV

Explanation: ***Magnesium sulfate IV***- **Magnesium sulfate** is the first-line and definitive treatment for the prevention and cessation of seizures in women with **eclampsia**.- It acts by stabilizing neuronal membranes and reducing neuromuscular irritability, providing effective seizure control superior to traditional *anticonvulsants*.*Labetalol IV*- Labetalol is an **antihypertensive** used to manage severe *hypertension* (BP 160/110 mmHg) in preeclampsia/eclampsia, but it does not treat or prevent the underlying seizures.- Control of blood pressure is secondary to achieving **seizure cessation** and prevention with magnesium sulfate in the immediate management protocol.*Immediate cesarean section*- Delivery is the definitive cure for eclampsia and severe preeclampsia, but immediate **maternal stabilization**, including seizure control (MgSO4) and blood pressure management, must precede delivery unless other emergent obstetric indications exist.- A planned delivery is necessary once the patient is stable, but the *seizures* must be controlled first, making MgSO4 the most **immediate** necessary step.*Diazepam IV*- While an effective general anticonvulsant, **diazepam** is generally reserved as a *second-line agent* if seizures persist despite adequate administration of magnesium sulfate.- Magnesium sulfate is preferred because it is more effective for eclamptic seizures and carries a lower risk of fetal respiratory depression and **neonatal hypotonia** compared to benzodiazepines.*Mannitol IV*- **Mannitol** is an osmotic diuretic primarily used to reduce increased *intracranial pressure* (ICP) or treat cerebral edema.- It is not the primary immediate agent for *seizure control* in eclampsia, which requires **magnesium sulfate**.

Question 6: A 34-year-old woman at 32 weeks gestation presents with severe headache and visual disturbances. BP is $165/105\mathrm{mmHg}$. Proteinuria is $3+$. Blood tests show normal platelets and liver enzymes. What is the most likely diagnosis?

A. Gestational hypertension
B. Severe pre-eclampsia (Correct Answer)
C. HELLP syndrome
D. Eclampsia
E. Chronic hypertension

Explanation: ***Severe pre-eclampsia*** - The presence of **hypertension** ($165/105\mathrm{mmHg}$) and significant **proteinuria ($3+$)** in a woman at 32 weeks gestation (after 20 weeks) indicates pre-eclampsia. - The additional presence of **severe symptoms** like **headache** and **visual disturbances**, along with **severe-range blood pressure** ($\geq 160/110\mathrm{mmHg}$), confirms the diagnosis of **severe pre-eclampsia**. *Gestational hypertension* - *Gestational hypertension* is characterized by new-onset **hypertension** after 20 weeks gestation in the absence of **proteinuria** or any **severe features**. - The patient's **$3+$ proteinuria** and **severe symptoms** (headache, visual disturbances) directly exclude this diagnosis. *HELLP syndrome* - **HELLP syndrome** is a severe form of pre-eclampsia defined by **Hemolysis**, **Elevated Liver enzymes**, and **Low Platelets** (thrombocytopenia). - The clinical vignette explicitly states that the patient's **platelets and liver enzymes are normal**, thereby ruling out HELLP syndrome. *Eclampsia* - **Eclampsia** is diagnosed by the occurrence of **generalized tonic-clonic seizures** or unexplained coma in a patient with pre-eclampsia. - While the patient has severe pre-eclampsia, the absence of **seizures** in the presentation means she has not yet progressed to eclampsia. *Chronic hypertension* - **Chronic hypertension** is hypertension diagnosed before pregnancy or before **20 weeks gestation**, or hypertension that persists beyond 12 weeks postpartum. - The **new-onset proteinuria** and severe symptoms arising after 20 weeks gestation are characteristic of a pregnancy-specific hypertensive disorder, specifically **pre-eclampsia**, rather than isolated chronic hypertension.

Question 7: A 37-year-old woman presents with fatigue, joint pain, and a photosensitive rash. She is anti-Ro positive and planning pregnancy. What is the recommended fetal monitoring?

A. Monthly ultrasounds
B. Serial fetal echocardiograms (Correct Answer)
C. Amniocentesis
D. Chorionic villus sampling
E. No additional monitoring

Explanation: ***Serial fetal echocardiograms***- Anti-Ro (SSA) antibodies cross the placenta and target the **fetal cardiac conduction system**, causing **congenital heart block (CHB)**, a serious complication.- Serial monitoring with fetal echocardiograms (starting around 16–18 weeks gestation) is crucial to detect early signs of CHB, allowing for timely treatment with maternal **fluorinated steroids**.*Monthly ultrasounds*- Standard monthly ultrasounds primarily monitor fetal growth and amniotic fluid volume but are often insufficient to reliably detect subtle changes in **fetal heart rhythm** characteristic of early CHB.- A dedicated **fetal echocardiogram** uses specialized techniques to visualize cardiac structures and assess the conduction system comprehensively.*Amniocentesis*- This is an invasive procedure used for **prenatal diagnosis of genetic and chromosomal disorders** by analyzing amniotic fluid, not for routine monitoring of cardiac function or rhythm.- The primary goal in an anti-Ro positive pregnancy is surveillance for development of CHB, which does not require genetic testing.*Chorionic villus sampling*- CVS is an invasive procedure typically performed in the first trimester (10–13 weeks) for **genetic and chromosomal analysis**.- It is not indicated for the surveillance or diagnosis of **fetal conduction abnormalities** caused by maternal autoantibodies, which usually manifest later in the second trimester (16–26 weeks).*No additional monitoring*- This approach is dangerous because **Anti-Ro antibodies** confer a 1–2% risk of the fetus developing **congenital heart block**, requiring specialized cardiac surveillance to prevent adverse outcomes.- Lack of appropriate surveillance can lead to late diagnosis of CHB, potentially resulting in **fetal hydrops** or the need for an immediate **pacemaker** after birth.

Question 8: A 33-year-old woman at 30 weeks gestation presents with sudden onset dyspnea and chest pain. She has a swollen left leg. D-dimer is elevated. What is the most appropriate investigation?

A. Chest X-ray
B. V/Q scan
C. CT pulmonary angiogram
D. Compression ultrasound of leg (Correct Answer)
E. Arterial blood gas

Explanation: ***Compression ultrasound of leg***- Given the clinical triad of sudden onset **dyspnea**, **chest pain**, a **swollen left leg**, and an elevated **D-dimer** in a pregnant woman, there is a high suspicion for **pulmonary embolism (PE)** secondary to **deep vein thrombosis (DVT)**.- **Compression ultrasound** is the most appropriate initial investigation as it is non-invasive and uses no ionizing radiation, making it safe in pregnancy. Confirming **DVT** in the leg allows for immediate initiation of **anticoagulation** for **venous thromboembolism (VTE)** without necessarily needing further chest imaging, thereby minimizing fetal radiation exposure.*Chest X-ray*- A **chest X-ray (CXR)** is often performed to rule out other causes of dyspnea (e.g., pneumonia, pneumothorax) and to assess if a subsequent **V/Q scan** would be interpretable (i.e., normal CXR is ideal for V/Q scan).- While important for initial assessment, a **CXR** is not diagnostic for **DVT** or **PE** itself and cannot confirm the presence of VTE to guide specific therapy.*V/Q scan*- A **ventilation-perfusion (V/Q) scan** uses less radiation than a **CT pulmonary angiogram (CTPA)** and is generally preferred in pregnancy if pulmonary imaging is deemed necessary.- However, if **DVT** is confirmed by ultrasound, treatment for **VTE** can be initiated without the need for immediate pulmonary imaging, especially given the clinical picture strongly pointing towards DVT as the source.*CT pulmonary angiogram*- A **CT pulmonary angiogram (CTPA)** is highly sensitive and specific for diagnosing **PE** and is preferred in cases where **V/Q scan** is inconclusive or unavailable, or in hemodynamically unstable patients.- However, **CTPA** delivers higher doses of ionizing radiation to both the **mother (breasts)** and the **fetus** compared to a V/Q scan or a non-radiating ultrasound, making the latter a safer initial diagnostic step in pregnancy when DVT is suspected.*Arterial blood gas*- An **arterial blood gas (ABG)** is useful for assessing the severity of respiratory compromise in patients with suspected **PE**, typically showing **hypoxemia** and **respiratory alkalosis** due to hyperventilation.- However, an **ABG** is not a diagnostic tool for **DVT** or **PE** itself and cannot confirm the presence or location of the thrombus to guide specific anticoagulant therapy.

Question 9: A 36-year-old woman at 34 weeks gestation develops sudden onset severe abdominal pain and vaginal bleeding. Her previous delivery was by cesarean section. Fetal heart rate shows bradycardia. What is the most likely diagnosis?

A. Placental abruption
B. Uterine rupture (Correct Answer)
C. Placenta previa
D. Vasa previa
E. Preterm labor

Explanation: ***Uterine rupture***- The presence of **sudden, severe abdominal pain**, **vaginal bleeding**, and profound **fetal bradycardia** in a woman with a history of **previous Cesarean section** is highly classic for uterine rupture, a catastrophic obstetrical emergency.- The prior CS scar is the most common predisposing factor, and the severe pain, often followed by retraction of the fetal presenting part, results from the tearing of the myometrium, leading to acute fetal compromise and maternal hemorrhage.*Placental abruption*- While it causes painful bleeding and potential fetal distress, placental abruption pain is typically sustained, associated with a **rigid (tender, hypertonic) uterus**, and is usually not described as a catastrophic tear.- Although fetal bradycardia can occur, the combination of **severe pain** and a **prior CS scar** makes rupture the more immediate concern.*Placenta previa*- Placenta previa typically presents as **painless bright red vaginal bleeding** and usually does not cause **severe abdominal pain** unless complicated by coexisting abruption, which is less common.- Fetal distress is less frequent in *previa* unless bleeding is massive enough to cause maternal shock, unlike the acute compromise suggested by profound bradycardia here.*Vasa previa*- This condition is characterized by **fetal vessel rupture** (often after membrane rupture) and primarily causes fetal blood loss, leading to rapid **fetal compromise** (bradycardia/sinusoidal trace).- *Vasa previa* bleeding is usually not associated with the severe maternal **abdominal pain** or the massive maternal hemorrhage expected with uterine rupture or abruption.*Preterm labor*- Preterm labor pain is characterized by **rhythmic uterine contractions** that lead to cervical change, not the **sudden, severe, non-contractile pain** associated with tissue tearing.- While preterm labor can sometimes be accompanied by some bleeding (bloody show), it does not typically result in the immediate, catastrophic **fetal bradycardia** seen here, which suggests acute compromise.

Question 10: A 34-year-old woman at 28 weeks gestation presents with severe itching, particularly on palms and soles. Bile acids are elevated. What is the most likely diagnosis?

A. Atopic dermatitis
B. Intrahepatic cholestasis of pregnancy (Correct Answer)
C. HELLP syndrome
D. Acute fatty liver of pregnancy
E. Scabies

Explanation: ***Intrahepatic cholestasis of pregnancy*** - The presentation of severe, generalized **pruritus**, especially on the **palms and soles**, during the third trimester is highly characteristic of this condition. - The definitive diagnosis relies on elevated serum **bile acids** (>10 µmol/L) in the absence of other primary liver pathology.*Atopic dermatitis* - This condition is characterized by an **eczematous rash** (papules, plaques) and is generally not localized solely to the palms and soles as isolated, severe pruritus. - It is a primary dermatological condition and does not result in the diagnostic elevation of serum **bile acids** seen in cholestasis.*HELLP syndrome* - HELLP is a life-threatening complication characterized by **H**emolysis, **E**levated **L**iver enzymes, and **L**ow **P**latelets, causing severe systemic illness (e.g., abdominal pain, nausea). - While it involves liver pathology, severe isolated pruritus and elevated bile acids are defining features of ICP, not **HELLP**.*Acute fatty liver of pregnancy* - AFLP is a fulminant process presenting with nausea, vomiting, **hypoglycemia**, coagulopathy, and **hepatic failure** (often requiring intensive care). - The clinical picture here is limited to isolated pruritus and elevated bile acids, which does not fit the severe systemic compromise or **acute liver failure** seen in AFLP.*Scabies* - Scabies is a skin infestation resulting in intensely pruritic papules and **burrows**, typically found in the finger web spaces, wrists, and belt line. - This diagnosis would not account for the significant elevation of **bile acids** found on laboratory testing, which indicates a hepatobiliary issue.

Question 11: A 39-year-old woman at 32 weeks gestation presents with severe headache and epigastric pain. BP is 170/110 mmHg. Liver enzymes are elevated and platelets are 85,000/μL. What is the most appropriate management?

A. Antihypertensive therapy alone
B. Magnesium sulfate and monitoring
C. Immediate delivery (Correct Answer)
D. Corticosteroids for fetal lungs
E. Plasma exchange

Explanation: ***Immediate delivery*** - This patient presents with severe hypertension, headache, epigastric pain, **thrombocytopenia** (<100,000/μL), and **elevated liver enzymes**, fulfilling the criteria for **HELLP syndrome** and severe preeclampsia. - Immediate delivery is the definitive management for stabilizing severe preeclampsia and **HELLP syndrome** to prevent catastrophic maternal complications such as **eclampsia**, **hepatic rupture**, or **cerebral hemorrhage**, regardless of the 32-week gestational age. *Antihypertensive therapy alone* - While essential to rapidly reduce blood pressure and prevent **maternal stroke**, antihypertensive medication does not reverse the underlying progressive multi-organ damage caused by **HELLP syndrome**. - Relying solely on blood pressure control risks rapid progression to severe maternal morbidity or mortality because the disease process is left untreated, making it an insufficient standalone treatment. *Magnesium sulfate and monitoring* - **Magnesium sulfate** is crucial for seizure prophylaxis (prevention of **eclampsia**) in severe preeclampsia and HELLP syndrome, and should be administered, but it is not the ultimate treatment for **HELLP syndrome** itself. - Expectant management (monitoring without delivery) is inappropriate in a patient with active signs of severe maternal instability and multisystem dysfunction, necessitating delivery for maternal safety. *Corticosteroids for fetal lungs* - Corticosteroids are used to enhance **fetal lung maturity** when delivery can be safely postponed for at least 24-48 hours in cases of preterm labor or planned preterm delivery. - The severity of the patient's symptoms and laboratory derangements (**HELLP syndrome**) indicates an immediate, life-threatening threat to maternal well-being, making delaying delivery for fetal benefit **contraindicated**. *Plasma exchange* - **Plasma exchange** is not indicated for the standard treatment of **HELLP syndrome**, as the underlying pathophysiology involves placental dysfunction leading to widespread endothelial damage. - This therapy is primarily reserved for differentiating and managing other thrombotic microangiopathies, such as **Thrombotic Thrombocytopenic Purpura (TTP)** or atypical Hemolytic Uremic Syndrome (aHUS), not uncomplicated HELLP syndrome.

Question 12: A 41-year-old woman presents with fatigue, weight gain, and dry skin. TSH is 18 mU/L free T4 is low. She is planning pregnancy. What is the target TSH level during pregnancy?

A. <1.0 mU/L
B. <2.5 mU/L (Correct Answer)
C. <4.0 mU/L
D. <6.0 mU/L
E. <10.0 mU/L

Explanation: ***<2.5 mU/L***- This TSH target is specific for women with **hypothyroidism** who are planning pregnancy or are in the **first trimester** of pregnancy.- Maintaining TSH consistently below this level is critical to ensure optimal maternal and fetal thyroid hormone status, which is essential for early **fetal neurodevelopment**.*<1.0 mU/L*- This level is generally too suppressive for routine hypothyroidism management during pregnancy and risks iatrogenic hyperthyroidism.- Such suppression is typically reserved for aggressive management of **differentiated thyroid cancer**.*<4.0 mU/L*- While this may be an acceptable upper TSH limit for non-pregnant adults, it is too high for the first trimester of pregnancy.- The presence of **human chorionic gonadotropin (hCG)** suppresses TSH, lowering the physiological upper threshold in early gestation.*<6.0 mU/L*- This target is significantly above established guidelines for optimal thyroid function during pregnancy and would indicate **suboptimal replacement therapy**.- Failure to treat TSH aggressively during the first trimester increases the risk of adverse outcomes like miscarriage and preterm delivery.*<10.0 mU/L*- A TSH target this high indicates severe, untreated, or significantly **undertreated hypothyroidism**, which poses a high risk to both the mother and the fetus.- The goal throughout all trimesters is to keep TSH within the low-normal, **trimester-specific reference ranges**, which are much stricter than this value.

Question 13: A 29-year-old pregnant woman at 24 weeks presents with sudden onset severe chest pain and dyspnea. She has a history of previous DVT. D-dimer is elevated. What is the most appropriate investigation?

A. Chest X-ray
B. V/Q scan (Correct Answer)
C. CT pulmonary angiogram
D. Echocardiogram
E. Arterial blood gas

Explanation: ***V/Q scan***- The **V/Q scan** delivers a lower dose of **ionizing radiation** to the fetus (especially the thyroid) compared to CT pulmonary angiogram (CTPA).- It is the preferred initial imaging modality for investigating pulmonary embolism (PE) in a stable pregnant patient, provided the **chest X-ray is normal**.*Chest X-ray*- CXR is performed initially to rule out other common causes of chest pain and dyspnea (e.g., **pneumonia** or **pneumothorax**).- It is generally **not diagnostic** for pulmonary embolism itself, though it helps determine if a V/Q scan or CTPA is more appropriate.*CT pulmonary angiogram*- While highly sensitive and accurate, **CTPA** exposes the maternal breast tissue to a higher radiation dose and may deliver a higher **fetal effective dose** compared to a V/Q scan.- It is generally reserved for pregnant patients whose chest X-rays are **abnormal** (precluding interpretable V/Q scan results) or if the V/Q scan is **non-diagnostic**.*Echocardiogram*- An **echocardiogram** assesses the strain on the right ventricle (RV) and is used primarily for **risk stratification** of massive or submassive PEs.- It helps in assessing **hemodynamic stability** and severity but is not the definitive diagnostic tool for identifying the embolus itself.*Arterial blood gas*- ABG findings like **hypoxemia** and **respiratory alkalosis** are highly suggestive of PE but are non-specific and can occur in many other pulmonary diseases.- It helps in quantifying the **severity of respiratory compromise** but does not confirm the anatomical presence of a pulmonary embolus.

Question 14: A 37-year-old woman at 34 weeks gestation presents with severe hypertension and visual disturbances. Blood tests show elevated liver enzymes and low platelets. What is the definitive treatment?

A. Antihypertensive therapy
B. Corticosteroids
C. Magnesium sulfate
D. Delivery (Correct Answer)
E. Plasma exchange

Explanation: ***Delivery***- The patient's presentation with severe hypertension, visual disturbances, elevated liver enzymes, and low platelets at 34 weeks gestation is characteristic of **severe preeclampsia with HELLP syndrome**.- The **definitive treatment** for preeclampsia and its severe complications like HELLP syndrome is the **delivery** of the fetus and placenta, which resolves the underlying placental dysfunction.*Antihypertensive therapy*- **Antihypertensive medications** are crucial for managing **severe hypertension** to prevent maternal complications such as stroke, but they do not treat the underlying cause of preeclampsia.- These therapies are supportive measures used to stabilize the mother, often *prior to* and *during* delivery, but are not curative.*Corticosteroids*- **Corticosteroids** (e.g., dexamethasone) may be given to accelerate **fetal lung maturity** if gestation is less than 34 weeks and, in some cases of HELLP syndrome, can transiently improve platelet counts.- They are an adjunctive treatment and do not serve as the definitive or curative intervention for the maternal disease process.*Magnesium sulfate*- **Magnesium sulfate** is administered for the prevention and treatment of **eclampsia** (seizures) in women with severe preeclampsia or HELLP syndrome.- While vital for maternal neurological protection, it does not address the fundamental placental pathology that necessitates delivery.*Plasma exchange*- **Plasma exchange** is generally reserved for severe **thrombotic microangiopathies** such as **Thrombotic Thrombocytopenic Purpura (TTP)**, which has a similar presentation to HELLP syndrome but different pathophysiology.- It is not the standard or definitive treatment for HELLP syndrome, which typically resolves rapidly after **delivery**.

Question 15: A 29-year-old woman at 36 weeks gestation presents with severe hypertension and proteinuria. Fetal monitoring shows signs of compromise. What is the most appropriate management?

A. Antihypertensive therapy
B. Magnesium sulfate
C. Immediate delivery (Correct Answer)
D. Corticosteroids
E. Bed rest

Explanation: ***Immediate delivery*** - Given the presentation of **severe preeclampsia** (evidenced by severe hypertension and proteinuria) at 36 weeks, coupled with signs of **fetal compromise**, immediate delivery is the definitive and most appropriate management. - Delivery is the only definitive cure for preeclampsia, and at 36 weeks, the risks of continuation far outweigh the risks of prematurity, especially when **fetal well-being** is immediately threatened. *Antihypertensive therapy* - Antihypertensives (e.g., Labetalol, Hydralazine) are essential to prevent **maternal stroke** and intracerebral hemorrhage. - However, this therapy is supportive, not curative, and does not address the underlying pathology or the urgent need to relieve **fetal compromise**. *Magnesium sulfate* - **Magnesium sulfate** is mandatory for seizure prophylaxis (**eclampsia prevention**) in women with severe preeclampsia. - While critical for maternal stability, initiating this alone without proceeding to delivery is insufficient when the fetus is suffering **distress** at a viable gestation. *Corticosteroids* - Antenatal corticosteroids (e.g., betamethasone) are primarily used to promote **fetal lung maturity** when delivery is expected before 34 weeks gestation. - At 36 weeks, the fetus is considered **near term**, and the 24–48 hour delay required for corticosteroids to be effective is clinically unacceptable in the setting of severe maternal disease and **fetal compromise**. *Bed rest* - **Bed rest** is outdated and ineffective management for severe preeclampsia and may increase the risk of maternal **thromboembolism**. - It offers no therapeutic benefit and is dangerous when the patient requires immediate intervention due to severe hypertension and **fetal distress**.

Question 16: A 34-year-old woman at 28 weeks gestation presents with severe headache and visual changes. BP is 170/110 mmHg. Urine protein 3+. Platelets are 90,000/μL. What is the most likely diagnosis?

A. Gestational hypertension
B. Pre-eclampsia
C. HELLP syndrome (Correct Answer)
D. Eclampsia
E. Chronic hypertension

Explanation: ***HELLP syndrome***- The presence of severe hypertension (170/110 mmHg), severe symptoms (headache, visual changes), significant proteinuria (3+), and particularly severe **thrombocytopenia** (platelets 90,000/μL) indicates a critical obstetric emergency.- HELLP is an acronym for **H**emolysis, **E**levated **L**iver enzymes, and **L**ow **P**latelets, representing a severe form of pre-eclampsia with distinct hematologic and hepatic involvement.*Gestational hypertension*- This diagnosis is appropriate only if the woman has hypertension **without proteinuria** and **without any signs of end-organ damage** or abnormal laboratory findings.- The presence of 3+ proteinuria, severe symptoms, and severe **thrombocytopenia** in this case rules out gestational hypertension.*Pre-eclampsia*- The patient meets the criteria for **pre-eclampsia with severe features** due to hypertension, proteinuria, and severe symptoms like headache and visual changes.- However, the specific and severe laboratory finding of **thrombocytopenia** (90,000/μL) dictates the more precise and severe diagnosis of **HELLP syndrome**.*Eclampsia*- Eclampsia is diagnosed by the occurrence of **new-onset generalized tonic-clonic seizures** in a woman with pre-eclampsia.- While severe headache and visual changes are concerning signs of impending eclampsia, the patient has not experienced a seizure, thus ruling out eclampsia at this point.*Chronic hypertension*- Chronic hypertension is defined as hypertension present **before 20 weeks of gestation** or pre-existing hypertension.- The development of new proteinuria, severe symptoms, and **thrombocytopenia** in the third trimester indicates superimposed pre-eclampsia or, more accurately, **HELLP syndrome**, rather than isolated chronic hypertension.

Question 17: A 33-year-old woman at 32 weeks gestation presents with severe abdominal pain and vaginal bleeding. The uterus is tender and tense. Fetal monitoring shows bradycardia. What is the most likely diagnosis?

A. Placenta previa
B. Placental abruption (Correct Answer)
C. Uterine rupture
D. Preterm labor
E. Vasa previa

Explanation: ***Placental abruption***- The classic signs include **severe abdominal pain**, **vaginal bleeding**, and a **tender, hypertonic (tense) uterus**, caused by premature separation of the placenta.- The presence of **fetal bradycardia** suggests significant fetal distress resulting from compromised placental oxygen transfer, necessitating immediate intervention.*Placenta previa*- This condition typically causes sudden onset of **painless, bright red vaginal bleeding** after 20 weeks gestation.- The uterus remains soft and non-tender, distinguishing it from the painful, tense uterus described in this clinical scenario.*Uterine rupture*- While acute and severe, rupture often presents with a sudden, sharp pain followed by a **loss of sensation of contractions** and **recession of the fetal head** or presenting part.- Fetal parts might become easily palpable outside the uterus, and the mother often develops profound shock quickly, whereas abruption maintains uterine tone.*Preterm labor*- Characterized by regular, painful contractions that lead to cervical change, but usually does not involve the severe, constant abdominal pain or the rigid, **tense uterus** seen here.- Significant vaginal bleeding is uncommon unless associated with cervical effacement or underlying placental complication.*Vasa previa*- Involves fetal vessels traversing the internal os, presenting with **painless bleeding** (often upon membrane rupture) that quickly leads to fetal decompensation (bradycardia).- The uterus remains soft and non-tender, and the bleeding is fetal in origin, not associated with a major uterine contraction or hematoma formation.

Question 18: A 29-year-old woman presents with sudden onset severe headache and vomiting. She is 38 weeks pregnant. BP is 180/120 mmHg. She has a generalized seizure. What is the most appropriate treatment?

A. Labetalol
B. Magnesium sulfate (Correct Answer)
C. Immediate delivery
D. Diazepam
E. Mannitol

Explanation: ***Magnesium sulfate*** - In a pregnant woman at term with severe hypertension and a generalized seizure, the diagnosis is **eclampsia**. **Magnesium sulfate** is the **first-line treatment** for the prevention and management of eclamptic seizures. - It acts as a central nervous system depressant and vasodilator, stabilizing neuronal membranes to effectively terminate and prevent recurrent seizures. *Labetalol* - Labetalol is an **antihypertensive medication** used to manage severe hypertension in preeclampsia or eclampsia, aiming to prevent complications like stroke. - However, it does **not** directly treat or prevent the seizures themselves; seizure control with magnesium sulfate takes precedence. *Immediate delivery* - Delivery of the fetus and placenta is the **definitive cure** for eclampsia by removing the underlying cause. - While crucial, maternal stabilization, particularly seizure control with **magnesium sulfate**, must generally precede delivery unless there is an immediate obstetric indication. *Diazepam* - **Benzodiazepines** like diazepam are considered **second-line agents** for eclamptic seizures, typically reserved for cases refractory to adequate doses of magnesium sulfate. - They carry a greater risk of maternal **respiratory depression** and neonatal central nervous system depression compared to magnesium sulfate. *Mannitol* - **Mannitol** is an osmotic diuretic used to reduce **intracranial pressure (ICP)** in conditions like cerebral edema or hemorrhagic stroke. - While eclampsia involves cerebral dysfunction, it's primarily due to vasospasm and endothelial dysfunction, and routine ICP management with mannitol is **not indicated** for seizure control.

Question 19: A 34-year-old woman presents with fatigue, joint pain, and photosensitive rash. She has positive anti-Ro antibodies and is planning pregnancy. What is the main fetal risk?

A. Neural tube defects
B. Congenital heart block (Correct Answer)
C. Growth restriction
D. Preterm labor
E. Cleft palate

Explanation: ***Congenital heart block***- The presence of **anti-Ro (SSA)** and **anti-La (SSB) antibodies** in a pregnant woman poses a significant risk for **Neonatal Lupus Erythematosus (NLE)**, specifically **congenital heart block**, due to transplacental antibody transfer.- These maternal antibodies target and damage the fetal cardiac conduction system, particularly the **AV node**, leading to **irreversible third-degree heart block** in the fetus.*Neural tube defects*- These developmental anomalies are primarily linked to deficiencies such as **folate deficiency** or exposure to certain teratogenic medications like **valproate**.- There is no direct or established causal relationship between maternal **anti-Ro antibodies** and the development of neural tube defects.*Growth restriction*- Fetal growth restriction (FGR) is more commonly associated with **active maternal systemic lupus erythematosus (SLE) disease** or concomitant **antiphospholipid syndrome (APS)**, leading to placental insufficiency.- While FGR can occur in pregnancies with autoimmune conditions, it is not the classic, directly antibody-mediated fetal risk specifically associated with **anti-Ro antibodies**.*Preterm labor*- Preterm labor is a general complication that can arise in pregnancies complicated by autoimmune diseases, often driven by factors like **active maternal inflammation**, placental dysfunction, or infections.- It is not the primary or specific fetal pathology directly caused by the transplacental passage and binding of **anti-Ro antibodies**.*Cleft palate*- **Cleft palate** and other craniofacial malformations are typically multifactorial, involving genetic predispositions or exposure to specific teratogenic agents (e.g., **phenytoin**).- Maternal **anti-Ro antibodies** are predominantly associated with fetal cardiac, dermatologic (rash), and hepatic manifestations, not structural defects like cleft palate.

Question 20: A 32-year-old woman at 20 weeks gestation presents with fever and right loin pain. Urine culture grows E. coli. What is the most appropriate antibiotic?

A. Trimethoprim
B. Nitrofurantoin
C. Amoxicillin (Correct Answer)
D. Ciprofloxacin
E. Gentamicin

Explanation: ***Amoxicillin***- **Amoxicillin**, a penicillin (Pregnancy Category B), is one of the safest antibiotic classes for treating infections, including pyelonephritis, in the second trimester.- Beta-lactams (penicillins and cephalosporins) are the preferred first-line agents for empiric treatment of **acute pyelonephritis** in pregnant women requiring admission.*Trimethoprim*- Trimethoprim is generally avoided during the first trimester due to its anti-folate properties, increasing the risk of **neural tube defects**.- It is often avoided during the third trimester as well due to the risk of **fetal kernicterus**, limiting its use throughout pregnancy.*Nitrofurantoin*- **Nitrofurantoin** is highly effective for uncomplicated **cystitis** as it concentrates primarily in the urine.- It is generally ineffective for treating **pyelonephritis** because it achieves insufficient therapeutic concentrations in the **renal parenchyma (kidney tissue)**.*Ciprofloxacin*- **Ciprofloxacin** belongs to the fluoroquinolone class, which is contraindicated in pregnancy.- Fluoroquinolones carry a theoretical risk of damaging developing **fetal cartilage and joints**, making them an unsafe choice.*Gentamicin*- **Gentamicin**, an aminoglycoside, is generally avoided as a first-line monotherapy during pregnancy.- It carries risks of **fetal ototoxicity** (hearing damage) and potential **nephrotoxicity**.

Question 21: A 39-year-old woman presents with recurrent miscarriages and thrombosis. She has positive anticardiolipin antibodies and lupus anticoagulant. What is the most appropriate treatment for future pregnancies?

A. Aspirin alone
B. Warfarin
C. Aspirin plus LMWH (Correct Answer)
D. Prednisolone
E. Immunoglobulin

Explanation: ***Aspirin plus LMWH***- Combination therapy using low-dose **aspirin** (antiplatelet) and prophylactic or therapeutic **low molecular weight heparin (LMWH)** is the established standard of care for pregnant women with **Antiphospholipid Syndrome (APS)** who have a history of thrombosis and/or recurrent fetal loss.- This regimen targets both platelet aggregation and the coagulation cascade, significantly improving live birth rates and preventing maternal **thromboembolism**.*Aspirin alone*- **Aspirin monotherapy** is considered inadequate for patients with a history of both major **thrombotic events** and **recurrent miscarriages** linked to APS.- It is typically reserved for lower-risk obstetric APS without prior thrombosis.*Warfarin*- **Warfarin** is a known human **teratogen**, causing severe fetal defects (e.g., **fetal warfarin syndrome**) when administered during the first trimester.- Due to this safety concern, all pregnant women requiring oral anticoagulation are transitioned to **heparin** (LMWH or unfractionated heparin).*Prednisolone*- **Prednisolone** (a glucocorticoid) is not the primary treatment for preventing **thrombosis** or pregnancy loss in APS; its role is limited to managing co-existing autoimmune conditions like **Systemic Lupus Erythematosus (SLE)**.- The critical mechanism failure in APS pregnancy is coagulation/placental vascular compromise, requiring direct **anticoagulation**, not immunosuppression.*Immunoglobulin*- **Intravenous Immunoglobulin (IVIG)** is a high-cost, specialized intervention reserved for highly **refractory cases** of APS-related fetal loss or in patients with co-existing conditions like severe immune thrombocytopenia.- It is not indicated as initial or standard therapy for the routine management of APS in pregnancy.

Question 22: A 43-year-old woman presents with fatigue, cold intolerance, and weight gain 6 months after childbirth. TSH is 15 mU/L, free T4 low. What is the most likely diagnosis?

A. Postpartum thyroiditis (Correct Answer)
B. Hashimoto's thyroiditis
C. Postpartum depression
D. Sheehan syndrome
E. De Quervain's thyroiditis

Explanation: ***Postpartum thyroiditis*** - This condition involves transient inflammation of the thyroid gland, typically presenting 4–8 months after childbirth in the hypothyroid phase, matching the patient's 6-month timing and symptoms. - The lab findings (high **TSH** and low **Free T4**) confirm **primary hypothyroidism**, resulting from the destructive thyroiditis. *Hashimoto's thyroiditis* - While PPT is considered a variant of Hashimoto's, the term Hashimoto's generally refers to chronic autoimmune thyroiditis leading to permanent hypothyroidism. - The specific context of new onset symptoms 6 months after delivery makes **Postpartum thyroiditis** the more accurate and focused diagnosis. *Postpartum depression* - Although symptoms like fatigue and weight changes overlap, the definitive biochemical findings of **primary hypothyroidism** (High TSH, Low Free T4) necessitate a thyroid diagnosis. - **Postpartum depression** is a diagnosis of exclusion that should only be considered after ruling out organic causes like thyroid dysfunction. *Sheehan syndrome* - Sheehan syndrome is caused by **pituitary necrosis** following severe obstetrical hemorrhage, leading to **secondary hypothyroidism**. - Secondary hypothyroidism is characterized by **low or inappropriately normal TSH** alongside low Free T4, contradicting this patient's high TSH. *De Quervain's thyroiditis* - This condition is typically characterized by a **painful** and often tender thyroid gland, following a recent viral upper respiratory infection. - While it can cause transient hypothyroidism, the lack of a painful gland and clear viral prodrome makes this diagnosis less likely than PPT in the postpartum setting.

Question 23: A 29-year-old woman at 34 weeks gestation presents with severe hypertension and seizures. What is the most appropriate immediate treatment?

A. Labetalol
B. Magnesium sulfate (Correct Answer)
C. Immediate delivery
D. Diazepam
E. Nifedipine

Explanation: ***Magnesium sulfate***- This is the standard, first-line agent for the prevention and treatment of **eclamptic seizures**, acting as a central nervous system (CNS) depressant and stabilizer of neuronal excitability.- It significantly reduces the risk of recurrent seizures and is superior to anticonvulsants like diazepam or phenytoin for eclampsia management.*Labetalol*- Labetalol is a primary agent used to manage acute, severe **maternal hypertension** (BP control) in preeclampsia or eclampsia.- It does not treat or prevent the underlying **eclamptic seizures**, which must be addressed immediately with magnesium sulfate.*Immediate delivery*- While delivery is the definitive *cure* for eclampsia, stabilizing the mother, specifically controlling the **seizures** and severe **hypertension**, must be the immediate focus.- Delivery should only proceed once the patient is stabilized after **magnesium sulfate** administration, unless there is imminent maternal or fetal compromise.*Diazepam*- Benzodiazepines like diazepam are considered second-line agents for eclampsia management, used only if seizures persist despite adequate **magnesium sulfate** therapy.- Routine use is discouraged due to risks of **neonatal depression** and increased rates of maternal respiratory depression compared to magnesium sulfate.*Nifedipine*- Nifedipine is a calcium channel blocker used for controlling acute severe **hypertension** in pregnancy, similar to labetalol.- Like other antihypertensives, it treats the blood pressure elevation but has no established role as a primary treatment for **eclamptic seizures**.

Question 24: A 33-year-old woman at 28 weeks gestation presents with sudden onset dyspnea and chest pain. D-dimer is elevated. What is the most appropriate investigation?

A. Chest X-ray
B. V/Q scan (Correct Answer)
C. CT pulmonary angiogram
D. Echocardiogram
E. Arterial blood gas

Explanation: ***V/Q scan***- The **Ventilation/Perfusion (V/Q) scan** is the preferred initial imaging modality for suspected PE in **pregnant patients** when the Chest X-ray (CXR) is normal, due to its significantly **lower fetal radiation exposure** compared to CTPA.- A V/Q scan that yields a high probability result is highly suggestive of PE, while a normal scan essentially rules out the diagnosis. *Chest X-ray*- A **CXR** should be performed initially in all patients with suspected PE to exclude other pulmonary pathology (e.g., pneumothorax, pneumonia) that may mimic PE symptoms.- While important for differential diagnosis, the CXR is rarely diagnostic for PE, as classic findings like the **Westermark sign** or **Hampton's hump** are uncommon. *CT pulmonary angiogram*- **CTPA** is highly sensitive for PE but delivers a higher radiation dose to both the fetus and the **maternal breast tissue** (increasing lifetime risk of cancer).- CTPA is usually reserved for situations where the initial CXR is abnormal (which limits the interpretability of a V/Q scan) or when the V/Q scan results are indeterminate. *Echocardiogram*- An **echocardiogram** is primarily used to assess the presence of **right ventricular (RV) strain** or dysfunction, a crucial prognostic marker in submassive or massive PE.- It helps differentiate PE from cardiac causes of chest pain/dyspnea but is not the study of choice for the definitive anatomical diagnosis of a pulmonary embolus. *Arterial blood gas*- **ABG** analysis often reveals **hypoxemia** and **respiratory alkalosis** (due to hyperventilation) in acute PE.- This test is non-specific, as these findings can occur in various causes of acute respiratory distress, thus an ABG cannot confirm the diagnosis of PE.

Question 25: A 34-year-old pregnant woman at 32 weeks presents with severe headache, visual disturbances, and RUQ pain. BP 180/110 mmHg, platelets 85,000/μL, AST 180 U/L. What is the most likely diagnosis?

A. Pre-eclampsia
B. HELLP syndrome (Correct Answer)
C. Acute fatty liver of pregnancy
D. Viral hepatitis
E. Gallstone disease

Explanation: ***HELLP syndrome*** - The patient's presentation with severe headache, visual disturbances, **RUQ pain**, **severe hypertension** (BP 180/110 mmHg), **thrombocytopenia** (platelets 85,000/μL), and **elevated liver enzymes** (AST 180 U/L) is the classic triad for HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets). - This syndrome represents a severe, life-threatening complication of pre-eclampsia, with the RUQ pain often indicating hepatic distension and subcapsular hemorrhage. *Pre-eclampsia* - While the patient exhibits symptoms of **severe pre-eclampsia** (headache, visual disturbances, severe hypertension), the specific laboratory findings of **markedly low platelets** and **significantly elevated liver enzymes** define the progression to HELLP syndrome, which is a more severe variant. - Pre-eclampsia is a broader diagnosis, characterized by hypertension and proteinuria or signs of end-organ damage, but HELLP syndrome highlights specific hematologic and hepatic involvement. *Acute fatty liver of pregnancy* - Acute fatty liver of pregnancy typically presents with profound nausea, vomiting, **hypoglycemia**, hepatic encephalopathy, and **jaundice**, rather than the primary hypertension and isolated thrombocytopenia seen here. - Although liver enzymes are elevated, the clinical picture, including severe headache, visual disturbances, and the specific laboratory pattern, is more indicative of HELLP syndrome. *Viral hepatitis* - Viral hepatitis can cause **elevated liver enzymes** but is generally not associated with severe **hypertension**, pronounced **thrombocytopenia**, or the specific neurological symptoms like visual disturbances in the absence of hepatic encephalopathy or other complications. - The prominent hypertension and its associated symptoms strongly suggest a hypertensive disorder of pregnancy, which is not a primary feature of viral hepatitis. *Gallstone disease* - Gallstone disease (e.g., cholecystitis) would cause **RUQ pain** but does not explain the patient's severe **hypertension**, generalized symptoms like headache and visual disturbances, or the significant **thrombocytopenia**. - Laboratory findings in uncomplicated gallstone disease would typically show elevated bilirubin or alkaline phosphatase, but not the specific hematologic and hepatic derangements characteristic of HELLP syndrome.

Question 26: A 31-year-old woman at 16 weeks gestation presents with severe nausea, vomiting, and dehydration. She has lost 8% of her pre-pregnancy weight. Urine shows 3+ ketones. What is the most appropriate management?

A. Oral antiemetics only
B. IV fluids and thiamine (Correct Answer)
C. Immediate termination
D. High-dose steroids
E. Enteral feeding

Explanation: ***IV fluids and thiamine***- This patient presents with **Hyperemesis Gravidarum (HG)**, evidenced by severe vomiting, dehydration, and significant weight loss (>5%), requiring immediate **intravenous crystalloid** treatment for fluid and electrolyte restoration.- Thiamine (Vitamin B1) must be administered concurrently, or before, glucose-containing fluids to prevent the precipitation of **Wernicke's encephalopathy**, a serious complication of prolonged vomiting and malnutrition.*Oral antiemetics only*- Oral antiemetics are insufficient as monotherapy when the patient exhibits signs of severe systemic illness, such as **dehydration**, significant weight loss (8%), and ketonuria.- Due to the severity, hospitalization and intensive **IV rehydration** and electrolyte correction are mandatory steps before focusing solely on antiemetic medication routes.*Immediate termination*- Termination of pregnancy is reserved only for extremely rare cases of HG that are completely refractory to all medical management and threaten the mother's life.- The immediate priority is stabilizing the patient through **fluid resuscitation** and nutritional support, not proceeding directly to termination.*High-dose steroids*- Corticosteroids (e.g., prednisolone) are generally considered third-line agents and are reserved for patients with HG refractory to first- and second-line antiemetics (such as **pyridoxine/doxylamine** or **ondansetron**).- They are not the most appropriate first management step for correcting acute, life-threatening metabolic derangements like dehydration.*Enteral feeding*- Enteral or parenteral **nutritional support** is reserved for patients who continue to experience weight loss, nutritional deficiency, or lack of significant improvement despite optimized intravenous rehydration and aggressive antiemetic regimens.- Initial management strictly focuses on correcting **fluid deficits** and administering necessary micronutrients like thiamine.

Question 27: A 35-year-old woman at 28 weeks gestation presents with severe headache, visual disturbances, and epigastric pain. Her BP is 170/110 mmHg. Urine shows 3+ protein. Platelet count is 90,000/μL. What is the most likely diagnosis?

A. Gestational hypertension
B. Pre-eclampsia
C. HELLP syndrome (Correct Answer)
D. Eclampsia
E. Chronic hypertension

Explanation: ***HELLP syndrome*** - This diagnosis is characterized by **H**emolysis (implied by severe features), **E**levated **L**iver enzymes (implied by **epigastric pain** due to liver capsule distension), and **L**ow **P**latelets (confirmed by **thrombocytopenia of 90,000/μL**). - The combination of **severe hypertension**, **proteinuria**, and these specific laboratory and clinical findings (headache, visual disturbances) at 28 weeks gestation is pathognomonic for **HELLP syndrome**. *Gestational hypertension* - **Gestational hypertension** is characterized by new-onset hypertension after 20 weeks gestation without **proteinuria** or signs of **end-organ damage**. - This patient has significant **proteinuria (3+)** and severe features including **thrombocytopenia** and **epigastric pain**, which rules out gestational hypertension alone. *Pre-eclampsia* - **Pre-eclampsia** involves new-onset hypertension and proteinuria, or hypertension with severe features; however, **HELLP syndrome** is a specific, severe *complication* defined by specific laboratory abnormalities. - Given the severe symptoms and documented **thrombocytopenia (90,000/μL)**, the diagnosis has progressed beyond generalized pre-eclampsia to the specific entity of **HELLP syndrome**. *Eclampsia* - **Eclampsia** is defined as pre-eclampsia complicated by new-onset generalized tonic-clonic **seizures**. - Although the patient has severe features (headache, visual changes), the critical feature of a **seizure** is absent in this presentation. *Chronic hypertension* - **Chronic hypertension** is defined as hypertension present before pregnancy or diagnosed before **20 weeks gestation**. - The acute onset of **proteinuria**, severe symptoms (headache, visual disturbances, epigastric pain), and **thrombocytopenia** indicate an acute pregnancy-induced disorder rather than isolated chronic hypertension.

Question 28: A 30-year-old pregnant woman at 32 weeks gestation presents with sudden severe abdominal pain and vaginal bleeding. On examination, the uterus is tender and tense. Fetal monitoring shows bradycardia. What is the most likely diagnosis?

A. Placenta previa
B. Placental abruption (Correct Answer)
C. Uterine rupture
D. Preterm labor
E. Vasa previa

Explanation: ***Placental abruption***- This diagnosis is characterized by the classic triad of **sudden severe abdominal pain**, **vaginal bleeding**, and a **tender/tense (hypertonic) uterus**, indicating premature separation of the placenta from the uterine wall.- **Fetal bradycardia** or distress occurs due to impaired maternal-fetal oxygen exchange resulting from the separation.*Placenta previa*- The hallmark presentation is **painless vaginal bleeding** after 20 weeks gestation, typically without severe abdominal pain.- The uterus usually remains **soft and non-tender** because there is no myometrial irritation or hypertonicity associated with the implantation site.*Uterine rupture*- Symptoms include sudden, severe pain and typically leads to cessation of contractions and often **loss of uterine tone** or easy palpation of fetal parts outside the uterus.- While associated with acute fetal distress, the presence of a **tense and tender uterus** makes abruption more likely than rupture.*Preterm labor*- This involves rhythmic **uterine contractions** leading to cervical change; while pain is present, the severe bleeding and intense **uterine rigidity** are not typical primary distinguishing features.- Fetal distress, while possible, is usually secondary to prolonged labor or other complications, and not the immediate presenting sign alongside the rigid uterus.*Vasa previa*- Presents with **painless vaginal bleeding** following rupture of membranes when fetal vessels overlie the cervix (rupture of the vessels).- It causes immediate and profound **fetal distress/bradycardia** but does not cause acute maternal abdominal pain or a tender, hypertonic uterus.

Question 29: A 35-year-old woman at 20 weeks gestation presents with fever, dysuria, and loin pain. Urine culture grows E. coli sensitive to amoxicillin. What is the most appropriate treatment?

A. Trimethoprim
B. Nitrofurantoin
C. Amoxicillin (Correct Answer)
D. Ciprofloxacin
E. Co-amoxiclav

Explanation: ***Amoxicillin***- The patient presents with **pyelonephritis** in pregnancy, and the urine culture confirms **E. coli sensitivity to amoxicillin**.- **Amoxicillin is a beta-lactam antibiotic**, generally considered **safe and effective in pregnancy** (Category B) for susceptible organisms.*Trimethoprim*- **Trimethoprim is contraindicated in the first trimester** of pregnancy due to its **folate antagonist** effects, potentially leading to neural tube defects.- Although its use in later trimesters is debated, **amoxicillin is a preferred and safer option** when indicated by culture sensitivity.*Nitrofurantoin*- While commonly used for **lower urinary tract infections (cystitis)** in pregnancy, **nitrofurantoin is less effective for pyelonephritis** due to poor tissue penetration.- It is **contraindicated in the third trimester (especially near term)** due to the risk of **hemolytic anemia in the neonate**.*Ciprofloxacin*- **Ciprofloxacin is a fluoroquinolone**, which is generally **contraindicated in pregnancy** due to concerns about **fetal cartilage damage**.- It should only be considered if safer alternatives are unavailable or ineffective, which is not the case here given amoxicillin sensitivity.*Co-amoxiclav*- While related to amoxicillin, the addition of **clavulanic acid in co-amoxiclav has been linked to a potential increased risk of necrotizing enterocolitis in premature infants**.- Given that **amoxicillin alone is effective** and well-tolerated, it is the more appropriate and safer choice for this patient.

Question 30: A 35-year-old woman presents with recurrent miscarriages (4 in 2 years), prolonged APTT, and a history of DVT. Anticardiolipin antibodies are positive. What is the most appropriate treatment during future pregnancies?

A. Aspirin alone
B. Warfarin
C. Aspirin and low molecular weight heparin (Correct Answer)
D. No treatment
E. Prednisolone

Explanation: ***Aspirin and low molecular weight heparin***- This combination is the standard prophylactic treatment for women with **Antiphospholipid Syndrome (APS)** who have a history of adverse pregnancy outcomes (recurrent miscarriages) or previous thrombosis (DVT). - **Low molecular weight heparin (LMWH)** addresses the hypercoagulable state and prevents **placental thrombosis**, while **aspirin** provides anti-platelet effects, significantly improving live birth rates.*Aspirin alone*- Monotherapy with aspirin (or LMWH) is associated with substantially higher rates of fetal loss compared to combination therapy in women with confirmed **obstetric APS** and recurrent miscarriage. - Aspirin alone provides anti-platelet effects but is often insufficient to fully counteract the severe **pro-coagulant state** and prevent placental injury in high-risk APS.*Warfarin*- Warfarin is a **Vitamin K antagonist** and readily crosses the placenta, making it highly **teratogenic** (causing **warfarin embryopathy**) if used during the first trimester. - Although affective for DVT management, it is contraindicated in pregnancy; **LMWH** is the preferred anticoagulant choice as it does not cross the placenta.*No treatment*- Given the confirmed diagnosis of Antiphospholipid Syndrome (positive antibodies, recurrent miscarriages, and DVT), withholding treatment guarantees a very high risk of recurrent thrombosis, miscarriage, and **fetal loss**. - The patient requires necessary anti-thrombotic prophylaxis to prevent potentially life-threatening maternal and fetal complications.*Prednisolone*- Corticosteroids like prednisolone are generally not indicated as monotherapy for preventing thrombosis or recurrent pregnancy loss in established **Antiphospholipid Syndrome** (APS). - It is typically reserved for cases where underlying systemic lupus erythematosus (SLE) contributes to the phenotype, and it does not replace the crucial need for **anticoagulation/antiplatelet therapy**.

Question 31: A 30-year-old woman presents with fatigue, weight gain, and constipation following childbirth 6 months ago. She also complains of hair loss and feeling cold. TSH is 25 mU/L, free T4 is low. What is the most likely diagnosis?

A. Postpartum thyroiditis (Correct Answer)
B. Hashimoto's thyroiditis
C. Postpartum depression
D. Sheehan syndrome
E. De Quervain's thyroiditis

Explanation: ***Postpartum thyroiditis***- The presentation of new onset hypothyroidism (high **TSH**, low **free T4**) approximately 6 months following childbirth is characteristic of the hypothyroid phase of **postpartum thyroiditis (PPT)**.- PPT is an autoimmune disorder occurring within 1 year of delivery, typically presenting initially as transient hyperthyroidism followed by a phase of **hypothyroidism** (4-12 months postpartum).*Hashimoto's thyroiditis*- While PPT is a transient form of autoimmune thyroiditis similar to Hashimoto's, the diagnosis of **PPT** is more specific given the strong temporal association with the recent delivery.- Hashimoto's is the most common cause of primary hypothyroidism globally, typically resulting in chronic, **permanent** thyroid failure, whereas PPT is often transient.*Postpartum depression*- Although fatigue and weight changes can overlap with depression, the severely abnormal thyroid function tests (very high **TSH**, low **T4**) confirm that **primary hypothyroidism** is the underlying medical etiology.- Postpartum depression is a psychiatric diagnosis and does not cause the specific laboratory derangements seen in **thyroid hormone levels**.*Sheehan syndrome*- Sheehan syndrome is caused by ischemic necrosis of the pituitary gland, leading to hypopituitarism and therefore causing **secondary** or central hypothyroidism.- Labs in Sheehan syndrome would show low or inappropriately normal **TSH** alongside low **free T4**, which contradicts the high TSH (primary hypothyroidism) seen in this patient.*De Quervain's thyroiditis*- De Quervain's (subacute) thyroiditis is typically characterized by a painful and tender thyroid gland, often following a viral illness, a key clinical feature absent in this case.- Like PPT, it can cause transient hypothyroidism, but the presence of **neck pain** and elevated **ESR** are essential differentiating features of De Quervain's.

Question 32: A 35-year-old woman presents with sudden onset severe headache, nausea, and visual disturbance. She is 35 weeks pregnant. Her BP is 180/120 mmHg and she has generalized seizure activity. What is the most appropriate immediate treatment?

A. IV labetalol
B. Magnesium sulfate (Correct Answer)
C. Immediate delivery
D. IV diazepam
E. Sublingual nifedipine

Explanation: ***Magnesium sulfate***- It is the first-line and definitive treatment for preventing and controlling **eclamptic seizures**, rapidly stabilizing the patient.- It functions as a **central nervous system (CNS) depressant** and prevents cortical irritability associated with eclampsia.*IV labetalol*- Labetalol is used to control severe maternal **hypertension** (e.g., BP 180/120 mmHg), but seizure control with magnesium sulfate takes absolute immediate priority.- It does not treat or prevent seizures; magnesium sulfate should be initiated first to stabilize the patient.*Immediate delivery*- While delivery is the **definitive treatment** for eclampsia, maternal stabilization (seizure control) must occur *before* proceeding with delivery, unless immediate fetal or maternal risk outweighs the need for stabilization.- Delivery is not the *immediate* treatment for current generalized seizure activity itself.*IV diazepam*- Benzodiazepines (like diazepam) are **second-line agents** reserved only for refractory seizures when magnesium sulfate fails to control them.- Magnesium sulfate is preferred because it is less likely to cause significant respiratory depression in the mother or neonate compared to diazepam.*Sublingual nifedipine*- Nifedipine is an **antihypertensive agent** used for managing severe hypertension, which is secondary to the immediate need for seizure termination.- Sublingual administration of nifedipine is typically discouraged in obstetrics due to unpredictable absorption and the risk of rapid, severe **hypotension**.

Question 33: A 25-year-old woman at 10 weeks gestation presents with nausea, vomiting, and inability to keep fluids down for 3 days. She has lost 3kg in weight. Urine shows 3+ ketones. What is the most appropriate management?

A. Oral antiemetics
B. IV fluids and antiemetics (Correct Answer)
C. Immediate delivery
D. Dietary advice only
E. Psychological support

Explanation: ***IV fluids and antiemetics*** - The patient's presentation with intractable nausea and vomiting, inability to keep fluids down, significant weight loss (3kg), and **ketonuria** (3+ ketones) are classic signs of **Hyperemesis Gravidarum (HG)**. - **Intravenous fluids** are crucial to correct severe **dehydration** and electrolyte imbalances, while parenteral antiemetics are necessary as oral intake is not tolerated due to persistent vomiting. *Oral antiemetics* - Given the patient's inability to keep fluids down, oral medications would be ineffective due to likely vomiting and poor absorption. - Oral antiemetics are appropriate for milder forms of **nausea and vomiting of pregnancy**, not for severe HG with evidence of **dehydration** and **ketosis**. *Immediate delivery* - **Immediate delivery** or termination of pregnancy is an extreme measure not indicated at 10 weeks gestation for HG, especially as it usually resolves spontaneously by the second trimester. - This intervention is only considered in extremely rare, life-threatening situations where HG is refractory to maximal medical therapy and causes severe, irreversible maternal complications like **Wernicke encephalopathy**. *Dietary advice only* - Dietary advice is suitable for mild cases of **nausea and vomiting of pregnancy**, but it is insufficient for a patient with established **Hyperemesis Gravidarum** manifesting with severe **dehydration**, **weight loss**, and **ketonuria**. - The severity of symptoms requires aggressive medical intervention, including **IV rehydration** and antiemetics, not just simple lifestyle modifications. *Psychological support* - While **psychological support** can be beneficial as an adjunct for the distress associated with HG, it does not address the immediate and urgent medical needs of **dehydration**, electrolyte imbalance, and nutritional deficits. - The priority is the physical stabilization of the patient through **IV fluids** and antiemetics, after which psychological support can be incorporated.

Question 34: A 30-year-old pregnant woman at 28 weeks gestation presents with sudden onset severe headache and blurred vision. Her BP is 170/110 mmHg. Urinalysis shows 2+ protein. What is the most appropriate initial treatment?

A. Sublingual nifedipine
B. IV labetalol (Correct Answer)
C. Oral methyldopa
D. IV hydralazine
E. Oral amlodipine

Explanation: ***IV labetalol***- **IV Labetalol** is the recommended first-line agent for the acute management of **severe hypertension** in pregnancy (BP \u2265 160/110 mmHg) because it acts rapidly and is safely titratable to reduce the risk of maternal stroke.- It provides effective blood pressure control while minimizing risks to the fetus and typically avoiding severe **maternal hypotension**, which could compromise placental perfusion.*Sublingual nifedipine*- **Sublingual preparations** of nifedipine are generally avoided in acute severe hypertension due to the risk of a **precipitous drop in blood pressure**.- This rapid drop can lead to uteroplacental hypoperfusion and **fetal distress**, making it unsuitable for initial stabilization of severe preeclampsia.*Oral methyldopa*- Methyldopa is a highly safe agent used predominantly for the **chronic management** of mild to moderate hypertension in pregnancy.- It has a **slow onset of action** (several hours) and is therefore ineffective for treating the acute hypertensive crisis presented here (BP 170/110 mmHg).*IV hydralazine*- IV hydralazine is an effective **vasodilator** and a traditional second-line agent for severe hypertension in pregnancy, often used if labetalol is contraindicated.- Compared to labetalol, it can cause more frequent side effects, including **maternal tachycardia** and severe headaches, making labetalol the preferred first choice.*Oral amlodipine*- Amlodipine is an oral **calcium channel blocker** typically used for maintenance therapy of chronic hypertension.- Its **onset of action is too slow** to address the immediate danger posed by severe-range blood pressure, which requires immediate, titratable IV therapy.

Question 35: A 30-year-old woman at 32 weeks gestation presents with sudden onset severe abdominal pain and vaginal bleeding. Her uterus is tender and tense on examination. Fetal heart rate shows late decelerations. What is the most likely diagnosis?

A. Placental abruption (Correct Answer)
B. Placenta previa
C. Uterine rupture
D. Preterm labor
E. Cervical laceration

Explanation: ***Placental abruption*** - The clinical triad of **sudden, severe abdominal pain**, **vaginal bleeding**, and a **tender, tense (hypertonic) uterus** strongly indicates placental abruption (premature separation of the placenta). - **Late decelerations** are signs of fetal distress due to compromised uteroplacental circulation, common with moderate to severe abruptions. *Placenta previa* - This condition involves the placenta covering the cervical os and typically presents with **painless vaginal bleeding**. - The uterus is usually **soft** and non-tender, unlike the tense, tender uterus seen in this patient. *Uterine rupture* - While presenting with sudden severe pain and fetal distress, rupture typically leads to a **loss of uterine tone** and recession of the presenting fetal part (palpable fetal parts). - This diagnosis is more common in women with previous **cesarean deliveries** or significant uterine trauma/surgery. *Preterm labor* - Preterm labor is characterized by rhythmic, painful **uterine contractions** and progressive cervical change. - While contractions cause pain, the pain is usually intermittent, and it is usually not associated with a **persistently tense and globally tender uterus** or significant bleeding. *Cervical laceration* - Cervical lacerations usually cause bleeding following trauma (e.g., sexual intercourse or vaginal examination). - This diagnosis does not account for the **severe abdominal pain**, **uterine hypertonicity**, or the severe degree of **fetal distress** (late decelerations).

Question 36: A 32-year-old pregnant woman at 36 weeks gestation presents with severe headache, visual disturbances, and epigastric pain. Her BP is 165/110 mmHg. Urine protein is 3+. What is the most likely diagnosis?

A. Gestational hypertension
B. Chronic hypertension
C. Pre-eclampsia (Correct Answer)
D. Eclampsia
E. HELLP syndrome

Explanation: ***Pre-eclampsia*** - The combination of **new-onset hypertension** (BP > 140/90 mmHg) and **proteinuria** (3+) developing after 20 weeks of gestation defines pre-eclampsia. - Severe features, including **BP 165/110 mmHg**, **severe headache**, **visual disturbances**, and **epigastric pain** (indicative of liver capsule distension), confirm the diagnosis of pre-eclampsia with severe features. *Gestational hypertension* - This diagnosis applies only if a patient develops hypertension after 20 weeks without any accompanying **proteinuria** or signs of **end-organ dysfunction**. - The presence of 3+ proteinuria and severe symptoms (headache, visual changes) explicitly excludes the diagnosis of simple **gestational hypertension**. *Chronic hypertension* - Chronic hypertension is defined as hypertension present before pregnancy or diagnosed before **20 weeks of gestation**. - This diagnosis is unlikely as the patient is 36 weeks pregnant, and the presentation of new severe features with proteinuria points toward a pregnancy-specific disorder. *Eclampsia* - Eclampsia is diagnosed when **tonic-clonic seizures** occur in a woman with pre-eclampsia. - While the patient has severe pre-eclampsia, the absence of reported **convulsions** means she currently does not meet the diagnostic criteria for eclampsia. *HELLP syndrome* - HELLP is a specific complication of pre-eclampsia defined by **Hemolysis**, **Elevated Liver enzymes**, and **Low Platelets**. - While the patient's severe symptoms (epigastric pain) suggest she may be developing HELLP, pre-eclampsia is the overall, most encompassing diagnosis based on the initial presentation of hypertension and proteinuria.

Question 37: A 39-year-old woman at 32 weeks gestation presents with severe headache, blurred vision, and RUQ pain. BP is 165/105 mmHg. Blood tests show AST 150 U/L, platelets 80,000/μL. What is the most appropriate management?

A. Antihypertensive therapy
B. Magnesium sulfate
C. Immediate delivery (Correct Answer)
D. Corticosteroids
E. Plasma exchange

Explanation: ***Immediate delivery*** - The clinical presentation of severe headache, blurred vision, RUQ pain, **hypertension (165/105 mmHg)**, **elevated AST (150 U/L)**, and **thrombocytopenia (80,000/μL)** defines **HELLP syndrome**, a life-threatening obstetric emergency. - At 32 weeks gestation, with signs of severe preeclampsia and HELLP syndrome, **immediate delivery** is the definitive treatment to prevent further maternal and fetal morbidity and mortality, as it removes the underlying placental cause. *Antihypertensive therapy* - **Antihypertensive therapy** is crucial for managing severe hypertension (BP 165/105 mmHg) to prevent **maternal complications** like stroke. - While essential for **maternal stabilization** prior to delivery, it addresses only a symptom and does not resolve the underlying pathology of HELLP syndrome. *Magnesium sulfate* - **Magnesium sulfate** is indicated for **seizure prophylaxis** in patients with severe preeclampsia or HELLP syndrome to prevent **eclampsia**. - It is a vital component of maternal management but serves as an adjunct and does not treat the HELLP syndrome itself, which requires delivery. *Corticosteroids* - **Antenatal corticosteroids** (e.g., betamethasone) are typically given to promote **fetal lung maturity** when delivery is anticipated before 34 weeks gestation. - In rapidly progressive or severe HELLP syndrome, the risks of delaying delivery to complete a full course of corticosteroids often outweigh the benefits, making immediate delivery paramount. *Plasma exchange* - **Plasma exchange** is primarily indicated for other microangiopathic hemolytic anemias such as **Thrombotic Thrombocytopenic Purpura (TTP)** or atypical Hemolytic Uremic Syndrome (aHUS). - While HELLP syndrome involves microangiopathic hemolysis, its resolution is achieved by **delivery of the placenta**, and plasma exchange is not typically a standard treatment.

Question 38: A 32-year-old pregnant woman at 36 weeks presents with sudden severe abdominal pain and cessation of fetal movements. Previous pregnancy was delivered by cesarean section. Fetal heart rate is absent and uterine contour is abnormal. What is the most likely diagnosis?

A. Placental abruption
B. Uterine rupture (Correct Answer)
C. Cord prolapse
D. Fetal death
E. Preterm labor

Explanation: ***Uterine rupture***- The combination of **sudden, severe tearing abdominal pain**, **absent Fetal Heart Rate (FHR)**, and **abnormal uterine contour** (often indicating extrusion of fetus/parts) is the classic presentation of uterine rupture.- A **previous Cesarean section** scar is the most significant risk factor for rupture in subsequent pregnancies, making this the most likely catastrophic diagnosis.*Placental abruption*- Although characterized by sudden pain and potential fetal demise, abruption typically presents with **vaginal bleeding** and a **firm, tender (woody) uterus**, without the loss of normal uterine contour.- The underlying issue is premature placental separation, which causes hemorrhage, not the structural disruption of the uterine wall suggested by the abnormal contour.*Cord prolapse*- This emergency is primarily characterized by sudden **fetal distress** or death following membrane rupture, where the cord descends ahead of the presenting part.- It rarely causes severe maternal abdominal pain, and the uterine contour remains normal.*Fetal death*- While the FHR is absent, indicating fetal demise, this is the *result* of a catastrophic event, not the event causing the acute severe maternal pain and **abnormal uterine contour**.- Uncomplicated fetal death typically presents with cessation of movements over hours or days, without sudden, acute maternal pain.*Preterm labor*- Labor involves regular, rhythmic uterine contractions resulting in cervical change, which causes pain that builds up, not a single, sudden, catastrophic pain event.- In uncomplicated preterm labor, the **FHR would still be audible**, and the **uterine contour would be normal**.

Question 39: A 34-year-old woman at 20 weeks gestation presents with fever, flank pain, and dysuria. Urine culture grows E. coli sensitive to amoxicillin. What is the most appropriate treatment?

A. Trimethoprim
B. Nitrofurantoin
C. Amoxicillin (Correct Answer)
D. Ciprofloxacin
E. Co-amoxiclav

Explanation: ***Amoxicillin***- This is an appropriate choice as it is a **Category B** drug, confirming it is safe for use throughout all trimesters of pregnancy, and the *E. coli* strain is specifically reported as **sensitive** to it.- Pyelonephritis in pregnancy requires treatment with safe, effective agents; **Amoxicillin** (or other beta-lactams like cephalosporins) meets both criteria.*Trimethoprim*- **Trimethoprim** is a **folate antagonist** and is generally avoided during the first trimester due to the risk of fetal **neural tube defects**.- Though the patient is in the second trimester, it is typically reserved only if safer alternatives like penicillins or cephalosporins cannot be used, prioritizing safety.*Nitrofurantoin*- **Nitrofurantoin** is generally effective only for lower UTIs (**cystitis**) because it does not achieve high concentrations in renal tissue, making it inappropriate for treating **pyelonephritis**.- While safe during the second trimester, it is avoided close to term (after 36 weeks) due to the risk of neonatal **hemolytic anemia**.*Ciprofloxacin*- **Ciprofloxacin** belongs to the class of **fluoroquinolones**, which are contraindicated throughout pregnancy.- These drugs are associated with potential risk of fetal **arthropathy** or damage to developing fetal cartilage.*Co-amoxiclav*- While safe in pregnancy (**Category B**), using the combination drug **Co-amoxiclav** is unnecessary when the organism is specifically sensitive to **Amoxicillin** alone.- Using the combination formulation increases the cost and risk of adverse effects, such as **diarrhea** or **hepatic dysfunction**, without providing additional clinical benefit here.

Question 40: A 44-year-old woman presents with recurrent miscarriages and a history of DVT. Blood tests show prolonged APTT, positive lupus anticoagulant, and anticardiolipin antibodies. What is the most appropriate treatment for future pregnancies?

A. Aspirin alone
B. Warfarin
C. Aspirin plus low molecular weight heparin (Correct Answer)
D. Prednisolone
E. Immunoglobulin

Explanation: ***Aspirin plus low molecular weight heparin*** - This combination is the standard of care for pregnant women with **Antiphospholipid Syndrome (APS)**, particularly those with a history of both thrombotic events (DVT) and recurrent miscarriages. - **Aspirin** helps prevent placental microthrombi, while **low molecular weight heparin (LMWH)** provides systemic anticoagulation to prevent DVT and improve live birth rates. *Aspirin alone* - While aspirin is a component of the treatment, **aspirin alone** is generally insufficient for women with a history of both DVT and recurrent miscarriages due to APS. - It does not adequately address the increased risk of **macrothrombosis** (like DVT) associated with APS in pregnancy. *Warfarin* - **Warfarin** is a **teratogen** and is contraindicated during most of pregnancy (especially the first trimester and near term) due to the risk of fetal warfarin syndrome and bleeding complications. - Although an effective anticoagulant, its risks far outweigh benefits for pregnancy management of APS compared to heparin. *Prednisolone* - **Prednisolone** (a corticosteroid) is not a primary treatment for preventing thrombosis or improving pregnancy outcomes in Antiphospholipid Syndrome. - It does not directly address the underlying **prothrombotic state** that leads to DVT and miscarriages in APS. *Immunoglobulin* - **Intravenous immunoglobulin (IVIG)** is not a standard or evidence-based treatment for preventing thrombosis or recurrent miscarriage in women with Antiphospholipid Syndrome. - Its use is generally limited to specific, refractory autoimmune conditions and is not indicated as a first-line therapy for APS in pregnancy.

Question 41: A 31-year-old woman at 28 weeks gestation presents with severe hypertension (BP 180/120 mmHg), proteinuria, and visual disturbances. Fetal monitoring shows signs of compromise. What is the most appropriate management?

A. Antihypertensive therapy and continue pregnancy
B. Magnesium sulfate and monitor
C. Immediate cesarean delivery (Correct Answer)
D. Corticosteroids for fetal lung maturity
E. Induction of labor

Explanation: ***Immediate cesarean delivery***- This patient exhibits signs of **severe preeclampsia** (BP 180/120 mmHg, proteinuria, visual disturbances) with superimposed **fetal compromise** at 28 weeks gestation, necessitating urgent intervention.- **Delivery** is the definitive treatment for preeclampsia, and given the severity and fetal distress, **immediate cesarean section** is required for rapid resolution and to safeguard both maternal and fetal well-being, as induction of labor would be too slow.*Antihypertensive therapy and continue pregnancy*- While **antihypertensive therapy** is crucial for managing severe hypertension and preventing maternal complications like stroke, it does not address the underlying pathology of **preeclampsia**.- Continuing pregnancy is contraindicated due to the features of **severe preeclampsia** and the presence of **fetal compromise**, which necessitate urgent delivery.*Magnesium sulfate and monitor*- **Magnesium sulfate (MgSO4)** is essential for the **prevention and treatment of eclamptic seizures**, but it is an adjunct to, not a replacement for, delivery in severe preeclampsia.- Monitoring alone is insufficient and unsafe in a patient with severe preeclampsia and **fetal distress**, as the condition will continue to worsen without delivery.*Corticosteroids for fetal lung maturity*- **Corticosteroids** (e.g., betamethasone) are given between 24 and 34 weeks gestation to accelerate **fetal lung maturity**, which is generally indicated when preterm birth is anticipated.- However, in cases of **severe preeclampsia** with acute fetal compromise requiring immediate delivery, delaying delivery for corticosteroid administration (which typically takes 24-48 hours to be effective) is not feasible or safe.*Induction of labor*- Delivery is the correct course of action, but **induction of labor** in a preterm fetus (28 weeks) with a potentially unripe cervix can be a prolonged process.- Given the **severe maternal condition** and **fetal compromise**, a prolonged induction carries increased risks and is less appropriate than the more rapid **cesarean delivery**.

Question 42: A 35-year-old woman presents with fatigue, weight gain, and depression 8 months postpartum. TSH is 12 mU/L, free T4 is low. She is breastfeeding. What is the most appropriate treatment?

A. No treatment until breastfeeding stops
B. Levothyroxine 25 µg daily
C. Levothyroxine 50 µg daily (Correct Answer)
D. Liothyronine
E. Combined T3/T4 therapy

Explanation: ***Levothyroxine 50 µg daily***- This is the standard initial replacement dose for a typically weight non-elderly adult with overt primary **hypothyroidism** (TSH >10 mU/L, low free T4).- **Levothyroxine (L-T4)** is the appropriate treatment as it is safe and compatible with **breastfeeding**; only small amounts enter the breast milk without adverse effects on the infant.*No treatment until breastfeeding stops*- Untreated overt hypothyroidism can severely affect the mother's mood, energy levels (**fatigue**, **depression**), and overall quality of life.- Treatment with **levothyroxine** is necessary and should not be delayed, as it is safe for the nursing infant and essential for maternal well-being.*Levothyroxine 25 µg daily*- This low dose is usually initiated only in elderly patients or those with pre-existing **cardiac comorbidities** to avoid potential exacerbations.- For overt hypothyroidism with a TSH of 12 mU/L, 25 µg is usually insufficient to promptly normalize TSH and adequately relieve symptoms.*Liothyronine*- **Liothyronine (T3)** has a very short half-life, leading to large fluctuations in serum levels and increasing the risk of **cardiac side effects** (e.g., palpitations, atrial fibrillation).- Monotherapy with T3 is not recommended because T4 replacement provides physiologic, stable peripheral conversion to T3.*Combined T3/T4 therapy*- Combined therapy is not standard first-line treatment and generally does not demonstrate superior outcomes compared to **levothyroxine** monotherapy.- L-T4 monotherapy is preferred because its long half-life allows for once-daily dosing and provides stable hormone levels.

Question 43: A 47-year-old woman presents with fatigue, joint pain, and photosensitive rash. Blood tests show positive ANA, anti-Sm antibodies, and low complement levels. She is planning pregnancy. What is the most concerning antibody for fetal complications?

A. Anti-Sm
B. Anti-dsDNA
C. Anti-Ro/SSA (Correct Answer)
D. Anti-RNP
E. Anti-Scl-70

Explanation: ***Anti-Ro/SSA*** - The presence of **Anti-Ro/SSA** antibodies (and Anti-La/SSB) is highly concerning during pregnancy because they can cross the **placenta** and cause **neonatal lupus syndrome**. - The most severe manifestation of neonatal lupus is **congenital heart block**, which requires permanent pacing and carries a risk of mortality. *Anti-Sm* - Anti-Sm antibodies are highly specific for **Systemic Lupus Erythematosus (SLE)** and, along with anti-dsDNA, indicate active disease. - However, they are not directly associated with specific fetal complications, such as **congenital heart block**, that Anti-Ro/SSA causes. *Anti-dsDNA* - High titers of **Anti-dsDNA** strongly correlate with severe maternal disease activity, particularly **lupus nephritis**. - While overall high maternal disease activity increases risks like preeclampsia and fetal loss, **anti-dsDNA** does not specifically cause neonatal lupus syndrome or heart block. *Anti-RNP* - Anti-RNP antibodies are characteristic of **Mixed Connective Tissue Disease (MCTD)**, but can also be found in SLE. - They are associated with risks like **fetal growth restriction** and maternal pulmonary complications, but not with **congenital heart block**. *Anti-Scl-70* - Anti-Scl-70 (topoisomerase I) is a marker primarily associated with the **diffuse cutaneous form of systemic sclerosis** (scleroderma). - These antibodies are not implicated in causing specific neonatal lupus complications like **congenital heart block** in the way Anti-Ro/SSA is.

Question 44: A 28-year-old woman at 32 weeks gestation presents with sudden onset shortness of breath and chest pain. D-dimer is elevated. CTPA shows bilateral pulmonary emboli. What is the most appropriate anticoagulant?

A. Warfarin
B. Dabigatran
C. Rivaroxaban
D. Low molecular weight heparin (Correct Answer)
E. Unfractionated heparin

Explanation: ***Low molecular weight heparin*** - **Low molecular weight heparin (LMWH)** is the preferred anticoagulant for treating acute venous thromboembolism (VTE) throughout all trimesters of pregnancy due to its established safety profile. - It is a large molecule that **does not cross the placenta**, ensuring minimal fetal exposure and preventing the risks associated with teratogenicity. *Warfarin* - Warfarin is a known **teratogen**, particularly during the first trimester (6th-12th week), causing **fetal warfarin syndrome** (e.g., chondrodysplasia punctata). - Although less risky in the third trimester, it carries a significant risk of **fetal intracranial hemorrhage** near delivery, necessitating a switch to heparin near term. *Dabigatran* - Dabigatran is a Direct Oral Anticoagulant (DOAC) that functions as a **direct thrombin inhibitor**. - DOACs are generally **contraindicated** during pregnancy due to the lack of sufficient human safety data and the potential for crossing the placenta and harming the fetus. *Rivaroxaban* - Rivaroxaban is a DOAC that functions as a **Factor Xa inhibitor**. - Similar to other DOACs, it is not recommended for use in pregnancy due to insufficient data regarding fetal safety and efficacy in this specific population. *Unfractionated heparin* - **Unfractionated heparin (UFH)** is safe in pregnancy as it does not cross the placenta, but it is typically reserved for patients with severe renal impairment or those in whom rapid reversal may be necessary. - LMWH is generally preferred over UFH because it requires **less frequent dosing**, has a more predictable response, and is associated with a lower risk of **heparin-induced thrombocytopenia (HIT)** and **osteoporosis**.

Question 45: A 29-year-old woman at 20 weeks gestation presents with fever, dysuria, and right loin pain. Urine culture grows E. coli resistant to amoxicillin but sensitive to cephalexin. What is the most appropriate treatment?

A. Amoxicillin
B. Cephalexin (Correct Answer)
C. Trimethoprim
D. Ciprofloxacin
E. Nitrofurantoin

Explanation: ***Cephalexin***- This **first-generation cephalosporin** is Pregnancy **Category B**, confirming its safety profile for use in the second trimester (20 weeks gestation).- The culture report explicitly indicates that the causative organism, *E. coli*, is **sensitive** to cephalexin, ensuring appropriate and targeted antibiotic coverage for the confirmed clinical diagnosis of acute pyelonephritis.*Amoxicillin*- The urine culture results clearly demonstrate that the *E. coli* isolate is **resistant** to amoxicillin, making this agent ineffective for treating the current infection.- Using a resistant antibiotic would result in **clinical failure**, allowing the **pyelonephritis** to progress and potentially harming both mother and fetus.*Trimethoprim*- Trimethoprim is a **folate antagonist** and is generally avoided throughout pregnancy, particularly in the first trimester, due to risks of **neural tube defects**.- Furthermore, current guidelines often favor cephalosporins or penicillins over trimethoprim for treating upper UTIs in pregnant women.*Ciprofloxacin*- **Fluoroquinolones** like ciprofloxacin are generally **contraindicated** in pregnancy (Category C/D) due to concerns regarding potential **fetal cartilage toxicity** and arthropathy.- Due to its safety profile, it should only be considered if no other effective and safer alternatives are available, which is not the case here.*Nitrofurantoin*- Nitrofurantoin is highly effective for lower UTIs (**cystitis**) but reaches inadequate therapeutic levels in the renal parenchyma, making it **ineffective** for treating **pyelonephritis** (upper UTI).- While safe in the second trimester, its poor tissue penetration excludes it as a primary treatment for upper urinary tract infections.

Question 46: A 39-year-old pregnant woman at 34 weeks gestation presents with severe headache, visual disturbances, and RUQ pain. BP is 170/110 mmHg. Blood tests show AST 180 U/L and platelets 75,000/μL. What is the most likely diagnosis?

A. Pre-eclampsia
B. HELLP syndrome (Correct Answer)
C. Acute fatty liver of pregnancy
D. Viral hepatitis
E. Cholestasis of pregnancy

Explanation: ***HELLP syndrome*** - The patient's presentation with severe headache, visual disturbances, RUQ pain, **hypertension (BP 170/110 mmHg)**, **elevated liver enzymes (AST 180 U/L)**, and **thrombocytopenia (platelets 75,000/μL)** are the classic diagnostic features of **HELLP syndrome**. - **HELLP syndrome** is a severe variant of pre-eclampsia, characterized by **Hemolysis**, **Elevated Liver enzymes**, and **Low Platelets**, typically manifesting in the third trimester. *Pre-eclampsia* - While the patient exhibits **hypertension** and symptoms like headache and visual disturbances consistent with pre-eclampsia, the degree of **elevated liver enzymes** and **severe thrombocytopenia** are more indicative of the HELLP variant. - Pre-eclampsia is defined by new-onset hypertension and proteinuria or signs of end-organ damage; however, the specific laboratory abnormalities here point to a more severe, distinct syndrome. *Acute fatty liver of pregnancy* - This condition presents with some overlapping symptoms like RUQ pain and elevated liver enzymes, but it typically involves more severe **liver failure**, often with **hypoglycemia**, **coagulopathy**, and **jaundice**, which are not prominently mentioned here. - Thrombocytopenia can occur but is usually less severe than in HELLP, and significant hypertension is not a primary diagnostic criterion for acute fatty liver of pregnancy. *Viral hepatitis* - **Viral hepatitis** would cause elevated liver enzymes and potentially RUQ pain, but it is less commonly associated with **severe hypertension** and **marked thrombocytopenia** as primary features in pregnancy-related presentations. - Diagnosis requires specific viral serology, and the overall clinical picture, especially the severe hypertension and thrombocytopenia, points away from viral hepatitis as the primary diagnosis. *Cholestasis of pregnancy* - This condition is primarily characterized by **severe generalized pruritus** (itching), often worse on the palms and soles, with elevated **bile acids**, and typically without a rash. - It does not typically present with **hypertension**, **headache**, **visual disturbances**, or significant **thrombocytopenia**, making it an unlikely diagnosis in this scenario.

Question 47: A 39-year-old woman at 32 weeks gestation presents with severe hypertension (BP 180/120 mmHg), proteinuria, and visual disturbances. Fetal monitoring shows signs of compromise. What is the most appropriate management?

A. Antihypertensive therapy and continue pregnancy
B. Magnesium sulfate and monitor
C. Immediate cesarean delivery (Correct Answer)
D. Corticosteroids for fetal lung maturity
E. Induction of labor

Explanation: ***Immediate cesarean delivery*** - This patient presents with **severe preeclampsia** (BP 180/120 mmHg, proteinuria, visual disturbances) and crucial signs of **fetal compromise** at 32 weeks gestation. Immediate delivery is the definitive treatment for severe preeclampsia, especially with maternal or fetal jeopardy. - Given the urgency due to **severe maternal hypertension** and **fetal compromise**, **cesarean delivery** is the quickest and safest method to deliver the baby, resolve the preeclampsia, and mitigate further risks to both mother and fetus. *Antihypertensive therapy and continue pregnancy* - Continuing the pregnancy is contraindicated due to the presence of **severe preeclampsia** with significant maternal symptoms and evidence of **fetal compromise**, which demand immediate intervention. - While **antihypertensive therapy** is necessary to manage blood pressure acutely, it only treats symptoms and does not address the underlying pathology or the immediate threat that necessitates delivery. *Magnesium sulfate and monitor* - **Magnesium sulfate** is essential for **seizure prophylaxis** in severe preeclampsia, but it is not the definitive treatment for the underlying condition or a substitute for delivery. - Merely monitoring the patient without immediate delivery in the face of **severe preeclampsia** and **fetal compromise** places both the mother (risk of **eclampsia**, stroke) and the fetus (risk of **stillbirth**) at unacceptable risk. *Corticosteroids for fetal lung maturity* - **Corticosteroids** (e.g., **betamethasone**) are administered to promote **fetal lung maturity** and reduce neonatal respiratory distress syndrome, typically between 24 and 34 weeks of gestation. - However, corticosteroids require 24-48 hours for optimal effect. In cases of **severe maternal or fetal jeopardy** demanding immediate delivery, waiting for steroid completion is not feasible. *Induction of labor* - **Induction of labor** may be considered in some preeclampsia cases, but it can be a prolonged process and its success depends on cervical favorability. - With severe features and **fetal compromise** requiring rapid resolution of the pregnancy, a **cesarean section** is generally preferred over induction to ensure a quicker and safer delivery.

Question 48: A 29-year-old woman at 20 weeks gestation presents with fever, flank pain, and dysuria. Urine culture grows E. coli resistant to amoxicillin but sensitive to cephalexin. What is the most appropriate treatment?

A. Amoxicillin
B. Cephalexin (Correct Answer)
C. Setraline

Explanation: ***Cephalexin*** - **Cephalexin**, a first-generation cephalosporin (Pregnancy Category B), is a suitable and safe choice for treating **pyelonephritis** in pregnant patients. - The urine culture confirms that the *E. coli* strain is **sensitive** to cephalexin, ensuring effective eradication of the infection. *Amoxicillin* - This antibiotic is inappropriate because the urine culture explicitly shows the *E. coli* causing the infection is **resistant** to **amoxicillin**. - Administering a resistant antibiotic would lead to treatment failure and potential worsening of the maternal and fetal condition, especially with pyelonephritis. *Setraline* - **Setraline (Sertraline)** is a selective serotonin reuptake inhibitor (SSRI), used for psychiatric conditions like depression or anxiety. - It has no therapeutic role in treating a bacterial infection such as **pyelonephritis**, which requires specific **antibiotic therapy**.

Question 49: A 36-year-old woman presents with fatigue, joint pain, and photosensitive rash. Blood tests show positive ANA, anti-Sm antibodies, and low complement levels. She is planning pregnancy. What is the most concerning antibody for fetal complications?

A. Anti-Sm
B. Anti-dsDNA
C. Anti-Ro/SSA (Correct Answer)
D. Anti-RNP
E. Anti-Scl-70

Explanation: ***Anti-Ro/SSA***- This antibody is the primary risk factor for **Neonatal Lupus Erythematosus (NLE)**, which includes severe complications like potentially fatal **congenital heart block (CHB)** and transient cutaneous lupus.- Because it crosses the placenta, Anti-Ro/SSA targets fetal cardiac conduction tissue, potentially leading to irreversible **third-degree AV block** typically diagnosed between 18 and 24 weeks of gestation.*Anti-Sm*- **Anti-Smith (Anti-Sm)** antibodies are highly specific for the diagnosis of **Systemic Lupus Erythematosus (SLE)**, but are not independently associated with a high direct risk of **congenital heart block** or the NLE syndrome.- The presence of Anti-Sm indicates established SLE, increasing the overall risk of maternal flares during pregnancy, but it is not the main concern for direct fetal morbidity.*Anti-dsDNA*- High titers of **Anti-dsDNA** strongly correlate with the severity of maternal SLE, particularly **lupus nephritis**, and often herald disease flares, which can worsen pregnancy outcomes.- Increased disease activity due to high Anti-dsDNA heightens the risks of complications like **preeclampsia**, intrauterine growth restriction (IUGR), and fetal loss secondary to placental damage, but the antibody itself does not cause **CHB**.*Anti-RNP*- **Anti-RNP** antibodies are characteristically associated with **Mixed Connective Tissue Disease (MCTD)**, or less often overlap syndromes and SLE, but their primary risk to the fetus is lower than Anti-Ro/SSA.- Although MCTD pregnancies may carry risks like pulmonary hypertension, Anti-RNP is not a primary pathogenic factor for **Neonatal Lupus Erythematosus** or **congenital heart block**.*Anti-Scl-70*- **Anti-Scl-70 (Topoisomerase I)** is the definitive marker for the **diffuse cutaneous form of Systemic Sclerosis (Scleroderma)**, which is a different disease process from the patient’s SLE presentation (indicated by anti-Sm).- This antibody is generally associated with serious maternal complications like **interstitial lung disease** and **scleroderma renal crisis**, but not fetal complications like congenital heart block.

Question 50: A 35-year-old woman at 34 weeks gestation presents with severe headache, blurred vision, and RUQ pain. BP is 165/105 mmHg. Blood tests show AST 150 U/L, platelets 80,000/μL. What is the most appropriate management?

A. Antihypertensive therapy
B. Magnesium sulfate
C. Immediate delivery (Correct Answer)
D. Corticosteroids
E. Plasma exchange

Explanation: ***Immediate delivery*** - The patient presents with **severe preeclampsia** complicated by **HELLP syndrome** (hemolysis, elevated liver enzymes, low platelets) at 34 weeks gestation. - **Immediate delivery** is the definitive management for HELLP syndrome and severe preeclampsia, especially at or beyond 34 weeks, as it resolves the underlying placental pathology. *Antihypertensive therapy* - While essential for **maternal blood pressure control** (e.g., Labetalol, Hydralazine) to prevent complications like stroke, it is an adjunctive treatment, not the definitive cure for HELLP syndrome. - It manages a symptom but does not address the progressive organ damage or the underlying pathology requiring termination of pregnancy. *Magnesium sulfate* - **Magnesium sulfate** is crucial for **seizure prophylaxis** in patients with severe preeclampsia or HELLP syndrome, preventing eclampsia. - However, it does not treat the underlying liver dysfunction or thrombocytopenia characteristic of HELLP syndrome; delivery remains the curative intervention. *Corticosteroids* - **Antenatal corticosteroids** (e.g., Betamethasone, Dexamethasone) are primarily administered to accelerate **fetal lung maturity** when delivery is anticipated before 34 weeks gestation. - While they can improve platelet counts in HELLP syndrome, at 34 weeks with severe disease, the urgency of delivery typically outweighs the benefit of delaying for full corticosteroid effect, making immediate delivery the priority. *Plasma exchange* - **Plasma exchange** is primarily indicated for other thrombotic microangiopathies such as **Thrombotic Thrombocytopenic Purpura (TTP)** or severe atypical Hemolytic Uremic Syndrome (aHUS). - It is not the standard treatment for HELLP syndrome, where delivery is the primary intervention.

Question 51: A 44-year-old woman presents with recurrent miscarriages and a history of DVT. Blood tests show prolonged APTT, positive lupus anticoagulant, and anticardiolipin antibodies. What is the most appropriate treatment for future pregnancies?

A. Aspirin alone
B. Warfarin
C. Aspirin plus low molecular weight heparin (Correct Answer)
D. Prednisolone
E. Immunoglobulin

Explanation: ***Aspirin plus low molecular weight heparin*** - This combination is the standard of care for obstetric **Antiphospholipid Syndrome** (APS), preventing both **fetal loss** and **maternal venous thromboembolism** (VTE) associated with the condition. - **Aspirin** reduces platelet aggregation, while **LMWH** provides anticoagulation, together mitigating the prothrombotic state and improving live birth rates.*Aspirin alone* - While low-dose aspirin is part of the regimen, **monotherapy** is insufficient for patients with definite APS and prior thrombosis (DVT) to prevent severe pregnancy complications and recurrent miscarriage. - It primarily provides antiplatelet effects but lacks the robust **anticoagulation** necessary to counteract the increased risk of placental thrombosis caused by the antibodies.*Warfarin* - **Warfarin** is highly **teratogenic** (Category X) and is contraindicated during the first trimester of pregnancy due to the risk of fetal embryopathy. - Although effective for long-term non-pregnant anticoagulation, it must be replaced by **heparin** during pregnancy for safety reasons.*Prednisolone* - **Glucocorticoids** like prednisolone are not shown to improve live birth rates in routine APS and are not the specific treatment for the primary **thrombophilic state**. - Treatment with corticosteroids is typically reserved for co-existing autoimmune disorders, such as a **lupus flare**, rather than isolated APS.*Immunoglobulin* - **Intravenous Immunoglobulin (IVIG)** is an expensive therapy reserved only for refractory cases of APS or those with other complex autoimmune co-morbidities. - IVIG has little evidence to support its use as first-line therapy compared to the established combination of **aspirin and heparin** for improving outcomes in obstetric APS.

Question 52: A 38-year-old woman presents with fatigue, weight gain, and depression 6 months postpartum. TSH is 8 mU/L, free T4 is low. She is breastfeeding. What is the most appropriate treatment?

A. No treatment until breastfeeding stops
B. Levothyroxine 25 µg daily
C. Levothyroxine 50 µg daily (Correct Answer)
D. Liothyronine
E. Combined T4/T3 therapy

Explanation: ***Levothyroxine 50 µg daily***- This patient presents with **overt hypothyroidism** (elevated TSH and low free T4) 6 months postpartum, causing significant symptoms like fatigue, weight gain, and depression, which necessitates immediate treatment.- **Levothyroxine** is the standard treatment for hypothyroidism and is considered **safe during breastfeeding** as minimal amounts transfer to breast milk, making it appropriate for the mother and safe for the infant. A starting dose of 50 µg is suitable for symptomatic overt hypothyroidism in a young adult to achieve euthyroidism.*No treatment until breastfeeding stops*- Overt hypothyroidism with significant symptoms requires prompt treatment to alleviate patient suffering and prevent potential complications, regardless of **breastfeeding status**.- **Levothyroxine** is well-established as safe for both the mother and the infant during lactation, therefore, delaying treatment is unnecessary and detrimental to the patient's health.*Levothyroxine 25 µg daily*- While levothyroxine is the correct medication, a dose of **25 µg daily** is typically too low for the initial treatment of symptomatic **overt hypothyroidism** in a young, otherwise healthy adult.- This lower dose is generally reserved for elderly patients, those with cardiac comorbidities, or individuals with **mild subclinical hypothyroidism**.*Liothyronine*- **Liothyronine** (synthetic T3) has a very short half-life, leading to rapid fluctuations in hormone levels and potentially more side effects, especially cardiac ones.- It is generally **not recommended** for routine long-term management of primary hypothyroidism due to these pharmacokinetic challenges and lack of superior outcomes compared to T4 monotherapy.*Combined T4/T3 therapy*- Current evidence does not support the routine use of **combined T4/T3 therapy** as superior to levothyroxine (T4) monotherapy for the majority of patients with primary hypothyroidism.- T4 monotherapy is preferred as the body converts T4 to T3 peripherally, providing stable and physiologic levels of both hormones.

Question 53: A 34-year-old woman at 28 weeks gestation presents with sudden onset shortness of breath and chest pain. D-dimer is elevated. CTPA shows bilateral pulmonary emboli. What is the most appropriate anticoagulant?

A. Warfarin
B. Dabigatran
C. Rivaroxaban
D. Low molecular weight heparin (Correct Answer)
E. Unfractionated heparin

Explanation: ***Low molecular weight heparin***- It is the preferred anticoagulant for the treatment of **venous thromboembolism (VTE)** during pregnancy because its large molecular structure prevents it from crossing the **placenta**, ensuring fetal safety.- LMWH has stable pharmacokinetics, allows for fixed subcutaneous dosing without routine laboratory monitoring, and carries a lower risk of causing **heparin-induced thrombocytopenia (HIT)** compared to unfractionated heparin.*Warfarin*- It is a known **teratogen** that can cross the placenta, leading to **fetal warfarin syndrome** (e.g., nasal hypoplasia) and increased risk of fetal hemorrhage, especially during the first trimester and near delivery.- Because of these significant fetal risks, warfarin is generally contraindicated throughout pregnancy for routine VTE treatment.*Dabigatran*- Dabigatran is a **Direct Oral Anticoagulant (DOAC)**; its use in pregnancy is contraindicated due to a significant lack of robust human data regarding fetal safety and outcomes.- As a small molecule, it is presumed to cross the placenta, posing an unknown but potentially high risk of fetal **hemorrhage** or teratogenicity.*Rivaroxaban*- Rivaroxaban is another **DOAC** that should not be used in pregnancy as it crosses the placenta in animal models, and safety data for the human fetus are absent.- Like other DOACs, the unknown effect on fetal development and the risk of **fetal bleeding** makes it unsafe during any trimester.*Unfractionated heparin*- While UFH is safe for the fetus as it does not cross the placenta, it is less preferred than LMWH for long-term pregnancy management because it requires continuous intravenous infusion or frequent injections and intensive monitoring of **aPTT**.- Long-term use of UFH carries a higher maternal risk of **osteoporosis** and HIT compared to LMWH.

Question 54: A 29-year-old woman at 32 weeks gestation presents with severe headache, visual disturbances, and RUQ pain. BP is 170/110 mmHg. Blood tests show thrombocytopenia and elevated liver enzymes. What is the most likely diagnosis?

A. Pre-eclampsia
B. HELLP syndrome (Correct Answer)
C. Acute fatty liver of pregnancy
D. Viral hepatitis
E. Cholestasis of pregnancy

Explanation: ***HELLP syndrome*** - The combination of **severe headache**, **visual disturbances**, **RUQ pain**, **BP 170/110 mmHg**, **thrombocytopenia**, and **elevated liver enzymes** defines **HELLP syndrome**. - It is a severe form of **pre-eclampsia** characterized by **Hemolysis**, **Elevated Liver enzymes**, and **Low Platelet count**. *Pre-eclampsia* - While pre-eclampsia includes **hypertension** and end-organ damage (like severe headache, visual disturbances, RUQ pain), it does not fully encompass the specific lab findings. - The presence of **thrombocytopenia** and significantly **elevated liver enzymes** points specifically to **HELLP syndrome**, which is a more severe variant. *Acute fatty liver of pregnancy* - This condition is often associated with more profound symptoms such as **jaundice**, **hypoglycemia**, and **disseminated intravascular coagulation (DIC)**, which are not mentioned. - Although liver enzymes are elevated, the specific combination of severe **hypertension** and **thrombocytopenia** is not typical for AFLP, but rather points to **HELLP syndrome**. *Viral hepatitis* - Viral hepatitis usually presents with extremely high **transaminase levels** and often **jaundice**, which are not the primary features here. - It does not typically cause acute-onset **severe hypertension** and **thrombocytopenia** in the context of pregnancy. *Cholestasis of pregnancy* - The primary symptom of cholestasis of pregnancy is severe generalized **pruritus**, especially on the palms and soles, and it's diagnosed by elevated **bile acids**. - It is not associated with **severe hypertension**, **thrombocytopenia**, or the neurological symptoms described in the patient.

Question 55: A 38-year-old woman presents with fatigue, weight gain, and cold intolerance 8 months after childbirth. TSH is 12 mU/L, free T4 is low. Anti-TPO antibodies are positive. What is the most likely diagnosis?

A. Postpartum thyroiditis (Correct Answer)
B. Hashimoto's thyroiditis
C. Postpartum depression
D. Sheehan syndrome
E. Iodine deficiency

Explanation: ***Postpartum thyroiditis***- The timing of presentation, 8 months after childbirth, combined with symptoms of hypothyroidism (fatigue, cold intolerance, weight gain) is highly suggestive of **Postpartum Thyroiditis (PPT)**.- PPT is an autoimmune process, confirmed by the positive **Anti-TPO antibodies**, typically leading to transient hypothyroidism (high **TSH**, low **free T4**) 4 to 12 months after delivery.*Hashimoto's thyroiditis*- While the lab findings (high TSH, low T4, positive Anti-TPO) are characteristic of **Hashimoto's**, this diagnosis implies chronic autoimmune thyroid disease.- Given the acute onset immediately following delivery, PPT is the initial and most specific diagnosis; Hashimoto's is diagnosed if the hypothyroidism persists beyond **12 months postpartum**.*Postpartum depression*- This diagnosis is characterized primarily by mood and behavioral disturbances and may cause related fatigue, but it does not account for the pathological hormonal imbalance (elevated **TSH**, low **free T4**).- This is a psychiatric diagnosis, whereas the patient's symptoms are fully explained by the **overt hormonal deficiency**.*Sheehan syndrome*- Sheehan syndrome is caused by ischemic necrosis of the pituitary gland following severe obstetric hemorrhage, resulting in **central hypothyroidism** (low or normal TSH, low free T4).- The patient's remarkably high TSH level (12 mU/L) indicates **primary hypothyroidism** originating in the thyroid gland, not pituitary failure.*Iodine deficiency*- Iodine deficiency is a cause of primary hypothyroidism, leading to high TSH and low T4, but it is rare in developed nations.- This condition is not an autoimmune process and would therefore not be associated with the presence of **Anti-TPO antibodies**.

Question 56: A 33-year-old woman at 20 weeks gestation presents with fever, dysuria, and right loin pain. Urine culture grows E. coli. What is the most appropriate antibiotic?

A. Trimethoprim
B. Nitrofurantoin
C. Amoxicillin (Correct Answer)
D. Ciprofloxacin
E. Gentamicin

Explanation: ***Amoxicillin*** - **Amoxicillin** is a penicillin (beta-lactam) and is classified as **Pregnancy Category B**, making it one of the safest first-line antibiotics for treating infections, including pyelonephritis, during pregnancy. - As an oral beta-lactam, it is often used as initial **empirical therapy** or for step-down treatment, provided the *E. coli* strain is confirmed to be sensitive. *Trimethoprim* - **Trimethoprim** is generally discouraged in the first trimester due to its **folate antagonism**, which poses a theoretical risk of teratogenicity. - It is also generally avoided in the third trimester due to the risk of **kernicterus** in the neonate by displacing bilirubin from albumin. *Nitrofurantoin* - This agent is primarily used for **cystitis** (lower UTI) or prophylaxis during pregnancy because it does not achieve adequate **therapeutic concentrations** in the renal parenchyma. - Therefore, it is ineffective for treating **pyelonephritis**, which involves infection of the kidney tissue (upper UTI). *Ciprofloxacin* - **Ciprofloxacin** is a fluoroquinolone, generally avoided during pregnancy (Pregnancy Category C/D) due to experimental evidence showing potential damage to developing **fetal cartilage** and joints (arthropathy). - Fluoroquinolones are typically reserved only for severe infections where safer alternatives are unavailable and benefits outweigh significant risks. *Gentamicin* - **Gentamicin** is an aminoglycoside (Pregnancy Category D), associated with risks of **ototoxicity** and **nephrotoxicity** to the fetus. - While it can be used intravenously for severe pyelonephritis, safer alternatives like cephalosporins or Amoxicillin are preferred for initial management or step-down therapy.

Question 57: A 29-year-old pregnant woman at 36 weeks presents with sudden onset severe chest pain and dyspnea. D-dimer is elevated. CT pulmonary angiogram shows multiple bilateral pulmonary emboli. What is the most appropriate treatment?

A. Warfarin
B. Unfractionated heparin
C. Low molecular weight heparin (Correct Answer)
D. Rivaroxaban
E. Thrombolysis

Explanation: ***Low molecular weight heparin***- This is the standard of care for treating **pulmonary embolism** during pregnancy because it does not cross the **placenta**, ensuring fetal safety.- It offers predictable dosing and allows outpatient management without the intense laboratory monitoring required by unfractionated heparin.*Warfarin*- **Warfarin** is a known teratogen and is contraindicated during pregnancy, particularly in the first trimester (leading to **Warfarin embryopathy**).- It also significantly increases the risk of maternal and fetal hemorrhage later in pregnancy as it crosses the placenta.*Unfractionated heparin*- While safe for the fetus, **unfractionated heparin (UFH)** requires constant intravenous infusion or frequent subcutaneous injections and close monitoring of the **aPTT**.- UFH is usually reserved for initial management in hemodynamically unstable patients or those with severe **renal impairment**.*Rivaroxaban*- **Rivaroxaban**, an oral direct Factor Xa inhibitor (DOAC), is contraindicated in pregnancy due to insufficient data regarding its **fetal safety** and potential teratogenicity.- Current guidelines prioritize agents with robust safety data, such as heparins (LMWH or UFH).*Thrombolysis*- **Thrombolysis** (fibrinolytic therapy) is generally reserved only for patients with **massive PE** who present with **hemodynamic instability** or shock.- The patient, though symptomatic, is presumed stable; thrombolysis carries a high risk of major bleeding and is not indicated as initial therapy for stable PE.

Question 58: A 32-year-old pregnant woman at 38 weeks gestation presents with sudden onset severe abdominal pain and cessation of fetal movements. Her previous pregnancy was delivered by cesarean section. On examination, the fetal heart rate is absent and the uterine contour is abnormal. What is the most likely diagnosis?

A. Placental abruption
B. Uterine rupture (Correct Answer)
C. Cord prolapse
D. Fetal death
E. Preterm labor

Explanation: ***Uterine rupture*** - The history of a previous **Cesarean section** is the most significant risk factor, and the classic features include sudden, **severe abdominal pain**, cessation of fetal movements, and signs of fetal demise. - The crucial differentiating finding is the **abnormal uterine contour** (often loss of tone or easily palpable fetal parts), indicating disruption of the **myometrium** and fetal expulsion into the peritoneal cavity.*Placental abruption* - While causing sudden **severe abdominal pain** and fetal compromise, abruption leads to a **firm, board-like uterus** due to internal hemorrhage, not an abnormal contour. - The most classic presenting feature is often painful vaginal bleeding, although concealed abruption is possible, the physical finding of an abnormal contour points away from abruption.*Cord prolapse* - This usually presents as sudden fetal distress (e.g., severe FHR decelerations) or the visualization/palpation of the cord in the vagina, but it is not typically associated with **acute, severe maternal abdominal pain**. - Cord prolapse primarily affects the fetus and does not cause the loss of uterine integrity or the consequent **abnormal uterine contour** seen in rupture.*Fetal death* - Fetal death (absent FHR) is the *result* of the underlying catastrophic event (rupture or severe abruption), not the primary diagnosis that explains the mother's intense **abdominal pain** and the physical exam finding of an abnormal uterine contour. - If fetal death occurred primarily (e.g., due to placental insufficiency), the mother would experience cessation of fetal movements but typically not acute, severe pain or change in **uterine shape**.*Preterm labor* - The patient is 38 weeks gestation, making the term **preterm labor** inappropriate, and while labor can be painful, the pain is expected to be intermittent (contractions). - Labor does not cause the catastrophic finding of the **absent fetal heart rate** and an **abnormal uterine contour**, which signifies a structural catastrophe.

Question 59: A 32-year-old pregnant woman at 38 weeks gestation presents with sudden onset severe abdominal pain and cessation of fetal movements. Her previous pregnancy was delivered by cesarean section. On examination, the fetal heart rate is absent and the uterine contour is abnormal. What is the most likely diagnosis?

A. Placental abruption
B. Uterine rupture (Correct Answer)
C. Cord prolapse
D. Fetal death
E. Preterm labor

Explanation: ***Uterine rupture*** - The history of a previous **Cesarean section** is the most significant risk factor, and the classic features include sudden, **severe abdominal pain**, cessation of fetal movements, and signs of fetal demise. - The crucial differentiating finding is the **abnormal uterine contour** (often loss of tone or easily palpable fetal parts), indicating disruption of the **myometrium** and fetal expulsion into the peritoneal cavity.*Placental abruption* - While causing sudden **severe abdominal pain** and fetal compromise, abruption leads to a **firm, board-like uterus** due to internal hemorrhage, not an abnormal contour. - The most classic presenting feature is often painful vaginal bleeding, although concealed abruption is possible, the physical finding of an abnormal contour points away from abruption.*Cord prolapse* - This usually presents as sudden fetal distress (e.g., severe FHR decelerations) or the visualization/palpation of the cord in the vagina, but it is not typically associated with **acute, severe maternal abdominal pain**. - Cord prolapse primarily affects the fetus and does not cause the loss of uterine integrity or the consequent **abnormal uterine contour** seen in rupture.*Fetal death* - Fetal death (absent FHR) is the *result* of the underlying catastrophic event (rupture or severe abruption), not the primary diagnosis that explains the mother's intense **abdominal pain** and the physical exam finding of an abnormal uterine contour. - If fetal death occurred primarily (e.g., due to placental insufficiency), the mother would experience cessation of fetal movements but typically not acute, severe pain or change in **uterine shape**.*Preterm labor* - The patient is 38 weeks gestation, making the term **preterm labor** inappropriate, and while labor can be painful, the pain is expected to be intermittent (contractions). - Labor does not cause the catastrophic finding of an **absent fetal heart rate** and an **abnormal uterine contour**, which signifies a structural catastrophe.

Question 60: A 39-year-old woman with gestational diabetes on metformin and insulin is reviewed at 36 weeks gestation. Her glycaemic control has been excellent throughout. She has had serial growth scans which show estimated fetal weight consistently on the 75th centile. Today's scan shows the estimated fetal weight is 3.6 kg (75th centile). She asks about the risk of shoulder dystocia and whether caesarean section should be considered. What is the most appropriate counselling?

A. Offer elective caesarean section as estimated fetal weight exceeds 3.5 kg in diabetic pregnancy
B. Recommend awaiting spontaneous labour as shoulder dystocia risk is not significantly increased
C. Offer elective caesarean section if estimated fetal weight exceeds 4.0 kg
D. Offer elective caesarean section if estimated fetal weight exceeds 4.5 kg (Correct Answer)
E. Recommend induction of labour at 37 weeks to prevent further fetal growth

Explanation: ***Offer elective caesarean section if estimated fetal weight exceeds 4.5 kg*** - According to **NICE** and **RCOG** guidelines, women with **diabetes in pregnancy** should be offered an elective caesarean section only if the **estimated fetal weight (EFW)** is greater than **4.5 kg**. - This threshold is set because the risk of **shoulder dystocia** and permanent brachial plexus injury increases significantly in diabetic pregnancies due to **asymmetric fetal growth** (larger trunk/shoulders relative to head circumference). *Offer elective caesarean section as estimated fetal weight exceeds 3.5 kg in diabetic pregnancy* - **3.5 kg** is within the normal range for birth weight, and there is no evidence that routine caesarean at this weight prevents significant morbidity. - **Over-intervention** at this weight would lead to unnecessary surgical risks without corresponding benefits in reducing **birth trauma**. *Recommend awaiting spontaneous labour as shoulder dystocia risk is not significantly increased* - In diabetic pregnancies, the risk of **shoulder dystocia** is inherently increased regardless of weight, but specific counselling on the mode of delivery is required. - Awaiting **spontaneous labour** may be inappropriate as diabetic patients are typically offered **induction of labour** or elective delivery between **37+0 and 38+6 weeks**. *Offer elective caesarean section if estimated fetal weight exceeds 4.0 kg* - While **4.0 kg** (macrosomia) increases the clinical suspicion of difficulty, it is not the evidence-based threshold for recommending an elective caesarean in **UK guidelines**. - Ultrasound EFW accuracy has a **margin of error of ±15%**, making a 4.0 kg cutoff unreliable for mandating surgical delivery. *Recommend induction of labour at 37 weeks to prevent further fetal growth* - **Induction of labour** is offered to diabetic patients for maternal/fetal indications, but doing so solely to prevent growth in a baby on the **75th centile** is not standard practice. - Early induction (e.g., at 37 weeks) just to "limit size" has not been shown to reduce the rates of **caesarean section** or **fetal injury** compared to management at 38 weeks.

Question 61: A 26-year-old woman is admitted at 35 weeks gestation with pre-eclampsia. Blood pressure is 156/102 mmHg on labetalol 200 mg three times daily. Blood tests show: platelets 132 × 10⁹/L, ALT 45 U/L, creatinine 78 µmol/L, urate 0.38 mmol/L. Urinary protein:creatinine ratio is 42 mg/mmol. CTG is reassuring. She has no symptoms. The team plans expectant management with close monitoring. What additional medication should be administered now?

A. Magnesium sulphate infusion for seizure prophylaxis
B. Betamethasone for fetal lung maturation
C. Increase labetalol to 400 mg three times daily
D. Add nifedipine modified release 10 mg twice daily
E. No additional medication required currently (Correct Answer)

Explanation: ***No additional medication required currently*** - The patient's **blood pressure** is currently managed around the target range, and she exhibits no **severe features** of pre-eclampsia (symptoms or significant biochemical derangement like platelets <100 or ALT >70). - Management at **35 weeks** for mild pre-eclampsia involves **expectant monitoring** of maternal and fetal well-being, with delivery typically planned at **37 weeks** unless maternal or fetal conditions deteriorate. *Magnesium sulphate infusion for seizure prophylaxis* - **Magnesium sulphate** is indicated for the prevention of seizures in **severe pre-eclampsia** or during the peripartum period if delivery is imminent or pre-eclampsia is worsening. - This patient is currently asymptomatic with non-severe pre-eclampsia criteria and does not meet the thresholds that would justify immediate **seizure prophylaxis**. *Betamethasone for fetal lung maturation* - **Corticosteroids** like betamethasone are generally recommended for fetal lung maturation if delivery is anticipated before **34 weeks** gestation, or between 34 and 35+6 weeks if delivery is planned within 7 days. - Since the patient is at **35 weeks** and being managed expectantly without plans for immediate delivery, routine administration is usually not indicated. *Increase labetalol to 400 mg three times daily* - The therapeutic goal for BP in pre-eclampsia is typically to maintain it below **150/100 mmHg** or **160/110 mmHg**, depending on guidelines. Her current reading of **156/102 mmHg** is elevated but not in the **severe hypertension** range (>160/110 mmHg). - Escalation of antihypertensive therapy is not mandatory unless there is a persistent trend of uncontrolled pressures, development of **severe features**, or the blood pressure consistently exceeds 160/110 mmHg. *Add nifedipine modified release 10 mg twice daily* - **Nifedipine** is an alternative or additive antihypertensive agent, but adding a second agent is reserved for patients whose BP remains uncontrolled on **maximal doses** of the first agent or if severe hypertension is present. - Current management prioritizes **monitoring** rather than immediate aggressive polypharmacy, as abrupt drops in BP can potentially compromise **placental perfusion**.

Question 62: A 35-year-old woman in her second pregnancy attends for her booking appointment at 12 weeks gestation. In her previous pregnancy, she had gestational diabetes requiring insulin and developed polyhydramnios. Her baby was delivered at 37 weeks by emergency caesarean section for fetal distress and weighed 4.2 kg. Her booking BMI is 31 kg/m² and random glucose today is 6.8 mmol/L. What is the most appropriate screening approach for gestational diabetes in this pregnancy?

A. Perform OGTT at 24-28 weeks gestation as per standard protocol
B. Perform OGTT at booking and again at 24-28 weeks if initial test is normal (Correct Answer)
C. Check HbA1c at booking only
D. Check fasting glucose at booking and arrange OGTT if ≥5.6 mmol/L
E. Commence insulin therapy immediately without screening tests

Explanation: ***Perform OGTT at booking and again at 24-28 weeks if initial test is normal***- Given her history of **previous gestational diabetes requiring insulin**, **macrosomic baby (4.2 kg)**, and **obesity (BMI 31)**, this patient has multiple significant risk factors for recurrent and early-onset GDM.- Current guidelines recommend **early screening** with an **OGTT at booking** (10-16 weeks) for women with a history of GDM. If this is normal, a repeat **OGTT at 24-28 weeks** is crucial due to the progressive nature of insulin resistance in pregnancy.*Perform OGTT at 24-28 weeks gestation as per standard protocol*- While an **OGTT at 24-28 weeks** is standard for women with *general* risk factors, it is insufficient for those with a **history of GDM**.- Delaying screening until the mid-trimester could miss **early-onset gestational diabetes** or even undiagnosed pre-existing diabetes, leading to prolonged fetal exposure to hyperglycemia.*Check HbA1c at booking only*- **HbA1c** at booking can identify pre-existing diabetes but is **less sensitive** than an OGTT for diagnosing GDM, especially early-onset forms.- A single test at booking does not account for the **progressive insulin resistance** that typically develops in the second and third trimesters, which is characteristic of GDM.*Check fasting glucose at booking and arrange OGTT if - Women previously affected by **gestational diabetes (GDM)** are considered high-risk for developing it again in subsequent pregnancies or even developing **type 2 diabetes** later in life. Therefore, early and repeated screening is vital.- The first screening with an **Oral Glucose Tolerance Test (OGTT)** should occur at the earliest opportunity (booking), ideally at 10-16 weeks. If results are normal, a repeat OGTT is recommended at **24-28 weeks** due to increasing insulin resistance as pregnancy progresses.*Perform OGTT at 24-28 weeks gestation as per standard protocol*- This approach is appropriate for women with *other* risk factors, such as a **BMI over 30**, but it is insufficient for women with a **history of GDM**.- Delaying screening until the second trimester may lead to missed diagnoses of **early-onset GDM** or undiagnosed pre-existing diabetes, resulting in suboptimal management and potential adverse outcomes.*Check HbA1c at booking only*- While **HbA1c** provides information about average glucose levels over the past 2-3 months, it is **not the primary diagnostic test** for GDM due to lower sensitivity compared to OGTT.- A single **HbA1c** measurement at booking may not detect GDM that develops later in pregnancy, missing the progressive nature of insulin resistance.*Check fasting glucose at booking and arrange OGTT if - Women previously affected by gestational diabetes are considered at **high-risk** for developing it again in their current or next pregnancies and even developing **type 2 diabetes** later in life. Therefore, early screening is crucial. - The initial screening with an **Oral Glucose Tolerance Test (OGTT)** should be performed at the booking appointment (ideally 10-16 weeks) to identify **pre-existing diabetes** or **early-onset GDM**. If the first test is normal, a repeat OGTT is indicated at **24-28 weeks gestation** as insulin resistance progresses with pregnancy.

Question 63: A 31-year-old woman presents to antenatal clinic at 29 weeks gestation with blood pressure 172/118 mmHg. She reports a severe headache and visual disturbances described as flashing lights. This is her first pregnancy. Urinalysis shows 2+ proteinuria. She is already taking labetalol 200 mg three times daily, started 2 weeks ago for gestational hypertension. What is the most appropriate immediate management?

A. Increase labetalol dose to 400 mg three times daily and review in 48 hours
B. Add nifedipine modified release 10 mg twice daily and review in 24 hours
C. Admit for immediate assessment and consideration of delivery (Correct Answer)
D. Prescribe sublingual nifedipine 10 mg immediately and review in 1 hour
E. Arrange urgent MRI brain to exclude intracranial pathology

Explanation: ***Admit for immediate assessment and consideration of delivery*** - This patient exhibits classic signs of **severe pre-eclampsia**, including **severe hypertension** (BP ">=" 160/110 mmHg), **proteinuria**, and **neurological features** like headache and visual disturbances. - **Immediate hospital admission** is critical for close monitoring, **antihypertensive management**, **seizure prophylaxis (magnesium sulfate)**, and urgent evaluation for **delivery**, especially given the uncontrolled hypertension despite current medication. *Increase labetalol dose to 400 mg three times daily and review in 48 hours* - Outpatient management, even with increased medication, is inappropriate for **severe pre-eclampsia** with **neurological symptoms**, as it poses an immediate risk of **eclampsia**, stroke, or placental abruption. - A **48-hour delay** in reassessment is unsafe for a patient presenting with uncontrolled severe hypertension and symptoms indicating **end-organ dysfunction**. *Add nifedipine modified release 10 mg twice daily and review in 24 hours* - Adding oral antihypertensives for outpatient review is insufficient when **severe pre-eclampsia** with impending complications is suspected, as this requires **inpatient stabilization** and comprehensive management. - A **24-hour delay** for review is too long given the acute severity and risk of **maternal and fetal morbidity/mortality**. *Prescribe sublingual nifedipine 10 mg immediately and review in 1 hour* - **Sublingual nifedipine** can cause a **rapid and precipitous drop in blood pressure**, which can compromise **placental perfusion** and lead to fetal distress, making it generally unsuitable in pregnancy for acute hypertension. - While rapid blood pressure control is needed, it should occur in a **monitored inpatient setting** with intravenous options, not with sublingual nifedipine in an uncontrolled environment. *Arrange urgent MRI brain to exclude intracranial pathology* - Although neurological symptoms are present, the overall clinical picture strongly points to **severe pre-eclampsia**, which is an obstetric emergency requiring immediate obstetric and medical management, not primarily neurological workup. - An **MRI brain** should not delay crucial interventions like blood pressure control, **seizure prophylaxis**, and assessment for delivery, which are paramount in managing severe pre-eclampsia.

Question 64: A 37-year-old woman with type 1 diabetes presents for pre-pregnancy counselling. She has had diabetes for 15 years and her most recent HbA1c is 68 mmol/mol (8.4%). She takes insulin aspart three times daily and insulin glargine once at night. Retinal screening 6 months ago showed background diabetic retinopathy. Her BMI is 26 kg/m². What is the single most important immediate action before conception?

A. Commence high-dose folic acid 5 mg daily
B. Refer for urgent ophthalmology review
C. Optimize glycaemic control to achieve HbA1c <48 mmol/mol (Correct Answer)
D. Switch insulin glargine to NPH insulin
E. Commence low-dose aspirin 150 mg daily

Explanation: ***Optimize glycaemic control to achieve HbA1c <48 mmol/mol***- Achieving an **HbA1c <48 mmol/mol (6.5%)** prior to conception is the most critical intervention to minimize the risk of **congenital malformations**, miscarriage, and neonatal death.- This patient's current HbA1c of **68 mmol/mol (8.4%)** puts her at high risk, and she should be advised to use **contraception** until targets are met.*Commence high-dose folic acid 5 mg daily*- While **5 mg folic acid** is essential for women with diabetes to prevent **neural tube defects**, it does not mitigate the broader teratogenic risks of poor maternal glycaemia.- It is a necessary concurrent step but remains secondary to the physiological stabilization of **blood glucose** levels.*Refer for urgent ophthalmology review*- **Retinal screening** is required pre-conception; however, this patient had screening 6 months ago showing only **background retinopathy**, which is not an acute contraindication to pregnancy.- Urgent referral is reserved for **proliferative retinopathy** or stable maculopathy requiring intervention before the rapid glycaemic changes of pregnancy.*Switch insulin glargine to NPH insulin*- Modern guidelines, including **NICE**, state that long-acting analogues like **insulin glargine** can be safely continued throughout pregnancy if they provide good control.- Switching to **NPH insulin** is no longer a mandatory immediate action and might temporarily worsen glycaemic stability during the transition.*Commence low-dose aspirin 150 mg daily*- **Aspirin** is indicated for women with diabetes to reduce the risk of **pre-eclampsia**, but it is typically started at **12 weeks gestation**.- There is no clinical benefit to starting aspirin during the **pre-conception period** compared to the crucial impact of glycaemic optimization.

Question 65: A 29-year-old primigravida is admitted at 33 weeks gestation with severe pre-eclampsia. Her blood pressure is 168/114 mmHg despite treatment with labetalol and nifedipine. She has 3+ proteinuria on dipstick. Blood tests show: platelets 89 × 10⁹/L, ALT 156 U/L, AST 142 U/L, LDH 680 U/L, haemoglobin 102 g/L. Blood film shows fragmented red cells. She is asymptomatic and CTG is reassuring. What is the most appropriate immediate management?

A. Continue expectant management with intensive monitoring
B. Administer magnesium sulphate and plan delivery within 24-48 hours (Correct Answer)
C. Arrange immediate delivery by emergency caesarean section
D. Commence intravenous hydralazine and continue expectant management
E. Administer platelet transfusion before delivery

Explanation: ***Administer magnesium sulphate and plan delivery within 24-48 hours***- The patient presents with **HELLP syndrome** (Hemolysis, Elevated Liver enzymes, Low Platelets), indicated by fragmented RBCs, high AST/ALT, and low platelets, which necessitates **definitive delivery**.- Planning delivery within 24-48 hours allows for maternal stabilization and the administration of **corticosteroids** for fetal lung maturity while **magnesium sulphate** prevents eclamptic seizures.*Continue expectant management with intensive monitoring*- Expectant management is inappropriate for **HELLP syndrome** at 33 weeks as it severely increases the risk of maternal complications like **placental abruption** or hepatic rupture.- Persistent **severe hypertension** despite dual therapy and laboratory evidence of organ failure are clear indications to end the pregnancy.*Arrange immediate delivery by emergency caesarean section*- Immediate emergency delivery is not mandatory because the patient is currently **asymptomatic** and the **CTG is reassuring**.- A controlled delivery within 24-48 hours is preferred to provide a window for **steroid benefit** to the neonate and to optimize the mother's coagulation status.*Commence intravenous hydralazine and continue expectant management*- While **hydralazine** can help control refractory hypertension, it does not treat the underlying pathology of **HELLP syndrome**.- Continuing expectant management solely based on blood pressure control ignores the progressive maternal **multi-organ dysfunction** evidenced by the blood results.*Administer platelet transfusion before delivery*- Platelet transfusion is generally not required unless the count is **<50 × 10⁹/L** (for vaginal delivery) or if there is active bleeding.- Since the current count is **89 × 10⁹/L** and there is no mention of hemorrhage, the priority remains the management of the underlying pre-eclampsia and timing of delivery.

Question 66: A 34-year-old woman undergoes oral glucose tolerance test at 28 weeks gestation due to BMI of 33 kg/m². Results show: fasting glucose 4.9 mmol/L, 2-hour glucose 8.2 mmol/L. She is given a blood glucose monitor and advised on diet and lifestyle modifications. After 1 week of monitoring, her blood glucose diary shows: fasting glucose 4.8-5.1 mmol/L on all days, and 1-hour post-prandial readings ranging from 7.4-8.6 mmol/L. What is the most appropriate next step in management?

A. Continue diet and lifestyle measures with further review in 2 weeks
B. Commence metformin therapy (Correct Answer)
C. Commence insulin therapy
D. Request review by specialist diabetes team within 1 week
E. Commence both metformin and insulin therapy simultaneously

Explanation: ***Commence metformin therapy***- The patient's **1-hour post-prandial glucose levels** (7.4-8.6 mmol/L) are consistently above target levels (e.g., <7.8 mmol/L or <7.0 mmol/L) after a 1-week trial of diet and lifestyle modifications.- When diet and lifestyle measures fail to achieve glycemic targets in gestational diabetes, **metformin** is typically the recommended first-line oral pharmacological agent, especially when fasting levels are well-controlled and post-prandial levels are elevated.*Continue diet and lifestyle measures with further review in 2 weeks*- This option is inappropriate because the patient's **post-prandial blood glucose targets are not being met** after a dedicated 1-week trial of diet and lifestyle changes.- Delaying pharmacological intervention when targets are consistently missed increases the risk of **adverse maternal and fetal outcomes**, such as macrosomia or pre-eclampsia.*Commence insulin therapy*- **Insulin** is usually reserved for cases where metformin is contraindicated, or if blood glucose levels are severely elevated at diagnosis (e.g., fasting >7.0 mmol/L), or if metformin fails to achieve glycemic control.- Given that her **fasting glucose is controlled** and there's no immediate indication of severe hyperglycemia or fetal macrosomia, metformin is the more appropriate initial pharmacological step.*Request review by specialist diabetes team within 1 week*- While a specialist diabetes team plays a crucial role in managing gestational diabetes, the immediate next step when targets are not met after a lifestyle trial is to **initiate appropriate pharmacological therapy**.- In many healthcare settings, primary care providers or obstetricians are equipped to commence **metformin** for gestational diabetes based on established protocols, without requiring an immediate specialist referral for initiation.*Commence both metformin and insulin therapy simultaneously*- Initiating both **metformin and insulin simultaneously** is not the standard first-line approach in gestational diabetes unless there is severe, uncontrolled hyperglycemia or significant fetal complications (e.g., severe macrosomia) at presentation.- Management typically follows a **stepwise escalation**, starting with a single agent and adding others only if glycemic targets remain unmet.

Question 67: A 32-year-old woman presents to the antenatal day unit at 36 weeks gestation with a blood pressure reading of 152/96 mmHg. She is asymptomatic. Her booking blood pressure at 10 weeks was 118/72 mmHg, and all subsequent readings have been normal until today. Repeat blood pressure after 20 minutes rest is 148/94 mmHg. Urinalysis shows no proteinuria. Blood tests show: platelets 198 × 10⁹/L, ALT 28 U/L, creatinine 62 µmol/L. What is the most accurate diagnosis?

A. Gestational hypertension (Correct Answer)
B. Pre-eclampsia
C. Chronic hypertension
D. White coat hypertension
E. Severe pre-eclampsia

Explanation: ***Gestational hypertension*** - This diagnosis is defined by new-onset **hypertension (≥140/90 mmHg)** occurring after **20 weeks of gestation** in a previously normotensive woman. - The patient meets these criteria at 36 weeks with a BP of 152/96 mmHg and **no proteinuria** or evidence of multi-organ dysfunction. *Pre-eclampsia* - Requires the presence of hypertension plus either **proteinuria** (e.g., PCR ≥30 mg/mmol) or **maternal organ dysfunction**, such as thrombocytopenia, elevated liver enzymes, or renal impairment. - In this case, the **urinalysis is clear**, and blood results for platelets, ALT, and creatinine are all within the **normal range**, ruling out pre-eclampsia. *Chronic hypertension* - Defined as hypertension that is present **before pregnancy** or diagnosed **before 20 weeks** of gestation. - This patient had a normal **booking blood pressure** (118/72 mmHg) at 10 weeks, which effectively rules out chronic hypertension. *White coat hypertension* - Characterized by elevated BP readings in a clinical setting but **normal readings** at home or during ambulatory monitoring. - This diagnosis is unlikely here because the blood pressure remained elevated (**148/94 mmHg**) even after a **20-minute rest** period, suggesting true hypertension. *Severe pre-eclampsia* - Diagnosed when pre-eclampsia is accompanied by severe features, such as BP **≥160/110 mmHg**, severe proteinuria, or clinical symptoms like **persistent headache and visual disturbances**. - The patient is currently **asymptomatic**, and her BP (152/96 mmHg) and blood markers do not meet the thresholds or criteria for severe disease.

Question 68: A 28-year-old woman with insulin-treated gestational diabetes is reviewed at 38 weeks gestation. Her diabetes has been well-controlled throughout. Growth scans show the estimated fetal weight is on the 55th centile. She has had an uncomplicated pregnancy otherwise and is keen to know about delivery planning. She asks about the timing of delivery. What is the most appropriate recommendation regarding timing of delivery?

A. Offer induction of labour at 38 weeks gestation
B. Offer induction of labour between 37+0 and 38+6 weeks gestation (Correct Answer)
C. Await spontaneous labour until 40 weeks, then offer induction
D. Offer elective caesarean section at 39 weeks gestation
E. Await spontaneous labour until 41 weeks, then offer induction

Explanation: ***Offer induction of labour between 37+0 and 38+6 weeks gestation*** - According to **NICE guidelines**, for women with **gestational diabetes** managed with **medication (insulin or metformin)**, elective birth is recommended within this specific window. - This timing is advised even with **well-controlled diabetes** and appropriate fetal growth to reduce the heightened risk of **stillbirth** and other perinatal complications. *Offer induction of labour at 38 weeks gestation* - While 38 weeks falls within the recommended range, current guidelines specify a **broader window of 37+0 to 38+6 weeks gestation** to allow for clinical flexibility and individual patient circumstances. - The exact timing within this window is individualized, making a specific 'at 38 weeks' less precise than the recommended range. *Await spontaneous labour until 40 weeks, then offer induction* - Waiting until 40 weeks is generally reserved for women with **gestational diabetes managed by diet and lifestyle alone**. - For **insulin-treated gestational diabetes**, delaying delivery to 40 weeks significantly increases the risk of **fetal macrosomia**, **shoulder dystocia**, and **stillbirth**. *Offer elective caesarean section at 39 weeks gestation* - An **elective caesarean section** is typically reserved for specific obstetric indications, such as **fetal macrosomia** (estimated fetal weight > 4.5 kg) or other complications, none of which are present here. - Given the **estimated fetal weight is on the 55th centile**, a **vaginal birth** via induction is the preferred mode of delivery in this uncomplicated case. *Await spontaneous labour until 41 weeks, then offer induction* - This approach is recommended for **uncomplicated low-risk pregnancies** and is not suitable for women with **insulin-treated gestational diabetes**. - Delaying delivery until 41 weeks in a diabetic pregnancy significantly increases the risk of **placental insufficiency**, **fetal distress**, and **intrauterine fetal demise**.

Question 69: A 36-year-old woman in her third pregnancy presents at 14 weeks gestation for routine antenatal care. In her previous pregnancy, she developed pre-eclampsia at 34 weeks requiring emergency caesarean section for severe disease. Her blood pressure today is 128/78 mmHg, and urinalysis shows no protein. Her BMI is 29 kg/m². She is otherwise well with no other medical history. What is the most appropriate prophylaxis to reduce her risk of pre-eclampsia?

A. Aspirin 75 mg daily from now until delivery
B. Aspirin 150 mg daily from now until 36 weeks gestation (Correct Answer)
C. Aspirin 75 mg daily from 16 weeks until 36 weeks gestation
D. Calcium supplementation 1000 mg daily throughout pregnancy
E. Low molecular weight heparin daily throughout pregnancy

Explanation: ***Aspirin 150 mg daily from now until 36 weeks gestation*** - For women with a history of **pre-eclampsia** in a previous pregnancy, **150 mg of aspirin** daily is the recommended dose to reduce the risk of recurrence. - Prophylaxis should ideally commence between **12 and 16 weeks gestation** and continue until **36 weeks gestation**, making immediate initiation at 14 weeks appropriate. *Aspirin 75 mg daily from now until delivery* - The **75 mg dose** is considered suboptimal for high-risk women; current evidence supports a **higher dose (150 mg)** for more effective **pre-eclampsia** prevention. - Continuing aspirin until **delivery** is generally not recommended due to increased risk of **peripartum bleeding**; discontinuation at 36 weeks is standard. *Aspirin 75 mg daily from 16 weeks until 36 weeks gestation* - The **75 mg dose** is less effective than **150 mg** for this high-risk patient. - Initiating prophylaxis at **16 weeks gestation** is slightly delayed; optimal efficacy is achieved with initiation between **12 and 16 weeks**. *Calcium supplementation 1000 mg daily throughout pregnancy* - **Calcium supplementation** is primarily recommended by WHO for populations with **low dietary calcium intake** to reduce pre-eclampsia risk. - It is not a substitute for **aspirin** in patients with a significant history of pre-eclampsia and generally not indicated as primary prophylaxis in well-nourished populations. *Low molecular weight heparin daily throughout pregnancy* - **Low molecular weight heparin (LMWH)** is indicated for conditions like **venous thromboembolism (VTE) prophylaxis** or in cases of **antiphospholipid syndrome (APS)**. - There is no robust evidence to support its use as a primary prophylactic agent for **pre-eclampsia** in the absence of other specific indications.

Question 70: A 30-year-old woman with gestational diabetes diagnosed at 26 weeks gestation attends clinic at 34 weeks for review. She has been managing with diet modification alone. Her home blood glucose monitoring shows: fasting glucose 5.0-5.4 mmol/L and 1-hour post-prandial readings 7.2-7.9 mmol/L. She reports good fetal movements. Ultrasound shows estimated fetal weight on 85th centile with abdominal circumference on 90th centile. What is the most appropriate management?

A. Continue diet control alone with weekly monitoring
B. Commence metformin therapy
C. Commence insulin therapy (Correct Answer)
D. Arrange immediate delivery by induction of labour
E. Commence both metformin and insulin therapy

Explanation: ***Commence insulin therapy***- The **ultrasound findings** of estimated fetal weight on the 85th centile and abdominal circumference on the **90th centile** indicate **fetal macrosomia** or accelerated growth, which is a key indicator for commencing pharmacological treatment, even with borderline glucose readings.- **Insulin** is the preferred first-line pharmacological treatment in gestational diabetes when there is evidence of fetal overgrowth, as it is highly effective in controlling maternal glucose without crossing the placenta, thereby reducing the risk of macrosomia and related complications.*Continue diet control alone with weekly monitoring*- Despite current management, the **fetal growth parameters** (EFW 85th centile, AC 90th centile) suggest that **diet control alone is insufficient** to achieve optimal glycaemic control and prevent fetal overgrowth.- Continuing diet alone would increase the risk of adverse outcomes such as **shoulder dystocia**, birth trauma, and neonatal **hypoglycaemia** due to uncontrolled fetal growth.*Commence metformin therapy*- While **metformin** is an oral agent that can be used for gestational diabetes, it is generally considered less effective than insulin in addressing **accelerated fetal growth** or confirmed macrosomia.- Metformin crosses the placenta and might not achieve the tight glucose control needed to manage significant fetal overgrowth effectively, making insulin a more appropriate choice in this scenario.*Arrange immediate delivery by induction of labour*- Immediate delivery at **34 weeks gestation** is premature and not indicated in a stable patient with good fetal movements and no acute complications.- Preterm delivery carries significant risks for the neonate, including **respiratory distress syndrome**, and is typically only considered for severe complications or after 37-38+6 weeks for GDM, often with poor control.*Commence both metformin and insulin therapy*- **Dual therapy** with both metformin and insulin is usually reserved for cases of gestational diabetes with more **severe hyperglycaemia** or when monotherapy (typically insulin) fails to achieve adequate control.- In this case, given the initial evidence of fetal overgrowth despite borderline maternal glucose, **insulin monotherapy** is the standard first step, with dose adjustments based on further monitoring.

Question 71: A 33-year-old woman presents at 11 weeks gestation for antenatal booking. She mentions that her sister recently had a baby with a neural tube defect. The woman herself has no history of neural tube defects in previous pregnancies and is not taking any anti-epileptic medications. She has been taking folic acid 400 micrograms daily since confirming her pregnancy 3 weeks ago. What advice should be given regarding folic acid supplementation?

A. Continue folic acid 400 micrograms daily until 12 weeks gestation
B. Increase to folic acid 5 mg daily for the remainder of pregnancy
C. Increase to folic acid 5 mg daily until 12 weeks gestation (Correct Answer)
D. Continue folic acid 400 micrograms daily for the remainder of pregnancy
E. Stop folic acid as she is past the critical period for neural tube defect prevention

Explanation: ***Increase to folic acid 5 mg daily until 12 weeks gestation*** - Women with a **first-degree relative** (such as a sibling) affected by a **neural tube defect (NTD)** are considered high-risk and require a higher dose of **5 mg folic acid daily**. - Supplementation at this dose is crucial until **12 weeks gestation**, as this is the period when the **neural tube closes** and the risk of NTDs is highest. *Continue folic acid 400 micrograms daily until 12 weeks gestation* - The **400 microgram dose** is the standard for low-risk women but is insufficient for those with a positive **family history** in a first-degree relative. - Current guidelines recommend moving to the **high-dose supplement (5 mg)** as soon as a high-risk factor is identified during the first trimester. *Increase to folic acid 5 mg daily for the remainder of pregnancy* - While the **5 mg dose** is correct for her risk profile, **folic acid supplementation** specifically for NTD prevention is generally not required beyond **12 weeks gestation**. - Continuing high-dose supplementation for the entire pregnancy is not supported by routine **obstetric guidelines** unless other specific medical indications exist. *Continue folic acid 400 micrograms daily for the remainder of pregnancy* - This option provides both an **insufficient dose** for a high-risk patient and an unnecessarily **extended duration** of supplementation. - A dose of **400 micrograms** fails to provide the maximal protective benefit against **NTD recurrence** in a high-risk individual. *Stop folic acid as she is past the critical period for neural tube defect prevention* - Although the **neural tube closure** occurs by about 4 weeks post-conception, antenatal guidelines recommend continuing supplementation until **12 weeks** to ensure optimal prevention and safety. - Stopping at **11 weeks** is premature and deviates from standard **antenatal booking protocols** that advise continuation until the end of the first trimester.

Question 72: A 25-year-old woman attends her booking appointment at 10 weeks gestation in her first pregnancy. She has no significant past medical history and takes no regular medications. Her BMI is 22 kg/m². Blood tests reveal haemoglobin 105 g/L, MCV 68 fL, and ferritin 8 µg/L. What is the most appropriate initial management of her anaemia?

A. Oral ferrous sulfate 200 mg once daily
B. Oral ferrous sulfate 200 mg twice daily (Correct Answer)
C. Intravenous iron infusion
D. Intramuscular iron injection
E. Blood transfusion

Explanation: ***Oral ferrous sulfate 200 mg twice daily***- The patient presents with **microcytic anaemia** (MCV 68 fL) and low **ferritin** (8 µg/L), which is diagnostic of **iron deficiency anaemia** in pregnancy.- According to clinical guidelines, the first-line treatment for iron deficiency anaemia in pregnancy is **oral iron** supplementation, and ferrous sulfate 200 mg twice daily provides an adequate dose of elemental iron. *Oral ferrous sulfate 200 mg once daily* - This dose provides **65 mg of elemental iron**, which is often insufficient to correct established **anaemia** and replenish iron stores, particularly in pregnancy where iron demands are significantly increased.- **Once-daily** dosing is more commonly used for **prophylaxis** in high-risk patients or for very mild deficiency, rather than active treatment of diagnosed anaemia with low ferritin. *Intravenous iron infusion* - **Intravenous iron** is generally reserved for patients who are **intolerant** of oral iron, have **malabsorption**, or require rapid correction of severe anaemia, especially in the late second or third trimester.- It is usually avoided in the **first trimester** unless there are exceptional clinical circumstances, as safety data is more limited compared to oral routes during early pregnancy. *Intramuscular iron injection* - **Intramuscular iron** is rarely used in modern practice because it is **painful**, has variable absorption, and can cause permanent **skin staining** at the injection site.- **Intravenous** iron is the preferred parenteral route if oral therapy is contraindicated or unsuccessful due to its better efficacy and reduced local adverse effects. *Blood transfusion* - **Blood transfusion** is reserved for **severe anaemia** (typically Hb < 70-80 g/L, depending on guidelines) or when there is acute **haemodynamic compromise**.- With a haemoglobin of **105 g/L**, this patient is stable, and a transfusion carries unnecessary risks such as **alloimmunization** and transfusion reactions.

Question 73: A 44-year-old woman in her fifth pregnancy presents to the emergency department at 35 weeks gestation with sudden onset severe headache, confusion, and right upper quadrant pain. Her blood pressure on arrival is 178/118 mmHg. She has one tonic-clonic seizure lasting 90 seconds while in the department. Blood tests show: Hb 108 g/L, platelets 78 × 10⁹/L, ALT 245 U/L, AST 268 U/L, LDH 850 U/L, urea 8.5 mmol/L, creatinine 145 μmol/L. Urinalysis shows 4+ protein. Which of the following represents the most appropriate immediate management sequence?

A. IV labetalol bolus, IV magnesium sulphate loading dose, arrange urgent delivery after maternal stabilisation (Correct Answer)
B. CT head scan, IV phenytoin loading, then consider delivery if scan normal
C. IV magnesium sulphate loading dose, IV antihypertensive, arrange immediate caesarean section without delay
D. IV diazepam for seizure control, oral antihypertensive, admit for observation and blood pressure monitoring
E. IV hydralazine, IV magnesium sulphate, await spontaneous labour onset

Explanation: ***IV labetalol bolus, IV magnesium sulphate loading dose, arrange urgent delivery after maternal stabilisation*** - The patient presents with **eclampsia** (seizure with pre-eclampsia) and features of **HELLP syndrome** (thrombocytopenia, elevated liver enzymes, hemolysis), requiring immediate control of **severe hypertension** and **seizures**. - **IV labetalol** is appropriate for rapid blood pressure control, and **IV magnesium sulphate** is the cornerstone for preventing and treating eclamptic seizures; delivery is the definitive treatment but should occur once the **mother is stabilized**. *CT head scan, IV phenytoin loading, then consider delivery if scan normal* - A **CT head scan** is generally not the first-line intervention in a clear case of eclampsia and would delay critical initial management. - **Phenytoin** is less effective than **magnesium sulphate** for eclamptic seizure control and is not the preferred anticonvulsant. *IV magnesium sulphate loading dose, IV antihypertensive, arrange immediate caesarean section without delay* - While magnesium sulphate and antihypertensives are correct, proceeding to an **immediate caesarean section without delay** can increase risks due to potential **coagulopathy** and unstable maternal condition before adequate stabilization. - **Maternal stabilization** (e.g., blood pressure control, cessation of seizures) is crucial before initiating urgent delivery to optimize outcomes. *IV diazepam for seizure control, oral antihypertensive, admit for observation and blood pressure monitoring* - **Diazepam** is not the first-line anticonvulsant for eclampsia due to risks of maternal and neonatal **respiratory depression**; **magnesium sulphate** is preferred. - An **oral antihypertensive** is insufficient for managing **hypertensive emergency** (BP 178/118 mmHg) in eclampsia; rapid-acting **intravenous agents** are necessary. *IV hydralazine, IV magnesium sulphate, await spontaneous labour onset* - Although **IV hydralazine** and **magnesium sulphate** are appropriate treatments for hypertension and seizures, **awaiting spontaneous labour** is contraindicated in eclampsia. - **Delivery** is the definitive treatment for eclampsia and must be expedited after maternal stabilization, as the condition will not resolve until the placenta is removed.

Question 74: A 36-year-old woman with insulin-treated gestational diabetes attends for review at 33 weeks gestation. Serial growth scans have shown progressive crossing of centiles: estimated fetal weight was on 65th centile at 28 weeks, 75th centile at 30 weeks, and 85th centile today at 33 weeks. Abdominal circumference is on 90th centile. Amniotic fluid index is 26 cm. Her capillary blood glucose readings show: fasting 4.8-5.4 mmol/L, 1-hour postprandial 6.2-7.5 mmol/L. What is the most appropriate management?

A. Increase insulin doses to achieve tighter glycaemic control and repeat scan in 2 weeks (Correct Answer)
B. Continue current insulin regime as glucose levels are at target and arrange delivery at 38 weeks
C. Diagnose suspected fetal macrosomia and offer elective caesarean section at 37 weeks
D. The polyhydramnios suggests poor glucose control; significantly increase insulin and recheck glucose monitoring technique
E. Arrange urgent delivery due to excessive fetal growth and polyhydramnios

Explanation: ***Increase insulin doses to achieve tighter glycaemic control and repeat scan in 2 weeks*** - Despite the maternal capillary blood glucose readings appearing within target ranges, the **progressive crossing of centiles** for estimated fetal weight and the **90th centile abdominal circumference** combined with **polyhydramnios (AFI 26 cm)** are clear indicators of **fetal hyperinsulinism** and inadequate glycaemic control. - The most appropriate action is to intensify maternal insulin therapy to achieve tighter control, aiming to slow excessive fetal growth, and then reassess the fetal parameters with a **repeat scan in 2 weeks**. *Continue current insulin regime as glucose levels are at target and arrange delivery at 38 weeks* - This option is incorrect because relying solely on seemingly normal maternal blood glucose levels is insufficient when there is clear sonographic evidence of **accelerating fetal growth** and **polyhydramnios**, both suggesting suboptimal glucose control affecting the fetus. - Continuing the current regimen would likely lead to further **fetal macrosomia**, increasing risks of birth trauma and neonatal complications, and a delivery at 38 weeks without addressing the underlying issue is not ideal. *Diagnose suspected fetal macrosomia and offer elective caesarean section at 37 weeks* - While **fetal macrosomia** is a significant concern, the estimated fetal weight at 33 weeks does not typically warrant an immediate diagnosis of macrosomia requiring delivery at 37 weeks, especially when intervention can still modify fetal growth. - The primary goal at this stage is to **optimize glucose control** to prevent further excessive growth, rather than prematurely committing to a surgical delivery, which carries its own risks. *The polyhydramnios suggests poor glucose control; significantly increase insulin and recheck glucose monitoring technique* - Although **polyhydramnios** correctly suggests poor glucose control and **rechecking glucose monitoring technique** is a good general practice, simply

Question 75: A 31-year-old woman is seen at 14 weeks gestation in her second pregnancy. In her first pregnancy, she developed severe early-onset pre-eclampsia at 29 weeks requiring emergency delivery. Her blood pressure today is 124/78 mmHg and urinalysis is negative. Blood tests including renal and liver function are normal. She is very anxious about recurrence. What is the most evidence-based intervention to reduce her risk of developing pre-eclampsia in this pregnancy?

A. Low-dose aspirin 150 mg daily commenced before 16 weeks and continued until delivery (Correct Answer)
B. Calcium supplementation 1 gram daily throughout pregnancy
C. Low-dose aspirin 75 mg daily commenced at 20 weeks until 36 weeks
D. Prophylactic low molecular weight heparin throughout pregnancy
E. Monthly uterine artery Doppler surveillance from 20 weeks

Explanation: ***Low-dose aspirin 150 mg daily commenced before 16 weeks and continued until delivery*** - A history of **early-onset pre-eclampsia** (before 34 weeks) is a major high-risk factor; starting **aspirin 150 mg** daily reduces the risk of recurrence significantly. - Effectiveness depends on early initiation, ideally before **16 weeks gestation**, to positively influence **trophoblastic invasion** and placentation. *Calcium supplementation 1 gram daily throughout pregnancy* - **Calcium supplementation** is primarily recommended for women with **low dietary intake** of calcium to reduce pre-eclampsia risk. - It is not the first-line evidence-based intervention for a patient with a specific high-risk history in populations with adequate calcium intake. *Low-dose aspirin 75 mg daily commenced at 20 weeks until 36 weeks* - While 75 mg was previously common, the **ASPRE trial** demonstrated that **150 mg** is more effective for preventing preterm pre-eclampsia. - Initiating treatment at **20 weeks** is too late to affect the physiologic remodeling of **spiral arteries**, which is necessary for prevention. *Prophylactic low molecular weight heparin throughout pregnancy* - **LMWH** is used for preventing **venous thromboembolism** or managing antiphospholipid syndrome, not for the routine prevention of pre-eclampsia. - There is no high-quality clinical evidence to support **heparin** as a superior or standard intervention compared to aspirin for pre-eclampsia prophylaxis. *Monthly uterine artery Doppler surveillance from 20 weeks* - **Uterine artery Doppler** is a **screening and monitoring tool** used to assess placental resistance and predict risk, not a preventive treatment. - While it provides useful diagnostic information, it does not biologically **reduce the risk** of developing the condition.

Question 76: A 39-year-old woman with twin pregnancy (dichorionic diamniotic) is reviewed at 28 weeks gestation. She underwent OGTT at 26 weeks due to previous macrosomic baby (birth weight 4.5 kg). Results were: fasting glucose 4.9 mmol/L, 2-hour glucose 7.2 mmol/L. She was reassured and discharged. She now presents with polyuria and polydipsia. Random glucose is 11.2 mmol/L. What is the most appropriate diagnostic interpretation and management?

A. This is normal physiological change in twin pregnancy; reassure and monitor symptoms
B. Gestational diabetes has developed since the previous normal OGTT; commence treatment as per protocol (Correct Answer)
C. The previous OGTT may have been a false negative; confirm diagnosis with repeat OGTT
D. She likely has developed type 2 diabetes in pregnancy; perform HbA1c testing
E. Random glucose is not diagnostic; arrange fasting glucose measurement

Explanation: ***Gestational diabetes has developed since the previous normal OGTT; commence treatment as per protocol*** - A **random plasma glucose** of **≥11.1 mmol/L** in the presence of classical symptoms such as **polyuria** and **polydipsia** is diagnostic of diabetes mellitus, requiring immediate treatment. - **Insulin resistance** naturally increases as pregnancy progresses, and this effect is amplified in **twin pregnancies** due to a larger placental mass, meaning gestational diabetes can develop even after a previously normal OGTT. *This is normal physiological change in twin pregnancy; reassure and monitor symptoms* - **Polyuria and polydipsia** are classic symptoms of **hyperglycemia** and are never considered normal physiological changes of pregnancy. - A **random glucose of 11.2 mmol/L** is significantly elevated and meets diagnostic criteria for diabetes, necessitating active intervention rather than reassurance. *The previous OGTT may have been a false negative; confirm diagnosis with repeat OGTT* - The previous OGTT results (fasting 4.9 mmol/L, 2-hour 7.2 mmol/L) were within normal limits at 26 weeks, indicating it was likely a true negative at that time, not a **false negative**. - With definitive symptoms and a diagnostic **random glucose** level, a repeat OGTT is unnecessary and would only delay crucial treatment for confirmed gestational diabetes. *She likely has developed type 2 diabetes in pregnancy; perform HbA1c testing* - While the patient has risk factors for diabetes (previous macrosomia), the current diagnosis is **Gestational Diabetes Mellitus (GDM)** given the onset during pregnancy. - **HbA1c** is not recommended for diagnosing diabetes during pregnancy due to physiological changes affecting red blood cell turnover, which can lead to inaccurate results. *Random glucose is not diagnostic; arrange fasting glucose measurement* - According to international guidelines (e.g., WHO), a **random plasma glucose of ≥11.1 mmol/L** combined with classical symptoms (polyuria, polydipsia) is sufficient for a definitive diagnosis of diabetes. - Requesting further tests like a **fasting glucose** would unnecessarily delay the initiation of treatment for significant maternal hyperglycemia, risking adverse fetal and maternal outcomes.

Question 77: A 28-year-old woman is admitted at 36 weeks gestation with blood pressure 158/105 mmHg and 2+ proteinuria on dipstick testing. She reports mild frontal headache but no visual disturbances or epigastric pain. Blood tests show: Hb 125 g/L, platelets 145 × 10⁹/L, ALT 45 U/L, AST 42 U/L, urea 5.2 mmol/L, creatinine 75 μmol/L. A 24-hour urine collection confirms proteinuria of 450 mg/24 hours. Cardiotocography is normal. She is commenced on oral labetalol. After 48 hours, her blood pressure is 145/92 mmHg on labetalol 200 mg three times daily. Repeat bloods are stable and she remains asymptomatic. What is the most appropriate management plan?

A. Continue expectant management with increased monitoring and plan delivery at 37 weeks (Correct Answer)
B. Increase labetalol dose and aim for delivery at 38-39 weeks
C. Commence magnesium sulphate prophylaxis and deliver immediately
D. Switch to nifedipine and continue monitoring until 40 weeks
E. Add methyldopa to labetalol and monitor for further 2 weeks

Explanation: ***Continue expectant management with increased monitoring and plan delivery at 37 weeks*** - This patient has **non-severe pre-eclampsia** (BP <160/110 mmHg, stable labs) at 36 weeks; the recommended management is to reach **37 weeks** for a term delivery to balance fetal and maternal risks. - **Expectant management** includes frequent blood pressure monitoring, bi-weekly blood tests (LFTs, U&Es, FBC), and **fetal surveillance** to ensure no progression to severe disease. *Increase labetalol dose and aim for delivery at 38-39 weeks* - While the dose could be adjusted, **pre-eclampsia** management guidelines advise against routine expectant management beyond **37 weeks** due to the risk of maternal and fetal complications. - Delaying delivery until 38-39 weeks in the presence of **proteinuria** and hypertension increases the risk of **placental abruption** and eclamptic seizures. *Commence magnesium sulphate prophylaxis and deliver immediately* - **Magnesium sulphate** is indicated for the prevention of seizures in **severe pre-eclampsia** or eclampsia, but this patient currently lacks severe features like end-organ damage or refractory hypertension. - **Immediate delivery** at 36 weeks is generally reserved for maternal or fetal distress, as delivery before 37 weeks increases the risk of **neonatal respiratory morbidity**. *Switch to nifedipine and continue monitoring until 40 weeks* - Nifedipine is a valid alternative, but switching medications does not change the fact that **pre-eclampsia** necessitates delivery by **37 weeks** rather than 40 weeks. - Continuing to **40 weeks** is inappropriate as pre-eclampsia is a progressive condition that only resolves upon **delivery of the placenta**. *Add methyldopa to labetalol and monitor for further 2 weeks* - Dual therapy may be required if BP remains uncontrolled, but this patient's BP is currently responding to 200mg **labetalol**, making an immediate second agent unnecessary. - Monitoring for a further 2 weeks would take the patient to **38 weeks**, which exceeds the standard recommendation for delivery at the **37-week threshold** for pre-eclamptic patients.

Question 78: A 41-year-old woman with type 2 diabetes mellitus presents at 20 weeks gestation for her anomaly scan. She was diagnosed with diabetes 3 years ago and has been taking metformin 1000 mg twice daily. Her HbA1c at booking (8 weeks) was 52 mmol/mol. The detailed fetal ultrasound scan is reported as normal. What additional fetal assessment should be offered?

A. Fetal echocardiography at 22-24 weeks gestation (Correct Answer)
B. Repeat anomaly scan at 24 weeks gestation
C. Amniocentesis for fetal karyotyping
D. Monthly growth scans from 24 weeks onwards
E. Fetal MRI to exclude neural tube defects

Explanation: ***Fetal echocardiography at 22-24 weeks gestation***- Pre-existing **Type 2 Diabetes** and suboptimal glycaemic control (HbA1c 52 mmol/mol at 8 weeks) significantly increase the risk of **congenital heart defects**.- A **fetal echocardiography** is a specialized ultrasound specifically designed to evaluate cardiac structures in detail, often indicated between **22-24 weeks gestation** in high-risk pregnancies, even if a routine anomaly scan appears normal.*Repeat anomaly scan at 24 weeks gestation*- A **routine anomaly scan** at 20 weeks was reported as normal, implying a thorough general anatomical survey has already been performed.- Repeating a general anomaly scan at 24 weeks is not the most targeted intervention for the specific increased risk of **cardiac anomalies** in diabetic pregnancies.*Amniocentesis for fetal karyotyping*- While diabetes is a risk factor for **structural malformations**, it is not a primary risk factor for **chromosomal aneuploidies**, which is what **amniocentesis for karyotyping** would investigate.- This is an **invasive procedure** with associated risks, and it is not routinely offered in diabetic pregnancies unless there are other indications for chromosomal analysis.*Monthly growth scans from 24 weeks onwards*- While **macrosomia** is a concern in diabetic pregnancies, **growth scans** for this purpose are typically initiated later, usually from **28 weeks gestation** according to most guidelines.- Growth scans primarily monitor fetal size and **amniotic fluid volume**, not the detailed structural integrity of organs like the heart.*Fetal MRI to exclude neural tube defects*- **Neural tube defects (NTDs)** are primarily screened for during the routine **20-week anomaly scan**, which was reported as normal in this case.- **Fetal MRI** is reserved for situations where ultrasound findings are unclear or require further detailed characterization, not as a first-line additional screening tool for NTDs after a normal anomaly scan.

Question 79: A 26-year-old woman attends the antenatal clinic at 32 weeks gestation. She was diagnosed with gestational hypertension at 30 weeks and started on labetalol 200 mg twice daily. Today her blood pressure is 136/84 mmHg. She reports no symptoms. Urinalysis is negative for protein. Bloods show: Hb 115 g/L, platelets 180 × 10⁹/L, ALT 25 U/L, creatinine 68 μmol/L. Fetal growth scan shows estimated fetal weight on 50th centile with normal liquor volume. What is the most appropriate ongoing management plan?

A. Continue current management with blood pressure and urine monitoring twice weekly (Correct Answer)
B. Increase labetalol dose to 400 mg twice daily to achieve target BP <130/80 mmHg
C. Reduce labetalol to 100 mg twice daily as blood pressure is well controlled
D. Admit for inpatient monitoring and daily blood tests
E. Arrange delivery at 34 weeks to prevent progression to pre-eclampsia

Explanation: ***Continue current management with blood pressure and urine monitoring twice weekly*** - The patient's blood pressure of **136/84 mmHg** is well-controlled on **labetalol**, falling within the recommended target range for **gestational hypertension** (typically <140/90 mmHg, often aiming for <135/85 mmHg). - Ongoing **blood pressure and urine monitoring twice weekly** is crucial for stable gestational hypertension to detect early signs of progression to **pre-eclampsia**, which is characterized by new-onset proteinuria. *Increase labetalol dose to 400 mg twice daily to achieve target BP <130/80 mmHg* - The current blood pressure is already within the acceptable range; **aggressive lowering below 130/80 mmHg** is generally not required and may risk **impaired placental perfusion**. - An increase in dose would only be considered if blood pressure consistently exceeded **140/90 mmHg** or specific stricter targets were indicated due to other complications. *Reduce labetalol to 100 mg twice daily as blood pressure is well controlled* - Reducing the current medication dose for **well-controlled hypertension** can lead to a **rebound in blood pressure** and loss of control, increasing the risk of complications. - Medication should be maintained at an effective dose unless there are signs of **hypotension** or significant adverse effects. *Admit for inpatient monitoring and daily blood tests* - Inpatient admission is typically reserved for cases of **severe hypertension** (BP ≥160/110 mmHg), suspected or confirmed **pre-eclampsia** with features of severe disease (e.g., proteinuria, organ dysfunction), or signs of **fetal compromise**. - This patient is asymptomatic, with normal blood tests (platelets, ALT, creatinine) and fetal well-being, making outpatient management appropriate. *Arrange delivery at 34 weeks to prevent progression to pre-eclampsia* - Delivery at **34 weeks gestation** would result in **prematurity** and is only indicated for severe, uncontrolled pre-eclampsia, significant fetal compromise, or other critical maternal conditions. - For women with stable gestational hypertension and no signs of pre-eclampsia, continuation of pregnancy until **37 weeks gestation** is generally recommended to optimize neonatal outcomes.

Question 80: A 35-year-old woman with well-controlled gestational diabetes on insulin therapy is reviewed at 39 weeks gestation. Her pregnancy has been otherwise uncomplicated with normal fetal growth on serial ultrasound scans and consistently reassuring cardiotocography. She asks about the timing of delivery. According to current UK guidance, what is the most appropriate advice regarding timing of birth?

A. Offer induction of labour between 37+0 and 38+6 weeks
B. Offer induction of labour between 38+0 and 39+6 weeks (Correct Answer)
C. Allow spontaneous labour up to 41 weeks with increased fetal monitoring
D. Recommend elective caesarean section at 38 weeks
E. Offer induction of labour between 39+0 and 40+6 weeks

Explanation: ***Offer induction of labour between 38+0 and 39+6 weeks*** - For women with **gestational diabetes** managed with **insulin** or oral medication in an otherwise uncomplicated pregnancy, induction is recommended between **38+0 and 39+6 weeks**. - This timing balances the increased risk of **stillbirth** and placental insufficiency against the risks of **iatrogenic prematurity**. *Offer induction of labour between 37+0 and 38+6 weeks* - This earlier window was previously suggested but older **NICE guidelines** have been refined; it is usually reserved for those with **poor glycaemic control** or other co-morbidities. - Induction before 38 weeks increases the risk of **neonatal respiratory distress** in pregnancies that are otherwise progressing normally. *Allow spontaneous labour up to 41 weeks with increased fetal monitoring* - Waiting until 41 weeks is inappropriate for patients on **insulin** due to the significantly elevated risk of **perinatal mortality**. - Spontaneous labour up to 40+6 weeks is only typically offered to women with **diet-controlled** gestational diabetes and no other complications. *Recommend elective caesarean section at 38 weeks* - **Caesarean section** is not routinely recommended based solely on a diagnosis of gestational diabetes. - Mode of delivery should be based on **obstetric indications** or maternal preference, with **vaginal delivery** being the primary aim for most. *Offer induction of labour between 39+0 and 40+6 weeks* - Waiting until after 40 weeks increases the risk of **macrosomia** and associated birth trauma like **shoulder dystocia** in diabetic pregnancies. - While some guidelines suggest up to 40+6 for diet-controlled GDM, those on **insulin** require earlier intervention to mitigate metabolic risks.

Question 81: A 33-year-old woman presents to the emergency department at 38 weeks gestation with sudden onset severe headache, visual disturbances with flashing lights, and epigastric pain. She has had an uncomplicated pregnancy until now. Blood pressure is 168/110 mmHg. Urinalysis shows 3+ protein. Blood tests reveal: platelets 95 × 10⁹/L, ALT 180 U/L, AST 195 U/L, creatinine 110 μmol/L. What is the most appropriate immediate management?

A. Commence IV magnesium sulphate and prepare for delivery (Correct Answer)
B. Administer oral labetalol and observe for 24 hours
C. Give IV hydralazine and arrange urgent CT head
D. Start oral nifedipine and await senior review
E. Administer IV labetalol and perform urgent Doppler studies

Explanation: ***Commence IV magnesium sulphate and prepare for delivery*** - The patient's symptoms (severe headache, visual disturbances, epigastric pain), severe hypertension (168/110 mmHg), proteinuria, and abnormal lab results (thrombocytopenia and elevated liver enzymes indicative of **HELLP syndrome**) point to **severe pre-eclampsia** with features of impending eclampsia, necessitating immediate **seizure prophylaxis** with IV magnesium sulphate. - At **38 weeks gestation**, the pregnancy is at term, and **delivery** is the definitive and most appropriate immediate management to resolve severe pre-eclampsia and prevent progression to eclampsia or other severe maternal and fetal complications. *Administer oral labetalol and observe for 24 hours* - **Oral antihypertensives** like labetalol are generally too slow and insufficient for the rapid blood pressure control required in **severe pre-eclampsia** with neurological symptoms. - **Observation for 24 hours** is inappropriate and unsafe given the life-threatening nature of the condition at term, as it risks progression to eclampsia, placental abruption, or further HELLP syndrome complications. *Give IV hydralazine and arrange urgent CT head* - While **IV hydralazine** can effectively lower blood pressure, it does not provide the crucial **seizure prophylaxis** that **magnesium sulphate** offers and is immediately needed for this patient. - An **urgent CT head** is not the first-line immediate management unless there are focal neurological deficits or persistent altered mental status *after* a seizure, but stabilizing the patient and preventing seizures is paramount. *Start oral nifedipine and await senior review* - **Oral nifedipine** is typically reserved for less severe hypertension or as an adjunct, and it lacks the rapid action needed for this patient's severe presentation. - **Awaiting senior review** without initiating definitive treatment like magnesium sulphate and preparing for delivery represents an unacceptable delay in a critical obstetric emergency. *Administer IV labetalol and perform urgent Doppler studies* - **IV labetalol** will address hypertension but does not provide the essential **seizure prophylaxis** required, which is a major immediate risk for this patient. - While **Doppler studies** assess fetal well-being, at **38 weeks gestation** with severe maternal compromise, the priority shifts to **maternal stabilization** and immediate delivery, as fetal viability is high and further delay is risky.

Question 82: A 29-year-old primigravida at 24 weeks gestation undergoes oral glucose tolerance test (OGTT) following detection of glycosuria at her routine antenatal visit. Results show fasting glucose 5.8 mmol/L and 2-hour glucose 8.6 mmol/L. She has a BMI of 28 kg/m² and no family history of diabetes. How should she be managed?

A. Reassure and repeat OGTT at 28 weeks
B. Diagnose gestational diabetes and commence diet and lifestyle modifications with home glucose monitoring (Correct Answer)
C. Commence metformin immediately without dietary intervention
D. Refer to diabetic specialist team but no immediate intervention needed
E. Diagnose impaired glucose tolerance and perform HbA1c testing

Explanation: ***Diagnose gestational diabetes and commence diet and lifestyle modifications with home glucose monitoring*** - According to **NICE guidelines**, gestational diabetes (GDM) is diagnosed if fasting glucose is **≥5.6 mmol/L** or 2-hour glucose is **≥7.8 mmol/L**; this patient exceeds both thresholds. - Initial management for GDM involves **dietary modification**, exercise, and **self-monitoring of blood glucose** (SMBG) to establish if glycemic targets can be met without medication. *Reassure and repeat OGTT at 28 weeks* - Reassurance is inappropriate because the patient currently meets the **diagnostic criteria** for GDM based on the 24-week test results. - Delaying management until 28 weeks increases the risk of **macrosomia**, polyhydramnios, and other **gestational complications**. *Commence metformin immediately without dietary intervention* - First-line management for GDM is typically a trial of **diet and exercise** for 1–2 weeks before introducing pharmacological agents. - **Metformin** or insulin is indicated only if blood glucose targets are not achieved through lifestyle changes or if fasting levels are significantly elevated (e.g., >7.0 mmol/L). *Refer to diabetic specialist team but no immediate intervention needed* - While referral to a **joint diabetes-antenatal clinic** is necessary, intervention should start immediately with education and glucose monitoring. - Delayed intervention neglects the period of **hyperglycemia**, which impacts fetal growth and maternal health. *Diagnose impaired glucose tolerance and perform HbA1c testing* - **HbA1c** is not recommended for diagnosing GDM as it is unreliable due to increased **red blood cell turnover** and physiological changes in pregnancy. - The term "impaired glucose tolerance" is not the standard clinical diagnosis in pregnancy; the results clearly define **Gestational Diabetes Mellitus**.

Question 83: A 37-year-old woman presents to the antenatal day unit at 31 weeks gestation with reduced fetal movements. This is her second pregnancy; her first child was delivered by emergency caesarean section for fetal distress at 39 weeks. Her booking BMI was 32 kg/m². Blood pressure today is 142/88 mmHg. Urinalysis shows trace protein. Cardiotocography is reassuring. What is the most appropriate initial investigation to assess for potential complications?

A. Umbilical artery Doppler ultrasound
B. Fetal growth scan with estimated fetal weight and amniotic fluid assessment (Correct Answer)
C. 24-hour urine protein collection
D. Maternal blood tests including urea, creatinine and liver function
E. Biophysical profile score

Explanation: ***Fetal growth scan with estimated fetal weight and amniotic fluid assessment*** - In a patient with **reduced fetal movements** and multiple risk factors (BMI >30, age >35, previous C-section), the primary concern is identifying **fetal growth restriction (FGR)** or **placental insufficiency**. - Assessing **estimated fetal weight (EFW)** and **amniotic fluid volume (AFV)** is the gold standard initial step to evaluate chronic fetal wellbeing and potential complications like **oligohydramnios**. *Umbilical artery Doppler ultrasound* - This is usually performed as a secondary measure if the **fetal growth scan** reveals a small-for-gestational-age fetus or other growth concerns. - While useful for assessing **placental resistance**, it does not provide the primary biometric data required to diagnose **growth restriction** itself. *24-hour urine protein collection* - This investigation is used to quantify protein in suspected **pre-eclampsia**, but a trace protein result and blood pressure of 142/88 mmHg do not yet meet diagnostic criteria. - The immediate priority in the context of **reduced fetal movements** is the assessment of the fetus rather than definitive proteinuria quantification. *Maternal blood tests including urea, creatinine and liver function* - These tests screen for multi-organ involvement in **pre-eclampsia**, which is a consideration given her blood pressure and BMI. - However, these are secondary to the **ultrasound assessment** of fetal growth and liquid when the presenting complaint is decreased movement. *Biophysical profile score* - The **Biophysical profile (BPP)** is a comprehensive assessment that includes CTG and ultrasound parameters, but it is time-consuming and often reserved for specific high-risk scenarios. - Current guidelines favor a **growth scan** and **liquor assessment** as the standard first-line anatomical and physiological evaluation for reduced movements.

Question 84: A 32-year-old woman with pre-existing chronic hypertension presents for pre-pregnancy counselling. She is currently taking ramipril 5 mg daily, which provides excellent blood pressure control. She has no other medical conditions and her renal function is normal. What advice should be given regarding her antihypertensive medication in pregnancy?

A. Continue ramipril throughout pregnancy as blood pressure control is optimal
B. Switch to labetalol before conception or as soon as pregnancy is confirmed (Correct Answer)
C. Continue ramipril in the first trimester then switch to nifedipine
D. Stop all antihypertensive medication and monitor blood pressure closely
E. Switch to atenolol as it is safer in pregnancy than ramipril

Explanation: ***Switch to labetalol before conception or as soon as pregnancy is confirmed***- **ACE inhibitors** like ramipril are strictly **contraindicated** in pregnancy due to associations with **major congenital malformations**, fetal renal failure, and oligohydramnios.- **Labetalol**, a combined alpha/beta-blocker, is a recommended first-line, safe antihypertensive for managing **chronic hypertension** during pregnancy.*Continue ramipril throughout pregnancy as blood pressure control is optimal*- Ramipril exposure during the second and third trimesters can lead to severe adverse fetal outcomes such as **oligohydramnios**, **fetal skull hypoplasia**, and **neonatal anuria/renal failure**.- The risks of **teratogenicity** and potential fetal demise far outweigh any maternal benefit of maintaining ramipril for blood pressure control.*Continue ramipril in the first trimester then switch to nifedipine*- Although the highest risk for severe fetal renal complications with ACE inhibitors is in the second and third trimesters, they should ideally be avoided from **conception**.- Guidelines recommend transitioning to safe alternatives like **nifedipine** or labetalol **before** conception or as soon as pregnancy is confirmed to avoid any early gestational exposure.*Stop all antihypertensive medication and monitor blood pressure closely*- Discontinuing antihypertensive medication in a patient with pre-existing **chronic hypertension** significantly increases the risk of **maternal stroke**, placental abruption, and **preeclampsia**.- Maintaining adequate blood pressure control is crucial throughout pregnancy to ensure optimal maternal health and fetal development.*Switch to atenolol as it is safer in pregnancy than ramipril*- **Atenolol** is associated with an increased risk of **intrauterine growth restriction (IUGR)** and fetal bradycardia, and is generally not a preferred first-line agent in pregnancy.- While considered safer than ACE inhibitors, **labetalol**, **nifedipine**, and **methyldopa** are generally preferred due to a more favorable safety profile.

Question 85: A 30-year-old woman with gestational diabetes is seen at 34 weeks gestation. She has been managing her condition with diet alone since diagnosis at 28 weeks. Her recent capillary blood glucose readings show: fasting 5.4 mmol/L, 1-hour post-breakfast 8.2 mmol/L, 1-hour post-lunch 7.8 mmol/L, 1-hour post-dinner 8.5 mmol/L. She reports good dietary compliance. What is the most appropriate next step in her management?

A. Continue diet alone and review in 2 weeks
B. Start metformin 500 mg once daily (Correct Answer)
C. Start insulin therapy
D. Start metformin 500 mg twice daily
E. Arrange urgent delivery within 48 hours

Explanation: ***Start metformin 500 mg once daily***- According to **NICE guidelines**, if blood glucose targets (fasting <5.3 mmol/L and 1-hour postprandial <7.8 mmol/L) are not met with diet alone, **metformin** should be offered as first-line pharmacological treatment.- This patient's **fasting (5.4 mmol/L)** and **postprandial (8.2/8.5 mmol/L)** readings are above targets, and it is standard practice to start with a low dose like **500 mg once daily** and titrate upward.*Continue diet alone and review in 2 weeks*- Pharmacological intervention is required because the patient is **not meeting glycemic targets** despite reporting good dietary compliance.- Delaying treatment for 2 weeks poses an unnecessary risk of **macrosomia** and other gestational diabetes-related complications.*Start insulin therapy*- **Insulin** is usually reserved as second-line treatment if targets are not met with metformin or if metformin is **contraindicated** or not tolerated.- Immediate insulin start is typically only indicated if the fasting glucose at diagnosis is significantly elevated (**>= 7.0 mmol/L**) or if there are signs of **fetal macrosomia**.*Start metformin 500 mg twice daily*- While the patient requires metformin, the standard clinical protocol is to initiate treatment at **500 mg once daily** to minimize **gastrointestinal side effects**.- Increasing to a twice-daily dose occurs during the **titration phase** based on subsequent blood glucose monitoring results.*Arrange urgent delivery within 48 hours*- There is no clinical indication for **preterm delivery** at 34 weeks based solely on mildly elevated blood glucose levels.- Delivery is usually planned between **37+0 and 38+6 weeks** for women with gestational diabetes, unless there are acute fetal or maternal complications.

Question 86: A 34-year-old woman attends her first antenatal appointment at 18 weeks gestation. She has no significant medical history. Her BMI is 22 kg/m². Blood pressure is 118/76 mmHg. She asks about the routine blood tests performed in pregnancy. Which autoantibody screening is routinely offered to all pregnant women in the UK antenatal care programme?

A. Anti-nuclear antibodies (ANA)
B. Anti-thyroid peroxidase (anti-TPO) antibodies
C. Anti-red cell antibodies (Correct Answer)
D. Anti-phospholipid antibodies
E. Anti-double stranded DNA antibodies

Explanation: ***Anti-red cell antibodies*** - Screening for **blood group** and **anti-red cell antibodies** is a mandatory part of the UK routine antenatal care, performed at booking and 28 weeks gestation. - This is critical for identifying **Rhesus D incompatibility** and other antibodies that could cause **haemolytic disease of the fetus and newborn (HDFN)**. *Anti-nuclear antibodies (ANA)* - **ANA** screening is not a routine test and is only indicated if there is clinical suspicion of **systemic lupus erythematosus (SLE)** or other connective tissue diseases. - Routine testing would lead to high rates of false positives, as low-titer ANA can be seen in healthy individuals. *Anti-thyroid peroxidase (anti-TPO) antibodies* - Routine screening for **TPO antibodies** is not recommended in the UK; thyroid function is only assessed if the patient is symptomatic or has a **pre-existing thyroid condition**. - While anti-TPO is associated with **postpartum thyroiditis**, it does not meet the criteria for universal population screening in pregnancy. *Anti-phospholipid antibodies* - Testing for **lupus anticoagulant** or **anti-cardiolipin antibodies** is reserved for women with specific histories, such as **recurrent miscarriage** or previous venous thromboembolism. - These are not screened in a low-risk patient with no significant medical history like the woman in this scenario. *Anti-double stranded DNA antibodies* - **Anti-dsDNA** is a highly specific marker for SLE and is used for monitoring **disease activity** rather than as a general screening tool. - It is only requested if the patient has a positive **ANA** or clinical features suggestive of active **lupus**.

Question 87: A 27-year-old woman with well-controlled gestational diabetes on metformin presents at 40 weeks gestation. She has been offered induction of labour. She asks why she cannot wait for spontaneous labour beyond 40 weeks as she has read that induction increases the risk of caesarean section. Her fetal growth scans have been normal and her most recent estimated fetal weight is 3.6 kg (50th centile). Her blood glucose control has been excellent with all values within target range. What is the most appropriate counselling regarding timing of delivery?

A. She can safely await spontaneous labour until 42 weeks with standard monitoring
B. Induction should be offered by 40+6 weeks due to increased risk of stillbirth with gestational diabetes (Correct Answer)
C. Elective caesarean section is recommended at 40 weeks due to gestational diabetes
D. She can await spontaneous labour until 41 weeks then should have induction
E. Immediate induction is required today as she has reached 40 weeks with gestational diabetes

Explanation: ***Induction should be offered by 40+6 weeks due to increased risk of stillbirth with gestational diabetes***- **NICE guidelines** recommend that women with **gestational diabetes** should be offered birth (induction or elective cesarean) between **38+0 and 40+6 weeks**.- Delivery is recommended by this time because gestational diabetes is associated with an increased risk of **late stillbirth** and other metabolic complications as the pregnancy progresses.*She can safely await spontaneous labour until 42 weeks with standard monitoring*- Awaiting spontaneous labor until **42 weeks** is inappropriate for diabetic patients due to the significantly elevated **risk of intrauterine fetal death** beyond 41 weeks.- Standard post-dates monitoring is insufficient to mitigate the specific **metabolic risks** associated with gestational diabetes in late pregnancy.*Elective caesarean section is recommended at 40 weeks due to gestational diabetes*- **Elective caesarean section** is generally only offered if there are specific complications such as **macrosomia** (EFW >4.5kg) or a previous history of shoulder dystocia.- For a patient with a **normal estimated fetal weight** (3.6kg) and good control, **induction of labor** is the preferred method for planned delivery.*She can await spontaneous labour until 41 weeks then should have induction*- While 41 weeks is close to the limit, the specific guidelines state delivery should be offered no later than **40+6 weeks** to optimize safety.- Recommending 41 weeks ignores the established clinical evidence that **stillbirth risk** rises more sharply in diabetic pregnancies after the 40th week.*Immediate induction is required today as she has reached 40 weeks with gestational diabetes*- While **induction** is offered from **38+0 weeks**, it is not immediately mandatory at **40 weeks** if the patient is well-controlled and fetal growth is normal.- The recommendation is to offer delivery by **40+6 weeks**, providing a window for discussion and preparation rather than requiring immediate intervention at 40 weeks exact.

Question 88: A 38-year-old woman in her fourth pregnancy presents to the antenatal clinic at 20 weeks gestation. She has previously had three normal vaginal deliveries. Her booking blood pressure at 10 weeks was 124/78 mmHg. Today her blood pressure is 156/98 mmHg on two readings 30 minutes apart. She is asymptomatic. Urinalysis is negative for protein. Blood tests show: Hb 125 g/L, platelets 256 × 10⁹/L, ALT 24 IU/L, creatinine 64 μmol/L. Which diagnosis best fits this clinical presentation?

A. Essential hypertension unmasked by pregnancy
B. Chronic hypertension
C. Gestational hypertension (Correct Answer)
D. Pre-eclampsia
E. White coat hypertension

Explanation: ***Gestational hypertension***- This is defined as new-onset **hypertension (≥140/90 mmHg)** occurring **after 20 weeks** of gestation without **proteinuria** or signs of end-organ damage.- The patient’s blood pressure was normal at 10 weeks, and her recent readings at 20 weeks show elevation with **negative protein** and normal lab results (ALT, creatinine, platelets).*Essential hypertension unmasked by pregnancy*- This refers to pre-existing hypertension that may not have been documented prior to pregnancy but becomes apparent during the clinical visits.- Since her **booking blood pressure** at 10 weeks was normal, and BP typically dips in the first trimester, a normal reading then makes this less likely than gestational hypertension.*Chronic hypertension*- Chronic hypertension is diagnosed if the high blood pressure is present **before pregnancy** or is detected **before 20 weeks** of gestation.- This patient’s normal BP at 10 weeks (124/78 mmHg) effectively excludes a diagnosis of **pre-existing** or chronic hypertension.*Pre-eclampsia*- Pre-eclampsia requires new-onset hypertension after 20 weeks plus **proteinuria** or evidence of **maternal organ dysfunction** (e.g., low platelets, high ALT).- This patient is **asymptomatic**, has no proteinuria on urinalysis, and her blood tests show normal **liver and renal function**.*White coat hypertension*- This occurs when BP is elevated in a clinical setting but normal during **ambulatory or home monitoring**.- While possible, the standard clinical diagnosis for new-onset clinical hypertension occurring exactly at the 20-week threshold in a previously normotensive woman is **gestational hypertension**.

Question 89: A 30-year-old primigravida is reviewed at 28 weeks gestation. She was diagnosed with gestational diabetes at 26 weeks and has been following dietary advice for two weeks. Her home blood glucose monitoring shows: fasting 5.1-5.4 mmol/L, 1-hour post-prandial values 7.2-8.1 mmol/L. She is compliant with diet and monitoring. Fetal growth scan shows estimated fetal weight on 60th centile with normal liquor volume. What is the most appropriate management?

A. Add metformin 500 mg once daily (Correct Answer)
B. Continue dietary management alone with review in 2 weeks
C. Add metformin 500 mg twice daily
D. Commence insulin therapy
E. Arrange admission for stabilisation of blood glucose

Explanation: ***Add metformin 500 mg once daily*** - The patient's **1-hour post-prandial glucose values** (up to 8.1 mmol/L) are consistently above the target of <7.8 mmol/L, despite **two weeks of compliant dietary management**. This indicates a need for pharmacological intervention. - **Metformin** is the recommended **first-line oral medication** for gestational diabetes after lifestyle modifications fail. Starting with a **low dose** (500 mg once daily) helps assess tolerance and minimizes **gastrointestinal side effects**.*Continue dietary management alone with review in 2 weeks* - This patient has already followed **lifestyle modifications** for two weeks, and her **post-prandial values** are still above the target of 7.8 mmol/L, indicating inadequate glycemic control. - Delaying treatment would increase the risk of **macrosomia**, pre-eclampsia, and other **maternal and fetal complications**, despite the current normal fetal growth.*Add metformin 500 mg twice daily* - While **metformin** is the correct medication, initiating with 500 mg twice daily as a starting dose is generally not recommended. - Guidelines suggest a **gradual titration** starting once daily to improve **tolerability** and reduce the incidence of **gastrointestinal side effects** like nausea and abdominal pain.*Commence insulin therapy* - **Insulin** is typically reserved as first-line treatment if the **fasting glucose** is significantly elevated (e.g., >7.0 mmol/L) or if metformin is contraindicated or ineffective. - For this patient, whose fasting levels are borderline and post-prandial values are only moderately elevated, a trial of **oral metformin** is the next appropriate step.*Arrange admission for stabilisation of blood glucose* - Admission for **blood glucose stabilization** is only indicated for patients with **severe hyperglycaemia**, metabolic instability like **ketoacidosis**, or acute fetal distress. - GDM management is primarily **outpatient-based**, with medication adjustments made based on home blood glucose monitoring.

Question 90: A 35-year-old woman with type 1 diabetes mellitus attends pre-pregnancy counselling. She has had diabetes for 15 years and her most recent HbA1c is 58 mmol/mol (7.5%). She takes insulin glargine 20 units at night and insulin aspart before meals. She also takes ramipril 5 mg daily for microalbuminuria and atorvastatin 20 mg daily for hyperlipidaemia. Her retinal screening last year showed no retinopathy. Which medication change is most important before conception?

A. Stop ramipril and commence labetalol
B. Stop atorvastatin and ramipril (Correct Answer)
C. Increase folic acid to 5 mg daily and stop atorvastatin
D. Stop all medications except insulin and commence aspirin 150 mg daily
E. Switch from insulin glargine to insulin detemir

Explanation: ***Stop atorvastatin and ramipril*** - Both **statins** (atorvastatin) and **ACE inhibitors** (ramipril) are strictly contraindicated in pregnancy due to their significant **teratogenic effects** on the fetus. - **ACE inhibitors** are associated with **fetal renal dysgenesis** and skull ossification defects, while **statins** may interfere with fetal cholesterol synthesis, which is essential for development. *Stop ramipril and commence labetalol* - While **ramipril** must be stopped due to its teratogenicity, **labetalol** is only indicated if the patient is actually **hypertensive**; this patient uses ramipril for **microalbuminuria**, not necessarily for blood pressure control. - Commencing a beta-blocker without a clear clinical indication for hypertension is not the most important immediate step compared to stopping both identified teratogens. *Increase folic acid to 5 mg daily and stop atorvastatin* - High-dose **folic acid (5 mg)** is indeed recommended for women with diabetes preconception, and stopping **atorvastatin** is correct; however, this option fails to address the critical need to discontinue **ramipril**, another major teratogen. - Both potentially harmful medications (statin and ACE inhibitor) must be addressed simultaneously before conception occurs for optimal fetal safety. *Stop all medications except insulin and commence aspirin 150 mg daily* - **Aspirin 150 mg** daily is indicated for **pre-eclampsia prophylaxis** in diabetic pregnancies, but it is typically commenced from **12 weeks gestation**, not during the pre-conception phase. - The instruction to "stop all medications" is imprecise and does not specifically highlight the critical need to discontinue known **teratogenic drugs** like ramipril and atorvastatin. *Switch from insulin glargine to insulin detemir* - Modern guidelines indicate that both **insulin glargine** and **insulin detemir** are considered safe for use throughout pregnancy and do not necessitate a switch if glycaemic control is stable. - This change is unnecessary and does not address the high-risk issues posed by the patient's **statin** and **ACE inhibitor** therapy, which are the primary concerns pre-conception.

Question 91: A 26-year-old woman attends the antenatal clinic at 36 weeks gestation for routine review. She has chronic hypertension and has been taking methyldopa 500 mg three times daily throughout pregnancy. Her blood pressure today is 152/98 mmHg. She is asymptomatic. Urinalysis shows 1+ proteinuria. Blood tests show: Hb 118 g/L, platelets 178 × 10⁹/L, ALT 32 IU/L, creatinine 76 μmol/L. Her booking blood pressure was 138/88 mmHg with no proteinuria. Fetal growth and amniotic fluid are normal on ultrasound. What is the most appropriate next step in management?

A. Increase methyldopa dose to 750 mg three times daily and review in one week
B. Send urine protein:creatinine ratio and review in clinic in 48 hours (Correct Answer)
C. Admit for inpatient monitoring and consider delivery
D. Add nifedipine 10 mg modified release twice daily and review in 48 hours
E. Continue current management and arrange routine follow-up in one week

Explanation: ***Send urine protein:creatinine ratio and review in clinic in 48 hours*** - The patient has **chronic hypertension** with new-onset **proteinuria** after 20 weeks gestation and elevated blood pressure, which is highly suspicious for **superimposed pre-eclampsia**. - A **uPCR (urine protein:creatinine ratio)** is the gold standard for quantifying proteinuria and confirming the diagnosis; a ratio **≥30 mg/mmol** is significant. *Increase methyldopa dose to 750 mg three times daily and review in one week* - While the BP is elevated, the priority is to **quantify proteinuria** to diagnose or rule out **superimposed pre-eclampsia** before adjusting medication. - A one-week review is too prolonged for a patient with potential **superimposed pre-eclampsia** at 36 weeks gestation, given the risks of rapid deterioration. *Admit for inpatient monitoring and consider delivery* - Inpatient admission and considering delivery are typically reserved for **severe pre-eclampsia** (BP ≥160/110 mmHg) or signs of **end-organ damage**. - The patient's blood pressure is not in the severe range, she is **asymptomatic**, and her laboratory values are currently normal. *Add nifedipine 10 mg modified release twice daily and review in 48 hours* - While adding a second anti-hypertensive might be necessary, the initial priority is to **confirm the diagnosis** of **superimposed pre-eclampsia** through proteinuria quantification. - Treating blood pressure alone without confirming the diagnosis overlooks the critical aspect of **gestational risk stratification** and management. *Continue current management and arrange routine follow-up in one week* - Ignoring new-onset **1+ proteinuria** in a pregnant woman with chronic hypertension is unsafe, as it indicates a potential progression to **superimposed pre-eclampsia**. - Routine follow-up is inadequate because **superimposed pre-eclampsia** can advance rapidly, increasing the risk of both **maternal and fetal complications**.

Question 92: A 37-year-old woman attends antenatal clinic at 12 weeks gestation in her second pregnancy. Her first pregnancy was complicated by gestational diabetes requiring insulin therapy. Her BMI is 33 kg/m². Random blood glucose today is 6.8 mmol/L. HbA1c is 42 mmol/mol (6.0%). She asks about screening for gestational diabetes in this pregnancy. What is the most appropriate screening approach for this woman?

A. Commence monthly HbA1c monitoring throughout pregnancy
B. Self-monitoring of blood glucose from now until delivery
C. No screening required as her HbA1c is normal
D. Arrange oral glucose tolerance test at 24-28 weeks only
E. Arrange oral glucose tolerance test at 16 weeks and again at 28 weeks if first test is normal (Correct Answer)

Explanation: ***Arrange oral glucose tolerance test at 16 weeks and again at 28 weeks if first test is normal***- For women with a history of **gestational diabetes** and other risk factors like **high BMI**, guidelines recommend early screening with an **oral glucose tolerance test (OGTT)**, typically around **16-18 weeks**.- If the initial OGTT is normal, a repeat test is advised at **24-28 weeks** because insulin resistance naturally increases in later pregnancy, raising the risk of developing GDM. *Commence monthly HbA1c monitoring throughout pregnancy* - **HbA1c** is not the primary screening tool for gestational diabetes due to physiological changes in red blood cell turnover during pregnancy affecting its reliability.- While useful for assessing long-term glycemic control, it does not replace the dynamic nature of an **OGTT** for diagnosing GDM. *Self-monitoring of blood glucose from now until delivery* - **Self-monitoring of blood glucose (SMBG)** is a management strategy used *after* a diagnosis of gestational diabetes has been made, to help manage blood sugar levels.- It is not an initial screening method for diagnosing the condition, and starting it before diagnosis would be premature and potentially cause unnecessary anxiety. *No screening required as her HbA1c is normal* - A normal **HbA1c** (e.g., 42 mmol/mol or 6.0%) at booking indicates the absence of pre-existing diabetes but does not rule out the development of **gestational diabetes**.- This patient has significant risk factors (previous GDM, BMI 33 kg/m²), making screening essential despite a normal early HbA1c. *Arrange oral glucose tolerance test at 24-28 weeks only* - While an **OGTT at 24-28 weeks** is standard for women with other risk factors (like obesity alone), it is insufficient for those with a **history of gestational diabetes**.- Patients with prior GDM are at higher risk for early-onset disease, necessitating earlier screening to detect and manage hyperglycemia promptly.

Question 93: A 32-year-old woman is admitted at 35 weeks gestation with severe pre-eclampsia. Blood pressure is 168/114 mmHg despite treatment with labetalol 200 mg three times daily. Blood tests show: platelets 98 × 10⁹/L, ALT 156 IU/L, AST 178 IU/L, bilirubin 32 μmol/L, creatinine 118 μmol/L, urea 8.2 mmol/L, LDH 642 IU/L. Blood film shows fragmented red cells. She has right upper quadrant pain and is being prepared for delivery. In addition to continuing antihypertensive therapy, what other medication should be administered immediately?

A. Intravenous magnesium sulphate (Correct Answer)
B. Intramuscular betamethasone
C. Intravenous tranexamic acid
D. Platelet transfusion
E. Intravenous hydrocortisone

Explanation: ***Intravenous magnesium sulphate*** - This patient presents with clear signs of **HELLP syndrome** (Haemolysis, Elevated Liver enzymes, Low Platelets) and **severe pre-eclampsia**, including microangiopathic hemolytic anemia (fragmented red cells, elevated LDH, elevated bilirubin), elevated liver enzymes, and thrombocytopenia, along with uncontrolled hypertension. - **Magnesium sulphate** is the cornerstone for **seizure prophylaxis** in women with severe pre-eclampsia or HELLP syndrome, and its immediate administration is critical to prevent eclampsia, especially with imminent delivery. *Intramuscular betamethasone* - **Corticosteroids** like betamethasone are primarily given to accelerate **fetal lung maturity**, usually indicated for pregnancies between 24 and 34+6 weeks gestation. - At 35 weeks gestation, the benefit for fetal lung maturity is less pronounced, and the immediate priority is maternal stabilization and **prevention of eclampsia** over fetal lung maturation. *Intravenous tranexamic acid* - **Tranexamic acid** is an antifibrinolytic agent used to prevent or reduce **blood loss**, particularly in cases of significant hemorrhage like **postpartum hemorrhage**. - While HELLP syndrome can increase the risk of bleeding due to thrombocytopenia and coagulopathy, there is no indication of active, severe hemorrhage warranting immediate tranexamic acid administration over seizure prophylaxis. *Platelet transfusion* - **Platelet transfusions** are typically considered for platelet counts below **20-50 × 10⁹/L** in HELLP syndrome, especially before invasive procedures like C-section or in the presence of active bleeding. - With a platelet count of **98 × 10⁹/L**, the patient is above the usual threshold for immediate prophylactic platelet transfusion, and the most pressing concern remains eclampsia prevention. *Intravenous hydrocortisone* - High-dose corticosteroids like hydrocortisone have been explored in the management of HELLP syndrome but are **not a standard or immediately indicated treatment** for improving maternal or neonatal outcomes. - It does not have a role in the **prevention of eclamptic seizures** or direct management of the severe hypertension present in this case.

Question 94: A 40-year-old woman in her third pregnancy attends the antenatal clinic at 16 weeks gestation. She has a history of previous pregnancies: first pregnancy resulted in emergency caesarean section at 32 weeks for severe pre-eclampsia with HELLP syndrome, and second pregnancy ended in miscarriage at 8 weeks. Her BMI is 28 kg/m². Blood pressure today is 128/82 mmHg. She is taking folic acid 400 micrograms daily. What is the most appropriate additional intervention at this stage?

A. Commence aspirin 75 mg daily
B. Commence aspirin 150 mg daily (Correct Answer)
C. Commence low molecular weight heparin prophylaxis
D. Arrange early glucose tolerance test at 20 weeks
E. Commence calcium supplementation 1 gram daily

Explanation: ***Commence aspirin 150 mg daily*** - This patient has one **high-risk factor** for pre-eclampsia (previous history of **HELLP syndrome** and severe pre-eclampsia requiring delivery at 32 weeks), necessitating aspirin prophylaxis. - Current **NICE guidelines** and recent evidence (such as the ASPRE trial) recommend a dose of **150 mg daily** started at 12–16 weeks for better efficacy compared to lower doses. *Commence aspirin 75 mg daily* - While 75 mg was historically used, modern practice and many hospital protocols now favor **150 mg** to ensure adequate suppression of **thromboxane synthesis**. - A lower dose may be less effective in preventing **pre-eclampsia** in patients with significant high-risk factors like previous early-onset disease. *Commence low molecular weight heparin prophylaxis* - **LMWH** is used for venous thromboembolism prophylaxis or for women with **antiphospholipid syndrome** (APS); this patient does not currently meet the criteria for APS despite a single miscarriage. - While her BMI and age are noted, she lacks the threshold of risk factors required to initiate **heparin** prophylaxis at 16 weeks based solely on the provided history. *Arrange early glucose tolerance test at 20 weeks* - Although she is **40 years old**, which is a risk factor for gestational diabetes, an Oral Glucose Tolerance Test (OGTT) is typically performed at **24–28 weeks**. - Prioritizing **aspirin** is more clinically urgent given the high recurrence risk of severe pre-eclampsia and the current 16-week window for intervention. *Commence calcium supplementation 1 gram daily* - Calcium supplementation is recommended by the **WHO** for populations with low dietary intake, but it is not standard first-line prophylaxis in the UK. - It does not replace the requirement for **aspirin**, which provides more robust protection against placental-mediated hypertensive disorders in high-risk women.

Question 95: A 28-year-old woman presents to the emergency department at 34 weeks gestation with a severe frontal headache of sudden onset that started 3 hours ago. She describes it as the worst headache of her life. Her blood pressure is 162/104 mmHg. She has photophobia and neck stiffness. Urinalysis shows 2+ proteinuria. Blood tests show: platelets 142 × 10⁹/L, ALT 45 IU/L, creatinine 82 μmol/L. Fundoscopy reveals no papilloedema. She is drowsy but oriented. What is the most appropriate immediate investigation?

A. CT head without contrast (Correct Answer)
B. MRI brain with gadolinium contrast
C. Lumbar puncture for cerebrospinal fluid analysis
D. Urine protein:creatinine ratio
E. Repeat blood tests including full blood count and liver function

Explanation: ***CT head without contrast***- The presentation of a sudden-onset **"worst headache of life"** combined with **neck stiffness** and **photophobia** is highly suggestive of a **subarachnoid haemorrhage (SAH)**.- A **non-contrast CT head** is the immediate gold-standard investigation to detect acute intracranial bleeding and is safe during pregnancy with appropriate fetal shielding.*MRI brain with gadolinium contrast*- While sensitive for certain pathologies, **MRI** is time-consuming in an emergency setting and is not the first-line choice for ruling out acute haemorrhage.- **Gadolinium contrast** is generally avoided in pregnancy as it crosses the placenta and its long-term effects on the fetus are not fully established.*Lumbar puncture for cerebrospinal fluid analysis*- A **lumbar puncture** is used to detect **xanthochromia** if the CT is negative but suspicion of SAH remains high.- It must never be performed before neuroimaging because of the risk of **brain herniation** if raised intracranial pressure is present.*Urine protein:creatinine ratio*- Although this patient has **pre-eclampsia** (hypertension and proteinuria), this test only quantifies the degree of proteinuria.- It does not address the acute, life-threatening neurological symptoms that require **urgent intracranial imaging**.*Repeat blood tests including full blood count and liver function*- These tests monitor for **HELLP syndrome** and other complications of pre-eclampsia but do not diagnose the cause of the sudden-onset headache.- Clinical priority must be given to excluding a **haemorrhagic stroke** or SAH, which are major causes of maternal mortality.

Question 96: A 33-year-old woman with gestational diabetes diagnosed at 27 weeks gestation is now 36 weeks pregnant. She has been managed with diet alone and her blood glucose control has been good with fasting values 4.8-5.1 mmol/L and 1-hour post-prandial values 6.8-7.4 mmol/L. Growth scans show the fetal abdominal circumference consistently on the 95th centile with estimated fetal weight on the 92nd centile. The head circumference and femur length are on the 50th centile. Amniotic fluid volume is normal. What is the most appropriate next step in management?

A. Continue current management and arrange induction of labour at 40 weeks
B. Commence insulin therapy and arrange growth scan in 2 weeks (Correct Answer)
C. Continue current management and arrange induction of labour at 38-39 weeks
D. Commence metformin therapy and arrange growth scan in 2 weeks
E. Continue current management and arrange delivery by elective caesarean section at 37 weeks

Explanation: ***Commence insulin therapy and arrange growth scan in 2 weeks***- Despite seemingly normal maternal glucose readings, an **abdominal circumference (AC) at the 95th centile** indicates **fetal macrosomia** and hyperinsulinemia, requiring pharmacological intensification.- **Insulin therapy** is preferred for immediate and precise glycemic control when ultrasound evidence shows asymmetrical fetal overgrowth to reduce the risk of **shoulder dystocia**.*Continue current management and arrange induction of labour at 40 weeks*- This approach ignores the **accelerated fetal growth**, which signifies that diet alone is failing to control fetal hyperinsulinism.- Delaying to **40 weeks** in a poorly controlled or macrosomic diabetic pregnancy increases the risks of **stillbirth** and birth trauma.*Continue current management and arrange induction of labour at 38-39 weeks*- While 38-39 weeks is a standard induction window for GDM, it is inappropriate here as **active intervention** (medication) is needed now to address the **rising abdominal circumference**.- Continuing current management fails to address the underlying **fetal overgrowth** occurring at 36 weeks.*Commence metformin therapy and arrange growth scan in 2 weeks*- **Metformin** is an option for GDM, but when there is clear evidence of **macrosomia** (AC >95th centile), **insulin** is the more effective and widely recommended first-line pharmacological treatment to halt rapid growth.- Transitioning to insulin is more reliable for achieving strict targets when the fetus already shows signs of **asymmetrical growth**.*Continue current management and arrange delivery by elective caesarean section at 37 weeks*- **Elective caesarean section** is generally reserved for estimated fetal weights exceeding **4.5 kg** or other obstetric indications, not as a primary response to high AC centiles.- This ignores the need to optimize **metabolic control** via insulin to stabilize fetal growth before delivery.

Question 97: A 36-year-old woman presents to the antenatal day unit at 30 weeks gestation with a blood pressure reading of 146/96 mmHg taken by her community midwife. This is her first pregnancy. Her booking blood pressure at 12 weeks was 118/72 mmHg. She is asymptomatic with no headache, visual disturbances, or epigastric pain. Repeat blood pressure in the unit is 148/94 mmHg. Urinalysis shows no proteinuria. Blood tests show: platelets 189 × 10⁹/L, ALT 28 IU/L, creatinine 68 μmol/L. What is the most appropriate initial management?

A. Reassure and discharge with routine follow-up as this is likely white coat hypertension
B. Commence labetalol 100 mg twice daily and arrange review in 48 hours (Correct Answer)
C. Admit for inpatient monitoring and further investigation
D. Commence aspirin 150 mg daily and arrange review in one week
E. Arrange ambulatory blood pressure monitoring and review in one week

Explanation: ***Commence labetalol 100 mg twice daily and arrange review in 48 hours*** - This patient has **gestational hypertension**, defined as a blood pressure of **≥140/90 mmHg** after 20 weeks of gestation in the absence of proteinuria or other features of pre-eclampsia. - Current **NICE guidelines** recommend pharmacological treatment for any pregnant woman with a blood pressure of **140/90 mmHg or higher**, and **labetalol** is the first-line medication. *Reassure and discharge with routine follow-up as this is likely white coat hypertension* - Persistent readings above 140/90 mmHg in both community and hospital settings confirm **gestational hypertension**, which requires active management. - Routine follow-up is insufficient as this condition carries a risk of progression to **pre-eclampsia** and requires monitoring every 48–72 hours. *Admit for inpatient monitoring and further investigation* - Admission is generally reserved for **severe hypertension** (≥160/110 mmHg) or those with clinical features of **pre-eclampsia** (e.g., proteinuria, organ dysfunction). - Since her bloods are normal and she is **asymptomatic**, outpatient management with close monitoring is appropriate and safe. *Commence aspirin 150 mg daily and arrange review in one week* - **Low-dose aspirin** is used for **preeclampsia prophylaxis** and should be started before 16 weeks gestation in high-risk patients, not as a treatment for acute hypertension. - A one-week review is too infrequent for a new diagnosis of gestational hypertension; the first review should occur within **48 hours**. *Arrange ambulatory blood pressure monitoring and review in one week* - **Ambulatory blood pressure monitoring (ABPM)** is helpful for diagnosing white-coat effect, but here the patient already has two elevated readings, justifying initiation of treatment. - Delaying management for a week increases the risk of maternal and fetal complications associated with uncontrolled **hypertensive disorders of pregnancy**.

Question 98: A 29-year-old woman in her first pregnancy attends the antenatal clinic at 26 weeks gestation. She underwent oral glucose tolerance test (OGTT) following a random glucose of 8.4 mmol/L at 24 weeks. Her OGTT results show: fasting glucose 5.8 mmol/L, 2-hour glucose 9.1 mmol/L. She has been commenced on dietary modifications two weeks ago. She presents her home blood glucose monitoring showing fasting values ranging 5.4-5.8 mmol/L and 1-hour post-prandial values of 8.2-9.5 mmol/L. What is the most appropriate next step in her management?

A. Continue diet and lifestyle modifications alone and review in 2 weeks
B. Add metformin therapy and continue dietary measures (Correct Answer)
C. Commence insulin therapy immediately
D. Arrange urgent endocrinology referral
E. Add glibenclamide therapy

Explanation: ***Add metformin therapy and continue dietary measures*** - This patient's **fasting glucose** (5.4-5.8 mmol/L) and **post-prandial** levels (8.2-9.5 mmol/L) remain above targets (<5.3 and <7.8 respectively) despite two weeks of **dietary modification**. - According to **NICE guidelines**, if glycemic targets are not met within 1-2 weeks of lifestyle changes, **metformin** should be initiated as the first-line pharmacological treatment for **gestational diabetes mellitus**. *Continue diet and lifestyle modifications alone and review in 2 weeks* - Continuing lifestyle measures alone is inappropriate because her blood glucose levels remain consistently **above target** after an adequate trial period. - Delays in achieving **glycemic control** increase the risk of maternal and neonatal complications such as **macrosomia** and birth trauma. *Commence insulin therapy immediately* - **Insulin** is typically reserved as first-line if the fasting glucose at diagnosis is **≥7.0 mmol/L** or if there are signs of **fetal macrosomia** or polyhydramnios. - For this patient, whose fasting levels are only mildly elevated, **metformin** is the preferred initial pharmacological step before escalating to insulin. *Arrange urgent endocrinology referral* - While multidisciplinary care is essential, **gestational diabetes** is managed by established local **diabetes-obstetric teams** rather than an urgent general endocrinology referral. - The immediate clinical priority is the initiation of **pharmacotherapy**, which should be managed within the routine antenatal diabetes pathway. *Add glibenclamide therapy* - **Glibenclamide** is not recommended as a first-line agent and is generally only considered for women who cannot tolerate **metformin** or who decline **insulin** therapy. - It is less commonly used than metformin in current clinical practice due to its specific profile and the effectiveness of other **glucose-lowering** options.

Question 99: A 31-year-old woman presents to the antenatal clinic at 14 weeks gestation for her booking appointment. She has no significant medical history. Her booking bloods reveal: Hb 102 g/L, MCV 71 fL, ferritin 8 mcg/L, HbA1c 34 mmol/mol. Blood pressure is 122/78 mmHg. She asks about the implications of her blood results. What is the most appropriate explanation regarding her anaemia?

A. This represents physiological haemodilution of pregnancy and requires no intervention
B. She has iron deficiency anaemia and should commence oral iron supplementation (Correct Answer)
C. She requires vitamin B12 and folate levels to exclude deficiency
D. This likely represents thalassaemia trait and partner screening should be arranged
E. She should be referred for haematology assessment for possible bone marrow disorder

Explanation: ***She has iron deficiency anaemia and should commence oral iron supplementation*** - The patient presents with **microcytic anaemia** (low MCV 71 fL) and a severely **low ferritin** (8 mcg/L), which is the most sensitive and specific indicator of **iron deficiency**. - In pregnancy, **iron requirements increase significantly**, and a haemoglobin of 102 g/L at 14 weeks gestation, coupled with confirmed iron deficiency, warrants immediate **oral iron supplementation**. *This represents physiological haemodilution of pregnancy and requires no intervention* - While **physiological haemodilution** does occur in pregnancy and lowers Hb, it typically results in **normocytic anaemia** and would not be associated with such a profoundly **low ferritin** level. - The combination of **microcytosis** and **low ferritin** points definitively to a pathological cause (iron deficiency) requiring intervention, not just observation. *She requires vitamin B12 and folate levels to exclude deficiency* - Deficiencies in **vitamin B12** or **folate** cause **macrocytic (megaloblastic) anaemia** (high MCV), which contradicts the patient's **microcytic** MCV of 71 fL. - The presence of **microcytosis** and **low ferritin** clearly establishes **iron deficiency anaemia**, making B12 and folate levels unnecessary as a primary diagnostic step for *this type* of anaemia. *This likely represents thalassaemia trait and partner screening should be arranged* - **Thalassaemia trait** causes **microcytic anaemia** but is typically associated with **normal or elevated ferritin** levels, as it is a disorder of globin chain synthesis, not iron availability. - Given the extremely **low ferritin** in this patient, **iron deficiency** is the primary diagnosis and should be treated first; thalassaemia screening (e.g., **Hb electrophoresis**) would only be considered if microcytosis persists after iron repletion. *She should be referred for haematology assessment for possible bone marrow disorder* - There is no indication of a **bone marrow disorder**, as the patient's anaemia is fully explained by **iron deficiency**, a common and treatable condition in pregnancy. - **Iron deficiency anaemia** in pregnancy is typically managed in the antenatal clinic with **oral iron supplementation**, and specialist haematology referral is not usually required unless there are complications or a failure to respond to treatment.

Question 100: A 34-year-old woman attends her booking appointment at 10 weeks gestation in her second pregnancy. She had a previous postpartum haemorrhage requiring blood transfusion. She takes no regular medications and has no known allergies. Her BMI is 32 kg/m². Blood pressure is 118/76 mmHg and urinalysis is normal. She is keen to know about vitamin supplementation during pregnancy. What is the recommended daily dose of folic acid supplementation for this woman throughout the first trimester?

A. 400 micrograms
B. 1 mg
C. 2.5 mg
D. 5 mg (Correct Answer)
E. 10 mg

Explanation: ***5 mg***- A high dose of **5 mg folic acid** is recommended for women with a **BMI 30 kg/m ** to decrease the risk of **neural tube defects (NTDs)**.- Other indications for this dose include maternal **diabetes**, use of **anti-epileptic drugs**, or a personal/family history of NTDs.*400 micrograms*- This is the standard dose for **low-risk women** without comorbid conditions or a high BMI.- It is insufficient for this patient due to her **obesity (BMI 32 kg/m )**, which increases the baseline risk of fetal malformations.*1 mg*- This dose is not a standard recommendation in national guidelines for any specific maternal risk group.- Clinical protocols strictly differentiate between the low-risk **400 mcg** dose and the high-risk **5 mg** dose.*2.5 mg*- There is no clinical evidence or guideline supporting the use of a **2.5 mg** dose for routine pregnancy supplementation.- For patients identified as high-risk, a full **5 mg** daily dose is required to provide adequate protection.*10 mg*- A **10 mg** dose exceeds the recommended therapeutic upper limit for folic acid in standard obstetric practice.- Excessive supplementation is not proven to provide additional benefit over the **5 mg** dose and is not part of standard guideline protocols.

Question 101: A 37-year-old woman with gestational diabetes on metformin 1000 mg twice daily is reviewed at 34 weeks gestation. Her recent blood glucose monitoring shows: fasting values 5.0-5.4 mmol/L and 1-hour post-prandial values 8.2-8.9 mmol/L despite dietary compliance. Ultrasound shows estimated fetal weight on 75th centile and normal amniotic fluid volume. Her metformin has been optimized and she is already on the maximum dose. She has no contraindications to insulin. What is the most appropriate modification to her treatment regimen?

A. Add long-acting insulin at bedtime while continuing metformin
B. Continue current metformin dose and arrange repeat scan in 2 weeks
C. Add gliclazide 40 mg daily while continuing metformin
D. Add short-acting insulin before meals while continuing metformin (Correct Answer)
E. Switch from metformin to a twice-daily mixed insulin regimen

Explanation: ***Add short-acting insulin before meals while continuing metformin***- The patient's **1-hour post-prandial** glucose levels (8.2-8.9 mmol/L) are above the target of **<7.8 mmol/L**, indicating she specifically needs mealtime glycemic control.- **Metformin** should be continued as it improves insulin sensitivity and reduces the total dose of insulin required during pregnancy.*Add long-acting insulin at bedtime while continuing metformin*- **Long-acting insulin** at bedtime is used to target **fasting hyperglycemia**, but this patient's fasting levels (5.0-5.4 mmol/L) are currently within the acceptable range (<5.3 mmol/L).- Adding basal insulin would not effectively address the primary issue of elevated **post-prandial excursions** seen in this patient.*Continue current metformin dose and arrange repeat scan in 2 weeks*- Failing to meet **glycemic targets** requires active medical intervention to reduce the risk of **macrosomia** and polyhydramnios, especially given the estimated fetal weight on the 75th centile.- Conservative management is inappropriate here because the glucose monitoring already proves that current **dietary compliance** and metformin are insufficient.*Add gliclazide 40 mg daily while continuing metformin*- **Gliclazide** (a sulfonylurea) is generally avoided in pregnancy as first-line add-on therapy due to concerns regarding **neonatal hypoglycemia** and cross-placental passage.- **Insulin** is the preferred second-line agent after metformin because it does not cross the placenta and allows for more precise titration without fetal risk.*Switch from metformin to a twice-daily mixed insulin regimen*- There is no clinical indication to discontinue **metformin**, as it provides baseline stability and prevents excessive weight gain during pregnancy.- A **twice-daily mixed regimen** is less flexible and less physiological than a basal-bolus or targeted bolus approach for managing specific post-meal spikes effectively.

Question 102: A 26-year-old woman attends her booking appointment at 8 weeks gestation. This is her second pregnancy; her first child was delivered by emergency caesarean section at 36 weeks for fetal distress. She has no medical problems and takes only folic acid 400 mcg daily. Her BMI is 24 kg/m². Blood tests show: Hb 118 g/L, ferritin 22 mcg/L, TSH 2.1 mIU/L. Her blood pressure is 118/72 mmHg. Urinalysis is normal. According to current NICE antenatal care guidelines, what additional screening test should be offered at this visit?

A. Screening for pre-eclampsia risk with uterine artery Doppler
B. Screening for fetal aneuploidy with cell-free DNA testing
C. Screening for group B streptococcus with vaginal-rectal swab
D. Screening for gestational diabetes with oral glucose tolerance test
E. Screening for asymptomatic bacteriuria with urine culture (Correct Answer)

Explanation: ***Screening for asymptomatic bacteriuria with urine culture***- **NICE guidelines** recommend offering screening for **asymptomatic bacteriuria** at the booking appointment to all pregnant women using a **midstream urine culture**.- Routine screening and treatment of asymptomatic bacteriuria reduce the risk of progressing to **pyelonephritis**, **preterm delivery**, and low birth weight.*Screening for pre-eclampsia risk with uterine artery Doppler*- This is not a routine screening test in **standard antenatal care**; pre-eclampsia risk is primarily assessed through clinical history and **blood pressure/proteinuria** monitoring.- Women at high risk are usually offered **aspirin** rather than routine specialized Doppler at the booking visit.*Screening for fetal aneuploidy with cell-free DNA testing*- While increasingly used, **cfDNA** is not the standard first-line screening; the **combined test** (nuchal translucency, PAPP-A, and beta-hCG) is the routine primary screening tool offered at 11-14 weeks.- On the NHS, cfDNA is typically offered as a **second-line test** following a high-risk result from the combined or quadruple test.*Screening for group B streptococcus with vaginal-rectal swab*- Universal screening for **Group B Streptococcus (GBS)** is not currently recommended by **NICE** or the RCOG in the UK.- Management focuses on identifying **risk factors** during labor to determine the need for **intrapartum antibiotic prophylaxis**.*Screening for gestational diabetes with oral glucose tolerance test*- The **OGTT** is typically performed between **24 and 28 weeks** of gestation for women with risk factors such as high BMI or a family history of diabetes.- This patient's **BMI of 24** and lack of risk factors mean she would not be offered an early OGTT at booking.

Question 103: A 29-year-old woman with type 1 diabetes is seen in the joint diabetes-obstetric clinic at 32 weeks gestation. She has been taking insulin aspart before meals and insulin detemir at bedtime. Her HbA1c is 52 mmol/mol (6.9%). Home blood glucose monitoring shows occasional pre-breakfast values of 5.8-6.2 mmol/L, with other readings within target. She has had two episodes of nocturnal hypoglycemia (glucose 2.8 and 3.1 mmol/L) in the past week. Growth scans show fetal abdominal circumference on 55th centile. What is the most appropriate adjustment to her insulin regimen?

A. Switch from insulin detemir to insulin glargine for better overnight control
B. Reduce evening insulin detemir dose and ensure bedtime snack (Correct Answer)
C. Add metformin to reduce insulin requirements and hypoglycemia risk
D. Increase evening insulin detemir to achieve lower fasting glucose levels
E. Switch to continuous subcutaneous insulin infusion (insulin pump)

Explanation: ***Reduce evening insulin detemir dose and ensure bedtime snack***- The patient is experiencing **recurrent nocturnal hypoglycemia** (glucose 2.8 and 3.1 mmol/L), which is a critical finding requiring immediate attention and indicates an excessive dose of **basal insulin** overnight.- Reducing the evening detemir dose directly addresses the hypoglycemia, and incorporating a **bedtime snack** with complex carbohydrates can help stabilize blood glucose levels and prevent further overnight drops.*Switch from insulin detemir to insulin glargine for better overnight control*- **Insulin detemir** is a well-established and safe long-acting insulin for use in pregnancy, and there is no inherent clinical advantage of switching to **insulin glargine** in this specific dose-related issue.- The problem stems from an **insulin dose mismatch** causing hypoglycemia, not the specific type of basal insulin being used.*Add metformin to reduce insulin requirements and hypoglycemia risk*- **Metformin** is not indicated for the primary management of **type 1 diabetes** in pregnancy, especially for correcting insulin-induced nocturnal hypoglycemia.- While metformin may be used adjunctively in some specific cases, it is not the appropriate first-line strategy when the core issue is an excessive basal insulin dose.*Increase evening insulin detemir to achieve lower fasting glucose levels*- Increasing the evening detemir dose would critically **worsen the nocturnal hypoglycemia**, posing a significant risk of severe adverse events for the mother.- In pregnant individuals with type 1 diabetes, preventing **hypoglycemia** is a paramount concern and takes precedence over aggressively lowering slightly elevated fasting glucose levels.*Switch to continuous subcutaneous insulin infusion (insulin pump)*- Switching to **CSII (insulin pump) therapy** is a complex change requiring extensive training and is generally reserved for patients unable to achieve glycemic targets with **multiple daily injections (MDI)**.- Given the patient's otherwise reasonable HbA1c and normal fetal growth, a simple and immediate **insulin dose adjustment** is the more appropriate intervention rather than a complete change in delivery method.

Question 104: A 42-year-old woman presents to the antenatal clinic at 16 weeks gestation in her fourth pregnancy. Her obstetric history includes: first pregnancy - spontaneous vaginal delivery at term; second pregnancy - emergency caesarean section at 30 weeks for severe pre-eclampsia; third pregnancy - spontaneous vaginal delivery at 37 weeks on antihypertensive medication for gestational hypertension. She has no chronic medical conditions. Her booking blood pressure was 132/84 mmHg. Today her BP is 128/78 mmHg. What is her risk category for developing pre-eclampsia in this pregnancy?

A. High-risk (one high-risk factor) - should receive aspirin prophylaxis (Correct Answer)
B. Moderate-risk (two or more moderate-risk factors) - should receive aspirin prophylaxis
C. Moderate-risk (one moderate-risk factor) - no aspirin prophylaxis indicated
D. Low-risk - routine antenatal care appropriate
E. High-risk (advanced maternal age and previous pre-eclampsia) - should receive aspirin and increased surveillance

Explanation: ***High-risk (one high-risk factor) - should receive aspirin prophylaxis*** - A history of **hypertensive disease** during a previous pregnancy (specifically **severe pre-eclampsia** in her second pregnancy) is classified as a **high-risk factor** according to NICE guidelines. - Patients with **one high-risk factor** are indicated for **aspirin prophylaxis** (75–150 mg) daily from 12 weeks gestation until birth to reduce the risk of recurrence. *Moderate-risk (two or more moderate-risk factors) - should receive aspirin prophylaxis* - While the patient has one moderate-risk factor (**age ≥40 years**), her history of pre-eclampsia automatically upgrades her to the **high-risk category**. - This classification is incorrect because the presence of even a single high-risk factor supersedes the requirement for multiple moderate-risk factors. *Moderate-risk (one moderate-risk factor) - no aspirin prophylaxis indicated* - Defining her as only moderate-risk ignores her significant obstetric history of **severe pre-eclampsia** and subsequent **gestational hypertension**. - Aspirin is indeed indicated in this patient due to her **high-risk** status, making the recommendation of "no prophylaxis" clinically inappropriate. *Low-risk - routine antenatal care appropriate* - Routine care is only for patients with no high or moderate risk factors; this patient has significant **risk factors** that require intervention. - Failing to identify her risk of **pre-eclampsia** could lead to a lack of necessary monitoring and preventive pharmacological treatment. *High-risk (advanced maternal age and previous pre-eclampsia) - should receive aspirin and increased surveillance* - Although she has these factors, **advanced maternal age** is a moderate-risk factor, not a high-risk factor on its own according to guidelines. - This option incorrectly combines a moderate factor into the high-risk definition, whereas the **previous pre-eclampsia** alone is the primary high-risk driver for prophylaxis.

Question 105: A 35-year-old woman is diagnosed with gestational diabetes at 26 weeks gestation following a screening OGTT (fasting 5.9 mmol/L, 2-hour 9.5 mmol/L). She is established on dietary modifications and home blood glucose monitoring. At review 2 weeks later, her fasting glucose values are consistently 5.6-6.2 mmol/L despite good compliance with diet. Her 1-hour post-prandial values are 6.5-7.2 mmol/L. What is the most appropriate adjustment to her management?

A. Add metformin and continue dietary measures (Correct Answer)
B. Add bedtime insulin and continue dietary measures
C. Add metformin for daytime glucose control and bedtime insulin for fasting glucose
D. Continue dietary management alone for a further 2 weeks before considering medication
E. Commence mixed insulin regimen twice daily

Explanation: ***Add metformin and continue dietary measures*** - Per **NICE guidelines**, if blood glucose targets (fasting <5.3 mmol/L) are not met within 1-2 weeks of lifestyle changes, **metformin** should be offered as the first-line pharmacological treatment. - This patient's **fasting glucose** remains elevated (5.6-6.2 mmol/L) despite diet, making the addition of an oral hypoglycemic agent the appropriate next step. *Add bedtime insulin and continue dietary measures* - **Insulin** is typically reserved as a second-line option if metformin is contraindicated, not tolerated, or if glucose targets are not met with metformin alone. - It may be considered first-line only if the **fasting glucose** is significantly higher (typically ">=7.0 mmol/L") at diagnosis or if there are signs of **fetal macrosomia**. *Add metformin for daytime glucose control and bedtime insulin for fasting glucose* - Starting a **combination therapy** of metformin and insulin simultaneously is premature at this stage as her post-prandial levels are already within the target range. - Management should follow a **step-wise approach**, assessing the response to metformin before adding insulin for nocturnal glucose control. *Continue dietary management alone for a further 2 weeks before considering medication* - Delaying treatment for another 2 weeks increases the risk of **fetal complications** like macrosomia and neonatal hypoglycemia since targets are already not being met. - Evidence suggests that failing to achieve **glycemic control** within the first 1-2 weeks of lifestyle intervention warrants immediate pharmacological escalation. *Commence mixed insulin regimen twice daily* - A **twice-daily mixed insulin** regimen is overly complex for initial therapy, especially since the patient's primary issue is fasting hyperglycemia rather than post-prandial spikes. - Such a regimen carries a higher risk of **hypoglycemia** compared to metformin or targeted basal insulin and is not the standard first-line intervention.

Question 106: A 27-year-old woman is admitted at 33 weeks gestation with severe pre-eclampsia (BP 165/110 mmHg, 3+ proteinuria). She is commenced on IV magnesium sulphate and labetalol. After 12 hours of treatment, she becomes drowsy with reduced respiratory rate of 8 breaths per minute. Her reflexes are absent. Oxygen saturation is 91% on room air. Blood tests show: magnesium level 4.2 mmol/L (therapeutic range 2-4 mmol/L), creatinine 145 μmol/L (previously 78 μmol/L). What is the most appropriate immediate management?

A. Stop magnesium sulphate infusion and administer calcium gluconate 10 mL of 10% solution IV (Correct Answer)
B. Reduce magnesium sulphate infusion rate by 50% and continue monitoring
C. Stop magnesium sulphate, give 100% oxygen, and prepare for intubation
D. Stop magnesium sulphate and commence immediate delivery by caesarean section
E. Administer naloxone 400 mcg IV and continue magnesium at same rate

Explanation: ***Stop magnesium sulphate infusion and administer calcium gluconate 10 mL of 10% solution IV*** - The patient exhibits classic signs of **magnesium toxicity**, including **respiratory depression** (rate 8 breaths/min), **absent deep tendon reflexes**, and a supratherapeutic **magnesium level of 4.2 mmol/L**. - The concurrent **acute kidney injury** (creatinine 145 μmol/L from 78 μmol/L) likely contributed to reduced magnesium excretion, necessitating immediate cessation of the infusion and administration of **calcium gluconate**, which is the direct **antidote** to reverse its neuromuscular effects. *Reduce magnesium sulphate infusion rate by 50% and continue monitoring* - Simply reducing the infusion rate is insufficient when there are severe signs of **magnesium toxicity** such as **respiratory compromise** and **absent reflexes**. - Given the patient's **renal impairment**, magnesium accumulation will persist even at a reduced rate, potentially leading to further worsening of symptoms and cardiac arrest. *Stop magnesium sulphate, give 100% oxygen, and prepare for intubation* - While stopping magnesium is correct and **respiratory support** with oxygen and potential intubation might be necessary, the most immediate and specific intervention for magnesium toxicity is the administration of **calcium gluconate**. - **Calcium gluconate** can rapidly reverse the neuromuscular blockade, potentially preventing the need for intubation by restoring **respiratory drive**. *Stop magnesium sulphate and commence immediate delivery by caesarean section* - While delivery is the definitive treatment for **pre-eclampsia**, the patient's immediate and life-threatening condition is **magnesium toxicity** leading to **respiratory depression**. - Maternal stabilization, including reversal of the magnesium toxicity, must take precedence over delivery to ensure maternal safety during any surgical procedure. *Administer naloxone 400 mcg IV and continue magnesium at same rate* - **Naloxone** is an opioid antagonist and has no therapeutic role in the management of **magnesium sulphate toxicity**. - Continuing the magnesium infusion at the same rate would exacerbate the patient's already severe toxicity, leading to further **respiratory depression** and potentially **cardiac arrest**.

Question 107: A 31-year-old woman with insulin-treated gestational diabetes presents at 35 weeks gestation for routine antenatal review. Her recent ultrasound scan shows estimated fetal weight on 95th centile with abdominal circumference >97th centile, suggesting fetal macrosomia. Amniotic fluid index is 26 cm (polyhydramnios). Her blood glucose control has been suboptimal despite increasing insulin doses. What is the most appropriate next step in her management?

A. Arrange elective caesarean section at 38 weeks gestation
B. Offer induction of labour between 37 and 38+6 weeks gestation (Correct Answer)
C. Continue expectant management with twice-weekly CTG monitoring until 40 weeks
D. Arrange emergency caesarean section within 48 hours
E. Increase surveillance but plan vaginal delivery at 40 weeks

Explanation: ***Offer induction of labour between 37 and 38+6 weeks gestation*** - For women with **gestational diabetes** managed with insulin or metformin, **NICE guidelines** recommend offering elective birth (induction or caesarean) between **37+0 and 38+6 weeks**. - This management is particularly crucial here due to **fetal macrosomia**, **polyhydramnios**, and **suboptimal glycemic control**, which increase the risk of **stillbirth** and **shoulder dystocia**. *Arrange elective caesarean section at 38 weeks gestation* - Elective **caesarean section** is generally reserved for estimated fetal weights exceeding **4.5 kg** in diabetic pregnancies or other specific obstetric indications. - While it is an option if induction is declined or contraindicated, **induction of labour** is the standard primary offer for timing of delivery. *Continue expectant management with twice-weekly CTG monitoring until 40 weeks* - Expectant management until **40 weeks** is inappropriate for a patient on insulin with **suboptimal control**, as the risk of **intrauterine death** increases significantly. - **CTG monitoring** does not mitigate the long-term metabolic risks or mechanical complications associated with macrosomia and polyhydramnios. *Arrange emergency caesarean section within 48 hours* - **Emergency caesarean section** is only indicated if there is evidence of **acute fetal distress** or maternal instability, neither of which is present at this 35-week review. - Delivering at **35 weeks** without acute indications unnecessarily risks **neonatal respiratory distress syndrome** and prematurity-related complications. *Increase surveillance but plan vaginal delivery at 40 weeks* - Planning delivery at **40 weeks** in a diabetic patient requiring insulin contradicts evidence-based guidelines which favor **earlier delivery** to prevent complications. - Increased surveillance cannot reverse the growth effects of **suboptimal glucose control**; therefore, intervention is required before the late term.

Question 108: A 33-year-old woman attends her booking appointment at 10 weeks gestation. She has a BMI of 38 kg/m², hypertension managed with methyldopa, and a family history of type 2 diabetes in both parents. She had a previous baby weighing 4.6 kg at birth. What is the most appropriate screening strategy for gestational diabetes in this pregnancy?

A. Perform oral glucose tolerance test at booking and repeat at 28 weeks if normal (Correct Answer)
B. Arrange oral glucose tolerance test at 24-28 weeks gestation only
C. Check HbA1c at booking and arrange OGTT at 28 weeks if HbA1c is normal
D. Commence home blood glucose monitoring immediately without OGTT
E. Perform random blood glucose at each antenatal visit and OGTT if elevated

Explanation: ***Perform oral glucose tolerance test at booking and repeat at 28 weeks if normal*** - Women with **multiple high-risk factors** like a **previous macrosomic baby** (≥4.5 kg), **BMI >30**, and a **family history of type 2 diabetes** require early screening for gestational diabetes (GDM) as soon as possible after booking. - A repeat **oral glucose tolerance test (OGTT) at 24-28 weeks** is crucial if the initial test is normal, as insulin resistance often peaks in the late second and third trimesters, potentially leading to later onset GDM. *Arrange oral glucose tolerance test at 24-28 weeks gestation only* - This strategy is typically reserved for women with **moderate risk factors** who do not have a history of previous GDM or other clear indications for early first-trimester screening. - Delaying the OGTT until 24-28 weeks in a patient with this many significant risk factors could miss **pre-existing undiagnosed type 2 diabetes** or early-onset GDM, which could lead to adverse outcomes. *Check HbA1c at booking and arrange OGTT at 28 weeks if HbA1c is normal* - **HbA1c** is not recommended as a primary screening tool for GDM due to physiological changes in pregnancy, such as increased **red cell turnover** and hemodilution, which can lead to falsely low results. - While HbA1c can help identify pre-existing type 2 diabetes, the **75g OGTT** remains the gold standard for diagnosing GDM, and waiting until 28 weeks for the OGTT would be too late for early detection in a high-risk patient. *Commence home blood glucose monitoring immediately without OGTT* - Home blood glucose monitoring is generally used for **managing** diagnosed GDM or as an alternative *screening* option for women with a **history of previous GDM** who prefer it over repeated OGTTs. - For women with risk factors but no prior diagnosis, a formal **diagnostic test (OGTT)** is required to establish the presence of GDM before commencing intensive self-monitoring. *Perform random blood glucose at each antenatal visit and OGTT if elevated* - **Random blood glucose** testing lacks the necessary sensitivity and specificity for effective screening of gestational diabetes and is not a recommended primary screening method. - Relying on intermittent random checks or **glycosuria** as a screening approach can result in missed diagnoses, potentially leading to suboptimal maternal and fetal outcomes.

Question 109: A 39-year-old woman in her third pregnancy attends the emergency department at 34 weeks gestation with a severe frontal headache and visual disturbances described as flashing lights. Her blood pressure is 178/118 mmHg. She has 3+ proteinuria on dipstick. Neurological examination shows brisk reflexes with 3 beats of clonus at the ankles. Bloods show normal platelet count and liver function. She is started on intravenous labetalol. What additional immediate management should be initiated?

A. Intravenous magnesium sulphate 4 g loading dose over 20 minutes followed by infusion (Correct Answer)
B. Oral nifedipine 10 mg immediate release
C. Intravenous hydralazine 5 mg bolus
D. Intramuscular betamethasone 12 mg
E. Emergency caesarean section under general anaesthesia

Explanation: ***Intravenous magnesium sulphate 4 g loading dose over 20 minutes followed by infusion*** - This patient presents with **severe pre-eclampsia** and clinical features of **imminent eclampsia**, including a severe headache, visual disturbances, and **clonus**. - **Magnesium sulphate** is the treatment of choice for the prevention of eclamptic seizures and should be initiated immediately to reduce the risk by over 50%. *Oral nifedipine 10 mg immediate release* - While blood pressure control is vital, **immediate-release nifedipine** is generally avoided in pregnancy due to the risk of sudden hypotension and fetal distress. - The patient is already receiving **intravenous labetalol**, which is a first-line agent for managing hypertensive crises in pregnancy. *Intravenous hydralazine 5 mg bolus* - **Hydralazine** is an alternative antihypertensive for acute control, but it is typically used if there is an inadequate response to **labetalol**. - It does not address the immediate risk of **seizure/eclampsia**, which is the primary concern given the neurological symptoms. *Intramuscular betamethasone 12 mg* - **Corticosteroids** are indicated at 34 weeks gestation to promote **fetal lung maturity** in anticipation of preterm delivery. - Although important, it is not the most immediate priority compared to preventing **maternal seizure** and stabilizing life-threatening blood pressure. *Emergency caesarean section under general anaesthesia* - Delivery is the definitive treatment for pre-eclampsia/eclampsia, but the mother must be **stabilized first** with antihypertensives and magnesium sulphate. - An **emergency caesarean** without stabilization significantly increases maternal and fetal morbidity and is not indicated before attempting medical management.

Question 110: A 28-year-old woman with diet-controlled gestational diabetes is reviewed at 37 weeks gestation. Her home blood glucose monitoring over the past 2 weeks shows: fasting values 4.8-5.1 mmol/L and 1-hour post-prandial values 6.9-7.5 mmol/L. Ultrasound scan today shows estimated fetal weight on 60th centile, normal liquor volume, and normal umbilical artery Doppler. She asks about the timing of delivery. What is the most appropriate advice regarding delivery timing?

A. Offer elective induction of labour at 38 weeks gestation
B. Recommend expectant management with weekly monitoring until 42 weeks if uncomplicated
C. Offer elective caesarean section at 38 weeks due to gestational diabetes
D. Offer elective induction of labour at 40 weeks or earlier if there are maternal or fetal complications (Correct Answer)
E. Recommend delivery at 37 weeks as she has completed this gestation

Explanation: ***Offer elective induction of labour at 40 weeks or earlier if there are maternal or fetal complications*** - This patient has **well-controlled gestational diabetes** (diet-controlled, normal blood glucose values) and a **normal fetal ultrasound**, indicating no immediate complications. - According to **NICE guidelines**, for women with diet-controlled gestational diabetes without complications, birth should be offered by **40+6 weeks gestation** to reduce the risk of stillbirth and other adverse outcomes associated with prolonged pregnancy in GDM. *Offer elective induction of labour at 38 weeks gestation* - Induction at **37+0 to 38+6 weeks** is typically reserved for women with gestational diabetes who require **medication (metformin or insulin)** for glycemic control or have evidence of **fetal macrosomia** or other complications. - Given this patient's **excellent diet-controlled glucose levels** and normal fetal growth (60th centile), early induction at 38 weeks is not clinically indicated. *Recommend expectant management with weekly monitoring until 42 weeks if uncomplicated* - Extending pregnancy to **42 weeks** in gestational diabetes significantly increases the risk of **fetal demise**, **macrosomia**, and **placental insufficiency**, even with good glucose control. - Current guidelines recommend against prolonged pregnancy beyond **40+6 weeks** for GDM, regardless of control method, to mitigate these risks. *Offer elective caesarean section at 38 weeks due to gestational diabetes* - **Gestational diabetes** itself is not an absolute indication for a **caesarean section**; vaginal delivery is the preferred mode unless specific obstetric complications, such as significant **macrosomia** or other contraindications, arise. - There is no indication for an elective caesarean section at 38 weeks here, as the patient's GDM is well-managed and the estimated fetal weight is normal (60th centile), suggesting no increased risk of **shoulder dystocia** requiring C-section. *Recommend delivery at 37 weeks as she has completed this gestation* - Elective delivery at **37 weeks** without specific indications (e.g., poor glycemic control, preeclampsia, fetal distress) is not recommended, as it may increase the risk of **neonatal respiratory distress syndrome** and other prematurity-related complications. - For **well-controlled gestational diabetes**, the benefits of allowing the pregnancy to progress closer to term (up to 40+6 weeks) generally outweigh the risks, as long as maternal and fetal surveillance remains reassuring.

Question 111: A 32-year-old primigravida at 29 weeks gestation presents to the antenatal day unit with a 48-hour history of persistent headache and epigastric pain. Her blood pressure is 156/102 mmHg. Urinalysis shows 2+ protein. Blood tests reveal: platelet count 95 × 10⁹/L, ALT 89 U/L, AST 102 U/L, LDH 550 U/L, and uric acid 0.42 mmol/L. Ultrasound shows normal fetal biometry and amniotic fluid volume. What is the most likely diagnosis?

A. Severe pre-eclampsia without HELLP syndrome
B. HELLP syndrome complicating pre-eclampsia (Correct Answer)
C. Acute fatty liver of pregnancy
D. Gestational hypertension with incidental thrombocytopenia
E. Obstetric cholestasis with hypertension

Explanation: ***HELLP syndrome complicating pre-eclampsia***- This patient demonstrates the classic triad of **Hemolysis** (elevated **LDH 550 U/L**), **Elevated Liver enzymes** (**ALT 89 U/L, AST 102 U/L**), and **Low Platelets** (**95 × 10⁹/L**).- Clinical features such as **epigastric pain**, headache, and **hypertension** with proteinuria (156/102 mmHg, 2+ protein) confirm **severe pre-eclampsia** as the underlying cause.*Severe pre-eclampsia without HELLP syndrome*- While the patient meets criteria for severe pre-eclampsia, the presence of **thrombocytopenia** (<100 × 10⁹/L) and **elevated transaminases** (ALT/AST >70 U/L) explicitly defines this as HELLP syndrome.- Managing these as distinct entities is crucial as HELLP syndrome indicates a higher risk of **maternal morbidity** and complications like hepatic rupture.*Acute fatty liver of pregnancy*- Typically manifests with **hypoglycemia**, prolonged **clotting times** (PT/APTT), and profound **hyperbilirubinemia**, which are not present here.- While it also features elevated liver enzymes, it is usually associated with **acute liver failure** signs and occurs later in the third trimester.*Gestational hypertension with incidental thrombocytopenia*- Gestational hypertension by definition lacks **proteinuria**, which this patient clearly has (**2+ protein** on urinalysis).- **Incidental thrombocytopenia** of pregnancy typically stays above 100 × 10⁹/L and would not be associated with **elevated LDH** or liver enzymes.*Obstetric cholestasis with hypertension*- Obstetric cholestasis is primarily characterized by **intense pruritus** (itching) and elevated **bile acids**, neither of which are described.- It does not cause **thrombocytopenia**, hemolysis, or the level of blood pressure elevation seen in this patient.

Question 112: A 36-year-old woman presents for antenatal booking at 11 weeks gestation in her first pregnancy. She has a history of systemic lupus erythematosus, currently in remission, and chronic hypertension managed with ramipril 5 mg once daily. Her blood pressure today is 142/88 mmHg. She is also taking hydroxychloroquine 200 mg twice daily. What is the most appropriate management regarding her antihypertensive medication?

A. Continue ramipril and monitor blood pressure regularly throughout pregnancy
B. Switch ramipril to labetalol and aim for blood pressure <135/85 mmHg (Correct Answer)
C. Stop all antihypertensive medication as blood pressure is acceptable in pregnancy
D. Switch ramipril to amlodipine and increase dose if blood pressure remains elevated
E. Continue ramipril but reduce the dose to 2.5 mg daily

Explanation: ***Switch ramipril to labetalol and aim for blood pressure <135/85 mmHg*** - **ACE inhibitors** like ramipril are **contraindicated** in pregnancy due to their **teratogenic effects**, specifically **fetal renal dysgenesis** and **oligohydramnios**, especially in the second and third trimesters. - **Labetalol** is a preferred first-line antihypertensive in pregnancy for **chronic hypertension** due to its established safety profile and efficacy, with a target blood pressure often set at **<135/85 mmHg** to reduce maternal and fetal risks. *Continue ramipril and monitor blood pressure regularly throughout pregnancy* - Continuing **ramipril** (an **ACE inhibitor**) poses significant risks to the developing fetus, including **renal malformations** and **intrauterine growth restriction**, making its continuation unsafe. - Current guidelines strongly recommend discontinuing **RAAS inhibitors** (ACEIs and ARBs) as soon as pregnancy is confirmed or planned, switching to safer alternatives. *Stop all antihypertensive medication as blood pressure is acceptable in pregnancy* - A blood pressure of 142/88 mmHg is **elevated** for a pregnant woman, particularly one with **chronic hypertension** and **SLE**, increasing risks of **preeclampsia**, **placental abruption**, and **maternal stroke**. - Uncontrolled hypertension in pregnancy can lead to severe maternal and fetal complications, necessitating appropriate pharmacologic management rather than discontinuation. *Switch ramipril to amlodipine and increase dose if blood pressure remains elevated* - While **amlodipine** (a calcium channel blocker) can be used in pregnancy, **labetalol** and **nifedipine** are generally considered the **first-line agents** for chronic hypertension due to more extensive data and guidelines recommending their use. - The initial switch should prioritize agents with the strongest evidence base for safety and efficacy in pregnancy. *Continue ramipril but reduce the dose to 2.5 mg daily* - The **teratogenic effects** of **ACE inhibitors** are a class effect and are not dose-dependent; even a reduced dose of ramipril still carries the risk of **fetal harm**. - Reducing the dose would not eliminate the fetal risks and may also lead to inadequate control of the mother's **chronic hypertension**, further complicating the pregnancy.

Question 113: A 30-year-old woman at 27 weeks gestation attends the antenatal clinic. She has just been diagnosed with gestational diabetes following an oral glucose tolerance test showing fasting glucose 5.8 mmol/L and 2-hour value of 9.2 mmol/L. She has been advised to start home blood glucose monitoring and dietary modifications. What are the recommended target blood glucose levels for women with gestational diabetes according to current NICE guidelines?

A. Fasting <5.3 mmol/L and 1-hour post-prandial <7.0 mmol/L
B. Fasting <5.3 mmol/L and 1-hour post-prandial <7.8 mmol/L (Correct Answer)
C. Fasting <5.6 mmol/L and 2-hour post-prandial <7.8 mmol/L
D. Fasting <6.0 mmol/L and 1-hour post-prandial <8.0 mmol/L
E. Fasting <5.0 mmol/L and 2-hour post-prandial <7.0 mmol/L

Explanation: ***Fasting <5.3 mmol/L and 1-hour post-prandial <7.8 mmol/L***- According to **NICE guidelines**, the target capillary plasma glucose for gestational diabetes is a **fasting** level below **5.3 mmol/L**.- The recommended **1-hour post-prandial** target is below **7.8 mmol/L** to reduce the risk of **fetal macrosomia** and neonatal complications.*Fasting <5.3 mmol/L and 1-hour post-prandial <7.0 mmol/L*- While the fasting target is correct, the **1-hour post-prandial** limit of **7.0 mmol/L** is unnecessarily restrictive and not supported by current NICE evidence.- Overly strict targets can lead to an increased risk of maternal **hypoglycemia** and unnecessary medical intervention.*Fasting <5.6 mmol/L and 2-hour post-prandial <7.8 mmol/L*- A fasting target of **5.6 mmol/L** is the threshold used for **diagnosing** gestational diabetes, not the therapeutic target for management.- The **2-hour post-prandial** target recommended by NICE is actually **<6.4 mmol/L**, making 7.8 mmol/L too high for a 2-hour reading.*Fasting <6.0 mmol/L and 1-hour post-prandial <8.0 mmol/L*- These levels are significantly higher than the recommended **NICE targets** and would increase the risk of **adverse pregnancy outcomes**.- Targets this high are generally discouraged as they fail to adequately control **maternal hyperglycemia** during pregnancy.*Fasting <5.0 mmol/L and 2-hour post-prandial <7.0 mmol/L*- Although a fasting level of **5.0 mmol/L** is within the healthy range, it is lower than the official **5.3 mmol/L** target required for clinical management.- The **2-hour post-prandial** target of **7.0 mmol/L** is incorrect, as guidelines specify **<6.4 mmol/L** for 2-hour measurements.

Question 114: A 34-year-old woman attends her booking appointment at 9 weeks gestation in her second pregnancy. Her first pregnancy was complicated by severe pre-eclampsia requiring delivery at 32 weeks. She has a BMI of 28 kg/m² and blood pressure of 118/76 mmHg. She is otherwise well with no significant medical history. According to current NICE guidelines, what is the most appropriate prophylactic medication to reduce her risk of pre-eclampsia?

A. Aspirin 75 mg once daily from 12 weeks gestation until delivery (Correct Answer)
B. Aspirin 150 mg once daily from 12 weeks gestation until delivery
C. Aspirin 75 mg once daily from 16 weeks gestation until delivery
D. Calcium supplementation 1000 mg daily from 12 weeks gestation
E. Low molecular weight heparin from 12 weeks gestation until delivery

Explanation: ***Aspirin 75 mg once daily from 12 weeks gestation until delivery*** - Patients with **one high-risk factor** (e.g., prior hypertensive disease in pregnancy, chronic hypertension, CKD, diabetes, or autoimmune disease) should receive **low-dose aspirin**. - NICE specifically recommends **75 mg daily** starting from **12 weeks gestation** until birth to reduce the risk of pre-eclampsia. *Aspirin 150 mg once daily from 12 weeks gestation until delivery* - While some international guidelines (such as FIGO) suggest **150 mg**, current **NICE guidelines** in the UK still formally advocate for the **75 mg** dose. - Higher doses may be used in practice for specific clinical scenarios, but it is not the standard recommendation for a single high-risk factor in UK board exams. *Aspirin 75 mg once daily from 16 weeks gestation until delivery* - Prophylaxis is most effective when initiated early in the second trimester; **12 weeks** is the recommended start point to optimize **trophoblastic invasion**. - Starting at **16 weeks** is considered suboptimal according to national guidelines for preventing the onset of pre-eclampsia. *Calcium supplementation 1000 mg daily from 12 weeks gestation* - **Calcium supplementation** is primarily recommended by the WHO for populations with **low dietary calcium intake**. - It is not routinely used as a primary prophylactic measure for pre-eclampsia in the UK where dietary intake is generally sufficient. *Low molecular weight heparin from 12 weeks gestation until delivery* - **Low molecular weight heparin (LMWH)** is indicated for the prevention of **venous thromboembolism** rather than pre-eclampsia prophylaxis. - It has no proven role in the routine management or prevention of hypertensive disorders of pregnancy for this patient's profile.

Question 115: A 39-year-old woman presents to the antenatal day unit at 32 weeks gestation with reduced fetal movements for 24 hours. Her booking BMI was 35 kg/m². She was diagnosed with gestational diabetes at 28 weeks and commenced on metformin. CTG is performed and is normal. During the assessment, her blood pressure is measured as 168/114 mmHg, repeated 30 minutes later is 164/110 mmHg. She reports no headache, visual disturbances, or epigastric pain. Urinalysis shows trace protein. What is the single most important immediate management priority?

A. Commence antihypertensive treatment to lower blood pressure urgently (Correct Answer)
B. Arrange urgent ultrasound scan to assess fetal growth and liquor volume
C. Take blood for full blood count, liver function tests, and renal function
D. Arrange quantification of proteinuria with protein:creatinine ratio
E. Commence magnesium sulphate for neuroprotection

Explanation: ***Commence antihypertensive treatment to lower blood pressure urgently*** - Severe hypertension (BP ≥160/110 mmHg) in pregnancy is a **medical emergency** requiring treatment within **30-60 minutes** to prevent catastrophic maternal complications like **hemorrhagic stroke**. - While other investigations are necessary, the **immediate priority** is to stabilize the mother by rapidly reducing blood pressure with appropriate **antihypertensive agents**. *Arrange urgent ultrasound scan to assess fetal growth and liquor volume* - Fetal assessment is important given the **reduced fetal movements** and suspected pre-eclampsia, but it is not the most immediate priority when the mother faces a **hypertensive crisis**. - The **normal CTG** provides some immediate reassurance regarding fetal well-being, allowing the focus to remain on urgent maternal stabilization. *Take blood for full blood count, liver function tests, and renal function* - These blood tests are crucial for assessing the severity of **pre-eclampsia** and ruling out complications like **HELLP syndrome** or acute kidney injury. - However, obtaining these results does not supersede the urgent need to acutely lower **dangerously high blood pressure** to prevent maternal stroke. *Arrange quantification of proteinuria with protein:creatinine ratio* - Quantification of proteinuria is essential for definitively diagnosing **pre-eclampsia**, especially when the dipstick shows trace protein. - However, the presence of **severe hypertension** with even trace proteinuria mandates immediate management to lower blood pressure, regardless of the exact protein:creatinine ratio. *Commence magnesium sulphate for neuroprotection* - **Magnesium sulphate** is indicated for the prevention of **eclampsia** in women with severe pre-eclampsia or for **fetal neuroprotection** in preterm delivery. - While important, it is not the primary immediate treatment for the acute reduction of severe **hypertensive crisis**, which must be addressed first to prevent maternal cerebrovascular events.

Question 116: A 34-year-old woman undergoes OGTT at 27 weeks gestation. Results show: fasting glucose 5.4 mmol/L and 2-hour glucose 9.2 mmol/L. She is diagnosed with gestational diabetes and referred to the diabetes in pregnancy clinic. She has been following dietary advice for 2 weeks. Her home blood glucose monitoring over the past week shows: fasting values 4.8-5.2 mmol/L and 1-hour post-prandial values 7.2-7.9 mmol/L. What is the most appropriate next step in management?

A. Start short-acting insulin before meals to control post-prandial glucose levels
B. Continue diet alone as all glucose values are within target ranges (Correct Answer)
C. Add metformin as post-prandial values are consistently above 7.5 mmol/L
D. Add long-acting insulin at bedtime to improve fasting glucose control
E. Add metformin and start short-acting insulin before meals

Explanation: ***Continue diet alone as all glucose values are within target ranges*** - According to **NICE guidelines**, target blood glucose levels for gestational diabetes are **fasting <5.3 mmol/L** and **1-hour post-prandial <7.8 mmol/L**. - This patient's readings (fasting 4.8-5.2 and 1-hour 7.2-7.9) are largely **within target range**, meaning her current **dietary intervention** is successful and should be continued. *Start short-acting insulin before meals to control post-prandial glucose levels* - **Short-acting insulin** is only indicated if post-prandial glucose levels remain consistently above the **7.8 mmol/L target** despite diet and/or metformin. - Escalating to insulin is unnecessary here as the majority of her post-meal readings are **not significantly or consistently elevated**. *Add metformin as post-prandial values are consistently above 7.5 mmol/L* - **Metformin** is considered if glucose targets are not met after 1-2 weeks of diet; however, the threshold for concern is **>7.8 mmol/L** for 1-hour post-prandial readings. - Her values are mostly below or right at the threshold, so **pharmacological therapy** is not yet required. *Add long-acting insulin at bedtime to improve fasting glucose control* - **Long-acting insulin** is used specifically to manage **elevated fasting glucose** levels that do not respond to diet or metformin. - Since her fasting values (4.8-5.2 mmol/L) are all below the **5.3 mmol/L target**, there is no clinical indication for basal insulin. *Add metformin and start short-acting insulin before meals* - A combination of **metformin and insulin** is typically reserved for cases where single-agent therapy fails or for women with very high glucose levels at diagnosis. - This aggressive approach is inappropriate for a patient whose glucose levels are currently **well-controlled on diet alone**.

Question 117: A 27-year-old primigravida attends her booking appointment at 10 weeks gestation. She has no significant medical history. Her booking blood pressure is 146/94 mmHg, repeated after 15 minutes rest is 144/92 mmHg. Urinalysis shows no proteinuria. She mentions that her blood pressure was checked by her GP 3 months ago before pregnancy and was 142/90 mmHg. What is the most accurate diagnosis and initial management approach?

A. White coat hypertension; arrange ambulatory blood pressure monitoring and reassess
B. Chronic hypertension; commence labetalol and arrange blood tests including renal function and echocardiography (Correct Answer)
C. Normal pregnancy-related blood pressure increase; provide reassurance and routine follow-up
D. Pre-eclampsia; admit for investigation and commence antihypertensive treatment
E. Gestational hypertension; commence labetalol and arrange blood tests for pre-eclampsia

Explanation: ***Chronic hypertension; commence labetalol and arrange blood tests including renal function and echocardiography*** - **Hypertension** is defined as **≥140/90 mmHg**. It is classified as **chronic** if it exists pre-conception or is detected before **20 weeks** gestation, as seen in this patient with prior elevated readings and current 10-week gestation. - Initial management includes first-line **labetalol** (a safe antihypertensive in pregnancy) and investigations to screen for **target organ damage**, such as renal dysfunction (blood tests) or left ventricular hypertrophy (**echocardiography**). *White coat hypertension; arrange ambulatory blood pressure monitoring and reassess* - While **ambulatory blood pressure monitoring** is useful, the patient had a documented elevated reading of **142/90 mmHg 3 months before pregnancy**, making it unlikely to be solely white coat effect and more indicative of underlying chronic hypertension. - In pregnancy, persistent clinic readings of **≥140/90 mmHg** warrant active management and baseline organ assessment, not just reassessment, due to potential maternal and fetal risks. *Normal pregnancy-related blood pressure increase; provide reassurance and routine follow-up* - Blood pressure typically **decreases** during the first and early second trimesters due to **systemic vasodilation** and reduced systemic vascular resistance. An increase to 140/90 mmHg or higher is abnormal. - Sustained readings above **140/90 mmHg** in pregnancy are associated with adverse outcomes and necessitate intervention, not just reassurance. *Pre-eclampsia; admit for investigation and commence antihypertensive treatment* - **Pre-eclampsia** is generally diagnosed **after 20 weeks** of gestation and is characterized by new-onset hypertension with **proteinuria** or other signs of end-organ dysfunction. - This patient is only at **10 weeks** gestation and has **no proteinuria**, ruling out pre-eclampsia at this stage. Early onset hypertension without proteinuria before 20 weeks points to chronic hypertension. *Gestational hypertension; commence labetalol and arrange blood tests for pre-eclampsia* - **Gestational hypertension** is defined as new-onset hypertension that develops **after 20 weeks** of gestation in a woman who was previously normotensive. - The patient's history of elevated blood pressure **prior to pregnancy** and the current presentation at **10 weeks** gestation preclude a diagnosis of gestational hypertension.

Question 118: A 36-year-old woman at 38 weeks gestation with diet-controlled gestational diabetes presents to the labour ward with regular contractions. On examination, she is 4 cm dilated with intact membranes. Her blood glucose on arrival is 4.2 mmol/L. She has been eating and drinking normally. CTG is reassuring. What is the most appropriate management of her blood glucose during labour?

A. Commence intravenous dextrose and insulin infusion immediately to maintain tight glycaemic control
B. Check capillary blood glucose every 1-2 hours and commence intravenous dextrose and insulin if glucose >7 mmol/L (Correct Answer)
C. Give subcutaneous insulin now to prevent hyperglycaemia during labour
D. Commence intravenous dextrose infusion prophylactically without insulin
E. No specific management needed; check blood glucose only if she develops symptoms of hypoglycaemia

Explanation: ***Check capillary blood glucose every 1-2 hours and commence intravenous dextrose and insulin if glucose >7 mmol/L*** - For women with **diet-controlled gestational diabetes**, glycaemic control during labour is managed by maintaining blood glucose between **4–7 mmol/L**. - NICE guidelines recommend hourly or **1–2 hourly monitoring** of capillary blood glucose, with a **sliding scale (VRIII)** only if levels exceed the target range. *Commence intravenous dextrose and insulin infusion immediately to maintain tight glycaemic control* - **Intravenous insulin (VRIII)** is not indicated unless the patient is poorly controlled or has capillary blood glucose levels outside the target range of **4–7 mmol/L**. - Routine use of a sliding scale at the start of labour is unnecessary for **diet-controlled GDM** patients who are currently euglycaemic. *Give subcutaneous insulin now to prevent hyperglycaemia during labour* - **Subcutaneous insulin** is difficult to titrate during the active phase of labour due to unpredictable absorption and the high **metabolic demands** of uterine contractions. - If insulin is required due to hyperglycaemia in labour, **intravenous administration** is preferred for rapid and precise control. *Commence intravenous dextrose infusion prophylactically without insulin* - Administering **prophylactic dextrose** without a clear clinical indication like hypoglycemia risks causing **maternal hyperglycaemia**. - Maternal hyperglycaemia during labour can lead to **fetal academia** and subsequent **neonatal hypoglycaemia** due to fetal hyperinsulinaemia. *No specific management needed; check blood glucose only if she develops symptoms of hypoglycaemia* - Relying solely on **symptoms** is dangerous as the physical stress of labour can mask the clinical signs of **hyperglycaemia or hypoglycaemia**. - Active **biochemical monitoring** is essential for all women with gestational diabetes to ensure optimal outcomes for the mother and the neonate.

Question 119: A 41-year-old woman in her fourth pregnancy attends the booking appointment at 11 weeks gestation. She had gestational diabetes in her previous two pregnancies, both requiring insulin treatment. Her pre-pregnancy BMI is 29 kg/m². She requests information about reducing her risk of gestational diabetes in this pregnancy. What is the most appropriate advice regarding lifestyle modifications and screening?

A. Arrange HbA1c or fasting glucose at booking, and OGTT at 24-28 weeks if initial test is normal; provide diet and exercise advice (Correct Answer)
B. Arrange monthly HbA1c monitoring throughout pregnancy; strict calorie-restricted diet recommended
C. Start metformin 500 mg twice daily prophylactically and arrange OGTT at 24-28 weeks only
D. Arrange OGTT at 16 weeks and again at 28 weeks; commence low-dose aspirin 150 mg once daily
E. She should commence insulin prophylactically at 20 weeks to prevent gestational diabetes

Explanation: ***Arrange HbA1c or fasting glucose at booking, and OGTT at 24-28 weeks if initial test is normal; provide diet and exercise advice*** - For women with **previous gestational diabetes**, NICE guidelines recommend early screening (**HbA1c** or **fasting glucose**) at **booking** to rule out pre-existing diabetes. - If the initial screening is normal, a formal **75g Oral Glucose Tolerance Test (OGTT)** is performed at **24–28 weeks** gestation to detect recurrence. *Arrange monthly HbA1c monitoring throughout pregnancy; strict calorie-restricted diet recommended* - Monthly **HbA1c** is not an evidence-based method for monitoring or screening for GDM as it reflects long-term glycemia rather than acute post-prandial spikes. - **Strict calorie restriction** is contraindicated in pregnancy; instead, focus should be on **low-glycemic index** foods and moderate physical activity. *Start metformin 500 mg twice daily prophylactically and arrange OGTT at 24-28 weeks only* - **Prophylactic metformin** is not currently recommended in standard clinical guidelines for the prevention of gestational diabetes. - Initial screening must occur at **booking** for high-risk patients, not just at 24-28 weeks, to identify undiagnosed **Type 2 diabetes**. *Arrange OGTT at 16 weeks and again at 28 weeks; commence low-dose aspirin 150 mg once daily* - While some guidelines suggest an early OGTT (16–18 weeks), the standard UK approach for previous GDM starts with **booking bloods** (**HbA1c/fasting glucose**). - **Low-dose aspirin** is indicated for the prevention of **pre-eclampsia** in high-risk groups, not for the prevention or screening of gestational diabetes. *She should commence insulin prophylactically at 20 weeks to prevent gestational diabetes* - **Prophylactic insulin** is not used to prevent GDM; pharmacological management is only initiated once a **diagnosis** is confirmed via OGTT or home monitoring. - Starting insulin without a diagnosis carries significant risks of **maternal hypoglycemia** and unnecessary medicalization of the pregnancy.

Question 120: A 28-year-old woman is admitted at 35 weeks gestation with new-onset hypertension (BP 152/98 mmHg) and 1+ proteinuria on dipstick. Blood tests show: haemoglobin 118 g/L, platelets 178 × 10⁹/L, ALT 28 U/L, AST 32 U/L, creatinine 68 μmol/L, uric acid 0.38 mmol/L. Protein:creatinine ratio is 45 mg/mmol. She has mild headache but no visual disturbances. CTG is reassuring. What is the most appropriate next step in her management?

A. Discharge home on oral labetalol with community midwife follow-up in 48 hours
B. Admit for observation, commence antihypertensive treatment, and plan delivery within 24-48 hours
C. Commence magnesium sulphate for seizure prophylaxis and plan immediate delivery
D. Admit for observation, commence antihypertensive treatment, and monitor with view to conservative management aiming for 37 weeks (Correct Answer)
E. Arrange urgent MRI brain to investigate headache before deciding on further management

Explanation: ***Admit for observation, commence antihypertensive treatment, and monitor with view to conservative management aiming for 37 weeks*** - The patient has **pre-eclampsia** (BP >140/90 mmHg and PCR >30 mg/mmol) without **severe features** (platelets, liver enzymes, creatinine within normal limits, mild headache without visual disturbances) at 35 weeks gestation. - For preterm pre-eclampsia without severe features, **conservative management** with inpatient monitoring and antihypertensive treatment is recommended to allow for fetal maturation, aiming for delivery at **37 weeks**. *Discharge home on oral labetalol with community midwife follow-up in 48 hours* - A new diagnosis of **pre-eclampsia** at 35 weeks requires **inpatient admission** for close monitoring of both maternal and fetal well-being due to the risk of rapid deterioration. - Relying solely on community follow-up in this scenario would be **unsafe** and could lead to missed worsening disease or fetal compromise. *Admit for observation, commence antihypertensive treatment, and plan delivery within 24-48 hours* - While admission and antihypertensive treatment are appropriate, **expedited delivery within 24-48 hours** is typically reserved for **severe pre-eclampsia** or significant fetal compromise. - Given the patient's stable condition, reassuring CTG, and lack of severe features, immediate delivery at 35 weeks would unnecessarily expose the neonate to risks of **prematurity-related complications**. *Commence magnesium sulphate for seizure prophylaxis and plan immediate delivery* - **Magnesium sulphate** is indicated for **severe pre-eclampsia** or impending eclampsia, neither of which the patient currently meets the criteria for. - Planning immediate delivery is not warranted as the patient is stable, the **CTG is reassuring**, and there are no signs of HELLP syndrome, eclampsia, or placental abruption. *Arrange urgent MRI brain to investigate headache before deciding on further management* - A **mild headache** is a common symptom in pre-eclampsia; in the absence of **focal neurological deficits**, severe headache, or visual disturbances, an urgent MRI is not the priority. - The immediate focus should be on managing the **hypertension** and monitoring the progression of pre-eclampsia, which are the main threats in this condition.

Question 121: A 32-year-old woman with insulin-treated gestational diabetes is reviewed at 32 weeks gestation. Her home blood glucose monitoring shows: fasting values 5.8-6.2 mmol/L and 1-hour post-prandial values 8.5-9.2 mmol/L. She is on 16 units of long-acting insulin at night and 8 units of short-acting insulin before each meal. Growth scan shows estimated fetal weight on 92nd centile. What is the most appropriate adjustment to her management?

A. Increase the long-acting insulin dose at night
B. Increase the short-acting insulin doses before meals (Correct Answer)
C. Add metformin 500 mg three times daily to her insulin regimen
D. Increase both long-acting and short-acting insulin doses equally
E. Continue current insulin doses and arrange repeat growth scan in 2 weeks

Explanation: ***Increase the short-acting insulin doses before meals*** - This patient's **1-hour post-prandial values** (8.5-9.2 mmol/L) are significantly above the target of **<7.8 mmol/L**, which is the primary driver of the **92nd centile fetal growth** (macrosomia). - Increasing **short-acting insulin** directly targets post-meal glucose spikes, reducing the risk of **macrosomia** and associated neonatal complications like hypoglycemia and birth trauma. *Increase the long-acting insulin dose at night* - While the fasting glucose is slightly elevated (target **<5.3 mmol/L**), the elevation in post-prandial readings is more pronounced and clinically impactful for fetal growth. - Addressing only the **long-acting insulin** would fail to correct the significant hyperglycemic excursions occurring after meals throughout the day. *Add metformin 500 mg three times daily to her insulin regimen* - Adding **metformin** is an option in gestational diabetes, but it is more efficient and appropriate to first adjust the doses of her **existing insulin regimen** to achieve rapid glycaemic control. - The immediate priority is titration of current insulin therapy given the **accelerated fetal growth** already evidenced on the growth scan, which mandates prompt and effective glucose lowering. *Increase both long-acting and short-acting insulin doses equally* - Insulin adjustments should be tailored to specific glucose patterns; a generalized **equal increase** may lead to nocturnal or pre-meal **hypoglycemia** if the basal or pre-meal levels are adequately controlled. - In this specific clinical scenario, the post-prandial readings require a more aggressive titration compared to the fasting readings, indicating a need for targeted adjustment. *Continue current insulin doses and arrange repeat growth scan in 2 weeks* - Continuing the current dose is inappropriate as the blood glucose levels are **consistently above target** and the fetus is already showing signs of **macrosomia** (>90th centile). - Delaying treatment adjustments for two weeks would increase the risk of both maternal and fetal complications associated with poorly controlled **gestational diabetes**, such as pre-eclampsia and fetal distress.

Question 122: A 35-year-old woman presents for her booking appointment at 13 weeks gestation in her first pregnancy. Her BMI is 33 kg/m². She has no previous history of gestational diabetes. Her sister had gestational diabetes in pregnancy. She is of Pakistani origin. Based on current guidelines, when should oral glucose tolerance testing be arranged for this patient?

A. At booking and again at 24-28 weeks gestation (Correct Answer)
B. At 20 weeks and again at 32 weeks gestation
C. At booking, 24-28 weeks, and 32 weeks gestation
D. At 16 weeks and again at 28 weeks gestation
E. At 24-28 weeks gestation only

Explanation: ***At booking and again at 24-28 weeks gestation*** - This patient has multiple cumulative risk factors for **gestational diabetes mellitus (GDM)**, including a high **BMI (>30 kg/m²)**, **South Asian ethnicity** (Pakistani origin), and a **first-degree relative** with GDM. - Current clinical guidelines recommend early screening with an **Oral Glucose Tolerance Test (OGTT)** or **HbA1c** at the **booking appointment** (or soon after 10 weeks) for women with significant risk factors, followed by a repeat **OGTT** at **24-28 weeks gestation** if the initial test is negative. *At 20 weeks and again at 32 weeks gestation* - These specific timings are not aligned with standard GDM screening protocols, which prioritize screening around **24-28 weeks** when **insulin resistance** is physiologically at its peak in pregnancy. - Screening at **32 weeks** is generally too late for initial diagnosis and management, potentially delaying interventions for **fetal macrosomia** or other complications. *At booking, 24-28 weeks, and 32 weeks gestation* - While screening at booking and 24-28 weeks is appropriate, there is no evidence-based recommendation for a routine **third OGTT at 32 weeks** for asymptomatic patients. - Timely diagnosis and management, typically established by the **mid-second trimester**, are key to achieving glycemic control. *At 16 weeks and again at 28 weeks gestation* - Although 28 weeks is within the appropriate window for repeat screening, **16 weeks** is not the standard earliest screening point for high-risk patients to detect pre-existing diabetes. - For those with multiple risk factors, screening should ideally occur as early as the **booking visit** (typically 10-13 weeks). *At 24-28 weeks gestation only* - This single screening approach is usually reserved for women with **only one moderate risk factor** for GDM, not for those with multiple significant risk factors. - Given the patient's several risk factors, an **earlier screening at booking** is crucial to identify **undiagnosed Type 2 diabetes** or early-onset GDM.

Question 123: A 30-year-old woman in her second pregnancy attends the antenatal clinic at 28 weeks gestation. Her booking blood pressure at 10 weeks was 118/72 mmHg. Today her blood pressure is 146/96 mmHg, confirmed on repeat measurement after 30 minutes rest. Urinalysis shows no proteinuria. She is asymptomatic with good fetal movements. Her booking bloods including renal function were normal. What is the most appropriate initial management?

A. Commence oral labetalol and arrange blood tests including full blood count, renal function, and liver function tests (Correct Answer)
B. Admit for 24-hour blood pressure monitoring and investigation for pre-eclampsia
C. Arrange ambulatory blood pressure monitoring over 24 hours and review results
D. Commence low-dose aspirin 150 mg once daily and review in 1 week
E. Reassure and arrange review in 2 weeks with repeat blood pressure measurement

Explanation: ***Commence oral labetalol and arrange blood tests including full blood count, renal function, and liver function tests*** - This patient has new-onset **gestational hypertension** (BP ">=" 140/90 mmHg after 20 weeks gestation) requiring **antihypertensive treatment** to prevent maternal and fetal complications. - **Labetalol** is a first-line agent, and baseline blood tests (FBC, renal, and liver function tests) are essential to screen for evolving **pre-eclampsia**, even without proteinuria. *Admit for 24-hour blood pressure monitoring and investigation for pre-eclampsia* - Admission is typically reserved for **severe hypertension** (BP ">=" 160/110 mmHg) or for symptomatic patients with suspected pre-eclampsia requiring immediate evaluation. - This patient's blood pressure is in the **non-severe range** and she is asymptomatic, making outpatient management with close follow-up more appropriate. *Arrange ambulatory blood pressure monitoring over 24 hours and review results* - **Ambulatory blood pressure monitoring (ABPM)** is primarily used for diagnosing **chronic hypertension** or differentiating white-coat hypertension, not for acute management of new-onset hypertension in the third trimester. - Delaying treatment to perform ABPM is not advisable in a 28-week pregnant woman with confirmed hypertension, as it can delay necessary intervention and increase risks. *Commence low-dose aspirin 150 mg once daily and review in 1 week* - **Low-dose aspirin** is indicated for the **prevention of pre-eclampsia** in high-risk individuals, ideally commenced before **16 weeks gestation**. - It is not an acute treatment for established hypertension and starting it at 28 weeks would not address the immediate need for blood pressure control. *Reassure and arrange review in 2 weeks with repeat blood pressure measurement* - Reassurance alone is inappropriate as a blood pressure of 146/96 mmHg at 28 weeks gestation requires active management and close monitoring. - Delaying re-evaluation for two weeks without intervention increases the risk of progression to **severe pre-eclampsia** or other hypertensive complications of pregnancy.

Question 124: What is the recommended target blood pressure for women with chronic hypertension during pregnancy according to current UK guidelines?

A. 120/80 mmHg or less
B. 130/80 mmHg or less
C. 135/85 mmHg or less (Correct Answer)
D. 140/90 mmHg or less
E. 150/100 mmHg or less

Explanation: ***135/85 mmHg or less*** - According to **NICE guidelines (NG133)**, the target blood pressure for women with chronic hypertension during pregnancy is **135/85 mmHg or less**. - This target aims to reduce the risk of **maternal complications** such as stroke while avoiding aggressive reduction that could impair **placental perfusion**. *120/80 mmHg or less* - Setting a target this low is not recommended in pregnancy as it may cause **fetal growth restriction** due to reduced blood flow to the placenta. - **Aggressive antihypertensive therapy** below physiological needs for pregnancy can lead to adverse neonatal outcomes. *130/80 mmHg or less* - While this is a common target for non-pregnant adults with comorbidities, it is not the specific threshold defined by **UK maternity guidelines**. - Maintaining pressure at this level is not evidenced to provide superior outcomes compared to the **135/85 mmHg** standard in a pregnant population. *140/90 mmHg or less* - A blood pressure of **140/90 mmHg** or higher is the threshold used to **diagnose** hypertension in pregnancy rather than the therapeutic target. - Leaving blood pressure at this upper limit increases the risk of progression to **pre-eclampsia** or secondary organ damage. *150/100 mmHg or less* - This level is considered **severe hypertension** in pregnancy and requires urgent medical intervention and monitoring. - Targeting this range would be insufficient for preventing **maternal morbidity** and ensuring a safe pregnancy course.

Question 125: A 38-year-old woman with gestational diabetes is reviewed at 36 weeks gestation. She has been diet-controlled throughout pregnancy with excellent glycaemic control. Today's growth scan shows estimated fetal weight on the 45th centile with normal liquor volume and normal umbilical artery Doppler. She asks about timing of delivery. What is the most appropriate recommendation?

A. Induction of labour should be offered at 37+0 weeks gestation
B. Induction of labour should be offered at 38+0 weeks gestation
C. She should await spontaneous labour up to 41+0 weeks gestation with routine monitoring (Correct Answer)
D. Elective caesarean section should be recommended at 38 weeks due to gestational diabetes
E. Induction of labour should be offered at 39+0 weeks gestation

Explanation: ***She should await spontaneous labour up to 41+0 weeks gestation with routine monitoring*** - According to **NICE guidelines**, women with **gestational diabetes (GDM)** managed by **diet alone** with no complications should be managed similarly to low-risk pregnancies regarding the timing of delivery. - Since her **glycaemic control** is excellent and the **fetal growth** is normal (45th centile), she can safely await spontaneous labor until **40+6 weeks**, with induction offered between 40+6 and 41+0 weeks. *Induction of labour should be offered at 37+0 weeks gestation* - Early induction at 37 weeks is typically reserved for cases with severe **maternal or fetal complications**, such as severe **preeclampsia** or significant **fetal growth restriction**. - Routine induction this early is not indicated for well-controlled, diet-managed GDM with normal fetal growth. *Induction of labour should be offered at 38+0 weeks gestation* - This timing is generally considered for women with GDM who require **insulin or metformin** for blood glucose control, which is not the case for this patient. - Inducing at 38 weeks in a diet-controlled patient with no complications unnecessarily increases the risk of **obstetric intervention**. *Elective caesarean section should be recommended at 38 weeks due to gestational diabetes* - **Gestational diabetes** itself is not an indication for an **elective caesarean section**; vaginal delivery is usually preferred unless there are specific obstetric contraindications. - A caesarean section might be discussed if there was significant **fetal macrosomia** (e.g., EFW > 4.5kg), but this fetus is on the **45th centile**. *Induction of labour should be offered at 39+0 weeks gestation* - Induction at 39 weeks is common for women on medical therapy (insulin/metformin), but it is not the standard recommendation for **diet-controlled GDM** with no other risk factors. - Current evidence and guidelines support waiting for **spontaneous labor** in this specific uncomplicated profile to improve birth outcomes.

Question 126: A 26-year-old primigravida presents to the emergency department at 37 weeks gestation with a severe frontal headache that started 6 hours ago. Her blood pressure is 162/108 mmHg. Urinalysis shows 2+ proteinuria. Blood tests show: platelet count 145 × 10⁹/L, ALT 52 U/L, creatinine 78 μmol/L. She is admitted and commenced on oral labetalol. Four hours later, her blood pressure is 155/102 mmHg despite two doses of labetalol. What is the most appropriate next step in management?

A. Increase the frequency of oral labetalol dosing
B. Add oral nifedipine modified release to labetalol
C. Give intravenous labetalol bolus and consider starting magnesium sulphate (Correct Answer)
D. Switch from oral labetalol to oral methyldopa
E. Commence intravenous hydralazine infusion only

Explanation: ***Give intravenous labetalol bolus and consider starting magnesium sulphate*** - The patient has **severe pre-eclampsia** (BP 162/108 mmHg, 2+ proteinuria, severe headache) that has failed to respond to initial oral labetalol therapy, with BP still above the severe threshold. - **Intravenous labetalol** is required for rapid control of acute severe hypertension, and **magnesium sulphate** is indicated for seizure prophylaxis to prevent **eclampsia** in patients with severe features like a persistent headache. *Increase the frequency of oral labetalol dosing* - Oral medications have a **slower onset of action** and are generally inadequate for the urgent management of **acute severe hypertension** in pregnancy, especially when initial oral therapy has failed. - Relying on increased oral dosing delays the necessary rapid blood pressure reduction, increasing the risk of maternal complications such as **stroke** or **eclampsia**. *Add oral nifedipine modified release to labetalol* - While **nifedipine** is an appropriate antihypertensive in pregnancy, oral modified-release formulations are not suitable for the **acute stabilization** required in symptomatic severe pre-eclampsia. - Guidelines prioritize **intravenous agents** (such as labetalol or hydralazine) when blood pressure remains persistently elevated above the severe threshold despite initial oral therapy. *Switch from oral labetalol to oral methyldopa* - **Methyldopa** is a slow-acting antihypertensive with a delayed onset of effect, typically taking 24–48 hours to achieve its full effect, making it unsuitable for managing **acute hypertensive emergencies**. - Switching to another oral agent does not address the immediate need for **parenteral therapy** to rapidly control blood pressure and neurological symptoms. *Commence intravenous hydralazine infusion only* - While **IV hydralazine** is an appropriate alternative to IV labetalol for acute blood pressure control in severe pre-eclampsia, this option overlooks the critical need for **magnesium sulphate**. - Management of severe pre-eclampsia with severe features (like severe headache) requires both **antihypertensive therapy** and **seizure prophylaxis** to mitigate both hemodynamic and neurological risks.

Question 127: A 33-year-old woman in her third pregnancy attends the antenatal clinic at 34 weeks gestation. She has chronic hypertension and was taking lisinopril pre-pregnancy, which was changed to labetalol at booking. Her blood pressure today is 138/88 mmHg. Urinalysis shows no proteinuria. She reports good fetal movements and has no symptoms. Her booking blood pressure was 132/84 mmHg. What is the most appropriate management?

A. Continue current dose of labetalol and review in 1 week (Correct Answer)
B. Increase labetalol dose and arrange twice-weekly blood pressure monitoring
C. Admit for blood pressure monitoring and investigation for pre-eclampsia
D. Switch from labetalol to methyldopa and review in 2 weeks
E. Add nifedipine to labetalol and review in 1 week

Explanation: ***Continue current dose of labetalol and review in 1 week*** - The patient's blood pressure of **138/88 mmHg** is well-controlled and below the threshold for intervention (**140/90 mmHg**), with no **proteinuria** or symptoms, indicating stable **chronic hypertension**. - Current guidelines recommend aiming for a blood pressure of **135/85 mmHg** or less; as her current readings are near this target and she is stable, routine **weekly antenatal review** is appropriate. *Increase labetalol dose and arrange twice-weekly blood pressure monitoring* - Increasing the dose of **labetalol** is only indicated if blood pressure consistently exceeds **140/90 mmHg** or if there are signs of clinical deterioration. - Unnecessary dose escalation can lead to **maternal hypotension** or potential adverse **fetal effects**, without additional benefit given her current stable BP. *Admit for blood pressure monitoring and investigation for pre-eclampsia* - Admission is typically reserved for cases of **severe hypertension** (≥160/110 mmHg) or strong suspicion of **pre-eclampsia**, which would involve new-onset significant **proteinuria** and/or maternal symptoms. - This patient's blood pressure is stable, she is asymptomatic, and has no proteinuria, ruling out the immediate need for admission or extensive pre-eclampsia workup. *Switch from labetalol to methyldopa and review in 2 weeks* - **Labetalol** is a highly effective and **first-line antihypertensive** in pregnancy; there is no medical indication to switch agents when the current regimen is stable and well-tolerated. - A **2-week review interval** is too prolonged for a patient with chronic hypertension at **34 weeks gestation**, where closer, typically weekly, monitoring is standard. *Add nifedipine to labetalol and review in 1 week* - **Combination therapy** with an additional antihypertensive like **nifedipine** is typically initiated when monotherapy fails to control blood pressure despite optimal dosing. - Adding a second agent unnecessarily at this stage could lead to **maternal hypotension** or other adverse effects without clinical justification, given her controlled blood pressure.

Question 128: A 29-year-old woman attends her routine antenatal appointment at 16 weeks gestation. She asks about screening for gestational diabetes. She has no previous history of gestational diabetes, her BMI is 27 kg/m², and she is of British Caucasian ethnicity. Her mother developed type 2 diabetes at age 65. What is the most appropriate advice regarding gestational diabetes screening for this patient?

A. She does not meet criteria for gestational diabetes screening and should not have an oral glucose tolerance test (Correct Answer)
B. She should have an oral glucose tolerance test at 24-28 weeks gestation only
C. She should have an oral glucose tolerance test now and again at 24-28 weeks if the first test is normal
D. She should have fasting glucose measured at each antenatal visit
E. She should have random glucose measured at booking and at 28 weeks gestation

Explanation: ***She does not meet criteria for gestational diabetes screening and should not have an oral glucose tolerance test***- According to **NICE guidelines**, screening for **gestational diabetes (GDM)** is risk-factor based; this patient’s **BMI of 27 kg/m²** is below the **>30 kg/m²** threshold.- She lacks other triggers such as a **previous macrosomic baby** (≥4.5kg), history of **GDM**, or being from a **high-prevalence ethnic group**.*She should have an oral glucose tolerance test at 24-28 weeks gestation only*- An **Oral Glucose Tolerance Test (OGTT)** at 24-28 weeks is reserved for patients with at least one **risk factor**, which this patient does not possess.- Her mother's diagnosis of **Type 2 Diabetes** at age 65 is common and does not automatically trigger screening unless it is a **first-degree relative** with early-onset or significant diabetic history in specific contexts.*She should have an oral glucose tolerance test now and again at 24-28 weeks if the first test is normal*- This intensive screening schedule is only indicated for women with **previous gestational diabetes**, who require an OGTT or **HbA1c** at booking.- Since this is her first pregnancy without known risk factors, performing an **early OGTT** at 16 weeks is clinically unnecessary.*She should have fasting glucose measured at each antenatal visit*- **Fasting glucose** is not used as a repetitive serial screening tool for GDM in the absence of risk factors or clinical signs like **glycosuria**.- Standard care involves monitoring for **glucose in the urine** during routine visits, but not formal blood glucose testing unless symptoms arise.*She should have random glucose measured at booking and at 28 weeks gestation*- **Random blood glucose** is not a recommended screening method for GDM as it lacks the sensitivity and standardization of the **75g OGTT**.- Routine screening in the UK is **targeted** rather than universal, so patients without risk factors do not receive glucose testing at these intervals.

Question 129: A 32-year-old woman in her second pregnancy is seen at 26 weeks gestation. Her booking blood pressure was 118/74 mmHg. Today it is measured as 152/98 mmHg. She is asymptomatic. Urinalysis shows trace protein. Blood tests reveal: Hb 112 g/L, WCC 9.2 × 10⁹/L, platelets 198 × 10⁹/L, urea 4.2 mmol/L, creatinine 75 μmol/L, ALT 28 U/L, AST 32 U/L. Protein:creatinine ratio is 25 mg/mmol. What is the most appropriate classification and management plan?

A. Pre-eclampsia; admit for blood pressure control and close monitoring
B. Gestational hypertension; start labetalol and review in 1 week
C. Chronic hypertension; start methyldopa and refer to specialist clinic
D. Pre-eclampsia; arrange twice-weekly outpatient monitoring
E. Gestational hypertension; arrange assessment within 48 hours (Correct Answer)

Explanation: ***Gestational hypertension; arrange assessment within 48 hours*** - **Gestational hypertension** is diagnosed when new-onset hypertension (BP ≥140/90 mmHg) develops after **20 weeks gestation** without significant **proteinuria** (PCR <30 mg/mmol) or other signs of organ dysfunction. - For non-severe gestational hypertension (BP 140-159/90-109 mmHg), **assessment within 48 hours** is recommended to monitor for progression, check maternal bloods, and fetal well-being, initiating treatment if required. *Pre-eclampsia; admit for blood pressure control and close monitoring* - **Pre-eclampsia** is not diagnosed as there is no significant **proteinuria** (PCR is 25 mg/mmol, below the diagnostic threshold of ≥30 mg/mmol) and no other features of **organ dysfunction**. - Admission for blood pressure control is generally reserved for **severe hypertension** (BP ≥160/110 mmHg) or cases with features of severe pre-eclampsia, which are not present here. *Gestational hypertension; start labetalol and review in 1 week* - While **labetalol** is a first-line antihypertensive in pregnancy, starting medication immediately without further assessment may not be necessary if the blood pressure is not severe, and a **one-week review** is too prolonged. - Initial management of new-onset hypertension in pregnancy requires closer follow-up, typically **within 48-72 hours**, to detect rapid progression to pre-eclampsia. *Chronic hypertension; start methyldopa and refer to specialist clinic* - **Chronic hypertension** is defined as hypertension present before pregnancy or diagnosed before **20 weeks gestation**; this patient had a normal booking blood pressure (118/74 mmHg) and developed hypertension at 26 weeks. - Therefore, the hypertension is pregnancy-induced, not chronic, making this diagnosis incorrect. *Pre-eclampsia; arrange twice-weekly outpatient monitoring* - The patient does not meet the diagnostic criteria for **pre-eclampsia** because her **protein:creatinine ratio (PCR)** of 25 mg/mmol is below the threshold for significant proteinuria (≥30 mg/mmol), and she is asymptomatic with normal blood tests. - Initiating a pre-eclampsia monitoring plan without a confirmed diagnosis could lead to unnecessary anxiety and interventions, as the current presentation is consistent with gestational hypertension.

Question 130: A 35-year-old woman with diet-controlled gestational diabetes attends at 38 weeks gestation. Her glucose monitoring over the past 4 weeks shows fasting values 4.6-5.1 mmol/L and 1-hour post-prandial values 6.8-7.4 mmol/L. Growth scan at 36 weeks showed estimated fetal weight on 48th centile. Today, symphysis-fundal height is 35 cm (on centile), BP is 128/76 mmHg, and urinalysis is normal. She has been offered induction of labour at 40 weeks but asks if she can wait for spontaneous labour beyond this. What is the most evidence-based response?

A. She should be strongly advised to have induction at 38 weeks due to gestational diabetes
B. She can wait beyond 40 weeks but requires twice-weekly CTG monitoring
C. Induction should be recommended by 40+6 weeks even with diet-controlled gestational diabetes (Correct Answer)
D. She requires caesarean section rather than induction due to gestational diabetes
E. She can safely wait until 42 weeks with standard monitoring as her diabetes is well-controlled on diet

Explanation: ***Induction should be recommended by 40+6 weeks even with diet-controlled gestational diabetes***- This recommendation aligns with **NICE guidelines (NG3)**, which suggest offering **induction of labour** by **40+6 weeks** for women with diet-controlled gestational diabetes.- This strategy aims to mitigate the slightly increased risk of **stillbirth** associated with GDM, while still allowing a window for spontaneous labour in low-risk cases.*She should be strongly advised to have induction at 38 weeks due to gestational diabetes*- Induction between **37+0 and 38+6 weeks** is typically recommended for women with GDM requiring **insulin or oral hypoglycemics**, or those with complications.- This patient's **glucose control is excellent** on diet, and fetal growth is normal, so early induction at 38 weeks is not indicated.*She can wait beyond 40 weeks but requires twice-weekly CTG monitoring*- While increased fetal surveillance may be considered if a patient declines induction, waiting *beyond* **40+6 weeks** for delivery is not the standard evidence-based recommendation for diet-controlled GDM.- The primary aim is to ensure timely delivery to minimize the risk of **late-term complications** associated with gestational diabetes.*She requires caesarean section rather than induction due to gestational diabetes*- **Gestational diabetes** is not an automatic indication for a **caesarean section**; vaginal delivery is usually the preferred route.- The **estimated fetal weight is on the 48th centile**, indicating no **macrosomia** that would necessitate a surgical birth.*She can safely wait until 42 weeks with standard monitoring as her diabetes is well-controlled on diet*- Waiting until **42 weeks** significantly increases the risk of **stillbirth** and other adverse perinatal outcomes, even in diet-controlled GDM.- Despite good glucose control, the underlying metabolic changes in GDM still warrant delivery by **40+6 weeks** to prevent these risks.

Question 131: A 30-year-old woman presents to the emergency department at 37 weeks gestation with sudden-onset severe headache and visual disturbances. Her blood pressure is 178/118 mmHg. She has 3+ proteinuria on dipstick. Blood tests show: platelets 156 × 10⁹/L, ALT 45 U/L, AST 52 U/L, creatinine 88 μmol/L. CTG shows baseline 145 bpm with normal variability and no decelerations. She has become increasingly drowsy. What is the single most important immediate intervention?

A. Administer magnesium sulphate (Correct Answer)
B. Perform immediate caesarean section
C. Give oral nifedipine 10 mg
D. Commence intravenous labetalol infusion
E. Arrange urgent CT head scan

Explanation: ***Administer magnesium sulphate*** - This patient presents with **severe pre-eclampsia** (BP 178/118 mmHg, 3+ proteinuria) and neurological symptoms (severe headache, visual disturbances, increasing drowsiness), indicating an imminent risk of **eclampsia** (seizures). - **Magnesium sulphate** is the cornerstone for **seizure prophylaxis** in severe pre-eclampsia, significantly reducing the risk of eclamptic seizures. *Perform immediate caesarean section* - While delivery is the definitive treatment for pre-eclampsia, the mother's condition must first be **stabilized** with magnesium sulphate and antihypertensives to mitigate perioperative risks. - Proceeding to immediate surgery without adequate stabilization increases the likelihood of **maternal stroke** or seizures during the procedure. *Give oral nifedipine 10 mg* - Oral nifedipine 10 mg is generally not the ideal choice for acutely managing severe hypertension in this context due to potentially **unpredictable absorption** and risk of **precipitous blood pressure drops**. - **Intravenous antihypertensives** or controlled-release oral formulations are preferred for safer and more controlled blood pressure reduction in an emergency. *Commence intravenous labetalol infusion* - Managing severe hypertension is crucial, but given the neurological symptoms, preventing **eclampsia** with magnesium sulphate is the single most important immediate priority. - While labetalol effectively lowers blood pressure and reduces **vascular risk**, it does not provide the **neuroprotection** against seizures that magnesium sulphate offers. *Arrange urgent CT head scan* - Although neurological changes like drowsiness warrant consideration of intracranial pathology, the clear diagnosis of **severe pre-eclampsia** means immediate **stabilization** takes precedence. - A CT head scan should only be considered after **seizure prophylaxis** has been initiated and blood pressure is actively being managed, or if symptoms persist despite treatment.

Question 132: A 40-year-old woman attends her booking appointment at 11 weeks gestation in her third pregnancy. Her previous pregnancies were uncomplicated with spontaneous vaginal deliveries at term. Her BMI is 35 kg/m², and her mother has type 2 diabetes. She is of South Asian ethnicity. According to NICE guidelines, when should she be offered OGTT screening for gestational diabetes?

A. At booking and at 24-28 weeks
B. Immediately at booking, then repeat at 28 weeks if normal
C. At 16-18 weeks, then repeat at 28 weeks if normal
D. At 24-28 weeks only (Correct Answer)
E. At 20-24 weeks, then repeat at 32 weeks if normal

Explanation: ***At 24-28 weeks only***- According to **NICE guidelines**, women with risk factors such as a **BMI ≥30 kg/m²**, **South Asian ethnicity**, or a **first-degree relative with diabetes** should be offered an **OGTT at 24-28 weeks**.- This patient does not have a history of **previous gestational diabetes**, which would necessitate earlier or repeat screening.*At booking and at 24-28 weeks*- Screening at **booking** (or shortly after) is specifically indicated for women who have had **gestational diabetes (GDM)** in a previous pregnancy.- Since this patient's previous pregnancies were uncomplicated, **early screening** is not the standard recommendation despite her other risk factors.*Immediately at booking, then repeat at 28 weeks if normal*- This specific protocol is not part of the standard **NICE screening pathway** for women without a **prior history of GDM**.- High risk based on **ethnicity and BMI** alone still follows the singular **24-28 week window** unless clinical symptoms develop earlier.*At 16-18 weeks, then repeat at 28 weeks if normal*- This early screening window is specifically reserved for women with **previous GDM** to detect early-onset glucose intolerance.- For a woman whose only risk factors are **BMI**, **family history**, and **ethnicity**, the standard physiological peak of **insulin resistance** at 24-28 weeks is the targeted time for testing.*At 20-24 weeks, then repeat at 32 weeks if normal*- These timeframes do not align with **NICE (NG3) recommendations** for routine gestational diabetes screening.- Routine screening is most effective during the **late second/early third trimester** (24-28 weeks), and 32 weeks is typically too late for primary screening.

Question 133: A 25-year-old woman presents to antenatal clinic at 32 weeks gestation with blood pressure of 146/96 mmHg. This is her first pregnancy and all previous blood pressure readings have been normal. Urinalysis shows no proteinuria. Blood tests show: Hb 118 g/L, platelets 245 × 10⁹/L, ALT 22 U/L, creatinine 62 μmol/L. She is asymptomatic. What is the most appropriate diagnosis and initial management?

A. Pre-eclampsia; admit for observation and commence antihypertensive therapy
B. Gestational hypertension; arrange repeat BP in 1 week with community midwife
C. White coat hypertension; arrange 24-hour ambulatory blood pressure monitoring
D. Gestational hypertension; admit for observation and twice-daily BP monitoring
E. Gestational hypertension; commence labetalol and review in 48-72 hours (Correct Answer)

Explanation: ***Gestational hypertension; commence labetalol and review in 48-72 hours*** - **Gestational hypertension** is diagnosed when new-onset hypertension (≥140/90 mmHg) occurs after **20 weeks of gestation** without **proteinuria** or biochemical organ dysfunction. - In this case, the blood pressure of 146/96 mmHg warrants **oral antihypertensive therapy** (first-line **labetalol**) with follow-up within 48-72 hours to ensure stabilization and monitor for progression to pre-eclampsia. *Pre-eclampsia; admit for observation and commence antihypertensive therapy* - A diagnosis of **pre-eclampsia** requires hypertension plus **proteinuria** or other features such as **low platelets**, elevated liver enzymes, or renal impairment, which are absent here. - Admission is generally reserved for **severe hypertension** (≥160/110 mmHg) or clinical/biochemical features of organ involvement. *Gestational hypertension; arrange repeat BP in 1 week with community midwife* - Waiting one week is inappropriate because current guidelines recommend **reviewing blood pressure** within 48-72 hours when starting medication to assess response. - This delay increases the risk of complications if the blood pressure rises further or if the condition evolves into **pre-eclampsia**. *White coat hypertension; arrange 24-hour ambulatory blood pressure monitoring* - While ambulatory monitoring can diagnose **white coat hypertension**, new-onset hypertension at **32 weeks gestation** is clinically significant and should be treated as gestational hypertension first. - Managing the risk of **maternofetal complications** takes priority over excluding white coat effects in a late-gestation patient with no previous hypertensive history. *Gestational hypertension; admit for observation and twice-daily BP monitoring* - **Admission** is not routinely required for mild-to-moderate gestational hypertension if the patient is **asymptomatic** and blood results are within normal limits. - This patient can be managed safely in the **outpatient setting** with maternal education on symptoms of pre-eclampsia and scheduled clinic reviews.

Question 134: A 38-year-old woman with gestational diabetes on metformin and insulin is reviewed at 34 weeks gestation. Growth scans show estimated fetal weight on 92nd centile with amniotic fluid index of 26 cm (polyhydramnios). Her glucose control shows fasting values 4.9-5.4 mmol/L and 1-hour post-prandial values 7.2-8.5 mmol/L. What modification to her management plan would be most appropriate?

A. Increase insulin doses to improve post-prandial control (Correct Answer)
B. Reduce metformin dose to prevent polyhydramnios
C. Arrange immediate delivery by caesarean section
D. Add glibenclamide to improve overall glycaemic control
E. Continue current management and arrange amniocentesis

Explanation: ***Increase insulin doses to improve post-prandial control*** - The patient's **1-hour post-prandial glucose** values (up to 8.5 mmol/L) exceed the standard target of **<7.8 mmol/L**, indicating suboptimal control. - The presence of **macrosomia** (fetal weight >90th centile) and **polyhydramnios** are complications of maternal hyperglycemia, necessitating stricter insulin titration to prevent further fetal overgrowth. *Reduce metformin dose to prevent polyhydramnios* - Reducing **metformin** would lead to higher maternal blood glucose levels, potentially worsening **polyhydramnios** and fetal macrosomia. - Metformin is used to sensitize tissues to insulin and lowering it would be counter-therapeutic in the context of poor glycemic control. *Arrange immediate delivery by caesarean section* - **Immediate delivery** at 34 weeks is premature; the aim is usually to optimize control and aim for delivery between **37-38 weeks** in complicated gestational diabetes. - A **caesarean section** is not automatically indicated solely based on macrosomia unless the estimated fetal weight exceeds specific thresholds (usually >4.5kg) or there are other obstetric indications. *Add glibenclamide to improve overall glycaemic control* - **Glibenclamide** (a sulfonylurea) is generally not the first-line preference when a patient is already failing on a combination of **insulin and metformin**. - Adjusting the **insulin dose** provides more precise and flexible control over glucose spikes compared to adding a fixed-dose oral hypoglycemic agent. *Continue current management and arrange amniocentesis* - **Amniocentesis** is not indicated here as the cause of polyhydramnios is clearly identified as **fetal polyuria** secondary to maternal hyperglycemia. - Continuing current management is inappropriate because the fetal growth and fluid status demonstrate that existing **glycemic targets** are not being met.

Question 135: A 27-year-old primigravida attends her booking appointment at 12 weeks gestation. She has a history of epilepsy controlled on lamotrigine 200 mg twice daily with no seizures for 3 years. She took folic acid 400 mcg daily from 6 weeks gestation when pregnancy was confirmed. On examination, her BP is 112/68 mmHg and BMI is 24 kg/m². What is the most appropriate advice regarding her antiepileptic medication and additional supplementation?

A. Continue current lamotrigine dose and increase folic acid to 5 mg daily (Correct Answer)
B. Reduce lamotrigine dose and continue folic acid 400 mcg daily
C. Continue current lamotrigine dose, explain higher folic acid was needed pre-conception but too late now
D. Stop lamotrigine and switch to levetiracetam immediately
E. Continue current lamotrigine dose, start vitamin K supplementation

Explanation: ***Continue current lamotrigine dose and increase folic acid to 5 mg daily*** - Women on **antiepileptic drugs (AEDs)** are at higher risk of neural tube defects and should receive a higher dose of **5 mg folic acid** throughout pregnancy. - **Lamotrigine** is among the safest AEDs during pregnancy, and the dose should be maintained at a level that provides effective **seizure control** to prevent maternal and fetal harm. *Reduce lamotrigine dose and continue folic acid 400 mcg daily* - Reducing the dose of AEDs in a seizure-free patient risks **breakthrough seizures**, which can cause fetal hypoxia or maternal injury. - The standard dose of **400 mcg folic acid** is insufficient for women taking AEDs; they require the high-dose **5 mg** protocol. *Continue current lamotrigine dose, explain higher folic acid was needed pre-conception but too late now* - Although the critical period for **neural tube closure** is the first trimester, high-dose folic acid is still recommended throughout pregnancy for patients on AEDs for overall fetal health. - It is never "too late" to optimize nutritional support and follow clinical guidelines for high-risk pregnancies. *Stop lamotrigine and switch to levetiracetam immediately* - Switching medications during pregnancy is generally avoided as it risks losing **seizure control** during the transition period. - Both **lamotrigine** and **levetiracetam** are considered first-line options in pregnancy due to lower teratogenic risk compared to sodium valproate. *Continue current lamotrigine dose, start vitamin K supplementation* - **Vitamin K** supplementation is indicated in the final month for women taking **enzyme-inducing** AEDs (e.g., carbamazepine, phenytoin) to prevent neonatal hemorrhage. - **Lamotrigine** is not an enzyme-inducing drug, so routine Vitamin K supplementation for the mother is not specifically required for this reason.

Question 136: A 33-year-old woman undergoes OGTT at 28 weeks gestation following detection of glycosuria at routine antenatal visit. Results show: fasting glucose 5.8 mmol/L and 2-hour glucose 9.2 mmol/L. Her BMI is 28 kg/m². She is referred to the diabetes in pregnancy clinic. What is the most appropriate initial management approach?

A. Commence metformin 500 mg twice daily immediately
B. Initiate insulin therapy with close monitoring
C. Provide dietary advice and self-monitoring, review in 1 week (Correct Answer)
D. Repeat OGTT in 2 weeks to confirm diagnosis
E. Commence metformin 500 mg once daily and provide dietary advice

Explanation: ***Provide dietary advice and self-monitoring, review in 1 week*** - According to **NICE guidelines**, the initial management for gestational diabetes (GDM) with a fasting glucose **below 7.0 mmol/L** is a trial of **diet and exercise** for 1–2 weeks. - Patients must be taught **self-monitoring of blood glucose** (fasting and 1-hour postprandial) to assess if lifestyle changes alone can reach glycemic targets before considering pharmacotherapy. *Commence metformin 500 mg twice daily immediately* - **Metformin** is typically indicated only if glycemic targets are not met after a trial of **lifestyle modification** or if the initial fasting glucose is significantly elevated (e.g., ≥7.0 mmol/L). - Immediate pharmacotherapy is generally reserved for more severe presentations or when there are signs of **fetal complications**. *Initiate insulin therapy with close monitoring* - **Insulin** is usually the first-line medication only if the fasting glucose is **≥7.0 mmol/L** at diagnosis, or if there are signs of **fetal macrosomia** or polyhydramnios. - For this patient with a fasting glucose of 5.8 mmol/L, insulin is premature as **lifestyle modifications** have not yet been attempted. *Repeat OGTT in 2 weeks to confirm diagnosis* - A single abnormal **OGTT** (fasting ≥5.6 mmol/L or 2-hour ≥7.8 mmol/L for GDM) is sufficient to diagnose **gestational diabetes**; repeating the test would cause unnecessary delay. - The presence of **glycosuria** combined with these specific biochemical results confirms the diagnosis, warranting immediate management. *Commence metformin 500 mg once daily and provide dietary advice* - While providing **dietary advice** is correct, commencing **metformin** at this stage bypasses the recommended initial step of **lifestyle-only intervention**. - Guidelines emphasize assessing the efficacy of **dietary changes** and increased physical activity for at least 1 week before introducing oral hypoglycemic agents.

Question 137: A 31-year-old woman is admitted at 36 weeks gestation with severe pre-eclampsia. Blood pressure is 168/116 mmHg despite oral labetalol 200 mg three times daily. Blood tests show: platelets 98 × 10⁹/L, ALT 125 U/L, creatinine 118 μmol/L, and proteinuria 4.2 g/24 hours. She reports mild epigastric discomfort. CTG is reassuring. What is the most appropriate immediate management plan?

A. Continue current management with repeat bloods in 24 hours
B. Commence magnesium sulphate and plan delivery within 24-48 hours (Correct Answer)
C. Add nifedipine and increase monitoring frequency
D. Immediate delivery by caesarean section
E. Start intravenous labetalol infusion and review in 6 hours

Explanation: ***Commence magnesium sulphate and plan delivery within 24-48 hours***- The patient presents with **severe pre-eclampsia** at 36 weeks, indicated by refractory hypertension, **thrombocytopenia** (platelets 98 x 10⁹/L), elevated **ALT** (125 U/L), **renal dysfunction** (creatinine 118 μmol/L), and **epigastric discomfort**, suggesting multi-organ involvement.- **Magnesium sulphate** is crucial for eclamptic seizure prophylaxis in severe pre-eclampsia, and delivery is the definitive treatment. Planning delivery within 24-48 hours is appropriate for stabilization given the **reassuring CTG** and 36 weeks gestation.*Continue current management with repeat bloods in 24 hours*- Delaying active management is inappropriate given the **severity of pre-eclampsia** and progressive **end-organ dysfunction** (thrombocytopenia, elevated ALT, renal impairment).- This approach would significantly increase the risk of serious maternal complications such as **eclampsia** or **HELLP syndrome** progression without intervention.*Add nifedipine and increase monitoring frequency*- While **nifedipine** could help with blood pressure control, it does not address the underlying pathology or the need for seizure prophylaxis and definitive treatment (delivery) in severe pre-eclampsia with multi-organ involvement.- Increased monitoring alone is insufficient for this clinical picture; active steps towards managing the disease progression are essential, not just symptom control.*Immediate delivery by caesarean section*- Although delivery is the definitive management, immediate caesarean section is not universally required, especially with a **reassuring CTG** and time for maternal optimization. - Often, a planned induction of labour can be considered if there are no immediate maternal or fetal indications for emergent operative delivery.*Start intravenous labetalol infusion and review in 6 hours*- Intravenous labetalol can manage acute severe hypertension, but it's a symptomatic treatment and does not prevent the progression of **pre-eclampsia** or address the need for delivery.- Reviewing in 6 hours without a concrete plan for **seizure prophylaxis** and **delivery** is inadequate given the patient's multi-system deterioration.

Question 138: A 36-year-old woman with pre-existing hypertension presents for pre-pregnancy counselling. She currently takes lisinopril 10 mg daily and her blood pressure is well controlled at 118/72 mmHg. She has no other medical conditions and her renal function is normal. Which antihypertensive medication should be recommended if she conceives?

A. Continue lisinopril throughout pregnancy
B. Change to labetalol before attempting conception (Correct Answer)
C. Change to atenolol before attempting conception
D. Stop all antihypertensive medication when pregnancy confirmed
E. Change to losartan before attempting conception

Explanation: ***Change to labetalol before attempting conception*** - **Labetalol** is considered a first-line treatment for chronic hypertension in pregnancy due to its established safety profile for the fetus. - High-risk medications should ideally be switched during **pre-pregnancy counselling** to ensure stable blood pressure control on a pregnancy-safe regimen before conception. *Continue lisinopril throughout pregnancy* - **ACE inhibitors** like lisinopril are strictly contraindicated in the second and third trimesters due to risks of **fetal renal dysgenesis** and oligohydramnios. - Use in pregnancy is associated with significant **teratogenicity**, including skull hypoplasia and intrauterine growth restriction. *Change to atenolol before attempting conception* - While a beta-blocker, **atenolol** is generally avoided in pregnancy as it is specifically linked to **fetal growth restriction (IUGR)**. - First-line beta-blocker therapy in this context is almost exclusively **labetalol** because it does not impair placental blood flow to the same extent. *Stop all antihypertensive medication when pregnancy confirmed* - Discontinuing treatment in a patient with established hypertension increases the risk of **maternal stroke** and placental abruption. - Management aims to maintain blood pressure below **140/90 mmHg** to prevent complications, necessitating a transition to safe alternatives rather than cessation. *Change to losartan before attempting conception* - **Losartan** is an Angiotensin II Receptor Blocker (ARB), which carries the same **boxed warning** as ACE inhibitors for fetal toxicity. - Exposure to ARBs during pregnancy causes **fetopathy** leading to renal failure, hypotension, and death of the fetus or neonate.

Question 139: A 29-year-old woman in her first pregnancy attends the antenatal day unit at 39 weeks gestation with reduced fetal movements for 12 hours. She has gestational diabetes managed with metformin 1000 mg twice daily. Cardiotocography shows a baseline rate of 150 bpm with good variability, two accelerations in 20 minutes, and no decelerations. Her blood pressure is 132/84 mmHg. Urinalysis shows 1+ protein. What is the most appropriate next step in management?

A. Reassure and discharge home with routine follow-up
B. Admit for induction of labour within 24 hours
C. Perform protein:creatinine ratio and arrange review within 24 hours (Correct Answer)
D. Repeat CTG in 4 hours and discharge if normal
E. Arrange urgent ultrasound for fetal biometry and Doppler studies

Explanation: ***Perform protein:creatinine ratio and arrange review within 24 hours*** - The presence of **1+ protein** on urinalysis at 39 weeks gestation requires quantification via **spot protein:creatinine ratio (PCR)** to screen for **preeclampsia**. - Although her blood pressure is currently within normal limits (132/84 mmHg), the combination of **gestational diabetes** and new-onset proteinuria necessitates further investigation and clinical review within **24 hours**. *Reassure and discharge home with routine follow-up* - Routine follow-up is inadequate because **new-onset proteinuria** in late pregnancy is a red flag that must be quantified to exclude **preeclampsia**. - Failure to investigate clinical changes in a **high-risk patient** (gestational diabetes at term) could result in missing a significant hypertensive disorder of pregnancy. *Admit for induction of labour within 24 hours* - Immediate **induction of labour** is not yet indicated as the **CTG is reassuring** and the diagnosis of preeclampsia hasn't been confirmed. - While delivery is often the definitive management for preeclampsia at term, **quantification of proteinuria** and assessment of bloods (FBC, LFTs, U&Es) are needed before deciding on the mode and timing of delivery. *Repeat CTG in 4 hours and discharge if normal* - Repeating the **CTG** only addresses the symptom of **reduced fetal movements**, which is already reassuring with the current baseline and accelerations. - It fails to address the abnormal **urinalysis finding**, which is the more pressing clinical concern regarding maternal safety at this stage. *Arrange urgent ultrasound for fetal biometry and Doppler studies* - **Biometry and Doppler studies** are typically used to assess fetal growth and placental function in chronic conditions or persistent reduced movements. - In this acute setting with a **normal CTG** at 39 weeks, the focus should be on ruling out **preeclampsia** rather than performing an urgent ultrasound for growth.

Question 140: What is the recommended frequency of ultrasound fetal growth surveillance for women diagnosed with gestational diabetes managed with insulin or oral hypoglycaemic agents according to current NICE guidelines?

A. Every 2 weeks from diagnosis
B. Every 4 weeks from diagnosis (Correct Answer)
C. Every 4 weeks from 28 weeks gestation
D. Every 2 weeks from 32 weeks gestation
E. At 28, 32 and 36 weeks gestation

Explanation: ***Every 4 weeks from diagnosis*** - For women with **gestational diabetes** managed with **insulin or oral hypoglycaemic agents**, NICE guidelines recommend ultrasound monitoring for **fetal growth** and **amniotic fluid volume** every 4 weeks. - This scanning frequency is designed to monitor for **macrosomia** and **polyhydramnios**, which are common complications when pharmacological intervention is required. *Every 2 weeks from diagnosis* - Monitoring every **two weeks** is considered overly intensive for standard gestational diabetes and is not supported by current NICE evidence for routine surveillance. - Such frequent scanning would increase **resource utilization** without proven clinical benefits in improving neonatal outcomes compared to the 4-week interval. *Every 4 weeks from 28 weeks gestation* - While 28 weeks is a common starting point for growth scans, the guideline specifically anchors the surveillance schedule to the **time of diagnosis**. - Using a fixed gestational age rather than the **diagnosis date** may lead to inappropriate gaps in monitoring if a woman is diagnosed early or late in the second trimester. *Every 2 weeks from 32 weeks gestation* - This frequency and timing are more commonly associated with high-risk conditions like **fetal growth restriction (FGR)** or specific placental pathologies. - For diabetes, the risk is typically **accelerated growth**, which is adequately monitored with the standard **4-week interval**. *At 28, 32 and 36 weeks gestation* - This fixed schedule does not account for the timing of **diagnosis** or the initiation of **pharmacological treatment**, which are the primary triggers for increased surveillance. - In contrast, women managed with **diet and lifestyle** alone are only required to have a single growth scan at **36 weeks**.

Question 141: A 42-year-old woman with gestational diabetes diagnosed at 27 weeks is now 38 weeks gestation. She has been managed with diet alone with good glycaemic control throughout. Her fasting glucose values have ranged 4.8-5.1 mmol/L and 1-hour post-prandial values 6.5-7.2 mmol/L. Ultrasound at 36 weeks showed estimated fetal weight on 55th centile with normal liquor volume. She asks about timing of delivery. What is the most appropriate management recommendation?

A. Immediate induction of labour at 38 weeks
B. Elective caesarean section at 38 weeks
C. Await spontaneous labour with surveillance until 40+6 weeks (Correct Answer)
D. Induction of labour at 39-40 weeks
E. Induction of labour at 37 weeks

Explanation: ***Await spontaneous labour with surveillance until 40+6 weeks*** - For women with **diet-controlled gestational diabetes (GDM)** and no other pregnancy complications, **expectant management** is recommended until 40+6 weeks. - The patient has **excellent glycemic control** and normal **fetal growth (55th centile)**, meaning the risk of stillbirth is not significantly higher than the general population at this stage. *Immediate induction of labour at 38 weeks* - Early induction at 38 weeks is generally reserved for women with GDM who require **insulin** or have poorly controlled blood glucose. - Inducing at this stage without clinical indication increases the risk of **failed induction** and unnecessary medical intervention. *Elective caesarean section at 38 weeks* - There is no indication for a **caesarean section** as fetal weight is normal and there are no signs of **macrosomia** or maternal distress. - Mode of delivery should be based on obstetric indications; GDM alone is not a reason for routine surgical delivery. *Induction of labour at 39-40 weeks* - This approach is typically considered for GDM patients on **medication** (Metformin or Insulin) to mitigate the increased risk of late-term complications. - In **diet-controlled** cases with normal scans, routine induction is not required before the standard post-dates threshold of **40+6 weeks**. *Induction of labour at 37 weeks* - Induction at **37 weeks** is considered early and would only be indicated in the presence of severe complications like **preeclampsia** or significant **fetal growth restriction**. - Premature induction at this stage carries risks for the neonate, such as **respiratory distress syndrome**, which is not justified in this stable patient.

Question 142: A 34-year-old woman presents at 23 weeks gestation for her first antenatal visit. She was previously healthy with no medical history. On examination, her blood pressure is 124/78 mmHg, BMI is 22 kg/m², and urinalysis shows no proteinuria. She smokes 10 cigarettes daily. Which additional investigation is most appropriate to perform at this visit given the late booking?

A. Oral glucose tolerance test
B. Quadruple test for fetal anomalies
C. Detailed anomaly ultrasound scan (Correct Answer)
D. First trimester combined screening test
E. Cervical length ultrasound

Explanation: ***Detailed anomaly ultrasound scan*** - The **fetal anomaly scan** is routinely performed between **18 and 20+6 weeks**; however, it should still be offered at **23 weeks** to detect major structural abnormalities. - It is the most appropriate next step for a **late booking** patient as it assesses fetal anatomy, placenta position, and amniotic fluid volume. *Oral glucose tolerance test* - An **OGTT** is typically performed between **24 and 28 weeks** gestation unless there are specific high-risk factors like previous **gestational diabetes** or a BMI >30. - While the patient smokes, she lacks the primary risk factors for early screening, and the scan takes priority at this specific encounter. *Quadruple test for fetal anomalies* - The **quadruple test** (screening for Down syndrome) is validated for use only up to **20 weeks and 0 days** gestation. - At **23 weeks**, the patient is outside the clinical window for this biochemical screening test to be accurate or useful. *First trimester combined screening test* - This test, which includes **nuchal translucency** and biochemical markers (PAPP-A and hCG), must be performed between **11 and 14 weeks**. - Since the patient is at **23 weeks**, the opportunity for this screening method has long passed. *Cervical length ultrasound* - **Cervical length** screening is not a routine part of antenatal care for low-risk, asymptomatic patients with no history of **preterm labor**. - This patient has no clinical indications, such as previous **mid-trimester loss** or cervical surgery, to warrant this specific investigation.

Question 143: A 28-year-old primigravida at 19 weeks gestation attends routine antenatal clinic. She mentions she has been reading about vitamin supplementation in pregnancy online and asks whether she should take vitamin D supplements. She has no medical problems, works indoors, and follows a vegetarian diet. She has medium-brown skin tone. What is the most appropriate advice?

A. Vitamin D supplementation is not necessary unless she develops symptoms of deficiency
B. She should take 400 IU (10 micrograms) vitamin D daily throughout pregnancy and while breastfeeding (Correct Answer)
C. She should have serum vitamin D levels checked and only supplement if deficient
D. She should take 800 IU (20 micrograms) vitamin D daily due to her darker skin tone
E. Vitamin D supplementation should only be taken during winter months when sun exposure is limited

Explanation: ***She should take 400 IU (10 micrograms) vitamin D daily throughout pregnancy and while breastfeeding*** - **NICE and RCOG guidelines** recommend universal supplementation of **10 micrograms (400 IU)** daily for all pregnant and breastfeeding women to ensure adequate bone health for mother and fetus. - This patient is at high risk due to her **medium-brown skin tone**, **vegetarian diet**, and **indoor work**, making daily supplementation essential. *Vitamin D supplementation is not necessary unless she develops symptoms of deficiency* - **Vitamin D deficiency** is often asymptomatic; waiting for clinical symptoms like **osteomalacia** or muscle weakness can lead to preventable maternal and neonatal complications. - Guidelines emphasize **preventative supplementation** rather than reactive treatment to avoid the risks of **neonatal hypocalcemia**. *She should have serum vitamin D levels checked and only supplement if deficient* - **Routine screening** of serum vitamin D levels is not recommended in uncomplicated pregnancies as it is not **cost-effective** and doesn't change the standard management. - Regardless of initial levels, the baseline safety and efficacy of **low-dose supplementation** justify its universal use. *She should take 800 IU (20 micrograms) vitamin D daily due to her darker skin tone* - While women with darker skin are at higher risk of deficiency, the **standard recommended dose** for general prevention remains **400 IU (10 micrograms)**. - Higher doses (e.g., 800-2000 IU) are generally reserved for women with **biochemically proven deficiency** or specific high-risk medical conditions. *Vitamin D supplementation should only be taken during winter months when sun exposure is limited* - In the UK and similar latitudes, **UVB radiation** is insufficient for skin synthesis of Vitamin D for most of the year, but pregnancy increases **metabolic demands** year-round. - To maintain consistent **calcium homeostasis**, continuous supplementation throughout the entire pregnancy and **breastfeeding** period is advised.

Question 144: A 37-year-old woman with twin pregnancy is seen at 20 weeks gestation. Her booking BP was 124/78 mmHg. Current BP is 148/96 mmHg. Urinalysis is negative for protein. Blood tests are all within normal limits including uric acid and liver function. She is asymptomatic. She attends again 4 days later and BP is 146/94 mmHg. Urine PCR is 22 mg/mmol. What is the most appropriate management strategy?

A. Diagnose gestational hypertension, commence labetalol, and arrange twice-weekly BP monitoring with weekly blood tests (Correct Answer)
B. Diagnose mild pre-eclampsia, admit for observation and commence antihypertensive therapy
C. Reassure that mild BP elevation is normal in twin pregnancy and continue routine antenatal care
D. Repeat BP measurement in 1 week and commence treatment only if persistently elevated
E. Arrange 24-hour ambulatory blood pressure monitoring to confirm diagnosis before treatment

Explanation: ***Diagnose gestational hypertension, commence labetalol, and arrange twice-weekly BP monitoring with weekly blood tests*** - **Gestational hypertension** is defined as new hypertension (BP ≥140/90 mmHg) presenting after **20 weeks of gestation** without significant proteinuria (PCR <30 mg/mmol). - NICE guidelines recommend initiating **antihypertensive treatment** (e.g., labetalol) when BP is persistently ≥140/90 mmHg to reduce the risk of progressing to **severe hypertension**. *Diagnose mild pre-eclampsia, admit for observation and commence antihypertensive therapy* - **Pre-eclampsia** requires the presence of hypertension plus **significant proteinuria** (PCR ≥30 mg/mmol) or other maternal organ dysfunction, which are absent here. - Admission is generally reserved for **severe hypertension** (≥160/110 mmHg) or clinical concerns of rapid deterioration, not for stable gestational hypertension. *Reassure that mild BP elevation is normal in twin pregnancy and continue routine antenatal care* - Elevated blood pressure is never considered "normal" and requires clinical intervention to prevent **maternal and fetal complications**. - **Twin pregnancies** are at a higher risk for hypertensive disorders, making active management and regular surveillance even more critical. *Repeat BP measurement in 1 week and commence treatment only if persistently elevated* - The diagnosis is already confirmed since the patient had elevated readings on two separate occasions (initial visit and 4 days later). - Delaying treatment increases the risk of **maternal stroke** and progression to **eclampsia** or HELLP syndrome. *Arrange 24-hour ambulatory blood pressure monitoring to confirm diagnosis before treatment* - While **ABPM** can rule out white-coat hypertension, it should not delay management when clinic readings are consistently elevated in a **high-risk pregnancy**. - Standard clinical protocol for **pregnancy-induced hypertension** prioritizes prompt initiation of monitoring and treatment once the threshold of 140/90 mmHg is met.

Question 145: A 25-year-old woman at 33 weeks gestation with gestational hypertension controlled on labetalol presents with sudden onset severe occipital headache, visual disturbance, and vomiting. BP is 188/118 mmHg. She has brisk reflexes with 3 beats of clonus. Urinalysis shows 2+ protein. CTG shows baseline 145 bpm with normal variability. While urgent bloods are being processed, what is the most important immediate pharmacological intervention?

A. Intravenous labetalol boluses to reduce BP to below 160/110 mmHg
B. Intravenous magnesium sulphate 4g loading dose over 5-10 minutes (Correct Answer)
C. Oral nifedipine 10 mg immediate release
D. Intravenous hydralazine 5 mg bolus
E. Intravenous dexamethasone 12 mg for fetal lung maturation

Explanation: ***Intravenous magnesium sulphate 4g loading dose over 5-10 minutes*** - This patient presents with **severe pre-eclampsia** (BP ≥160/110 mmHg, 2+ proteinuria, and severe symptoms) and features of **impending eclampsia**, specifically severe headache, visual disturbance, hyperreflexia, and clonus. - **Magnesium sulphate** is the gold standard for **seizure prophylaxis** in severe pre-eclampsia and eclampsia, and its immediate administration is crucial to prevent maternal seizures, which are life-threatening. *Intravenous labetalol boluses to reduce BP to below 160/110 mmHg* - While **acute blood pressure control** is vital to reduce the risk of **maternal stroke** and other complications, the most immediate life-saving intervention when impending eclampsia is suspected (due to clonus) is seizure prophylaxis. - **IV labetalol** is a first-line agent for severe hypertension in pregnancy, but stabilization of the central nervous system with magnesium takes immediate precedence in the setting of neurologic triggers like **clonus**. *Oral nifedipine 10 mg immediate release* - **Oral nifedipine** is an appropriate antihypertensive for acute BP management in pregnancy, but **immediate-release** formulations should be used with caution due to the risk of precipitous hypotension. - Crucially, it does not address the underlying **cerebral irritability** or the immediate threat of eclamptic seizures, which is the primary concern given the patient's neurological signs. *Intravenous hydralazine 5 mg bolus* - **Intravenous hydralazine** is an alternative for acute hypertensive crisis in pregnancy, typically used if labetalol is contraindicated or ineffective. - However, similar to other antihypertensives, its administration is secondary to the immediate need for **magnesium sulphate** for the prevention of impending eclampsia in this critical scenario. *Intravenous dexamethasone 12 mg for fetal lung maturation* - **Corticosteroids** like dexamethasone are essential for promoting **fetal lung maturity** at 33 weeks gestation, especially when preterm delivery is anticipated. - While important for fetal outcome, it is not the **most immediate pharmacological intervention** for the mother's acute, life-threatening condition of impending eclampsia.

Question 146: A 34-year-old woman presents for pre-pregnancy counselling. She has well-controlled epilepsy on lamotrigine 200 mg twice daily and has been seizure-free for 3 years. She is keen to optimize her pregnancy planning. Apart from folic acid supplementation, what advice regarding her lamotrigine is most appropriate?

A. Continue current dose and arrange for lamotrigine levels to be monitored monthly during pregnancy (Correct Answer)
B. Attempt to wean off lamotrigine before conception as seizure-free for 3 years
C. Switch to levetiracetam which has a better safety profile in pregnancy
D. Reduce lamotrigine dose by 50% before conception to minimize fetal exposure
E. Continue current dose with plan to increase dose if seizures occur during pregnancy

Explanation: ***Continue current dose and arrange for lamotrigine levels to be monitored monthly during pregnancy*** - **Lamotrigine clearance** increases significantly during pregnancy, primarily due to **estrogen-induced glucuronidation**, which can lead to subtherapeutic levels and a risk of seizure recurrence. - **Therapeutic drug monitoring** is crucial to maintain effective **seizure control**, which is paramount for both maternal well-being and fetal safety, given lamotrigine's relatively **low teratogenic risk**. *Attempt to wean off lamotrigine before conception as seizure-free for 3 years* - Discontinuing effective antiepileptic medication carries a significant risk of **seizure relapse**, which can result in **maternal injury** and fetal hypoxia during pregnancy. - While seizure-free for 3 years is positive, the risks of stopping a proven medication before or during pregnancy typically outweigh the benefits, especially with a relatively safe drug like lamotrigine. *Switch to levetiracetam which has a better safety profile in pregnancy* - Both **lamotrigine and levetiracetam** are considered among the safest antiepileptic drugs in pregnancy, with comparable **low risks of teratogenicity**. - Switching from a well-controlled, effective regimen to another medication unnecessarily introduces a risk of **seizure breakthrough** and is generally not recommended unless there is a clear clinical indication. *Reduce lamotrigine dose by 50% before conception to minimize fetal exposure* - Arbitrarily reducing the dose increases the risk of **breakthrough seizures**, which can lead to more severe maternal and fetal complications than controlled medication exposure. - The goal is to use the **lowest effective dose** to prevent seizures, and the current dose has proven effective for 3 years. *Continue current dose with plan to increase dose if seizures occur during pregnancy* - This approach is reactive and potentially dangerous; waiting for a seizure to occur means the patient has already experienced a loss of **seizure control**. - Proactive **therapeutic drug monitoring** allows for timely dose adjustments based on serum levels, preventing seizures before they manifest.

Question 147: A 32-year-old woman at 24 weeks gestation undergoes OGTT following detection of glycosuria at routine antenatal visit. Results show: fasting glucose 6.8 mmol/L, 2-hour glucose 9.2 mmol/L. She has BMI 28 kg/m² and no other risk factors. She is referred to the joint diabetes and antenatal clinic. What dietary advice should be the initial focus of management?

A. Low glycaemic index carbohydrate diet with carbohydrates distributed evenly throughout the day (Correct Answer)
B. Strict carbohydrate restriction to less than 100g per day
C. High protein, low fat diet with limited carbohydrate intake at breakfast
D. Mediterranean-style diet with unrestricted complex carbohydrates
E. Calorie restriction of 1500 kcal per day to achieve weight loss

Explanation: ***Low glycaemic index carbohydrate diet with carbohydrates distributed evenly throughout the day*** - For a patient with **gestational diabetes (GDM)**, the initial focus is on diet modification including **low glycaemic index (GI)** foods and steady distribution to prevent glucose spikes. - NICE guidelines suggest avoiding long gaps between meals and distributing **carbohydrates** across three meals and snacks to maintain stable **blood glucose levels**. *Strict carbohydrate restriction to less than 100g per day* - Severe **carbohydrate restriction** is discouraged during pregnancy as it can lead to **ketonuria**, which may negatively impact fetal neurodevelopment. - Carbohydrates should still comprise approximately **40-50%** of total energy intake for adequate fetal growth. *High protein, low fat diet with limited carbohydrate intake at breakfast* - While some patients experience higher **post-prandial glucose** spikes after breakfast, initial advice focuses on general **low GI** distribution rather than strictly limiting breakfast carbohydrates. - The primary goal of medical nutrition therapy is achieving **glycaemic targets** through balanced portions rather than just increasing protein intake. *Mediterranean-style diet with unrestricted complex carbohydrates* - Although a Mediterranean-style diet is healthy, **carbohydrate portions** must still be controlled and distributed even if they are complex to manage **2-hour postprandial glucose**. - "Unrestricted" intake is inappropriate in GDM as even healthy complex carbohydrates can exceed **metabolic capacity** and raise blood sugar levels. *Calorie restriction of 1500 kcal per day to achieve weight loss* - **Weight loss** is not recommended during pregnancy; management should focus on **weight maintenance** or slow gain regardless of initial BMI. - Excessive **caloric restriction** risks nutritional deficiencies for the fetus and mother, and is not the primary mechanism for treating GDM.

Question 148: A 40-year-old woman at 31 weeks gestation with chronic hypertension on methyldopa 500 mg three times daily presents with BP 156/102 mmHg. She reports new-onset headache and epigastric discomfort. Blood tests show: platelets 178 × 10⁹/L, ALT 38 IU/L, AST 42 IU/L, uric acid 0.38 mmol/L, creatinine 88 μmol/L, LDH 520 IU/L. PCR is 45 mg/mmol. Blood film shows occasional schistocytes. What is the most likely diagnosis?

A. Severe pre-eclampsia superimposed on chronic hypertension
B. Chronic hypertension with inadequate blood pressure control
C. HELLP syndrome
D. Microangiopathic haemolytic anaemia secondary to severe pre-eclampsia (Correct Answer)
E. Thrombotic thrombocytopenic purpura

Explanation: ***Microangiopathic haemolytic anaemia secondary to severe pre-eclampsia*** - The presence of **schistocytes** on blood film and an **elevated LDH** (520 IU/L) directly indicates **microangiopathic haemolytic anaemia (MAHA)**. - This finding, combined with **new-onset headache**, **epigastric discomfort**, **proteinuria (PCR 45 mg/mmol)**, and **worsening hypertension** in a patient with chronic hypertension, points to **severe pre-eclampsia** as the underlying cause. *Severe pre-eclampsia superimposed on chronic hypertension* - While the patient exhibits clear signs of **severe pre-eclampsia superimposed on chronic hypertension**, this diagnosis is less specific than identifying the established **MAHA** indicated by the blood film and LDH. - Superimposed pre-eclampsia is broadly correct but does not highlight the critical and specific hematological complication observed. *Chronic hypertension with inadequate blood pressure control* - This diagnosis fails to account for the **new-onset proteinuria (PCR 45 mg/mmol)** and the development of **severe symptoms** like headache and epigastric discomfort. - Inadequate control of chronic hypertension alone does not explain the **biochemical evidence of hemolysis**, such as elevated LDH and schistocytes. *HELLP syndrome* - The full diagnostic criteria for HELLP syndrome are not met: the **platelet count (178 × 10⁹/L)** is not below 100 × 10⁹/L, and the **liver enzymes (ALT 38, AST 42 IU/L)** are not significantly elevated (typically >70 IU/L). - Although hemolysis is present, the absence of severe thrombocytopenia and marked liver enzyme elevation means HELLP syndrome is not the most precise diagnosis at this stage. *Thrombotic thrombocytopenic purpura* - TTP typically presents with a pentad including **severe thrombocytopenia** (often <20 × 10⁹/L), **fever**, and pronounced **neurological symptoms**, none of which are definitively present or severe enough in this case. - The clinical context of late pregnancy with **hypertension** and **proteinuria** makes severe pre-eclampsia with MAHA a far more likely diagnosis than TTP.

Question 149: A 36-year-old woman in her fourth pregnancy attends at 11 weeks gestation for booking. Her previous pregnancies include: one uncomplicated vaginal delivery at term, one early pregnancy loss at 8 weeks, and one late miscarriage at 21 weeks due to cervical insufficiency treated with emergency cerclage which was unsuccessful. She is otherwise healthy. What is the most appropriate management of her current pregnancy?

A. Arrange elective cervical cerclage at 12-14 weeks gestation (Correct Answer)
B. Perform serial transvaginal ultrasound cervical length measurements from 14 weeks and insert cerclage if cervix shortens
C. Prescribe vaginal progesterone from 16 weeks and monitor cervical length fortnightly
D. Advise pelvic rest and reduced activity, with hospital admission if symptoms develop
E. Arrange cervical assessment at 16 weeks and consider cerclage only if cervical length <25 mm

Explanation: ***Arrange elective cervical cerclage at 12-14 weeks gestation*** - This patient has a clear history of **cervical insufficiency**, demonstrated by a prior mid-trimester loss at 21 weeks and a failed rescue cerclage, making a **history-indicated (elective) cerclage** the treatment of choice. - **Elective cerclage** is ideally performed between **12 and 14 weeks** gestation to provide structural support before the cervix begins to shorten or dilate. *Perform serial transvaginal ultrasound cervical length measurements from 14 weeks and insert cerclage if cervix shortens* - This approach, known as **ultrasound-indicated cerclage**, is typically reserved for women with a less definitive history or an isolated history of **spontaneous preterm birth**. - Given the high-risk history of a mid-trimester loss despite intervention, waiting for **cervical shortening** to appear on ultrasound poses an unnecessary risk of another failure. *Prescribe vaginal progesterone from 16 weeks and monitor cervical length fortnightly* - **Vaginal progesterone** is primarily indicated for women with a history of spontaneous preterm birth and a **short cervix** (<25mm), but it is not the primary treatment for established cervical insufficiency. - In cases of mechanical cervical weakness, **progesterone alone** is less effective than a surgical cerclage in preventing recurrent mid-trimester loss. *Advise pelvic rest and reduced activity, with hospital admission if symptoms develop* - **Pelvic rest** and activity restriction have not been clinically proven to improve outcomes or prevent pregnancy loss in patients with **cervical insufficiency**. - Relying on symptom development is dangerous, as cervical insufficiency is characteristically **painless** and can lead to rapid, irreversible membrane prolapse. *Arrange cervical assessment at 16 weeks and consider cerclage only if cervical length <25 mm* - Monitoring for a **cervical length <25 mm** is appropriate for women at moderate risk, but this patient's history of a failed emergency cerclage warrants a more **proactive surgical intervention**. - Waiting until 16 weeks to assess the cervix may be too late for an elective procedure if the **cervical changes** occur early in the second trimester.

Question 150: A 27-year-old primigravida attends her booking appointment at 9 weeks gestation. She is taking no regular medications. Her blood tests reveal: Hb 102 g/L, MCV 72 fL, ferritin 8 μg/L. She is asymptomatic. What is the most appropriate initial management?

A. Prescribe ferrous sulphate 200 mg once daily and recheck FBC at 28 weeks
B. Prescribe ferrous sulphate 200 mg twice daily and recheck FBC in 2-4 weeks (Correct Answer)
C. Arrange urgent haematology referral for investigation of microcytic anaemia
D. Prescribe ferrous fumarate 210 mg twice daily and recheck FBC at 20-24 weeks
E. Advise dietary iron supplementation only as anaemia is mild

Explanation: ***Prescribe ferrous sulphate 200 mg twice daily and recheck FBC in 2-4 weeks***- The patient has **iron deficiency anaemia** (IDA) defined in the **first trimester** as Hb <110 g/L; her low **ferritin** (8 μg/L) and low **MCV** confirm the diagnosis.- Guidelines recommend **oral iron supplementation** with monitoring of the Full Blood Count (FBC) within **2–4 weeks** to ensure an adequate rise in **hemoglobin** (typically 10-20 g/L over 2 weeks).*Prescribe ferrous sulphate 200 mg once daily and recheck FBC at 28 weeks*- While once-daily dosing may be used for prophylaxis, **established anaemia** requires higher therapeutic doses to replenish stores quickly.- Waiting until **28 weeks** to recheck the FBC is inappropriate as it delays the identification of non-responders and risks worsening anaemia as pregnancy progresses.*Arrange urgent haematology referral for investigation of microcytic anaemia*- An **urgent haematology referral** is not indicated for a clear case of nutritional IDA with low ferritin in a pregnant patient.- Management should be initiated in **primary care** or the booking clinic, as microcytosis in this context is most likely due to iron deficiency.*Prescribe ferrous fumarate 210 mg twice daily and recheck FBC at 20-24 weeks*- Although ferrous fumarate is an acceptable alternative to ferrous sulphate, the **recheck interval** is too long.- Monitoring must occur within **2–4 weeks** of initiation to confirm treatment efficacy and patient **compliance** before mid-pregnancy.*Advise dietary iron supplementation only as anaemia is mild*- **Dietary modifications** alone are insufficient to correct established IDA in pregnancy due to the high **fetal and placental demands** for iron.- Pharmacological **iron replacement** is necessary when the ferritin is significantly depleted and Hb is below trimester-specific thresholds.

Question 151: A 31-year-old woman with diet-controlled gestational diabetes at 35 weeks gestation attends for growth scan. Estimated fetal weight is on the 45th centile. Her fasting glucose averages 5.3 mmol/L and 1-hour post-prandial readings average 8.2 mmol/L over the past week. She has been compliant with dietary advice. What is the most appropriate management?

A. Continue dietary management alone and plan delivery at 40-41 weeks
B. Commence metformin and continue monitoring with plan for delivery at 38-39 weeks (Correct Answer)
C. Commence insulin therapy and arrange weekly growth scans
D. Commence metformin and plan for delivery at 40-41 weeks if well controlled
E. Continue dietary management and offer induction at 38-39 weeks

Explanation: ***Commence metformin and continue monitoring with plan for delivery at 38-39 weeks*** - This patient's **1-hour post-prandial glucose** averages 8.2 mmol/L, which exceeds the **NICE target** of ody

Question 152: A 38-year-old woman at 26 weeks gestation presents with blood pressure 152/98 mmHg at routine antenatal clinic. She is asymptomatic. Her booking BP at 10 weeks was 118/72 mmHg. Urinalysis shows trace protein. Blood tests show: platelets 245 × 10⁹/L, ALT 28 IU/L, creatinine 68 μmol/L. PCR is 18 mg/mmol. What is the most appropriate initial classification and management?

A. Gestational hypertension; commence labetalol and review in antenatal day unit in 48 hours (Correct Answer)
B. Mild pre-eclampsia; admit for observation and commence antihypertensive therapy
C. Gestational hypertension; arrange twice-weekly BP monitoring and weekly bloods as outpatient
D. Chronic hypertension; commence nifedipine and routine antenatal care
E. White coat hypertension; reassure and continue routine antenatal care

Explanation: ***Gestational hypertension; commence labetalol and review in antenatal day unit in 48 hours*** - This patient has **new-onset hypertension** (≥140/90 mmHg) at 26 weeks gestation with **no significant proteinuria** (PCR 18 mg/mmol is below the threshold of 30 mg/mmol), confirming the diagnosis of gestational hypertension. - **Labetalol** is a first-line antihypertensive in pregnancy, and commencing treatment for BP 152/98 mmHg with close follow-up in an antenatal day unit within 48 hours is appropriate to monitor for effectiveness and progression. *Mild pre-eclampsia; admit for observation and commence antihypertensive therapy* - Pre-eclampsia requires evidence of **significant proteinuria** (e.g., PCR ≥30 mg/mmol) or **maternal organ dysfunction**, neither of which are present in this case (PCR 18 mg/mmol, normal platelets and liver enzymes). - Admission for observation is typically reserved for more severe hypertension (≥160/110 mmHg) or if there are signs and symptoms of severe pre-eclampsia. *Gestational hypertension; arrange twice-weekly BP monitoring and weekly bloods as outpatient* - While the classification of gestational hypertension is correct, a BP of 152/98 mmHg warrants immediate **antihypertensive therapy** rather than just monitoring, to reduce maternal and fetal risks. - Current guidelines recommend initiating treatment for persistently elevated blood pressure (e.g., ≥140/90 mmHg) in pregnancy. *Chronic hypertension; commence nifedipine and routine antenatal care* - **Chronic hypertension** is defined as hypertension present before pregnancy or diagnosed before **20 weeks gestation**. - This patient had a normal booking BP of 118/72 mmHg at 10 weeks, ruling out chronic hypertension. *White coat hypertension; reassure and continue routine antenatal care* - **White coat hypertension** can only be diagnosed if home or ambulatory blood pressure monitoring confirms normal readings outside the clinic, which has not been done here. - Given the sustained elevated blood pressure in the clinic, simply reassuring the patient without further investigation or management would be inappropriate and potentially harmful.

Question 153: What is the recommended timing for the routine anomaly ultrasound scan in pregnancy according to UK antenatal screening guidelines?

A. 16-18 weeks gestation
B. 18-20 weeks gestation
C. 18-20+6 weeks gestation (Correct Answer)
D. 20-22 weeks gestation
E. 22-24 weeks gestation

Explanation: ***18-20+6 weeks gestation*** - According to the **NHS Fetal Anomaly Screening Programme (FASP)**, the routine mid-trimester scan should be ideally performed between **18+0 and 20+6 weeks** gestation. - This window provides the best balance for **optimal visualization** of fetal structures and sufficient time for further diagnostic testing if an anomaly is identified. *16-18 weeks gestation* - Performing the scan this early may result in incomplete visualization as certain organs, particularly the **fetal heart and brain structures**, are not yet sufficiently developed. - It is outside the recommended **national screening guidelines** for a routine anomaly assessment. *18-20 weeks gestation* - While this range is partially correct, it excludes the critical **extra six days** (up to 20+6) defined in the formal protocol. - Accuracy in gestation terminology is vital for **clinical coding** and ensuring patients are seen within the legal and medical framework. *20-22 weeks gestation* - This range extends beyond the primary target window, which can limit the timeframe for **follow-up invasive testing** like amniocentesis. - Scanning primarily after 20 weeks may reduce the time available for parents to make **informed decisions** regarding the pregnancy. *22-24 weeks gestation* - At this late stage, **fetal bone ossification** can create shadows that make it more difficult to view internal structures like the heart. - This timeframe is significantly beyond the **UK screening standard** and is typically only used for specific follow-up scans or late-booking patients.

Question 154: A 35-year-old woman in her second pregnancy is admitted at 34 weeks gestation with blood pressure 162/108 mmHg and 3+ proteinuria on dipstick. Blood tests show: platelets 95 × 10⁹/L, ALT 78 IU/L, AST 82 IU/L, creatinine 115 μmol/L. She is commenced on labetalol and magnesium sulphate. Four hours later she develops right upper quadrant pain and her blood pressure rises to 178/115 mmHg despite treatment. What is the most likely diagnosis requiring urgent consideration?

A. Acute fatty liver of pregnancy
B. HELLP syndrome with subcapsular liver haematoma (Correct Answer)
C. Acute cholecystitis
D. Hepatic infarction secondary to severe pre-eclampsia
E. Placental abruption with referred pain

Explanation: ***HELLP syndrome with subcapsular liver haematoma*** - The patient exhibits core features of **HELLP syndrome**, including **thrombocytopenia** (platelets 95 × 10⁹/L) and **elevated transaminases** (ALT 78, AST 82) alongside severe pre-eclampsia (BP 162/108 mmHg, 3+ proteinuria). - New-onset **right upper quadrant (RUQ) pain** and worsening hypertension despite treatment are red flags for a **subcapsular liver haematoma**, a serious complication of HELLP syndrome with high risk of **hepatic rupture**. *Acute fatty liver of pregnancy* - This condition typically presents with significant **hypoglycemia**, severe **coagulopathy** (elevated PT/INR), and **jaundice**, which are not the primary features highlighted in this case. - While it causes liver enzyme elevation and can occur in late pregnancy, the **thrombocytopenia** and acute worsening with RUQ pain fit HELLP better. *Acute cholecystitis* - This would present with **RUQ pain**, often radiating to the back or shoulder, and possibly fever or a positive **Murphy’s sign**, but it cannot account for the low **platelets**, severe **proteinuria**, or elevated liver enzymes (other than a mild, secondary elevation). - It is a local gallbladder pathology and does not explain the systemic features of **pre-eclampsia** and HELLP syndrome. *Hepatic infarction secondary to severe pre-eclampsia* - Hepatic infarction is an extremely rare complication and typically associated with **massively elevated transaminases** (often in the thousands), much higher than the values seen here (ALT 78, AST 82). - While it can cause RUQ pain, the full clinical picture of **thrombocytopenia** and elevated liver enzymes in the context of severe pre-eclampsia points more strongly to HELLP syndrome with its complications. *Placental abruption with referred pain* - **Placental abruption** typically presents with painful **vaginal bleeding**, uterine tenderness, and fetal distress rather than isolated right upper quadrant pain. - While it is a serious complication of severe **hypertension**, it does not explain the specific **biochemical abnormalities** of **thrombocytopenia** and elevated liver enzymes as well as HELLP syndrome does.

Question 155: A 29-year-old woman at 16 weeks gestation attends her antenatal appointment. She has a BMI of 32 kg/m². Her mother developed type 2 diabetes at age 45. Her booking glucose was 4.8 mmol/L and HbA1c was 38 mmol/mol. She asks about her risk of developing gestational diabetes. What is the most appropriate advice regarding oral glucose tolerance testing?

A. She should have OGTT now at 16 weeks gestation
B. She should have OGTT at 24-28 weeks gestation only (Correct Answer)
C. She requires OGTT at both 16 weeks and 24-28 weeks gestation
D. She does not require OGTT as her booking tests were normal
E. She should have random glucose testing at each antenatal visit instead

Explanation: ***She should have OGTT at 24-28 weeks gestation only*** - According to **NICE guidelines**, patients with risk factors such as a **BMI >30 kg/m²** or a **first-degree relative with diabetes** should be offered a 75g 2-hour **OGTT** at 24–28 weeks gestation. - This patient qualifies for screening due to her high BMI and family history, but since she has no history of **previous gestational diabetes**, early testing at 16 weeks is not required. *She should have OGTT now at 16 weeks gestation* - Early OGTT (at booking or 16 weeks) is specifically reserved for women who have had **gestational diabetes in a previous pregnancy**. - Testing at 16 weeks is not the standard protocol for patients whose only risk factors are **obesity** or **family history** without a prior GDM diagnosis. *She requires OGTT at both 16 weeks and 24-28 weeks gestation* - Dual testing at both time points is indicated for women with **prior gestational diabetes** to detect early recurrence or development of type 2 diabetes. - For a primigravida or someone with no history of the condition, a single test at **24–28 weeks** is sufficient to catch the peak of insulin resistance typically seen in GDM. *She does not require OGTT as her booking tests were normal* - Normal **booking glucose** (4.8 mmol/L) and **HbA1c** (38 mmol/mol) only rule out pre-existing type 2 diabetes; they do not predict the development of **gestational diabetes**, which often manifests later in pregnancy. - Risk factors like a **BMI of 32 kg/m²** and a **first-degree relative with diabetes** mandate formal screening regardless of initial normal results. *She should have random glucose testing at each antenatal visit instead* - **Random glucose testing** and **urinalysis for glycosuria** are not sufficiently sensitive or specific to be used as primary screening or diagnostic tools for gestational diabetes. - The gold standard for diagnosing gestational diabetes in high-risk groups remains the **oral glucose tolerance test (OGTT)** performed at the appropriate gestational age.

Question 156: A 33-year-old woman at 37 weeks gestation with gestational diabetes on insulin therapy presents for routine antenatal assessment. Her blood glucose levels have been well controlled. Fetal ultrasound shows estimated fetal weight on 95th centile with abdominal circumference above the 95th centile. Amniotic fluid index is 26 cm. What is the most appropriate next step in management?

A. Perform amniocentesis to assess fetal lung maturity
B. Increase insulin dose and reassess in one week
C. Arrange elective caesarean section at 38 weeks
D. Offer induction of labour at 37-38 weeks (Correct Answer)
E. Continue expectant management until 40 weeks with weekly monitoring

Explanation: ***Offer induction of labour at 37-38 weeks*** - For women with **gestational diabetes mellitus (GDM)** on **insulin therapy**, guidelines recommend offering delivery (induction or elective C-section) between **37+0 and 38+6** weeks. - The presence of **macrosomia** (EFW >95th centile) and **polyhydramnios** (AFI 26 cm) increases the risk of **shoulder dystocia** and stillbirth, making delivery at 37-38 weeks the safest management.*Perform amniocentesis to assess fetal lung maturity* - This procedure is no longer routinely recommended because **corticosteroids** and modern neonatal care have reduced the need for lung maturity testing. - At **37 weeks**, the fetus is considered late-term, and the risks of continued macrocosmic growth outweigh the benefits of testing for lung maturity.*Increase insulin dose and reassess in one week* - The patient already has **well-controlled blood glucose**, and maternal glucose levels do not immediately reverse existing **fetal macrosomia** or polyhydramnios. - Delaying delivery to adjust medication at 37 weeks increases the risk of **stillbirth** without significant benefit to fetal size.*Arrange elective caesarean section at 38 weeks* - **Elective caesarean section** is generally only specifically indicated for GDM if the estimated fetal weight is **>4.5 kg** to prevent shoulder dystocia. - Unless there are specific contraindications to vaginal birth, **induction of labour** is the first-line recommendation for delivery initiation.*Continue expectant management until 40 weeks with weekly monitoring* - Expectant management beyond 38+6 weeks in insulin-dependent GDM is associated with an increased risk of **intrauterine fetal death**. - Monitoring does not mitigate the mechanical risks associated with **macrosomia** and polyhydramnios that are already present.

Question 157: A 28-year-old primigravida is diagnosed with pre-eclampsia at 34 weeks gestation. Her blood pressure is controlled on labetalol. Blood tests show: platelets 92 × 10⁹/L, ALT 105 U/L, bilirubin 18 μmol/L, LDH 620 U/L, creatinine 88 μmol/L. Blood film shows fragmented red cells. What syndrome has developed and what is the most appropriate management?

A. Acute fatty liver of pregnancy; deliver immediately regardless of fetal maturity
B. HELLP syndrome; give corticosteroids and plan delivery within 24-48 hours (Correct Answer)
C. Thrombotic thrombocytopenic purpura; commence plasmapheresis urgently
D. Severe pre-eclampsia; continue conservative management with twice-daily blood tests
E. Disseminated intravascular coagulation; give fresh frozen plasma and deliver immediately

Explanation: ***HELLP syndrome; give corticosteroids and plan delivery within 24-48 hours*** - The patient exhibits the classic triad of **Hemolysis** (fragmented red cells, elevated LDH), **Elevated Liver enzymes** (ALT 105 U/L), and **Low Platelets** (92 × 10⁹/L), which precisely defines **HELLP syndrome**. - At 34 weeks gestation, management involves stabilizing the mother, administering **corticosteroids** (e.g., betamethasone) for fetal lung maturity, and planning delivery within a **24-48 hour window**. *Acute fatty liver of pregnancy; deliver immediately regardless of fetal maturity* - **Acute fatty liver of pregnancy (AFLP)** typically presents with more profound **hypoglycemia**, prolonged coagulation times (e.g., PT/APTT), and sometimes more severe **hyperbilirubinemia** than seen here. - Although AFLP also requires urgent delivery, the specific combination of **hemolysis** and **elevated LDH** strongly points towards HELLP syndrome rather than AFLP. *Thrombotic thrombocytopenic purpura; commence plasmapheresis urgently* - **Thrombotic thrombocytopenic purpura (TTP)** often includes features like **fever**, significant **neurological symptoms**, and severe **renal failure**, which are not described in this pre-eclamptic patient. - While both conditions can cause **schistocytes** (fragmented red cells), the clinical context of hypertension and pregnancy-related liver dysfunction makes **HELLP syndrome** the more fitting diagnosis. *Severe pre-eclampsia; continue conservative management with twice-daily blood tests* - The development of **HELLP syndrome** signifies a severe manifestation of pre-eclampsia that requires active intervention, not conservative management, due to the high risk of maternal complications like **liver rupture** or placental abruption. - Continuing conservative management is inappropriate once there is laboratory evidence of progressive **hemolysis**, **thrombocytopenia**, and **hepatic dysfunction** at 34 weeks. *Disseminated intravascular coagulation; give fresh frozen plasma and deliver immediately* - **Disseminated intravascular coagulation (DIC)** is characterized by widespread activation of the clotting cascade, leading to consumption of clotting factors and platelets, typically resulting in prolonged **PT**, **aPTT**, and decreased **fibrinogen**. - While DIC can complicate HELLP, the primary diagnosis based on the presented labs is HELLP; **fresh frozen plasma** is primarily used for bleeding or severe coagulopathy in DIC, not as initial management for HELLP itself.

Question 158: A 36-year-old woman with insulin-treated gestational diabetes at 32 weeks gestation reports reduced fetal movements for the past 8 hours. Her blood glucose has been well controlled with fasting values 4.8-5.1 mmol/L. CTG is normal. What is the most appropriate further assessment?

A. Perform ultrasound for biophysical profile (Correct Answer)
B. Admit for continuous CTG monitoring for 24 hours
C. Reassure and discharge home with routine follow-up
D. Arrange umbilical artery Doppler assessment
E. Advise kick counting and return if further episodes

Explanation: ***Perform ultrasound for biophysical profile*** - In **high-risk pregnancies**, such as those complicated by **insulin-treated gestational diabetes**, a **normal CTG** alone is insufficient to exclude fetal compromise after reports of **reduced fetal movements (RFM)**. - The **biophysical profile** (BPP) provides a comprehensive assessment of **fetal well-being**, including fetal tone, movement, breathing, and **amniotic fluid volume**, which is crucial in managing high-risk pregnancies and mitigating the risk of **stillbirth**. *Admit for continuous CTG monitoring for 24 hours* - While **continuous CTG monitoring** is valuable for confirmed fetal distress or during labor, a currently **normal CTG** does not immediately necessitate 24-hour admission without further diagnostic information. - This approach would delay obtaining comprehensive data on **fetal growth** or **amniotic fluid volume** that a detailed ultrasound can provide. *Reassure and discharge home with routine follow-up* - **Reduced fetal movements** in a patient with **insulin-treated gestational diabetes** is a significant warning sign that mandates further investigation and should never be simply reassured. - Discharging without a thorough assessment of **fetal well-being** and **placental function** would be unsafe and could lead to adverse **fetal outcomes**. *Arrange umbilical artery Doppler assessment* - **Umbilical artery Doppler** is primarily used to evaluate **placental function** and **fetal blood flow**, particularly in cases of suspected **fetal growth restriction** or placental insufficiency. - While it provides important information, it is not as comprehensive as a **biophysical profile** for assessing overall **fetal well-being** (e.g., fetal tone, breathing, movement, and amniotic fluid) following an episode of RFM. *Advise kick counting and return if further episodes* - **Kick counting** is generally not recommended as a primary standalone management strategy for **reduced fetal movements**, especially in **high-risk pregnancies**. - Relying solely on maternal perception via kick counts can cause unnecessary anxiety and may delay critical assessment and intervention, as current guidelines emphasize prompt evaluation of any **subjective change** in fetal movement.

Question 159: A 41-year-old woman with chronic hypertension on amlodipine 5 mg daily becomes pregnant. At her booking visit at 8 weeks, her blood pressure is 136/88 mmHg. What is the most appropriate management of her antihypertensive medication?

A. Stop amlodipine and commence labetalol 200 mg twice daily
B. Continue amlodipine at current dose throughout pregnancy
C. Stop amlodipine and monitor blood pressure; restart treatment if BP ≥140/90 mmHg (Correct Answer)
D. Increase amlodipine to 10 mg daily to ensure optimal control
E. Switch to methyldopa 250 mg three times daily

Explanation: ***Stop amlodipine and monitor blood pressure; restart treatment if BP 140/90 mmHg*** - According to guidelines (e.g., **NICE**), if **chronic hypertension** is well-controlled (BP <140/90 mmHg) at booking, stopping treatment is a valid strategy due to the physiological **BP drop** in early pregnancy. - This approach minimizes **fetal drug exposure** while ensuring treatment is re-introduced only if blood pressure exceeds the target threshold of **140/90 mmHg**. *Stop amlodipine and commence labetalol 200 mg twice daily* - Switching to **labetalol** is unnecessary if the patient's blood pressure is already **below 140/90 mmHg** and a drug-free period is feasible. - While labetalol is a **first-line** agent in pregnancy, initiating it immediately when current control is good and observation is possible is not the primary management step. *Continue amlodipine at current dose throughout pregnancy* - **Amlodipine** has less comprehensive **safety data** in pregnancy compared to established first-line antihypertensives like labetalol or nifedipine. - Standard practice is to review medications with limited pregnancy data and consider switching to those with a more robust safety profile, or discontinuing if possible. *Increase amlodipine to 10 mg daily to ensure optimal control* - Increasing the dose is inappropriate because her current blood pressure (136/88 mmHg) is already within the **target range** for chronic hypertension during pregnancy. - Doubling the dose would unnecessarily increase **fetal exposure** and potential maternal side effects without a clinical indication for tighter control. *Switch to methyldopa 250 mg three times daily* - **Methyldopa** is considered a safe option in pregnancy, but an immediate switch is not required if the patient's blood pressure is well-controlled and **monitoring without medication** is a viable initial strategy. - Like labetalol, it should be reserved for when blood pressure consistently reaches or exceeds the treatment threshold of **140/90 mmHg**.

Question 160: A 32-year-old woman attends pre-pregnancy counselling. She takes sodium valproate 800 mg twice daily for epilepsy, which is well controlled with no seizures for 3 years. What is the most appropriate advice regarding her medication in pregnancy?

A. Continue current dose and add high-dose folic acid 5 mg daily
B. Gradually reduce to minimum effective dose and take folic acid 5 mg daily
C. Switch to lamotrigine or levetiracetam before conception if possible (Correct Answer)
D. Stop sodium valproate immediately and monitor seizure activity
E. Continue sodium valproate but arrange monthly fetal ultrasound scans

Explanation: ***Switch to lamotrigine or levetiracetam before conception if possible*** - **Sodium valproate** is highly **teratogenic**, associated with a significant risk of **congenital malformations** (e.g., neural tube defects) and **neurodevelopmental delays** (e.g., lower IQ) in offspring. - Current guidelines (e.g., NICE, MHRA) strongly recommend avoiding **valproate** in women of childbearing potential, advocating for a switch to safer alternatives like **lamotrigine** or **levetiracetam** *prior to conception* if seizure control can be maintained.*Continue current dose and add high-dose folic acid 5 mg daily* - While **high-dose folic acid (5 mg)** is crucial to reduce the risk of **neural tube defects**, it does not mitigate the overall high **teratogenic risk** of **sodium valproate** for other congenital anomalies and neurodevelopmental problems. - Continuing valproate at a high dose is generally contraindicated for planned pregnancy due to unacceptable risks, even with folic acid supplementation.*Gradually reduce to minimum effective dose and take folic acid 5 mg daily* - Although the **teratogenic risk** of **sodium valproate** is dose-dependent, even reduced doses still carry a significantly higher risk compared to safer alternative **antiepileptic drugs**. - The primary goal in pre-conception counseling for women on **valproate** is to optimize medication to the safest effective regimen *before* pregnancy, which typically involves switching to a less teratogenic drug rather than just reducing the dose.*Stop sodium valproate immediately and monitor seizure activity* - **Abrupt cessation** of **antiepileptic drugs** like **sodium valproate** is dangerous and can precipitate **seizures** or **status epilepticus**, posing severe risks to the mother. - Any changes to antiepileptic medication, especially discontinuation, must be **gradual** and carefully supervised by a specialist to ensure continued **seizure control**.*Continue sodium valproate but arrange monthly fetal ultrasound scans* - **Fetal ultrasound scans** can detect some **structural malformations** but cannot prevent them, nor can they assess the risk of **neurodevelopmental disorders** associated with valproate exposure. - The most critical period for **teratogenesis** is in the **first trimester**, and continuing **valproate** without seeking a safer alternative is not considered appropriate management.

Question 161: A 35-year-old woman with diet-controlled gestational diabetes at 38 weeks gestation declines induction of labour. She requests expectant management. What is the most appropriate counselling regarding this decision?

A. Agree to expectant management with twice-weekly CTG and growth scans until 42 weeks
B. Explain increased risk of stillbirth and birth trauma; offer induction at 39 weeks if she declines 38 weeks (Correct Answer)
C. Respect her decision and arrange routine care with induction offered at 41 weeks
D. Arrange senior obstetric review and consider application for court order
E. Insist on induction by 38+6 weeks due to mandatory guidelines

Explanation: ***Explain increased risk of stillbirth and birth trauma; offer induction at 39 weeks if she declines 38 weeks***- Counselling must include the increased risk of **stillbirth** (which rises after 38 weeks in GDM) and **birth trauma/shoulder dystocia** related to **macrosomia**.- NICE guidelines recommend offering induction between **37+0 and 38+6 weeks**; if declined, a balanced discussion should follow to explore alternative plans like induction at 39 weeks.*Agree to expectant management with twice-weekly CTG and growth scans until 42 weeks*- Waiting until **42 weeks** is not recommended in GDM due to the significant rise in **perinatal mortality** and placental insufficiency.- **Twice-weekly CTG** has not been proven to reliably prevent stillbirth in the context of prolonged GDM pregnancy.*Respect her decision and arrange routine care with induction offered at 41 weeks*- Routine care (induction at 41 weeks) is for low-risk pregnancies; **gestational diabetes** classifies the pregnancy as high-risk, requiring earlier intervention.- Delaying to 41 weeks without highlighting specific **GDM-associated risks** fails the requirement for informed consent and clinical safety.*Arrange senior obstetric review and consider application for court order*- Competent pregnant women have the **autonomy** to refuse any medical intervention, including induction of labour.- A **court order** is inappropriate and unethical as the patient has the right to make decisions about her own body even if they carry risk.*Insist on induction by 38+6 weeks due to mandatory guidelines*- Guidelines are **recommendations**, not mandatory laws, and must be adapted to individual patient preferences through **shared decision-making**.- "Insisting" undermines the **patient-provider relationship** and ignores the ethical principle of respect for patient autonomy.

Question 162: A 27-year-old woman at 14 weeks gestation attends antenatal clinic. She mentions she has a cat at home. She has no previous immunity to toxoplasmosis. What advice should be given regarding toxoplasmosis prevention?

A. Rehome the cat until after delivery
B. Avoid handling the cat and have someone else clean the litter tray daily
C. Wear gloves when cleaning the litter tray, which should be done every 3-4 days (Correct Answer)
D. Arrange monthly toxoplasmosis serology screening throughout pregnancy
E. Keep the cat indoors and wear gloves for all contact with the animal

Explanation: ***Wear gloves when cleaning the litter tray, which should be done every 3-4 days*** - **Toxoplasma gondii** oocysts excreted in cat feces typically require **1 to 5 days** to sporulate and become infectious, so frequent cleaning reduces risk. - Using **gloves** and performing thorough hand hygiene are key protective measures for non-immune pregnant women who must handle litter. *Rehome the cat until after delivery* - **Rehoming** is considered an unnecessary and extreme measure that causes undue stress to the owner and the animal. - The risk of transmission can be effectively managed through **hygiene practices** and proper fecal disposal without removing the pet. *Avoid handling the cat and have someone else clean the litter tray daily* - General handling of cats (petting) poses **no significant risk** of toxoplasmosis; the primary concern is contact with infectious feces. - While having someone else clean the tray is ideal, it is the **litter management**, not the presence of the cat, that requires specific avoidance. *Arrange monthly toxoplasmosis serology screening throughout pregnancy* - Routine **serological screening** for toxoplasmosis is not recommended in standard UK antenatal care due to low prevalence. - Emphasis is placed on **primary prevention** (hygiene/diet) rather than repeated diagnostic testing in asymptomatic women. *Keep the cat indoors and wear gloves for all contact with the animal* - Protective clothing like gloves is only necessary for high-risk activities like **gardening** or cleaning **litter trays**, not for normal interaction. - Keeping a cat indoors may reduce its hunting of infected prey, but it is an **overly restrictive** recommendation compared to hygiene basics.

Question 163: A 31-year-old woman presents at 25 weeks gestation with blood pressure 172/115 mmHg. She has no symptoms and urinalysis shows trace protein. Blood tests show: platelets 165 × 10⁹/L, ALT 35 U/L, creatinine 72 μmol/L. What is the most appropriate immediate antihypertensive management?

A. Oral labetalol 200 mg stat, then 200 mg twice daily (Correct Answer)
B. Oral nifedipine MR 20 mg twice daily
C. Intravenous labetalol 20 mg bolus followed by infusion
D. Oral methyldopa 250 mg three times daily
E. Intravenous hydralazine 5 mg bolus, repeated every 30 minutes

Explanation: ***Oral labetalol 200 mg stat, then 200 mg twice daily***- Severe hypertension (BP ≥160/110 mmHg) in an **asymptomatic pregnant woman** requires prompt but controlled blood pressure reduction, for which **oral labetalol** is a first-line agent to prevent maternal complications like stroke.- The **stat dose** followed by regular dosing ensures a rapid initial effect without causing a sudden, dangerous drop in blood pressure that could compromise **fetal perfusion**.*Oral nifedipine MR 20 mg twice daily*- While **oral nifedipine** (modified-release) is an acceptable alternative for hypertension in pregnancy, **labetalol** is often preferred as a first-line agent for initial severe hypertension management as per guidelines.- The MR formulation might not provide the **immediate rapid blood pressure control** needed for severe hypertension, and this regimen lacks an initial stat dose.*Intravenous labetalol 20 mg bolus followed by infusion*- **Intravenous antihypertensives**, such as IV labetalol, are reserved for **hypertensive emergencies** or crises where there is evidence of impending organ damage (e.g., severe headache, visual changes, pulmonary edema) or eclampsia.- Since the patient is **asymptomatic**, rapid reduction via IV medications can lead to **placental hypoperfusion** and potential **fetal distress**, making oral agents a safer initial choice.*Oral methyldopa 250 mg three times daily*- **Methyldopa** is a safe and commonly used antihypertensive in pregnancy, especially for chronic hypertension, but it has a **slow onset of action** (typically 24-48 hours).- This slow action makes it unsuitable for the **immediate management** of severe hypertension (172/115 mmHg) where a more rapid blood pressure reduction is required to prevent acute complications.*Intravenous hydralazine 5 mg bolus, repeated every 30 minutes*- **Intravenous hydralazine** is a potent direct vasodilator often used in the management of **hypertensive emergencies** or **eclampsia** when other agents are insufficient or contraindicated.- Its use in an **asymptomatic patient** with severe hypertension is generally not recommended as a first-line immediate therapy due to the risk of **precipitous drops in blood pressure** and reflex tachycardia.

Question 164: A 38-year-old woman with gestational diabetes controlled on diet alone attends for routine growth scan at 34 weeks. The estimated fetal weight is on the 92nd centile and the abdominal circumference is on the 95th centile. Amniotic fluid index is normal. What is the most appropriate management?

A. Continue current management and repeat growth scan at 38 weeks
B. Commence metformin immediately
C. Commence insulin therapy immediately (Correct Answer)
D. Arrange induction of labour at 37 weeks
E. Refer for fetal medicine opinion regarding early delivery

Explanation: ***Commence insulin therapy immediately***\n- In gestational diabetes, evidence of **accelerated fetal growth** (EFW >90th centile, AC >95th centile) indicates poor glycemic control despite diet, necessitating pharmacological intervention to prevent **macrosomia** and risks like **shoulder dystocia**.\n- **Insulin therapy** is the most effective and preferred treatment for rapidly achieving tight glycemic control and reducing further excessive fetal weight gain, especially when macrosomia is already evident.\n\n*Continue current management and repeat growth scan at 38 weeks*\n- Current management (diet alone) is insufficient as the fetus is already demonstrating **macrosomia**, indicating persistent hyperglycemia despite dietary control.\n- Delaying active intervention until 38 weeks increases the risk of severe **birth trauma** and long-term metabolic complications for the neonate due to uncontrolled fetal growth.\n\n*Commence metformin immediately*\n- While **metformin** can be used in GDM, it is less potent than insulin and may not be sufficient to reverse or halt significant fetal overgrowth, especially when macrosomia is already established.\n- Insulin offers more precise and immediate glucose lowering, which is crucial when fetal growth is already accelerated.\n\n*Arrange induction of labour at 37 weeks*\n- Induction of labor for GDM is typically considered at 37-38+6 weeks, but the immediate priority at 34 weeks is to control maternal glucose levels to slow down fetal growth.\n- Inducing at 37 weeks without addressing the **hyperglycemia** and its impact on fetal growth in the interim would not optimally reduce **macrosomia-related complications**.\n\n*Refer for fetal medicine opinion regarding early delivery*\n- **Fetal macrosomia** due to GDM, when the AFI is normal, usually falls within the scope of routine obstetric management with glycemic control adjustments.\n- Early delivery at 34 weeks without medical indication (e.g., severe pre-eclampsia, fetal distress) would result in **iatrogenic prematurity**, introducing unnecessary risks to the neonate.

Question 165: A 29-year-old woman presents to antenatal clinic at 36 weeks gestation with blood pressure 138/92 mmHg. This is her first elevated reading. Urinalysis shows no protein. She is asymptomatic. Blood tests show: platelets 198 × 10⁹/L, ALT 28 U/L, creatinine 65 μmol/L. What is the most appropriate classification and management?

A. Gestational hypertension; arrange follow-up within 48 hours with blood tests (Correct Answer)
B. White coat hypertension; reassure and arrange 24-hour ambulatory monitoring
C. Mild pre-eclampsia; admit for observation and commence labetalol
D. Gestational hypertension; arrange follow-up in 7 days with blood pressure check
E. Chronic hypertension; commence labetalol and routine antenatal care

Explanation: ***Gestational hypertension; arrange follow-up within 48 hours with blood tests*** - **Gestational hypertension** is defined as new-onset hypertension (BP ≥140/90 mmHg or persistent elevation) presenting after **20 weeks of gestation** without significant **proteinuria** or signs of end-organ dysfunction. - Given the advanced **36 weeks gestation** and it being the first elevated reading, prompt follow-up within **48 hours** with blood tests is crucial to monitor for progression to **pre-eclampsia** and reassess maternal and fetal well-being. *White coat hypertension; reassure and arrange 24-hour ambulatory monitoring* - While **24-hour ambulatory monitoring** can identify **white coat hypertension**, a single elevated reading at **36 weeks gestation** necessitates a more cautious approach due to the immediate risk of developing **pre-eclampsia**. - Reassurance alone is inappropriate; the priority is to rule out or manage potential **gestational hypertension** or **pre-eclampsia** rather than immediately attributing it to white coat effect. *Mild pre-eclampsia; admit for observation and commence labetalol* - This patient lacks the key diagnostic criteria for **pre-eclampsia**, specifically significant **proteinuria** and any signs of end-organ dysfunction or adverse features. - Her normal **platelets**, **ALT**, and **creatinine** values indicate no current biochemical evidence of pre-eclampsia, thus admission and immediate medication are not warranted. *Gestational hypertension; arrange follow-up in 7 days with blood pressure check* - A **7-day follow-up** interval is too long for a first elevated **blood pressure** reading at **36 weeks gestation**, as clinical conditions can rapidly deteriorate in late pregnancy. - National guidelines recommend more frequent monitoring, typically within **48-72 hours**, to promptly detect any worsening of hypertension or development of **proteinuria**, which would indicate pre-eclampsia. *Chronic hypertension; commence labetalol and routine antenatal care* - **Chronic hypertension** is defined as hypertension that predates pregnancy or develops before **20 weeks of gestation**, neither of which applies to this patient who presents with her first elevated reading at 36 weeks. - While **labetalol** is an appropriate antihypertensive in pregnancy, pharmacological treatment is typically initiated for consistently sustained readings ≥140/90 mmHg, and after proper classification, not for a single reading of 138/92 mmHg.

Question 166: A 34-year-old woman with gestational diabetes at 30 weeks gestation has consistently elevated fasting glucose readings of 5.8-6.2 mmol/L despite maximal dietary modifications. Her post-prandial readings are within target. She is already taking metformin 2 g daily in divided doses. What is the most appropriate next step in management?

A. Add glibenclamide to the current regimen
B. Replace metformin with insulin therapy
C. Add short-acting insulin before meals
D. Add intermediate or long-acting insulin at bedtime (Correct Answer)
E. Continue current management and increase monitoring frequency

Explanation: ***Add intermediate or long-acting insulin at bedtime*** - Persistent **elevated fasting glucose** (above 5.3 mmol/L) in gestational diabetes, despite maximal dietary modifications and **metformin**, necessitates the addition of insulin. - **Intermediate or long-acting insulin** given at bedtime effectively targets **nocturnal hepatic glucose production**, which is the primary contributor to high morning fasting glucose readings. *Add glibenclamide to the current regimen* - While **glibenclamide** can be used in pregnancy, **insulin** is generally preferred for tighter and more predictable glycemic control in gestational diabetes, especially for **fasting hyperglycemia**. - Insulin offers more precise titration and is considered superior in achieving glycemic targets without the potential risks associated with sulfonylureas like increased risk of neonatal hypoglycemia. *Replace metformin with insulin therapy* - There is no indication to discontinue **metformin** as it is well-tolerated and likely contributing to the patient's **in-target post-prandial glucose levels**. - **Metformin** can be continued alongside insulin, often reducing the overall insulin requirement and improving **insulin sensitivity**. *Add short-acting insulin before meals* - **Short-acting (bolus) insulin** is indicated for managing **post-prandial hyperglycemia**, but the patient's post-prandial readings are already within target. - Adding short-acting insulin would not address the specific issue of **elevated fasting glucose** and could potentially lead to hypoglycemia if post-prandial levels are already controlled. *Continue current management and increase monitoring frequency* - Persistently elevated **fasting glucose** increases the risk of adverse maternal and fetal outcomes, including **fetal macrosomia**, shoulder dystocia, and neonatal hypoglycemia. - Continuing current management without escalation is not appropriate when glycemic targets are not met; a change in **pharmacological therapy** is required to improve control.

Question 167: What is the recommended folic acid supplementation dose for women with a previous child affected by neural tube defect who are planning pregnancy?

A. 400 micrograms daily from before conception until 12 weeks gestation
B. 1 mg daily from before conception until 12 weeks gestation
C. 5 mg daily from before conception until 12 weeks gestation (Correct Answer)
D. 5 mg daily throughout pregnancy
E. 400 micrograms daily throughout pregnancy

Explanation: ***5 mg daily from before conception until 12 weeks gestation*** - Women at **high risk**, such as those with a **previous pregnancy affected by a neural tube defect (NTD)**, require a higher dose of **5 mg (5000 mcg)** to effectively reduce recurrence risk. - This supplementation must begin **at least one month before conception** and continue until the **12th week of gestation**, covering the critical window of **neural tube closure**. *400 micrograms daily from before conception until 12 weeks gestation* - This is the standard dose recommended for **low-risk women** in the general population to prevent primary NTDs. - It is insufficient for women with high-risk factors like **diabetes**, **BMI ≥30**, or an **affected previous sibling**. *1 mg daily from before conception until 12 weeks gestation* - While higher than the standard dose, **1 mg** is not the globally recognized evidence-based guideline for secondary prevention of NTDs. - Clinical guidelines specifically mandate the **5 mg dose** to achieve the necessary protective serum folate levels in high-risk scenarios. *5 mg daily throughout pregnancy* - Although the 5 mg dose is correct, the requirement specifically focuses on the first trimester during **organogenesis**. - Continuing 5 mg after **12 weeks** does not offer additional protection against NTDs as the **neural tube** is already closed by this stage. *400 micrograms daily throughout pregnancy* - This provides the baseline dose but fails to address the **increased risk profile** of a woman with a previous history of NTD. - While folic acid is beneficial for erythropoiesis in later pregnancy, the **pre-conception high-dose loading** is the vital intervention for this patient.

Question 168: A 26-year-old primigravida attends her 20-week anomaly scan. The sonographer reports that the placenta is covering the internal cervical os. The woman is asymptomatic with no vaginal bleeding. What is the most appropriate management plan?

A. Admit for bed rest until 28 weeks gestation
B. Arrange repeat transvaginal ultrasound at 32 weeks
C. Schedule elective caesarean section at 37 weeks
D. Advise pelvic rest and arrange rescan at 36 weeks for delivery planning (Correct Answer)
E. Prescribe vaginal progesterone to reduce bleeding risk

Explanation: ***Advise pelvic rest and arrange rescan at 36 weeks for delivery planning***- For a placenta covering the **internal os** at the 20-week anomaly scan, it is standard practice to advise **pelvic rest** (avoidance of intercourse) and perform follow-up scans.- While initial rescanning often occurs at 32 weeks, a rescan at **36 weeks** is crucial for final delivery planning as many cases resolve due to the development of the **lower uterine segment**.*Admit for bed rest until 28 weeks gestation*- **Hospitalization** and bed rest are not indicated for asymptomatic patients with placenta previa detected in the second trimester.- Modern guidelines do not support routine **prophylactic bed rest**, as it increases the risk of **venous thromboembolism** without improving outcomes.*Arrange repeat transvaginal ultrasound at 32 weeks*- Although a 32-week scan is part of the monitoring pathway, the definitive timing for final delivery planning in asymptomatic women is later in the third trimester.- This option alone is incomplete compared to the comprehensive management that includes **pelvic rest** and late-term planning.*Schedule elective caesarean section at 37 weeks*- Scheduling a delivery at 20 weeks is **premature** because approximately 90% of low-lying placentas migrate away from the os as the pregnancy progresses.- Management hinges on the placental position confirmed during the **third-trimester** follow-up scans.*Prescribe vaginal progesterone to reduce bleeding risk*- **Vaginal progesterone** is used for the prevention of preterm birth in women with a short cervix, not for managing placenta previa.- There is no clinical evidence that progesterone reduces the risk of **antepartum hemorrhage** associated with abnormal placental implantation.

Question 169: A 33-year-old woman attends her booking appointment at 12 weeks gestation. Her BMI is 34 kg/m². She has no previous history of gestational diabetes but her mother has type 2 diabetes. When should oral glucose tolerance testing be offered?

A. At booking and repeated at 28 weeks if normal
B. At 24-28 weeks gestation only (Correct Answer)
C. At 16 weeks and again at 28 weeks
D. At booking, 20 weeks, and 28 weeks
E. Monthly from 20 weeks until delivery

Explanation: ***At 24-28 weeks gestation only*** - According to **NICE guidelines**, an **Oral Glucose Tolerance Test (OGTT)** is recommended at **24-28 weeks** for women with one or more risk factors, such as a **BMI ≥30 kg/m²** or a **first-degree relative with diabetes**. - This patient has risk factors (BMI 34 kg/m² and mother with type 2 diabetes) but **no history of previous gestational diabetes**, meaning early screening at booking is not indicated. *At booking and repeated at 28 weeks if normal* - This protocol is strictly reserved for women who have had **gestational diabetes (GDM) in a previous pregnancy** to screen for early-onset GDM or pre-existing diabetes. - The patient in this scenario has **no history of previous GDM**, making initial screening at booking inappropriate. *At 16 weeks and again at 28 weeks* - Screening at **16 weeks** is not a standard recommendation for patients whose only risk factors are **obesity** and **family history** without a prior GDM history. - The physiological **insulin resistance** that defines GDM typically becomes clinically significant and detectable during the **late second trimester**. *At booking, 20 weeks, and 28 weeks* - Frequent screening at these specific intervals is not supported by current evidence-based guidelines and could increase **healthcare costs** and patient burden unnecessarily. - The standard **24-28 week window** provides the optimal balance for diagnostic sensitivity and clinical utility in moderate-risk profiles. *Monthly from 20 weeks until delivery* - Monthly OGTT testing is not recommended as it is an **invasive, time-consuming procedure** that does not offer additional diagnostic benefit over a single correctly timed test. - Once a patient tests negative at **28 weeks**, repeat screening is generally only performed if new clinical signs such as **polyhydramnios** or **fetal macrosomia** develop.

Question 170: A 30-year-old woman at 28 weeks gestation presents with headache and visual disturbances. Her blood pressure is 156/98 mmHg. Urinalysis shows 2+ protein. Blood results show: platelets 145 × 10⁹/L, ALT 42 U/L, creatinine 78 μmol/L. She reports normal fetal movements. What is the most appropriate initial management?

A. Admit for observation and commence oral labetalol (Correct Answer)
B. Arrange urgent delivery within 24 hours
C. Prescribe magnesium sulphate prophylaxis immediately
D. Discharge with twice-weekly blood pressure monitoring
E. Commence intravenous hydralazine stat

Explanation: ***Admit for observation and commence oral labetalol***- The patient's presentation with new-onset hypertension (BP 156/98 mmHg), proteinuria (2+), headache, and visual disturbances at 28 weeks gestation is diagnostic of **pre-eclampsia with severe features**, necessitating **hospital admission** for close maternal and fetal monitoring.- **Oral labetalol** is a first-line antihypertensive medication commonly used to manage blood pressure in pre-eclampsia to prevent further progression and complications, aiming for a target SBP <150 mmHg and DBP <100 mmHg.*Arrange urgent delivery within 24 hours*- **Urgent delivery** is not indicated as the initial management at **28 weeks gestation** unless there are signs of severe maternal or fetal compromise such as uncontrolled hypertension, eclampsia, HELLP syndrome, placental abruption, or non-reassuring fetal status.- For pre-eclampsia with severe features before 34 weeks, **expectant management** is typically pursued, involving close monitoring, blood pressure control, and administration of **antenatal corticosteroids** to promote fetal lung maturity.*Prescribe magnesium sulphate prophylaxis immediately*- **Magnesium sulphate** is primarily indicated for the prevention of seizures in women with **severe pre-eclampsia** (e.g., BP ≥160/110 mmHg, significant end-organ dysfunction) or actual eclampsia, or when delivery is imminent.- While the patient is symptomatic, her blood pressure (156/98 mmHg) and lab values (platelets 145 × 10⁹/L, ALT 42 U/L, creatinine 78 μmol/L) do not meet all criteria for immediate magnesium sulphate initiation as the very first step, especially before optimizing blood pressure control.*Discharge with twice-weekly blood pressure monitoring*- **Discharge** is inappropriate for a patient presenting with **symptomatic pre-eclampsia** at 28 weeks gestation, as this condition carries a significant risk of rapid deterioration.- Inpatient management is crucial to monitor for worsening hypertension, proteinuria, development of **HELLP syndrome**, **eclampsia**, or fetal distress, ensuring timely intervention.*Commence intravenous hydralazine stat*- **Intravenous hydralazine** is reserved for the acute management of **hypertensive crisis** in pregnancy, defined as sustained SBP ≥160 mmHg or DBP ≥110 mmHg, to prevent maternal stroke.- The patient's blood pressure of 156/98 mmHg, while elevated, does not meet the threshold for a hypertensive crisis requiring *stat* intravenous antihypertensive therapy, making oral agents a more appropriate initial choice.

Question 171: A 37-year-old woman presents at 19 weeks gestation with blood pressure 146/94 mmHg. This is repeated 4 hours later and is 148/96 mmHg. She is asymptomatic and urine dipstick shows no proteinuria. Blood tests including renal function, liver function, and full blood count are normal. Her booking BP at 8 weeks was 156/98 mmHg. What is the most appropriate initial management of her blood pressure?

A. No treatment required as BP <150/100 mmHg
B. Start labetalol and aim for BP <140/90 mmHg
C. Start labetalol and aim for BP <135/85 mmHg (Correct Answer)
D. Arrange 24-hour ambulatory blood pressure monitoring before starting treatment
E. Start methyldopa and aim for BP <130/80 mmHg

Explanation: ***Start labetalol and aim for BP <135/85 mmHg*** - The patient has **chronic hypertension**, diagnosed by elevated blood pressure (156/98 mmHg) before **20 weeks gestation** at her booking appointment. - Current guidelines recommend initiating antihypertensive treatment (first-line **labetalol**) for chronic hypertension in pregnancy when BP is ≥140/90 mmHg, with a target BP of **<135/85 mmHg** to optimize maternal and fetal outcomes. *No treatment required as BP <150/100 mmHg* - While a higher threshold like 150/100 mmHg may apply to certain forms of hypertension in pregnancy, **chronic hypertension** typically warrants treatment at a lower threshold of **≥140/90 mmHg**. - The patient's current repeated readings of 146/94 mmHg and 148/96 mmHg are consistently above this treatment threshold, indicating that intervention is necessary. *Start labetalol and aim for BP <140/90 mmHg* - Although **labetalol** is an appropriate first-line medication, a target blood pressure of **<140/90 mmHg** is generally considered insufficient for optimal management of chronic hypertension in pregnancy. - Current recommendations, such as those from NICE, advocate for a stricter target of **<135/85 mmHg** to significantly reduce the risk of severe hypertension and complications like **superimposed pre-eclampsia**. *Arrange 24-hour ambulatory blood pressure monitoring before starting treatment* - **Ambulatory blood pressure monitoring (ABPM)** is typically used to confirm a diagnosis of hypertension or rule out **white-coat hypertension**. - In this case, the patient has established **chronic hypertension** with consistent elevated readings at 8 weeks and 19 weeks, making ABPM an unnecessary delay to appropriate and timely treatment. *Start methyldopa and aim for BP <130/80 mmHg* - While **methyldopa** is a safe and acceptable alternative for hypertension in pregnancy, **labetalol** is often preferred as a first-line agent due to efficacy and tolerability. - Aiming for a target blood pressure as low as **<130/80 mmHg** is generally considered **too aggressive** in pregnancy and could potentially compromise **uteroplacental perfusion**, negatively impacting fetal growth and well-being.

Question 172: A 35-year-old woman at 24 weeks gestation is referred after screening OGTT shows fasting glucose 4.8 mmol/L and 2-hour value 10.2 mmol/L. She has a BMI of 42 kg/m² and previous macrosomia (birthweight 4.6 kg). She begins dietary management and home glucose monitoring. One week later, her glucose diary shows fasting values 5.1-5.5 mmol/L and 1-hour post-prandial values 7.2-8.4 mmol/L. Ultrasound shows estimated fetal weight on 78th centile with normal liquor volume. What is the most appropriate management?

A. Continue dietary management alone as most values are acceptable
B. Start metformin for post-prandial glucose control (Correct Answer)
C. Start insulin for post-prandial glucose control
D. Start metformin and insulin combination therapy
E. Arrange repeat ultrasound in 1 week before deciding on treatment

Explanation: ***Start metformin for post-prandial glucose control*** - According to **NICE guidelines**, if blood glucose targets (fasting <5.3 mmol/L or 1-hour post-prandial <7.8 mmol/L) are not met within 1-2 weeks of lifestyle changes, **metformin** should be initiated as first-line therapy. - This patient’s 1-hour readings (up to **8.4 mmol/L**) exceed the recommended threshold, and given her high **BMI** and history of **macrosomia**, pharmacological intervention is necessary to minimize risks. *Continue dietary management alone as most values are acceptable* - While some values are within range, the recurrent readings above **7.8 mmol/L** indicate that lifestyle modifications alone are insufficient to maintain **glycemic control**. - Delaying treatment in a patient with a high risk of **fetal macrosomia** and therapeutic failure on diet increases the risk of adverse obstetric outcomes. *Start insulin for post-prandial glucose control* - **Insulin** is typically reserved as a first-line agent if the fasting glucose is significantly elevated (e.g., >7.0 mmol/L) at diagnosis or if metformin is **contraindicated**. - Since the patient is only mildly above target and just starting pharmacotherapy, **metformin** is the preferred initial step before escalating to insulin. *Start metformin and insulin combination therapy* - **Combination therapy** is typically implemented only when targets are not met despite being on the maximum tolerated dose of **metformin**. - Starting both simultaneously is premature as the majority of patients achieve adequate control with **metformin monotherapy** initially. *Arrange repeat ultrasound in 1 week before deciding on treatment* - Management decisions in **gestational diabetes** are primarily driven by the **maternal glucose diary** rather than awaiting evidence of fetal overgrowth. - Waiting for ultrasound changes (like **polyhydramnios** or increased abdominal circumference) means the fetus has already been exposed to the harmful effects of **hyperglycemia**.

Question 173: A 40-year-old woman with pre-existing type 2 diabetes presents for pre-pregnancy counselling. She is currently on metformin 1000 mg twice daily and sitagliptin 100 mg once daily. Her HbA1c is 58 mmol/mol (7.5%). She is also on atorvastatin 20 mg daily for hyperlipidaemia. What is the most appropriate advice regarding her medications before conception?

A. Continue all current medications as diabetes control is acceptable
B. Stop sitagliptin and atorvastatin, continue metformin, start folic acid 5 mg daily
C. Stop sitagliptin and atorvastatin, start insulin therapy, start folic acid 5 mg daily (Correct Answer)
D. Continue metformin and sitagliptin, stop atorvastatin, start folic acid 5 mg daily
E. Stop all medications and aim for dietary control only

Explanation: ***Stop sitagliptin and atorvastatin, start insulin therapy, start folic acid 5 mg daily*** - **Sitagliptin** (DPP-4 inhibitor) and **atorvastatin** (statin) are generally contraindicated or not recommended in pregnancy due to potential **teratogenic risks** (atorvastatin) or insufficient safety data (sitagliptin). - The current **HbA1c of 7.5% (58 mmol/mol)** is above the recommended preconception target of **<6.5% (<48 mmol/mol)**. **Insulin** is the safest and most effective medication to achieve tight glycemic control in pregnancy, and high-dose **folic acid (5 mg)** is essential to reduce the risk of **neural tube defects** in diabetic pregnancies. *Continue all current medications as diabetes control is acceptable* - The **HbA1c of 7.5% (58 mmol/mol)** is considered suboptimal for preconception; the target should ideally be **<6.5% (<48 mmol/mol)** to minimize risks of congenital malformations. - **Atorvastatin** is contraindicated in pregnancy due to its **teratogenic potential**, and **sitagliptin** lacks sufficient safety data, making their continuation unsafe. *Stop sitagliptin and atorvastatin, continue metformin, start folic acid 5 mg daily* - While **metformin** is generally considered safe in pregnancy, it is unlikely to be sufficient as a sole agent to reduce an **HbA1c of 7.5%** to the strict preconception target, especially after discontinuing sitagliptin. - Guidelines recommend transitioning to **insulin therapy** when oral agents are insufficient to achieve optimal glycemic control before and during pregnancy, ensuring fetal safety. *Continue metformin and sitagliptin, stop atorvastatin, start folic acid 5 mg daily* - **Sitagliptin** should be discontinued prior to conception due to limited and insufficient safety data regarding its use during pregnancy, favoring agents with established safety profiles. - Although stopping the statin and initiating high-dose folic acid are correct steps, the recommendation to continue **sitagliptin** makes this option inappropriate for preconception counseling. *Stop all medications and aim for dietary control only* - A patient requiring **dual oral antihyperglycemic agents** with an **HbA1c of 7.5%** indicates that dietary control alone is insufficient to manage her diabetes effectively. - Discontinuing all medications without initiating a safe and effective alternative like **insulin** would lead to uncontrolled **hyperglycemia**, significantly increasing the risk of **miscarriage**, **fetal anomalies**, and other adverse pregnancy outcomes.

Question 174: A 32-year-old woman in her second pregnancy attends for routine antenatal care at 26 weeks gestation. Her oral glucose tolerance test shows fasting glucose 4.9 mmol/L and 2-hour glucose 11.8 mmol/L. She is started on dietary management and glucose monitoring. After 1 week of optimal dietary compliance, her glucose levels show: fasting 5.2-5.4 mmol/L (all values), 1-hour post-prandial 6.8-7.2 mmol/L. What is the most appropriate management?

A. Continue dietary management and review in 2 weeks (Correct Answer)
B. Start metformin 500 mg once daily
C. Start insulin therapy
D. Refer to specialist diabetes team for urgent review
E. Increase monitoring frequency to 6 times daily

Explanation: ***Continue dietary management and review in 2 weeks***- The patient's blood glucose levels are currently within the **NICE target ranges** (fasting <5.6 mmol/L and 1-hour post-prandial <7.8 mmol/L).- Since her fasting levels (5.2-5.4 mmol/L) and post-prandial levels (6.8-7.2 mmol/L) are well-controlled on **dietary modification**, no pharmacological intervention is required at this time.*Start metformin 500 mg once daily*- **Metformin** is indicated only if blood glucose targets are not met within 1–2 weeks of dietary changes and exercise.- Starting medication unnecessarily increases the risk of side effects like **gastrointestinal upset** without clinical benefit since she is meeting her targets.*Start insulin therapy*- **Insulin therapy** is typically reserved for women with very high fasting glucose at diagnosis or those who do not respond to metformin and diet.- It is not indicated here as the patient is achieving **euglycemia** through lifestyle modifications alone.*Refer to specialist diabetes team for urgent review*- While a specialist team oversees **gestational diabetes (GDM)**, an **urgent review** is not needed when glucose profiles are stable and within range.- Routine follow-up is sufficient for patients who demonstrate excellent **glycemic control** and compliance.*Increase monitoring frequency to 6 times daily*- Current monitoring is sufficient to confirm that her **dietary compliance** is effectively managing her GDM.- Increasing frequency adds **unnecessary burden** to the patient without changing the clinical management plan, given her stable readings.

Question 175: A 25-year-old primigravida at 38 weeks gestation presents to the antenatal day unit with severe headache and visual disturbances. Her blood pressure is 172/114 mmHg. Blood tests show: platelets 82 × 10⁹/L, ALT 156 U/L, AST 178 U/L, bilirubin 28 μmol/L, creatinine 124 μmol/L, urea 8.2 mmol/L. Urine protein:creatinine ratio is 68 mg/mmol. What is the most appropriate immediate management?

A. Commence oral labetalol and arrange induction of labour within 48 hours
B. Give intravenous labetalol, magnesium sulfate prophylaxis, and plan delivery within 24-48 hours (Correct Answer)
C. Give intravenous hydralazine and arrange emergency caesarean section
D. Give intravenous magnesium sulfate and arrange induction of labour within 24 hours
E. Stabilise with antihypertensives and conservative management for 1 week

Explanation: ***Give intravenous labetalol, magnesium sulfate prophylaxis, and plan delivery within 24-48 hours***- The patient presents with **severe pre-eclampsia** (BP >160/110, headache, visual changes, proteinuria) and features suggestive of **HELLP syndrome** (thrombocytopenia, elevated liver enzymes).- Immediate **intravenous labetalol** is crucial for rapid blood pressure control to prevent maternal cerebrovascular events, while **magnesium sulfate** provides **eclampsia prophylaxis**. Delivery within 24-48 hours is indicated at 38 weeks gestation after maternal stabilization.*Commence oral labetalol and arrange induction of labour within 48 hours*- **Oral labetalol** is too slow to achieve adequate and rapid blood pressure control in **severe hypertension** and does not address the immediate risk of **eclampsia**.- It lacks the crucial component of **magnesium sulfate** for seizure prevention in a patient with symptomatic severe pre-eclampsia.*Give intravenous hydralazine and arrange emergency caesarean section*- While **intravenous hydralazine** can be used for hypertension, an **emergency caesarean section** is not the immediate first step unless there is acute fetal distress or maternal compromise unresponsive to medical management.- The primary goal is maternal stabilization through **antihypertensives** and **seizure prophylaxis** before definitive delivery planning.*Give intravenous magnesium sulfate and arrange induction of labour within 24 hours*- This option correctly identifies the need for **magnesium sulfate** but critically omits immediate **intravenous antihypertensive therapy** for the severe blood pressure of 172/114 mmHg.- Failure to rapidly control severe hypertension significantly increases the risk of maternal **stroke** and other cardiovascular complications.*Stabilise with antihypertensives and conservative management for 1 week*- **Conservative management** for an additional week is highly inappropriate and dangerous in a patient at 38 weeks with **severe pre-eclampsia** and features of **HELLP syndrome**.- This approach dramatically increases risks of **eclampsia**, **placental abruption**, acute kidney injury, and other severe maternal and fetal complications.

Question 176: A 28-year-old woman at 22 weeks gestation is diagnosed with gestational diabetes following an OGTT showing fasting glucose 5.8 mmol/L and 2-hour value 9.2 mmol/L. She is commenced on dietary management. Which of the following glucose monitoring targets should she aim for?

A. Fasting <5.3 mmol/L and 1-hour post-prandial <7.8 mmol/L
B. Fasting <5.6 mmol/L and 1-hour post-prandial <7.8 mmol/L (Correct Answer)
C. Fasting <5.6 mmol/L and 2-hour post-prandial <6.4 mmol/L
D. Fasting <6.0 mmol/L and 2-hour post-prandial <7.8 mmol/L
E. Fasting <5.3 mmol/L and 2-hour post-prandial <7.0 mmol/L

Explanation: ***Fasting <5.6 mmol/L and 1-hour post-prandial <7.8 mmol/L***- According to **NICE guidelines**, women with **gestational diabetes** should aim for a fasting glucose target of **less than 5.6 mmol/L**.- The recommended **1-hour post-prandial** target is **less than 7.8 mmol/L**, which is widely used to reduce the risk of **macrosomia**.*Fasting <5.3 mmol/L and 1-hour post-prandial <7.8 mmol/L*- A **fasting target of <5.3 mmol/L** is typically reserved for women with **pre-existing Type 1 or Type 2 diabetes** who are pregnant.- While tighter control is good, **5.6 mmol/L** is the specific diagnostic and management threshold for **gestational diabetes** in the UK.*Fasting <5.6 mmol/L and 2-hour post-prandial <6.4 mmol/L*- While the **fasting target** is correct, this option is less ideal because **1-hour monitoring** is generally preferred in the UK for GDM.- Although a **2-hour target of <6.4 mmol/L** is a valid alternative in some contexts, the 1-hour target provides better clinical correlation with **fetal outcomes** according to NICE.*Fasting <6.0 mmol/L and 2-hour post-prandial <7.8 mmol/L*- A **fasting glucose of <6.0 mmol/L** is too high and is associated with increased risks of **neonatal hypoglycemia** and birth complications.- The **2-hour target of 7.8 mmol/L** is also too lenient; that value is actually the threshold for the **1-hour post-prandial** target, not the 2-hour.*Fasting <5.3 mmol/L and 2-hour post-prandial <7.0 mmol/L*- This combination mix-matches different guidelines; **<7.0 mmol/L** is not the standard **NICE** target for 2-hour post-prandial monitoring for GDM.- The **fasting target of <5.3 mmol/L** again applies primarily to **pre-existing diabetes** rather than the standard management of GDM.

Question 177: What is the definition of severe hypertension in pregnancy according to current UK guidelines?

A. Blood pressure ≥140/90 mmHg on two occasions
B. Blood pressure ≥150/100 mmHg on two occasions
C. Blood pressure ≥160/110 mmHg (Correct Answer)
D. Systolic blood pressure ≥170 mmHg or diastolic blood pressure ≥120 mmHg
E. Blood pressure ≥140/90 mmHg with proteinuria

Explanation: ***Blood pressure ≥160/110 mmHg*** - In the UK, **NICE guidelines** define **severe hypertension** in pregnancy as a sustained blood pressure of **160/110 mmHg** or higher. - This threshold indicates a medical emergency requiring **urgent antihypertensive treatment** to prevent maternal **cerebrovascular accidents** and eclampsia. *Blood pressure ≥140/90 mmHg on two occasions* - This is the diagnostic criterion for **hypertension in pregnancy** (either gestational hypertension or chronic hypertension) rather than severe hypertension. - Readings should be confirmed on at least **two occasions**, typically 4-6 hours apart, or within a shorter period if immediate treatment is indicated. *Blood pressure ≥150/100 mmHg on two occasions* - This level is considered **moderate hypertension** in pregnancy and usually warrants the initiation or intensification of **antihypertensive treatment**. - However, it does not meet the specific threshold of **160/110 mmHg** required to classify it as severe hypertension by UK guidelines. *Systolic blood pressure ≥170 mmHg or diastolic blood pressure ≥120 mmHg* - While these represent **extremely high and dangerous blood pressure levels**, the definition of severe hypertension in pregnancy specifically begins at **160/110 mmHg**. - Waiting for blood pressure to reach these higher values before classifying it as severe would delay **critical intervention** and significantly increase maternal and fetal risks. *Blood pressure ≥140/90 mmHg with proteinuria* - This combination of signs is characteristic of **pre-eclampsia**, a multi-system disorder unique to pregnancy, rather than solely a definition of **hypertensive severity**. - Although pre-eclampsia can involve severe hypertension, this option describes the **syndrome** itself, not the direct numerical cut-off for severe hypertension.

Question 178: A 36-year-old woman in her third pregnancy presents at 17 weeks gestation with a blood pressure of 152/98 mmHg. This is confirmed on repeat measurement. She has no symptoms and urine dipstick shows no proteinuria. Her booking blood pressure at 10 weeks was 118/76 mmHg. She has no past medical history. What is the most likely diagnosis?

A. Chronic hypertension (Correct Answer)
B. Gestational hypertension
C. White coat hypertension
D. Pre-eclampsia
E. Secondary hypertension

Explanation: ***Chronic hypertension*** - **Chronic hypertension** in pregnancy is defined as hypertension present before pregnancy or diagnosed **before 20 weeks** of gestation. The patient's blood pressure elevation at 17 weeks falls within this diagnostic window. - Although her booking blood pressure was normal at 10 weeks, the physiological **nadir in blood pressure** during the early second trimester can often temporarily mask pre-existing hypertension, which then becomes evident as blood pressure rises again later. *Gestational hypertension* - This diagnosis is reserved for new-onset hypertension occurring specifically **after 20 weeks** of gestation, without associated proteinuria or other signs of pre-eclampsia. - Since this patient is only at **17 weeks** gestation, she does not meet the necessary temporal criteria for gestational hypertension. *White coat hypertension* - This refers to a phenomenon where blood pressure readings are elevated in a clinical setting but are normal when measured outside this environment. - While possible, confirming this would require **ambulatory blood pressure monitoring (ABPM)** or home blood pressure readings, and it's not the primary diagnostic label for new-onset hypertension detected at 17 weeks. *Pre-eclampsia* - **Pre-eclampsia** typically occurs **after 20 weeks** of gestation and requires the presence of new-onset hypertension *plus* **proteinuria** or other signs of end-organ dysfunction. - This patient lacks **proteinuria** and is asymptomatic, and her gestation is at 17 weeks, thus ruling out pre-eclampsia based on both timing and clinical features. *Secondary hypertension* - While secondary causes (such as renal artery disease, thyroid dysfunction, or adrenal disorders) can lead to hypertension, they are generally less common in this demographic without other specific symptoms. - In the absence of an obvious underlying cause or atypical features, hypertension identified in the first half of pregnancy is formally classified as **chronic hypertension**, making this a less likely primary diagnosis without further investigation.

Question 179: A 33-year-old woman with chronic hypertension on enalapril 10 mg daily attends for pre-pregnancy counselling. Her blood pressure is well controlled at 125/78 mmHg. She has no other medical conditions and BMI is 24 kg/m². What is the most appropriate advice regarding her antihypertensive medication?

A. Continue enalapril throughout pregnancy as it provides good control
B. Switch to labetalol before conception (Correct Answer)
C. Stop all antihypertensives and monitor blood pressure closely
D. Switch to methyldopa before conception
E. Reduce enalapril dose to 5 mg daily before conception

Explanation: ***Switch to labetalol before conception*** - **Enalapril**, an **ACE inhibitor**, is **teratogenic** and **fetotoxic**, especially during the second and third trimesters, with risks including **renal dysgenesis**, oligohydramnios, and skull hypoplasia. - **Labetalol** is a recommended **first-line antihypertensive** for chronic hypertension in pregnancy due to its established **safety profile** and efficacy for both mother and fetus. *Continue enalapril throughout pregnancy as it provides good control* - Continuing **enalapril** is contraindicated as it carries a significant risk of severe **congenital malformations** and neonatal **renal failure**. - Guidelines mandate switching to a safer alternative **prior to conception** or immediately upon confirmation of pregnancy. *Stop all antihypertensives and monitor blood pressure closely* - Discontinuing medication for chronic hypertension increases the risk of **uncontrolled hypertension**, leading to **maternal complications** like stroke and **superimposed pre-eclampsia**. - Active management to maintain blood pressure below **135/85 mmHg** is essential for optimal maternal and fetal outcomes. *Switch to methyldopa before conception* - While **methyldopa** is considered safe in pregnancy, **labetalol** or nifedipine are often preferred first-line agents due to better tolerability and less frequent dosing requirements. - Methyldopa can cause bothersome side effects such as **sedation**, **dizziness**, and **depression**. *Reduce enalapril dose to 5 mg daily before conception* - Reducing the dose of **enalapril** does not eliminate its **teratogenic** and **fetotoxic risks** during pregnancy. - The appropriate advice is to completely discontinue the **ACE inhibitor** and switch to a known safe medication for pregnancy, rather than adjusting the dose.

Question 180: A 27-year-old woman presents for her first antenatal appointment at 11 weeks gestation. She has epilepsy controlled on carbamazepine 400 mg twice daily with no seizures for 3 years. She takes no other medications and did not receive pre-pregnancy counselling. What is the most important immediate management regarding her medication?

A. Continue carbamazepine and prescribe high-dose folic acid 5 mg daily
B. Switch to lamotrigine immediately
C. Stop carbamazepine and monitor for seizures
D. Reduce carbamazepine dose by 50%
E. Continue carbamazepine at current dose and arrange detailed fetal anomaly scan (Correct Answer)

Explanation: ***Continue carbamazepine at current dose and arrange detailed fetal anomaly scan*** - By **11 weeks gestation**, the neural tube has already closed (completes by day 28 post-conception), so changing medications will not prevent major **congenital malformations** caused by first-trimester exposure. - Maintaining the current dose is vital to prevent **seizures**, which pose a significant risk of **hypoxia** and trauma to both the mother and the fetus. *Continue carbamazepine and prescribe high-dose folic acid 5 mg daily* - While **5 mg folic acid** is recommended for women on antiepileptics, it is most effective when started **pre-conception** to prevent neural tube defects. - Starting it at 11 weeks is less critical than arranging for **detailed morphology ultrasound** screening because organogenesis is largely complete. *Switch to lamotrigine immediately* - Switching medications during pregnancy risks a **seizure breakthrough** during the titration period required for drugs like **lamotrigine**. - Sudden changes to antiepileptic therapy should be avoided once pregnancy is confirmed unless the risk of the drug far outweighs the risk of the seizure. *Stop carbamazepine and monitor for seizures* - Abruptly stopping medication in a stable patient can trigger **status epilepticus**, which has a high maternal and fetal **mortality rate**. - International guidelines state that epilepsy should be managed with the **lowest effective dose** of a single agent that controls seizures, rather than complete cessation. *Reduce carbamazepine dose by 50%* - Arbitrarily reducing the dose increases the risk of **sub-therapeutic levels**, especially as blood volume increases and drug metabolism changes during pregnancy. - Dose adjustments should be guided by **clinical seizure control** and, in some cases, plasma level monitoring rather than a fixed percentage reduction.

Question 181: A 38-year-old nulliparous woman at 35 weeks gestation is diagnosed with gestational diabetes. Her fasting glucose is 6.8 mmol/L and 1-hour post-prandial values range from 8.5-9.2 mmol/L. Ultrasound shows estimated fetal weight on 92nd centile and polyhydramnios with AFI of 26 cm. What is the most appropriate management plan?

A. Start metformin and review in 1 week
B. Start insulin therapy immediately and arrange consultant review (Correct Answer)
C. Arrange induction of labour at 37 weeks
D. Start metformin and arrange induction at 40 weeks
E. Intensive dietary modification and daily glucose monitoring

Explanation: ***Start insulin therapy immediately and arrange consultant review*** - Per **NICE guidelines**, insulin is indicated for women with gestational diabetes if the **fasting glucose** is ≥7.0 mmol/L or if it is ≥6.0 mmol/L with complications like **macrosomia** or **polyhydramnios**. - This patient presents with multiple complications including **fetal weight >90th centile** and **polyhydramnios (AFI 26 cm)**, necessitating rapid glycemic control that only **insulin** provides. *Start metformin and review in 1 week* - **Metformin** is usually the first-line pharmacological treatment when diet fails, but it is insufficient for patients presenting with clinical evidence of **fetal macrosomia** or very high glucose levels. - A review in 1 week is too long a delay given the significant **polyhydramnios** and the advanced gestational age of **35 weeks**. *Arrange induction of labour at 37 weeks* - While **induction of labour** between 37+0 and 38+6 weeks is recommended for women on medication, the immediate priority is achieving **glycemic control** to prevent further complications. - Management must focus on stabilization with **insulin** before finalising the mode and timing of delivery. *Start metformin and arrange induction at 40 weeks* - Waiting until **40 weeks** is inappropriate for a patient with poorly controlled gestational diabetes and **fetal complications**, as it increases the risk of **stillbirth** and shoulder dystocia. - **Metformin** alone would take too long to titrate and likely fail to achieve the required rapid normalization of maternal glucose. *Intensive dietary modification and daily glucose monitoring* - **Dietary modification** is the initial step for mild cases, but this patient's fasting glucose of **6.8 mmol/L** and fetal symptoms bypass this conservative stage. - Failure to initiate **pharmacotherapy** immediately in the presence of **macrosomia** constitutes suboptimal care and risks urgent obstetric complications.

Question 182: A 31-year-old woman with gestational diabetes at 28 weeks gestation has fasting glucose levels consistently between 5.8-6.2 mmol/L despite optimal dietary modification for 2 weeks. Her post-prandial glucose levels are within target range. Her BMI is 28 kg/m². What is the most appropriate next step in management?

A. Continue dietary management alone and review in 2 weeks
B. Start metformin 500 mg once daily (Correct Answer)
C. Start insulin therapy
D. Start glibenclamide 2.5 mg once daily
E. Arrange early delivery at 38 weeks

Explanation: ***Start metformin 500 mg once daily*** - The patient's **fasting glucose levels (5.8-6.2 mmol/L)** are consistently above the target of **<5.3 mmol/L (or <5.6 mmol/L per NICE)** despite two weeks of optimal **dietary modification**. - According to guidelines for gestational diabetes, if glycemic targets are not met with lifestyle interventions after 1-2 weeks, **metformin** is generally the first-line oral pharmacological agent to be initiated. *Continue dietary management alone and review in 2 weeks* - This approach is inappropriate because the patient has already completed a **2-week trial of diet** without achieving the required glycemic targets. - Prolonged **hyperglycemia** increases the risk of fetal complications, so treatment should not be delayed further. *Start insulin therapy* - **Insulin** is usually reserved for cases where **metformin** is contraindicated, not tolerated, or if glucose levels are significantly higher (e.g., fasting >7.0 mmol/L at diagnosis). - While insulin is effective, metformin is the preferred **first-line oral agent** as it is associated with less **maternal weight gain** and a lower risk of **neonatal hypoglycemia**. *Start glibenclamide 2.5 mg once daily* - **Glibenclamide** is a sulfonylurea that is generally considered **second-line** therapy when metformin is not tolerated or targets are not met. - It is rarely used as a first-line agent because it is associated with a higher risk of **neonatal hypoglycemia** compared to metformin. *Arrange early delivery at 38 weeks* - Decisions regarding **delivery timing** are typically made later in the pregnancy based on glycemic control, ultrasound findings (e.g., **fetal growth**), and overall clinical status. - The immediate priority at 28 weeks gestation is achieving **glycemic control** through medication, rather than planning delivery logistics.

Question 183: A 34-year-old woman at 16 weeks gestation in her second pregnancy presents for routine antenatal care. Her first pregnancy was complicated by severe pre-eclampsia requiring delivery at 31 weeks. She has a BMI of 33 kg/m² and her blood pressure today is 128/82 mmHg. Urine dipstick is negative for protein. What is the most appropriate prophylaxis to reduce her risk of pre-eclampsia?

A. Aspirin 75 mg daily from 12 weeks until delivery
B. Aspirin 150 mg daily from 12 weeks until delivery (Correct Answer)
C. Aspirin 75 mg daily from 20 weeks until delivery
D. Labetalol 100 mg twice daily
E. No prophylaxis required as current blood pressure is normal

Explanation: ***Aspirin 150 mg daily from 12 weeks until delivery*** - This patient has a **high-risk factor** (history of severe pre-eclampsia requiring preterm delivery) and a **moderate-risk factor** (BMI >30), necessitating pharmacological prophylaxis. - Current guidelines and the **ASPRE trial** support the use of **150 mg of Aspirin** daily starting before 16 weeks to significantly reduce the risk of preterm pre-eclampsia. *Aspirin 75 mg daily from 12 weeks until delivery* - While 75 mg was historically recommended, **150 mg** is now the preferred evidence-based dose for superior reduction in pre-eclampsia incidence among high-risk patients. - A lower dose of 75 mg may be less effective in patients with a **high BMI**, as seen in this clinical scenario (BMI 33 kg/m²). *Aspirin 75 mg daily from 20 weeks until delivery* - Prophylaxis started at **20 weeks** is less effective because the process of **impaired placentation** and spiral artery remodeling begins much earlier in pregnancy. - Guidelines emphasize starting aspirin ideally by **12 weeks** and no later than 16 weeks to achieve the necessary clinical benefit. *Labetalol 100 mg twice daily* - Labetalol is an **antihypertensive medication** used to manage existing hypertension, not a prophylactic agent to prevent the development of pre-eclampsia. - Starting an antihypertensive is inappropriate here as the patient's current blood pressure is within the **normal range** (128/82 mmHg). *No prophylaxis required as current blood pressure is normal* - The need for prophylaxis is determined by **risk factors** in the medical history (previous severe pre-eclampsia), not the blood pressure reading at the booking visit. - Normal blood pressure in the early second trimester does not predict the subsequent development of **placental dysfunction** later in pregnancy.

Question 184: A 29-year-old woman at 15 weeks gestation attends her antenatal appointment. She has no previous medical history. Her blood results show: Hb 101 g/L, MCV 72 fL, ferritin 8 μg/L. She is asymptomatic. What is the most appropriate initial management?

A. Oral ferrous sulfate 200 mg once daily
B. Intravenous iron infusion
C. Oral ferrous sulfate 200 mg twice daily (Correct Answer)
D. Blood transfusion
E. Reassurance and repeat bloods in 4 weeks

Explanation: ***Oral ferrous sulfate 200 mg twice daily***- The patient has **iron deficiency anaemia** (Hb < 105 g/L in the second trimester and low **ferritin**); standard UK guidelines recommend 65 mg of elemental iron (e.g., **200 mg ferrous sulfate**) twice or three times daily for treatment.- Target restoration of iron stores is crucial to reduce the risks of **preterm delivery**, **low birth weight**, and postpartum haemorrhage.*Oral ferrous sulfate 200 mg once daily*- This dose is often used for **prophylaxis** or for patients who cannot tolerate higher doses due to GI side effects.- It is generally considered insufficient for the initial therapeutic management of established **microcytic anaemia** where rapid stores replacement is needed.*Intravenous iron infusion*- Reserved for patients who are **intolerant** of oral iron, show a lack of response to oral treatment, or require rapid iron replacement in late pregnancy (usually after **34 weeks**).- It is not the appropriate **initial management** for an asymptomatic patient at 15 weeks gestation.*Blood transfusion*- Transfusion is only indicated for **severe symptomatic anaemia** or when there is acute **haemodynamic compromise**.- With an Hb of 101 g/L and no symptoms, the risks of transfusion (e.g., **TRALI**, alloimmunisation) far outweigh the benefits.*Reassurance and repeat bloods in 4 weeks*- This approach is inappropriate as the patient already meets the diagnostic criteria for **anaemia in pregnancy** (Hb < 105 g/L in second trimester).- Delaying treatment allows the anaemia to worsen, potentially leading to **fetal growth restriction** and worsening maternal symptoms.

Question 185: A 31-year-old woman with insulin-treated gestational diabetes presents at 39 weeks gestation in spontaneous labour. Her cervix is 4 cm dilated with regular contractions. She last ate four hours ago. Her capillary blood glucose is 7.2 mmol/L. She is contracting three times in 10 minutes. What is the most appropriate immediate management of her diabetes during labour?

A. Continue usual subcutaneous insulin regimen with hourly blood glucose monitoring (Correct Answer)
B. Discontinue subcutaneous insulin and commence intravenous insulin infusion with dextrose
C. Withhold insulin and monitor blood glucose hourly, treating only if glucose >7.0 mmol/L
D. Continue usual subcutaneous insulin with blood glucose checks every 2 hours
E. Administer variable rate intravenous insulin infusion only, without dextrose

Explanation: ***Continue usual subcutaneous insulin regimen with hourly blood glucose monitoring*** - For women with **gestational diabetes** managed with insulin, current guidelines recommend continuing their subcutaneous regimen while maintaining **hourly capillary blood glucose** monitoring during labor. - The target blood glucose range during labor is **4–7 mmol/L**; since her glucose is 7.2 mmol/L, frequent monitoring is required to ensure it stays close to this range without immediately switching to intensive interventions. *Discontinue subcutaneous insulin and commence intravenous insulin infusion with dextrose* - **Intravenous insulin (VRIII)** with dextrose is primarily indicated for women with **Type 1 diabetes** or those whose glucose remains outside the 4–7 mmol/L range despite usual treatment. - Starting an IV infusion is unnecessary at this stage as she is stable and her blood glucose is only **minimally elevated** above the target range. *Withhold insulin and monitor blood glucose hourly, treating only if glucose >7.0 mmol/L* - **Withholding insulin** in a patient who requires it for glycemic control risks significant **hyperglycemia**, which increases the risk of neonatal hypoglycemia after delivery. - Proper management involves continuing the treatment that has been maintaining her control rather than waiting for **hyperglycemic excursions** to react. *Continue usual subcutaneous insulin with blood glucose checks every 2 hours* - Blood glucose checks every **two hours** are insufficient for insulin-treated patients in the **active phase** of labor. - **Hourly monitoring** is mandatory to detect rapid changes in metabolic demand and insulin sensitivity during uterine contractions and physical exertion. *Administer variable rate intravenous insulin infusion only, without dextrose* - Administering a **Variable Rate Intravenous Insulin Infusion (VRIII)** without concurrent dextrose is dangerous as it significantly increases the risk of **maternal hypoglycemia**. - This approach is not standard practice for **gestational diabetes** in labor and represents an inappropriate escalation of care for this patient's current status.

Question 186: A 26-year-old primigravida attends her booking appointment at 10 weeks gestation. She has no medical history and takes only folic acid 400 micrograms daily. Her BMI is 22 kg/m², BP is 118/72 mmHg. Booking blood tests show: haemoglobin 125 g/L, platelets 245 × 10⁹/L. She is rhesus D negative. Her partner's blood group is unknown. Which additional supplement should be recommended routinely from now until the end of the first trimester?

A. Vitamin D 10 micrograms daily only
B. Iron 200mg daily only
C. Increase folic acid to 5mg daily and add vitamin D 10 micrograms daily
D. Continue folic acid 400 micrograms daily and add vitamin D 10 micrograms daily (Correct Answer)
E. Vitamin B12 50 micrograms daily and vitamin D 10 micrograms daily

Explanation: ***Continue folic acid 400 micrograms daily and add vitamin D 10 micrograms daily*** - **Folic acid** at 400 micrograms daily is recommended for all low-risk women from pre-conception until **12 weeks gestation** to reduce the risk of **neural tube defects**. - **Vitamin D** at 10 micrograms (400 IU) daily is universally recommended for all pregnant and breastfeeding women throughout pregnancy to support **maternal and fetal bone health**. *Vitamin D 10 micrograms daily only* - This option is incomplete as the patient is only at **10 weeks gestation** and still requires **folic acid supplementation** until 12 weeks. - While **Vitamin D** is essential, continuing **folic acid** is a critical priority during the **first trimester** for neural tube development. *Iron 200mg daily only* - Routine **iron supplementation** is not indicated in pregnancy unless the woman has confirmed **anaemia** (Haemoglobin <110 g/L in the first trimester). - The patient's booking **haemoglobin (125 g/L)** is within the normal range, so iron supplementation is unnecessary and could cause side effects like constipation. *Increase folic acid to 5mg daily and add vitamin D 10 micrograms daily* - A higher dose of **folic acid (5mg)** is reserved for high-risk patients, such as those with a **BMI >30**, pre-existing **diabetes**, or a history of **neural tube defects**. - This patient has a healthy **BMI of 22 kg/m²** and no relevant medical history, meaning the standard 400 microgram dose is appropriate. *Vitamin B12 50 micrograms daily and vitamin D 10 micrograms daily* - Routine **Vitamin B12** supplementation is not part of standard antenatal guidelines for the general population. - It is typically only recommended for pregnant women who follow a **vegan diet** or have a known **Vitamin B12 deficiency**.

Question 187: A 37-year-old woman presents at 24 weeks gestation for her OGTT following a previous pregnancy complicated by gestational diabetes. Fasting glucose is 6.8 mmol/L and 2-hour value is 9.2 mmol/L. She is referred to the joint diabetes-antenatal clinic. At this first specialist appointment three days later, what is the most appropriate initial management strategy?

A. Trial of diet and exercise modifications with review in 1-2 weeks
B. Commence metformin immediately and arrange dietitian review
C. Commence insulin therapy immediately given high glucose values
D. Arrange for immediate dietitian consultation and commence self-monitoring, starting metformin if targets not met within one week (Correct Answer)
E. Repeat OGTT to confirm diagnosis before commencing treatment

Explanation: ***Arrange for immediate dietitian consultation and commence self-monitoring, starting metformin if targets not met within one week***- This approach aligns with guidelines for **gestational diabetes** where **fasting glucose** is between **5.6 and 6.9 mmol/L**. Initial management focuses on **medical nutrition therapy** (dietitian consultation) and empowering the patient through **self-monitoring of blood glucose**.- It also provides a clear **escalation plan**: if blood glucose targets are not met with lifestyle modifications within one week, **metformin** is the recommended first-line pharmacological agent.*Trial of diet and exercise modifications with review in 1-2 weeks*- While diet and exercise are crucial, this option is incomplete as it lacks the essential component of **self-monitoring of blood glucose (SMBG)**, which is vital to assess the efficacy of lifestyle changes.- It also doesn't specify a clear timeframe or the next steps (e.g., pharmacotherapy) if initial modifications are insufficient to meet glycemic targets.*Commence metformin immediately and arrange dietitian review*- Immediate pharmacological intervention with **metformin** is typically considered if the **fasting plasma glucose** is ** ≥ 7.0 mmol/L**, or if there are concerns like early evidence of **macrosomia**.- With a fasting glucose of **6.8 mmol/L**, there is still a window for a supervised trial of lifestyle modification before initiating medication, though prompt referral to a dietitian is critical.*Commence insulin therapy immediately given high glucose values*- **Insulin therapy** is usually reserved for cases where **metformin is contraindicated**, or when initial **metformin** and lifestyle interventions fail to achieve glycemic targets, or if **fasting glucose is ≥ 7.0 mmol/L** at diagnosis.- For a fasting value of **6.8 mmol/L**, metformin is generally the preferred initial pharmacological agent if lifestyle changes are inadequate.*Repeat OGTT to confirm diagnosis before commencing treatment*- The given **OGTT results** (fasting 6.8 mmol/L and 2-hour 9.2 mmol/L) already meet the diagnostic criteria for **gestational diabetes** (e.g., NICE criteria: fasting >5.6 mmol/L and/or 2-hour >7.8 mmol/L).- **Repeating the OGTT** would unnecessarily delay the initiation of crucial management, which could increase the risk of maternal and fetal complications associated with uncontrolled hyperglycemia.

Question 188: A 30-year-old woman is diagnosed with gestational hypertension at 32 weeks gestation with BP 142/92 mmHg. She is started on labetalol 100mg three times daily. At review one week later, her BP is 136/88 mmHg. She mentions feeling tired and occasionally dizzy on standing. Urinalysis remains negative for protein. What is the most appropriate adjustment to her management?

A. Continue current dose as BP is well controlled
B. Increase labetalol to 200mg three times daily to achieve better control
C. Reduce labetalol to 100mg twice daily (Correct Answer)
D. Switch from labetalol to nifedipine modified-release
E. Stop labetalol and monitor BP twice weekly

Explanation: ***Reduce labetalol to 100mg twice daily*** - The patient's symptoms of **tiredness and dizziness on standing** are highly suggestive of **postural hypotension**, indicating that the current dose of labetalol is likely too high. - While the clinic BP of 136/88 mmHg is well-controlled, it's crucial to prevent **over-treatment** which can compromise **uteroplacental perfusion**, making a dose reduction the safest next step. *Continue current dose as BP is well controlled* - Although the BP is near the target of **135/85 mmHg**, the presence of symptomatic side effects like **orthostatic hypotension** makes the current regimen inappropriate. - Ignoring these symptoms can lead to **falls** and potentially reduced **placental blood flow**, necessitating a dose adjustment. *Increase labetalol to 200mg three times daily to achieve better control* - Increasing the dose would exacerbate the patient's **hypotensive symptoms**, significantly increasing the risk of maternal discomfort and potential complications. - The current BP is already close to the therapeutic target for gestational hypertension, so an **escalation of therapy** is clinically unwarranted. *Switch from labetalol to nifedipine modified-release* - Switching medications is unnecessary as labetalol is a safe and effective agent, and the problem appears to be a **dose-related side effect** rather than a drug intolerance. - **Nifedipine** can also cause vasodilatory side effects like dizziness, and simply switching drugs might not resolve the underlying issue of **over-medication**. *Stop labetalol and monitor BP twice weekly* - Stopping the medication entirely risks a rebound of **gestational hypertension**, which can progress to **pre-eclampsia** if left uncontrolled. - Pharmacotherapy is still indicated to manage the patient's condition, with the goal of finding the **minimum effective dose** to maintain adequate BP control without adverse effects.

Question 189: A 35-year-old woman with diet-controlled gestational diabetes is reviewed at 36 weeks gestation. Serial growth scans show estimated fetal weight consistently on the 45th centile with normal liquor volume. Her glucose diary shows excellent control with all fasting values 4.5-5.1 mmol/L and post-prandial values 5.8-7.2 mmol/L. She specifically asks about the need for induction of labour, having read that women with gestational diabetes require earlier delivery. What is the most appropriate advice regarding timing of delivery?

A. Offer induction at 37-38 weeks due to gestational diabetes diagnosis
B. Offer induction at 38-39 weeks as this optimises outcomes in gestational diabetes
C. Offer induction at 39-40 weeks to reduce risk of stillbirth
D. Recommend awaiting spontaneous labour up to 40+6 weeks with standard monitoring (Correct Answer)
E. Recommend expectant management beyond 41 weeks given excellent glucose control

Explanation: ***Recommend awaiting spontaneous labour up to 40+6 weeks with standard monitoring*** - For women with **gestational diabetes (GDM)** controlled by **diet and exercise alone** with no other complications, **NICE guidelines** recommend elective birth should be offered by **40+6 weeks**. - This patient has **excellent glycaemic control**, normal fetal growth (45th centile), and normal liquor, making earlier intervention unnecessary and allowing for expectant management. *Offer induction at 37-38 weeks due to gestational diabetes diagnosis* - Induction at **37-38+6 weeks** is specifically recommended for women with GDM who require **medication** (insulin or oral hypoglycaemics) or have complications. - Routine early induction at this stage for **diet-controlled GDM** increases the risk of unnecessary obstetric intervention without clear evidence of benefit. *Offer induction at 38-39 weeks as this optimises outcomes in gestational diabetes* - While this window is often used for medically managed GDM, it is not the standard for **uncomplicated diet-controlled** cases. - In the absence of **macrosomia** or poor control, awaiting spontaneous labour up to 40+6 weeks is safe and supported by guidelines. *Offer induction at 39-40 weeks to reduce risk of stillbirth* - While the risk of **stillbirth** is a concern in GDM, women with excellent **dietary control** and normal fetal growth have a risk profile similar to the general population until 41 weeks. - Inducing before **40+6 weeks** in this specific scenario is not mandatory and should be based on maternal preference rather than routine protocol. *Recommend expectant management beyond 41 weeks given excellent glucose control* - Management beyond **40+6 weeks** is not recommended for GDM patients because the risk of **stillbirth** and placental insufficiency increases significantly after this point. - Even with **excellent glycaemic control**, the diagnosis of GDM warrants offering induction by the end of the 40th week to mitigate late-term risks.

Question 190: A 28-year-old woman presents to the antenatal day unit at 33 weeks gestation with reduced fetal movements. Cardiotocography is reassuring. Her BP is 148/96 mmHg (booking BP was 110/70 mmHg). Urinalysis shows protein 2+. Blood tests reveal: haemoglobin 118 g/L, platelets 145 × 10⁹/L, ALT 32 U/L, creatinine 68 μmol/L. Urine protein:creatinine ratio is 35 mg/mmol. She is asymptomatic. What is the most appropriate classification of her condition?

A. Mild pre-eclampsia (Correct Answer)
B. Moderate pre-eclampsia
C. Severe pre-eclampsia
D. Gestational hypertension with incidental proteinuria
E. Chronic hypertension with superimposed pre-eclampsia

Explanation: ***Mild pre-eclampsia*** - This patient has **new-onset hypertension** (BP 148/96 mmHg) after **20 weeks gestation** and **significant proteinuria** (Urine PCR 35 mg/mmol, which is ≥30 mg/mmol), fulfilling the primary diagnostic criteria for pre-eclampsia. - It is classified as **mild (non-severe)** because she is **asymptomatic**, her BP is below the **severe threshold** (160/110 mmHg), and her blood tests (platelets, ALT, creatinine) are within **normal ranges**, indicating no end-organ dysfunction. *Moderate pre-eclampsia* - This classification term, **"moderate pre-eclampsia"**, is **not standardly used** in many current clinical guidelines, which typically differentiate pre-eclampsia into **non-severe** and **severe** categories. - Management and intervention decisions are primarily guided by the presence or absence of **severe features**, rather than an intermediate

Question 191: What is the recommended target range for 1-hour post-prandial blood glucose in women with gestational diabetes according to NICE guidelines?

A. Less than 6.4 mmol/L
B. Less than 7.0 mmol/L
C. Less than 7.8 mmol/L (Correct Answer)
D. Less than 8.5 mmol/L
E. Less than 9.0 mmol/L

Explanation: ***Less than 7.8 mmol/L***- According to **NICE guidelines (NG3)**, the recommended target for blood glucose measured **1 hour** after a meal in women with **gestational diabetes** is below **7.8 mmol/L**.- Achieving this target significantly helps to reduce the risk of **fetal macrosomia** and other adverse neonatal outcomes linked to maternal hyperglycemia.*Less than 6.4 mmol/L*- This value represents the **2-hour post-prandial** blood glucose target, not the **1-hour** target, for women with gestational diabetes according to NICE.- Applying this stricter threshold for a 1-hour measurement would be overly aggressive and could increase the risk of maternal **hypoglycemia**.*Less than 7.0 mmol/L*- This is not a specific **NICE target** for **1-hour post-prandial** glucose in gestational diabetes management.- While **7.0 mmol/L** is a fasting plasma glucose threshold for diagnosing diabetes, it is not relevant for post-meal monitoring in this context.*Less than 8.5 mmol/L*- This target is too high and exceeds the evidence-based recommendations by **NICE** for optimal glycemic control in gestational diabetes.- Blood glucose levels consistently at or above this level **1 hour post-prandially** are associated with an increased risk of **large-for-gestational-age (LGA)** infants and other complications.*Less than 9.0 mmol/L*- This value is well above any acceptable clinical target for **1-hour post-prandial** glucose in the management of gestational diabetes.- Such high glucose levels significantly elevate the risk of severe complications, including **polyhydramnios**, fetal distress, and increased need for obstetric interventions.

Question 192: A 41-year-old woman attends for combined screening at 12 weeks gestation in her fourth pregnancy. She has had three previous term deliveries with no complications. Her BMI is 28 kg/m² and she has no medical conditions. Blood tests show her HbA1c is 42 mmol/mol (6.0%). Which single investigation or management is most appropriate based on her age alone?

A. Oral glucose tolerance test at 24-28 weeks
B. Repeat HbA1c at 16 weeks to exclude pre-existing diabetes
C. Offer referral for diagnostic testing with chorionic villus sampling (Correct Answer)
D. Commence aspirin 150mg daily from 12 weeks
E. Arrange detailed anomaly scan at 16 weeks instead of routine 20-week scan

Explanation: ***Offer referral for diagnostic testing with chorionic villus sampling*** - At 41 years old, the patient's **advanced maternal age** significantly increases the baseline risk for **chromosomal abnormalities** such as **Trisomy 21** (Down syndrome). - Combined screening only provides a risk assessment; offering **diagnostic testing** like **CVS** (typically performed between 11-14 weeks) provides a definitive diagnosis based on this elevated age-related risk. *Oral glucose tolerance test at 24-28 weeks* - While advanced maternal age is a risk factor for **gestational diabetes (GDM)**, screening with an **OGTT** is typically performed later in pregnancy, specifically between **24 and 28 weeks**. - The immediate and most critical concern at 12 weeks gestation, specifically considering her age, is the elevated risk of **fetal aneuploidy**. *Repeat HbA1c at 16 weeks to exclude pre-existing diabetes* - An HbA1c of 42 mmol/mol (6.0%) in early pregnancy is considered to be in the **non-diabetic range** (the diagnostic threshold for diabetes outside pregnancy is 48 mmol/mol). - Repeating HbA1c at 16 weeks is not a standard protocol for diagnosing or excluding **pre-existing diabetes** based on this initial value, and an earlier **OGTT** would be performed if there were strong concerns. *Commence aspirin 150mg daily from 12 weeks* - Maternal age of **40 years or older** is classified as a **moderate risk factor** for **pre-eclampsia** according to current guidelines (e.g., NICE). - **Aspirin prophylaxis** (150mg daily) is typically recommended for individuals with one high-risk factor or **two or more moderate risk factors**, and this patient only has one moderate risk factor. *Arrange detailed anomaly scan at 16 weeks instead of routine 20-week scan* - The routine **mid-pregnancy anomaly scan** is generally performed between **18 and 20+6 weeks of gestation** to allow for optimal visualization of fetal structures. - Advancing the scan to 16 weeks is not standard practice based on maternal age alone, although earlier targeted scans might be considered for specific indications like very high risk of **cardiac anomalies**.

Question 193: A 24-year-old primigravida attends her booking appointment at 9 weeks gestation. She mentions that her sister developed pre-eclampsia in her first pregnancy requiring early delivery at 34 weeks. She asks about her own risk and whether anything can be done to reduce it. Her booking BP is 112/68 mmHg, BMI is 23 kg/m², and she has no other medical history. What is the most appropriate advice?

A. She has a moderate risk factor; commence aspirin 150mg daily from 12 weeks (Correct Answer)
B. She has a high risk factor; commence aspirin 75mg daily now and calcium supplementation
C. She has no significant risk factors; reassure and arrange routine antenatal care
D. She has a moderate risk factor; arrange more frequent BP monitoring from 20 weeks
E. Commence aspirin 150mg daily now and continue until delivery

Explanation: ***She has a moderate risk factor; commence aspirin 150mg daily from 12 weeks***- According to **NICE guidelines**, patients with **two or more moderate risk factors** require aspirin prophylaxis; this patient is a **primigravida** and has a **family history of pre-eclampsia** (sister). - The recommended dose is **150mg aspirin daily**, starting from **12 weeks gestation** until birth to effectively reduce the risk of developing pre-eclampsia. *She has a high risk factor; commence aspirin 75mg daily now and calcium supplementation* - **High-risk factors** include chronic hypertension, CKD, or autoimmune diseases, none of which this patient possesses. - Current guidelines recommend a higher dose of **150mg aspirin** rather than 75mg, and **calcium supplementation** is only indicated if dietary intake is deficient. *She has no significant risk factors; reassure and arrange routine antenatal care* - This is incorrect because the patient has two **moderate risk factors** (nulliparity and family history in a first-degree relative). - Failing to prescribe **aspirin prophylaxis** in this scenario misses an evidence-based opportunity to prevent serious maternal and fetal complications. *She has a moderate risk factor; arrange more frequent BP monitoring from 20 weeks* - While monitoring is essential, it is a diagnostic step and does not serve as a **preventative intervention** like aspirin does. - Guidelines emphasize **chemoprophylaxis with aspirin** for women with two moderate risk factors to improve placentation early in pregnancy. *Commence aspirin 150mg daily now and continue until delivery* - Although the dose is correct, **aspirin prophylaxis** is typically advised to begin at **12 weeks gestation**, and she is currently only at 9 weeks. - Starting before 12 weeks is not the standard protocol for pre-eclampsia prevention as the most critical period for **trophoblast invasion** modulation begins later.

Question 194: A 36-year-old woman with gestational diabetes on insulin therapy attends for growth scan at 38 weeks gestation. The estimated fetal weight is on the 92nd centile and amniotic fluid index is raised at 26 cm. Her diabetes has been well controlled with most glucose readings within target. She had a previous spontaneous vaginal delivery of a 3.6 kg baby at term. What is the most appropriate counselling regarding mode of delivery?

A. Offer induction of labour at 39 weeks with caesarean section if labour fails to progress
B. Recommend elective caesarean section due to suspected fetal macrosomia
C. Offer induction of labour at 38 weeks given the current gestation (Correct Answer)
D. Recommend awaiting spontaneous labour up to 40 weeks with continuous glucose monitoring
E. Recommend elective caesarean section only if estimated fetal weight exceeds 4.5 kg

Explanation: ***Offer induction of labour at 38 weeks given the current gestation***- For women with **gestational diabetes** requiring **insulin**, NICE guidelines recommend offering elective birth (induction or caesarean) between **37+0 and 38+6 weeks**.- Despite good glycaemic control, the **92nd centile weight** and **polyhydramnios** (AFI 26 cm) suggest fetal markers of diabetes complications, making immediate induction at 38 weeks appropriate.*Offer induction of labour at 39 weeks with caesarean section if labour fails to progress*- While **39 weeks** is acceptable for some, this patient is already at 38 weeks with evidence of **macrosomia** and polyhydramnios, necessitating earlier intervention.- Modern guidelines emphasize that those on pharmacological treatment should be offered delivery by the end of the **38th week**.*Recommend elective caesarean section due to suspected fetal macrosomia*- Suspected **fetal macrosomia** alone is not an absolute indication for **caesarean section** in diabetic patients unless the estimated weight is significantly higher.- This patient has a history of a successful **previous vaginal delivery**, increasing the likelihood of a successful induction and vaginal birth.*Recommend awaiting spontaneous labour up to 40 weeks with continuous glucose monitoring*- Waiting until **40 weeks** is generally reserved for diet-controlled gestational diabetes without fetal complications; it is not recommended for those on **insulin**.- Delaying delivery in insulin-dependent patients increases the risk of **stillbirth** and complications like **shoulder dystocia** due to ongoing fetal growth.*Recommend elective caesarean section only if estimated fetal weight exceeds 4.5 kg*- While a threshold of **4.5 kg** is often used to discuss the risks of vaginal birth in diabetes, it does not preclude the offer of **induction of labour** at an earlier gestation.- This option ignores the need for timed delivery (37-38 weeks) based on **insulin therapy** and current fetal ultrasound findings.

Question 195: A 33-year-old woman is admitted at 37 weeks gestation with severe pre-eclampsia. Her BP is 162/108 mmHg despite labetalol 200mg three times daily. Blood tests show: platelet count 78 × 10⁹/L, ALT 145 U/L, AST 178 U/L, creatinine 125 μmol/L. She complains of severe right upper quadrant pain and has generalised oedema. She has had one previous uncomplicated pregnancy. What is the single most important immediate management priority?

A. Administer magnesium sulphate and plan delivery within 24-48 hours (Correct Answer)
B. Increase labetalol dose and recheck blood pressure in 30 minutes
C. Arrange urgent CT scan of abdomen to exclude hepatic rupture
D. Administer intravenous hydralazine and commence fluid restriction
E. Give platelet transfusion to correct thrombocytopenia before any intervention

Explanation: ***Administer magnesium sulphate and plan delivery within 24-48 hours*** - This patient exhibits signs of **HELLP syndrome** (low platelets, elevated liver enzymes, RUQ pain) and severe pre-eclampsia at **37 weeks gestation**, where the definitive treatment is delivery. - **Magnesium sulphate** is the mandatory immediate priority for **seizure prophylaxis** (eclampsia prevention) in patients with severe pre-eclampsia, especially with features like RUQ pain indicating liver involvement. *Increase labetalol dose and recheck blood pressure in 30 minutes* - While blood pressure control is necessary, simply adjusting oral medications is insufficient for a patient with **multi-organ dysfunction** and term pregnancy complicated by severe pre-eclampsia/HELLP syndrome. - **Delivery** is the only cure for pre-eclampsia/HELLP; delaying the decision to deliver increases the risk of maternal and fetal complications, and this option does not address seizure risk. *Arrange urgent CT scan of abdomen to exclude hepatic rupture* - Although severe right upper quadrant pain can indicate **subcapsular hepatic hematoma**, a CT scan is not the first priority unless there is acute **hemodynamic instability** or suspicion of rupture. - Management of the underlying severe pre-eclampsia and stabilization with **magnesium sulphate** takes precedence over non-essential or delayed imaging. *Administer intravenous hydralazine and commence fluid restriction* - **Hydralazine** is an option for acute hypertensive crises, but the patient's current BP (162/108) requires management in the context of broader HELLP syndrome, not as the single most important immediate priority. - **Fluid restriction** is important to prevent pulmonary edema in pre-eclampsia, but it is a supportive measure, not the primary, most urgent management priority for a patient at risk of seizures and requiring delivery. *Give platelet transfusion to correct thrombocytopenia before any intervention* - Platelet transfusion is generally reserved for counts **<20 × 10⁹/L** or if there is active bleeding/impending surgery with counts below 50 × 10⁹/L. - A platelet count of **78 × 10⁹/L** does not require immediate transfusion and should not delay the administration of **magnesium sulphate** or delivery planning, which are more critical for maternal safety.

Question 196: A 29-year-old nulliparous woman is reviewed at 34 weeks gestation. She has diet-controlled gestational diabetes diagnosed at 28 weeks. Her fasting glucose values over the past 2 weeks have ranged from 5.0-5.4 mmol/L and post-prandial values from 6.8-7.8 mmol/L. Ultrasound scan today shows estimated fetal weight on 75th centile with amniotic fluid index within normal limits. What is the most appropriate management of her glycaemic control?

A. Continue with diet control only
B. Commence metformin (Correct Answer)
C. Commence insulin therapy
D. Commence metformin and insulin in combination
E. Recheck fasting and post-prandial glucose in one week

Explanation: ***Commence metformin*** - NICE guidelines recommend pharmacological intervention if **glucose targets** (fasting <5.3 mmol/L and 1-hour post-prandial <7.8 mmol/L) are not met through diet and exercise within 1–2 weeks. - This patient's post-prandial readings (6.8-7.8 mmol/L) are consistently at the upper limit or **exceeding the target**, making **metformin** the first-line oral hypoglycemic agent to initiate when diet fails. *Continue with diet control only* - Diet control has already been attempted for two weeks, and glucose levels remain above the recommended **NICE targets**, indicating a need for escalation. - Delaying treatment increases the risk of **macrosomia**, **neonatal hypoglycemia**, and other gestational complications, even if the current fetal weight is on the 75th centile. *Commence insulin therapy* - **Insulin** is usually reserved as first-line if the fasting glucose is >7.0 mmol/L at diagnosis or if there is evidence of **fetal macrosomia** or polyhydramnios requiring urgent control. - In this case, the patient is currently on diet control alone and has not yet failed a trial of **metformin**, which is the preferred initial medication for mild elevations. *Commence metformin and insulin in combination* - Combination therapy is typically indicated only if **metformin monotherapy** fails to achieve adequate glycemic control or if blood glucose is severely elevated at presentation. - Starting both simultaneously is premature given the current blood glucose values are only **marginally above target** and fetal growth is within normal limits for now. *Recheck fasting and post-prandial glucose in one week* - Monitoring without intervention is inappropriate because the current data already demonstrates that **dietary modifications** have failed to meet targets over two weeks. - NICE recommends moving to pharmacological therapy promptly to achieve **euglycemia** rather than continuing a failed management strategy and risking complications.

Question 197: A 32-year-old woman in her second pregnancy attends the community midwife at 22 weeks gestation for a routine antenatal appointment. Her blood pressure is 138/88 mmHg. Her booking BP at 10 weeks was 118/72 mmHg. Urinalysis shows no proteinuria. She is asymptomatic with no visual symptoms or epigastric pain. Blood tests show normal renal function and normal platelet count. What is the most appropriate initial management?

A. Start labetalol and review in one week
B. Arrange blood pressure monitoring twice weekly and review if BP ≥140/90 mmHg (Correct Answer)
C. Admit for further assessment and monitoring
D. Reassure and continue routine antenatal care
E. Request 24-hour urine collection for protein quantification

Explanation: ***Arrange blood pressure monitoring twice weekly and review if BP 140/90 mmHg*** - This patient has a significant rise in **blood pressure** after 20 weeks gestation, currently at **138/88 mmHg**, which requires increased surveillance to detect **gestational hypertension** or **pre-eclampsia**. - Per guidelines, while this level does not yet meet the **140/90 mmHg threshold** for pharmacological treatment, **monitoring twice weekly** is the appropriate step to ensure early intervention if pressures rise further. *Start labetalol and review in one week* - Antihypertensive treatment like **labetalol** is typically initiated when blood pressure consistently exceeds **140/90 mmHg** in pregnancy. - Starting medication prematurely without meeting the threshold or having evidence of **end-organ damage** is not recommended for mild elevations below 140/90 mmHg. *Admit for further assessment and monitoring* - **Admission** is generally reserved for patients with **severe hypertension** ( 160/110 mmHg) or those showing symptoms of **pre-eclampsia**. - Since the patient is **asymptomatic**, has **no proteinuria**, and normal lab results, outpatient management is considered safe and appropriate. *Reassure and continue routine antenatal care* - Routine care is insufficient because the patient has developed a meaningful increase from her **booking BP (118/72 mmHg)** after the 20-week mark. - Ignoring this trend risks missing the progression to **pre-eclampsia**, which carries significant maternal and **fetal risks**. *Request 24-hour urine collection for protein quantification* - Protein quantification (via **PCR** or 24-hour collection) is only indicated if **urinalysis** shows 1+ or more of protein on a dipstick. - As this patient ’s urinalysis showed **no proteinuria**, there is no current indication to perform more invasive or time-consuming protein testing.

Question 198: A 27-year-old woman attends for antenatal booking at 8 weeks gestation. She has a BMI of 34 kg/m². Her past medical history includes polycystic ovary syndrome. Her mother was diagnosed with type 2 diabetes aged 48 years. She had a previous baby weighing 4.2 kg at term. What is the most appropriate timing for her first oral glucose tolerance test (OGTT)?

A. Now at booking (Correct Answer)
B. At 16 weeks gestation
C. At 20 weeks gestation
D. At 24-28 weeks gestation
E. Only if symptomatic

Explanation: ***Now at booking***- This patient presents with multiple significant risk factors for **gestational diabetes (GDM)** or undiagnosed pre-existing diabetes, including a **BMI of 34 kg/m² (obesity)**, **polycystic ovary syndrome (PCOS)**, a **first-degree relative with type 2 diabetes**, and a history of a **macrosomic baby (4.2 kg)**.- **NICE guidelines** and other major recommendations advise offering an **oral glucose tolerance test (OGTT)** as early as possible after booking (ideally at 8-12 weeks) for women with such a high-risk profile, to allow for prompt diagnosis and management.*At 16 weeks gestation*- While some guidelines might consider screening at 16-18 weeks for certain elevated risks, for a patient with this many and severe risk factors, waiting until 16 weeks would unduly delay critical early diagnosis and intervention.- The aim is to identify **hyperglycemia** as soon as possible in pregnancy to mitigate associated risks, making an earlier test at booking more appropriate.*At 20 weeks gestation*- This timing does not align with established **GDM screening protocols**, which typically recommend either early screening at booking or later in the second trimester (24-28 weeks).- Delaying the initial test to 20 weeks in a high-risk individual could lead to prolonged exposure of the fetus to **hyperglycemia**, potentially increasing the risks of complications such as **fetal macrosomia** and pre-eclampsia.*At 24-28 weeks gestation*- This is the standard timing for **routine OGTT screening** for women who have at least one risk factor (e.g., BMI >30 or family history), but who do not have the cumulative high-risk profile requiring earlier intervention.- For this patient, while a repeat OGTT might be performed at 24-28 weeks if the initial booking test is negative, the **first OGTT** should be conducted much earlier due to her substantial risk factors.*Only if symptomatic*- **Gestational diabetes** is frequently **asymptomatic**, meaning many women with the condition do not experience noticeable symptoms.- Relying solely on symptoms for diagnosis is an ineffective and dangerous approach that would lead to missed cases, delaying necessary management and increasing the risk of **maternal and fetal complications**, including **macrosomia**.

Question 199: A 30-year-old woman books for antenatal care at 9 weeks gestation. She was born in Vietnam and immigrated to the UK 5 years ago. She has had no previous pregnancies. She is unsure of her vaccination history. According to current UK antenatal screening guidelines, which infection screening should be offered at the booking appointment?

A. HIV, hepatitis B, hepatitis C, and syphilis
B. HIV, hepatitis B, rubella immunity, and syphilis (Correct Answer)
C. HIV, hepatitis B, syphilis, and toxoplasmosis
D. HIV, hepatitis B, syphilis, and cytomegalovirus
E. HIV, hepatitis B, rubella immunity, syphilis, and varicella immunity

Explanation: ***HIV, hepatitis B, rubella immunity, and syphilis*** - According to **UK National Screening Committee (NSC)** and **NICE** guidelines, these four conditions comprise the standard infectious disease screening offered at the **booking appointment**. - Screening facilitates interventions to prevent **mother-to-child transmission** for HIV, Hep B, and syphilis, and identifies the need for **postnatal MMR vaccination** for rubella susceptibility. *HIV, hepatitis B, hepatitis C, and syphilis* - **Hepatitis C** is not currently part of the routine universal antenatal screening programme in the UK. - It is typically only offered to women identified as having **high-risk factors**, rather than being a standard booking test for all. *HIV, hepatitis B, syphilis, and toxoplasmosis* - **Toxoplasmosis** screening is not recommended in the UK as there is a lack of evidence that routine screening/treatment improves outcomes. - Prevention focuses on **hygiene advice** regarding cat litter and undercooked meat rather than blood tests at booking. *HIV, hepatitis B, syphilis, and cytomegalovirus* - **Cytomegalovirus (CMV)** screening is not part of the standard UK antenatal panel because there is no established vaccine or proven treatment to prevent fetal infection. - Professional bodies emphasize **hand hygiene** and avoiding sharing food/utensils with young children to reduce risk instead. *HIV, hepatitis B, rubella immunity, syphilis, and varicella immunity* - Routine screening for **varicella (chickenpox) immunity** is not standard practice for every pregnant woman at the booking visit. - Testing for varicella antibodies is usually reserved for women with no clear history of infection who have a **significant exposure** during pregnancy.

Question 200: A 32-year-old woman at 30 weeks gestation presents with BP 144/94 mmHg. She is asymptomatic. Urine PCR is 18 mg/mmol. Blood tests show: platelets 210 × 10⁹/L, ALT 32 U/L, creatinine 62 µmol/L. She is commenced on labetalol. At 34 weeks, her BP remains 142/92 mmHg on labetalol 200 mg TDS, but all other parameters remain normal. What is the optimal timing for delivery?

A. Immediate delivery at 34 weeks
B. 37 weeks gestation (Correct Answer)
C. 38 weeks gestation
D. 39 weeks gestation
E. Await spontaneous labour up to 40 weeks

Explanation: ***37 weeks gestation***- This patient has **gestational hypertension** as evidenced by blood pressure ≥ 140/90 mmHg after 20 weeks gestation, without significant **proteinuria** (PCR 18 mg/mmol is below the 30 mg/mmol threshold for pre-eclampsia) or end-organ dysfunction.- Current guidelines, such as NICE, recommend planned delivery at **37+0 weeks** for gestational hypertension to reduce the risk of maternal complications without increasing neonatal morbidity.*Immediate delivery at 34 weeks*- This aggressive approach is typically indicated for **severe pre-eclampsia**, HELLP syndrome, or fetal distress, none of which are present in this stable, asymptomatic patient.- Delivering at 34 weeks would result in unnecessary **iatrogenic prematurity** and its associated neonatal health risks.*38 weeks gestation*- Delaying delivery until 38 weeks in a patient with gestational hypertension who is on medication increases the risk of developing **pre-eclampsia** or other severe hypertensive complications.- The evidence-based optimal timing for delivery in stable gestational hypertension to balance maternal and neonatal outcomes is specifically at **37 weeks**.*39 weeks gestation*- Expectant management until 39 weeks is generally reserved for women with very mild gestational hypertension, often without the need for pharmacological intervention.- As this woman requires **labetalol** to manage her blood pressure, delaying delivery beyond 37 weeks increases the risk of worsening maternal condition without significant fetal benefit.*Await spontaneous labour up to 40 weeks*- Allowing a pregnancy complicated by gestational hypertension, especially when medicated, to proceed to **40 weeks** or beyond significantly increases the risk of serious adverse outcomes.- These risks include an elevated chance of **placental abruption**, severe pre-eclampsia, and stillbirth, making planned delivery the safer option.

Question 201: A 39-year-old woman with pre-existing type 2 diabetes is reviewed at 8 weeks gestation. Her medications include metformin 1g BD and gliclazide 80 mg BD. HbA1c is 58 mmol/mol. She is taking folic acid 5 mg daily. What is the most important medication change required?

A. Stop metformin and commence insulin
B. Stop gliclazide and commence insulin (Correct Answer)
C. Continue current medications and recheck HbA1c in 4 weeks
D. Stop both oral agents and commence insulin
E. Increase gliclazide dose to improve control

Explanation: ***Stop gliclazide and commence insulin*** - **Gliclazide** (a sulfonylurea) is contraindicated in pregnancy due to the risk of **neonatal hypoglycemia** and potential **teratogenicity**, making its discontinuation essential. - **Insulin** is the first-line pharmacotherapy for diabetes in pregnancy when glycemic targets (HbA1c <48 mmol/mol) are not met, as it effectively controls blood glucose and **does not cross the placenta**, ensuring fetal safety. *Stop metformin and commence insulin* - **Metformin** is generally considered safe and can be continued in pregnancy for women with type 2 diabetes, helping to manage **glycemic control** and potentially reducing insulin requirements. - Unnecessarily stopping metformin would remove a beneficial agent and could lead to higher **insulin doses** or poorer control. *Continue current medications and recheck HbA1c in 4 weeks* - An **HbA1c of 58 mmol/mol** (approximately 7.5%) is well above the recommended target for pregnancy (typically <48 mmol/mol or 6.5%) and requires immediate intervention to reduce risks of **fetal malformations** and **macrosomia**. - Continuing **gliclazide** in pregnancy is unsafe due to the risk of **neonatal hypoglycemia** and should be stopped immediately, not continued. *Stop both oral agents and commence insulin* - While stopping gliclazide is correct, **metformin** can generally be continued in pregnancy, as it is considered safe and may provide benefits in glycemic control and **weight management**. - The optimal approach often involves continuing metformin while initiating or intensifying **insulin therapy** to achieve tight glycemic control. *Increase gliclazide dose to improve control* - Increasing the dose of **gliclazide** (a sulfonylurea) is contraindicated in pregnancy due to significant risks of **fetal hyperinsulinemia** and **neonatal hypoglycemia**. - For inadequate glycemic control during pregnancy, the appropriate action is to initiate or increase **insulin therapy**, not to adjust potentially harmful oral agents.

Question 202: A 26-year-old primigravida at 36 weeks gestation with gestational diabetes controlled on insulin presents with reduced fetal movements for 8 hours. CTG shows baseline rate 145 bpm with normal variability, no accelerations, and no decelerations. What is the most appropriate management?

A. Reassure and discharge home with advice to monitor movements
B. Repeat CTG in 4 hours
C. Perform vibroacoustic stimulation and continue CTG (Correct Answer)
D. Arrange immediate delivery by caesarean section
E. Admit for twice-daily CTG monitoring

Explanation: ***Perform vibroacoustic stimulation and continue CTG*** - The absence of accelerations on CTG indicates a **non-reactive trace**, which may be caused by a **fetal sleep cycle** (usually lasting 20-40 minutes) or fetal compromise, especially in a high-risk pregnancy with **gestational diabetes**. - **Vibroacoustic stimulation (VAS)** is the next step to provoke fetal movement and accelerations, aiming to confirm fetal well-being before more invasive interventions are considered. *Reassure and discharge home with advice to monitor movements* - Discharging the patient is inappropriate because a **non-reactive CTG** in the context of **reduced fetal movements** and high-risk **gestational diabetes (GDM) on insulin** requires further evaluation. - Guidelines mandate that fetal well-being must be confirmed via a **reactive trace** or ultrasound before the patient can safely be sent home. *Repeat CTG in 4 hours* - Delaying the assessment for 4 hours is unsafe in a high-risk pregnancy with potentially compromised fetal status; the **fetal sleep cycle** should be addressed immediately. - Management should be active, using **fetal acoustic stimulation** or prolonged monitoring to ensure the trace becomes reactive within 40-60 minutes. *Arrange immediate delivery by caesarean section* - Immediate delivery is not indicated when the CTG shows **normal baseline variability** and no decelerations, as these findings suggest the fetus is not in acute distress. - **Caesarean section** carries significant maternal-fetal risks and should only be performed if there is definitive evidence of **fetal distress** or after failed conservative measures. *Admit for twice-daily CTG monitoring* - Admission for twice-daily monitoring is not indicated until a definitive diagnosis or assessment of the **current episode** of reduced fetal movements is completed. - The immediate priority is to convert the **non-reactive CTG** into a reactive one or proceed to a **biophysical profile** or Doppler studies to determine if delivery is necessary.

Question 203: A 35-year-old woman at 18 weeks gestation is found to have BP 158/102 mmHg at routine antenatal appointment. Review of her notes shows BP was 154/98 mmHg at booking at 8 weeks. She has no symptoms. Urine dipstick is negative for protein. Blood tests are normal. What is the most accurate diagnosis?

A. Chronic hypertension (Correct Answer)
B. Gestational hypertension
C. Pre-eclampsia
D. White coat hypertension
E. Pregnancy-induced hypertension

Explanation: ***Chronic hypertension*** - Defined as hypertension present **before 20 weeks gestation** or pre-dating the pregnancy; this patient had elevated BP at her **8-week booking** appointment. - Since the blood pressure remains elevated at 18 weeks without **proteinuria**, it confirms a baseline hypertensive state rather than a pregnancy-specific onset. *Gestational hypertension* - This diagnosis refers to new-onset hypertension occurring **after 20 weeks gestation** in a previously normotensive woman. - It is excluded here because the patient's records specifically document high blood pressure at the **8-week mark**. *Pre-eclampsia* - Characterized by new hypertension after 20 weeks combined with significant **proteinuria** or maternal **organ dysfunction**. - The absence of protein on a **urine dipstick** and normal blood tests at 18 weeks rule out this condition for the current presentation. *White coat hypertension* - Refers to elevated BP readings only in clinical settings, with normal readings at home or via **ambulatory monitoring**. - While possible, the consistent elevation at **different time points** (8 and 18 weeks) strongly points toward established **chronic hypertension** as the accurate diagnosis. *Pregnancy-induced hypertension* - This is an umbrella term often used interchangeably with **gestational hypertension**, occurring late in the second or third trimester. - It does not apply to hypertension that is present at **booking** or during the first trimester of pregnancy.

Question 204: A 40-year-old woman is diagnosed with gestational diabetes at 26 weeks following an oral glucose tolerance test with fasting glucose of 5.8 mmol/L and 2-hour glucose of 9.1 mmol/L. She has been referred to the diabetes in pregnancy clinic. Which additional antenatal intervention is specifically recommended due to her gestational diabetes diagnosis?

A. Growth scans every 2 weeks from diagnosis
B. Growth scans at 28, 32, and 36 weeks gestation
C. Additional ultrasound scan at 28 weeks and then every 4 weeks (Correct Answer)
D. Weekly biophysical profile from 32 weeks
E. Twice-weekly cardiotocography from 28 weeks

Explanation: ***Additional ultrasound scan at 28 weeks and then every 4 weeks***- For women with **gestational diabetes (GDM)**, ultrasound monitoring for **fetal growth** and **amniotic fluid volume** is specifically recommended at **28, 32, and 36 weeks**.- This intervention aims to detect **macrosomia** and **polyhydramnios**, which are indicators of fetal hyperinsulinemia and suboptimal **glycemic control**.*Growth scans every 2 weeks from diagnosis*- Monitoring every 2 weeks is not routine practice for GDM as it is **excessive** and does not provide additional evidence-based clinical benefit over standard 4-week intervals.- Frequent scans are generally reserved for high-risk cases of **fetal growth restriction (FGR)** or specific maternal complications.*Growth scans at 28, 32, and 36 weeks gestation*- While the schedule of 28, 32, and 36 weeks is correct, the standard description of this protocol in clinical guidelines is often framed as an **additional scan at 28 weeks** followed by **4-weekly monitoring**.- This distinguishes the specific GDM monitoring pathway from regular antenatal care which lacks serial late-trimester growth assessments.*Weekly biophysical profile from 32 weeks*- **Biophysical profiles** are not routinely indicated for GDM unless there are specific concerns regarding **fetal wellbeing** or significant maternal complications.- Routine growth scans are preferred as they specifically monitor for the complications most typical of diabetes, such as **asymmetric macrosomia**.*Twice-weekly cardiotocography from 28 weeks*- Routine **cardiotocography (CTG)** is not recommended for GDM unless there are clinical indications like reduced fetal movements or poor glucose control.- Starting **twice-weekly CTG** from 28 weeks is not supported by guidelines, as fetal monitoring usually intensifies closer to the **delivery date** if treatment (insulin) is required.

Question 205: A 31-year-old woman attends her dating scan which confirms she is at 13 weeks gestation. Combined screening shows: nuchal translucency 2.1 mm, PAPP-A 0.4 MoM, beta-hCG 1.8 MoM, giving a risk of 1:85 for trisomy 21. She declines invasive testing but asks about additional screening. What should be offered?

A. Non-invasive prenatal testing (NIPT) (Correct Answer)
B. Repeat combined screening at 16 weeks
C. Quadruple test at 16 weeks
D. Detailed anomaly scan at 20 weeks only
E. Amniocentesis despite her declining invasive testing

Explanation: ***Non-invasive prenatal testing (NIPT)*** - **NIPT** is the most appropriate next step for women with a **high-risk (≥1:150)** result from initial screening who decline immediate invasive procedures. - It analyzes **cell-free fetal DNA** in the mother's blood, offering a detection rate of over **99% for trisomy 21** with a very low false-positive rate. *Repeat combined screening at 16 weeks* - **Combined screening** is only valid between **11 weeks 2 days and 14 weeks 1 day** of gestation and is not repeated later in pregnancy. - Repeating the same screening test does not narrow the risk and delays further diagnostic or screening clarity. *Quadruple test at 16 weeks* - The **quadruple test** is an alternative second-trimester screening for trisomy 21 used only when **combined screening** was missed or technically impossible. - It is less accurate than the combined test and is not intended to be used as a follow-up for a **high-risk** result already obtained. *Detailed anomaly scan at 20 weeks only* - While the **middle-trimester scan** is routine for structural anomalies, it is not a primary screening tool for **trisomy 21** and cannot confirm chromosomal status. - Relying solely on this scan would ignore the current **high-risk result** of 1:85 and miss the window for earlier definitive information. *Amniocentesis despite her declining invasive testing* - **Amniocentesis** and Chorionic Villus Sampling (CVS) are diagnostic procedures that carry a risk of **miscarriage**, and patient autonomy must be respected. - Performing an **invasive procedure** against the woman's expressed wishes violates the fundamental medical principle of **informed consent**.

Question 206: A 28-year-old woman presents at 32 weeks gestation with BP 168/112 mmHg, headache, and visual disturbances. Urine PCR is 180 mg/mmol. Blood tests show: platelets 88 × 10⁹/L, ALT 245 U/L, creatinine 142 µmol/L. She is commenced on intravenous magnesium sulphate and labetalol. After 6 hours, she develops absent tendon reflexes and respiratory rate of 8 breaths per minute. What is the immediate management?

A. Stop magnesium sulphate and give intravenous calcium gluconate 10 mL of 10% solution (Correct Answer)
B. Reduce magnesium sulphate infusion rate by half
C. Give intravenous furosemide 40 mg
D. Arrange immediate dialysis
E. Intubate and ventilate

Explanation: ***Stop magnesium sulphate and give intravenous calcium gluconate 10 mL of 10% solution***- The patient exhibits clear signs of **magnesium toxicity**, characterized by **absent tendon reflexes** (indicates serum magnesium levels typically >4 mmol/L) and severe **respiratory depression** (respiratory rate of 8 breaths per minute, indicates serum magnesium levels typically >5 mmol/L).- **Calcium gluconate** is the specific antidote that directly antagonizes the neuromuscular effects of magnesium; it must be administered slowly and is the immediate life-saving intervention alongside cessation of the magnesium infusion.*Reduce magnesium sulphate infusion rate by half*- Reducing the infusion rate is insufficient for **acute, severe magnesium toxicity** presenting with life-threatening respiratory depression and must be stopped entirely.- The patient's elevated **creatinine** indicates impaired renal clearance, which increases the risk of rapid magnesium accumulation, necessitating complete cessation rather than just reduction.*Give intravenous furosemide 40 mg*- While **loop diuretics** like furosemide can increase renal excretion of magnesium, they act too slowly to manage emergency **respiratory depression**.- Diuretics may also worsen the intravascular volume depletion often seen in **severe pre-eclampsia**, and are not the first-line antidote for acute toxicity.*Arrange immediate dialysis*- **Hemodialysis** is an effective way to remove magnesium but is reserved for severe toxicity cases, especially those with **oliguric renal failure** or refractory symptoms that do not respond to calcium gluconate.- It is not the immediate first-line treatment and would take too long to initiate in a patient with acute **respiratory depression**.*Intubate and ventilate*- **Airway management** and ventilatory support may be necessary if the patient progresses to respiratory arrest, but it is a supportive measure, not the primary treatment for the underlying metabolic cause.- The immediate priority is the administration of the **pharmacological antagonist (calcium gluconate)** to reverse the neuromuscular blockade induced by magnesium.

Question 207: A 37-year-old woman with gestational diabetes at 34 weeks gestation has growth scans showing estimated fetal weight on 95th centile with abdominal circumference on 97th centile. She has been managing with diet alone. Fasting glucose is 5.8 mmol/L and 2-hour postprandial glucose is 8.2 mmol/L. What is the most appropriate management?

A. Continue with diet management and repeat growth scan in 2 weeks
B. Commence metformin and continue current monitoring
C. Commence insulin and increase monitoring frequency (Correct Answer)
D. Arrange delivery at 37 weeks regardless of glucose control
E. Admit for continuous glucose monitoring

Explanation: ***Commence insulin and increase monitoring frequency*** - Per **NICE guidelines**, insulin should be offered to women with GDM if blood glucose targets are not met with diet and there is evidence of **fetal macrosomia** (abdominal circumference >97th centile). - The patient's **fasting glucose (5.8 mmol/L)** and **postprandial glucose (8.2 mmol/L)** are above target thresholds, necessitating pharmacological intervention to reduce the risk of **shoulder dystocia** and birth trauma. *Continue with diet management and repeat growth scan in 2 weeks* - This approach is inappropriate because the current management has already failed to achieve **glycemic control**, as evidenced by the high glucose readings. - Delaying treatment increases the risk of **fetal hyperinsulinemia** and further acceleration of fetal growth. *Commence metformin and continue current monitoring* - While metformin is often first-line for GDM, **insulin** is specifically preferred when there is evidence of **macrosomia** or polyhydramnios reflecting suboptimal control. - The severity of current **hyperglycemia** and fetal size suggests that metformin alone may be insufficient to achieve rapid and strict control. *Arrange delivery at 37 weeks regardless of glucose control* - Delivery timing is usually individualized; however, the immediate priority is to **optimize glycemic control** to minimize risks during the remaining weeks of pregnancy. - Decisions regarding **iugr** or macrosomia-related delivery are generally made closer to term, and induction before 37 weeks is typically reserved for severe complications. *Admit for continuous glucose monitoring* - Inpatient admission is not routinely required for initiating insulin in GDM, as it can be safely managed in the **outpatient setting** with specialized nursing support. - **Continuous glucose monitoring** is an adjunct tool but does not replace the immediate need for therapeutic intervention with insulin.

Question 208: A 33-year-old woman at 24 weeks gestation is found to have a blood pressure of 152/98 mmHg at routine antenatal clinic. She is asymptomatic. Booking BP at 12 weeks was 118/76 mmHg. Urine dipstick shows trace protein. Blood tests show: creatinine 68 µmol/L, ALT 28 U/L, platelets 245 × 10⁹/L. What is the most appropriate next investigation?

A. Urine protein:creatinine ratio (Correct Answer)
B. 24-hour urine collection for protein quantification
C. Renal ultrasound scan
D. Serum uric acid level
E. Repeat blood pressure in 4 weeks

Explanation: ***Urine protein:creatinine ratio*** - In a patient with new-onset **gestational hypertension** (BP ≥140/90 after 20 weeks), a spot **urine protein:creatinine ratio (uPCR)** is the first-line investigation to quantify proteinuria and diagnose **preeclampsia**. - NICE guidelines recommend **uPCR** because it is faster and more convenient than 24-hour collection, with a threshold of **≥30 mg/mmol** indicating significant proteinuria. *24-hour urine collection for protein quantification* - While previously the gold standard, it is no longer the first-line method because it is **prone to collection errors** and causes significant **delays in diagnosis**. - This test is now generally reserved for cases where **uPCR** results are borderline or uncertain. *Renal ultrasound scan* - This investigation is used to identify **structural renal disease**, which is not suspected here as the **serum creatinine** (68 µmol/L) is within the normal range. - It does not help in the acute diagnosis or management of **preeclampsia** or **gestational hypertension**. *Serum uric acid level* - Elevated **uric acid** can be a marker of disease severity and increased fetal risk in **preeclampsia**, but it is not a diagnostic tool for the condition itself. - It should not take priority over the quantification of **proteinuria**, which is a core diagnostic criterion. *Repeat blood pressure in 4 weeks* - Waiting four weeks is inappropriate and dangerous; new-onset hypertension after 20 weeks requires **immediate evaluation** to rule out **preeclampsia**. - Patients with a BP of 152/98 mmHg should be monitored closely, typically with **repeat measurements** within the same day or week depending on clinical severity.

Question 209: A 29-year-old woman with gestational diabetes controlled on metformin presents at 38 weeks gestation for induction of labour. Her fasting glucose this morning was 5.2 mmol/L. She asks about glucose monitoring during labour. What is the most appropriate intrapartum glucose management?

A. Capillary blood glucose monitoring every 4 hours, aiming for 4-7 mmol/L
B. Capillary blood glucose monitoring hourly, aiming for 4-7 mmol/L (Correct Answer)
C. Capillary blood glucose monitoring every 2 hours, aiming for 4-10 mmol/L
D. No glucose monitoring required as she is on metformin only
E. Continuous intravenous insulin infusion regardless of glucose levels

Explanation: ***Capillary blood glucose monitoring hourly, aiming for 4-7 mmol/L*** - **NICE guidelines** recommend that all women with **gestational diabetes (GDM)**, regardless of whether they are treated with diet, metformin, or insulin, should have **hourly** glucose monitoring during established labor. - Maintaining blood glucose within the **4–7 mmol/L** range is critical to minimize the risk of **neonatal hypoglycemia** following delivery. *Capillary blood glucose monitoring every 4 hours, aiming for 4-7 mmol/L* - Monitoring every **4 hours** is insufficient during the active phase of labor because glucose levels can fluctuate rapidly due to the metabolic demands of uterine contractions. - This frequency is generally reserved for the latent phase or for women with low-risk pregnancies without **glycemic control issues**. *Capillary blood glucose monitoring every 2 hours, aiming for 4-10 mmol/L* - An upper target of **10 mmol/L** is too high for intrapartum management and is associated with increased risks of **fetal hyperglycemia** and subsequent neonatal complications. - **Every 2 hours** does not meet the standard of care for intrapartum monitoring in GDM where tighter **hourly surveillance** is mandated. *No glucose monitoring required as she is on metformin only* - Although **metformin** has a lower risk of maternal hypoglycemia than insulin, the physiological stress of labor can still cause **maternal hyperglycemia**. - Even diet-controlled patients require monitoring to ensure the fetus is not exposed to high glucose levels, which can trigger **fetal hyperinsulinemia**. *Continuous intravenous insulin infusion regardless of glucose levels* - A **sliding scale** or continuous insulin infusion is not routinely required unless blood glucose levels exceed **7 mmol/L** during labor. - Routine use in all GDM patients would unnecessarily increase the risk of **maternal hypoglycemia** and requires invasive intravenous access.

Question 210: A 34-year-old woman at 30 weeks gestation presents with a 24-hour history of severe generalised pruritus, particularly affecting her palms and soles, worse at night. She has no rash. Blood tests show: ALT 180 U/L (normal 5-40), bile acids 42 µmol/L (normal <10). Blood pressure is 118/72 mmHg, urine dipstick negative for protein. What is the most important immediate management step?

A. Commence ursodeoxycholic acid and plan delivery at 37-38 weeks (Correct Answer)
B. Arrange immediate delivery by caesarean section
C. Prescribe antihistamines and repeat liver function tests in 2 weeks
D. Commence high-dose corticosteroids
E. Perform liver ultrasound to exclude gallstones

Explanation: ***Commence ursodeoxycholic acid and plan delivery at 37-38 weeks***- The patient's presentation of **palmar/solar pruritus**, elevated **ALT**, and **bile acids >10 µmol/L** (specifically 42 µmol/L) confirms a diagnosis of **Intrahepatic Cholestasis of Pregnancy (ICP)**.- **Ursodeoxycholic acid** is the primary treatment to improve maternal symptoms and biochemical markers, while **planned delivery at 37-38 weeks** is recommended to mitigate the increased risk of **stillbirth** associated with severe cholestasis.*Arrange immediate delivery by caesarean section*- Immediate delivery at **30 weeks gestation** is premature and is only indicated if there is evidence of acute **fetal compromise** or maternal instability.- The goal is to balance the risks of **preterm birth** complications against the risk of late-gestation stillbirth.*Prescribe antihistamines and repeat liver function tests in 2 weeks*- **Antihistamines** provide very limited relief for the pruritus of ICP as the itching is mediated by **bile salt deposition**, not histamine release.- Repeating tests in 2 weeks without initiating treatment is inappropriate because **bile acids >40 µmol/L** represent a high-risk state requiring active management.*Commence high-dose corticosteroids*- **Corticosteroids** are not the standard treatment for ICP; they are typically used for fetal lung maturity in threatened preterm labor or in cases of **HELLP syndrome**.- High-dose steroids do not effectively lower bile acid levels or reduce the risk of **fetal demise** in obstetric cholestasis.*Perform liver ultrasound to exclude gallstones*- While a **liver ultrasound** may be useful to exclude other hepatobiliary pathologies, it is not the most important immediate management step for the safety of the fetus.- Delaying the initiation of **ursodeoxycholic acid** while waiting for imaging would postpone necessary treatment for severe maternal symptoms and fetal risk reduction.

Question 211: A 25-year-old primigravida at 16 weeks gestation attends routine antenatal clinic. Her booking bloods showed blood group O negative and antibody screen was negative. She asks about anti-D prophylaxis. What is the correct advice regarding routine antenatal anti-D prophylaxis?

A. Single dose at 28 weeks gestation only
B. Two doses at 28 and 34 weeks gestation (Correct Answer)
C. Single dose at 34 weeks gestation only
D. Three doses at 20, 28 and 34 weeks gestation
E. Only given after delivery if baby is rhesus positive

Explanation: ***Two doses at 28 and 34 weeks gestation*** - In **Rhesus-negative** women who are not yet sensitized, a standard clinical regimen involves administering two doses of **anti-D immunoglobulin** at **28 and 34 weeks** gestation. - This approach, known as **Routine Antenatal Anti-D Prophylaxis (RAADP)**, effectively reduces the risk of sensitization from silent **fetomaternal hemorrhage** during the third trimester. *Single dose at 28 weeks gestation only* - While a **single-dose regimen** is an alternative, the standard single-dose protocol usually requires a higher dose (typically **1500 IU**) specifically between **28 and 30 weeks**. - Only one dose at 28 weeks would not align with the standard 2-dose regimen requirements to ensure coverage until delivery. *Single dose at 34 weeks gestation only* - Administering anti-D only at **34 weeks** leaves the patient at risk for sensitization during the early third trimester starting from 28 weeks. - Prophylaxis must begin by **28-30 weeks** to be clinically effective in preventing **haemolytic disease of the newborn**. *Three doses at 20, 28 and 34 weeks gestation* - Starting prophylaxis at **20 weeks** is not indicated as routine; significant **fetal-to-maternal bleeding** is rare before the third trimester. - Standard guidelines do not recommend a **three-dose** schedule for routine antenatal care. *Only given after delivery if baby is rhesus positive* - This was the historical protocol; however, it is now considered insufficient because sensitization often occurs **antenatally** before birth. - While a dose is given **postpartum** within 72 hours, it must be preceded by **routine antenatal prophylaxis** for maximum protection.

Question 212: A 31-year-old woman attends the antenatal clinic at 12 weeks gestation for her booking appointment. She has no significant medical history. Blood tests reveal haemoglobin 105 g/L, MCV 72 fL, ferritin 8 µg/L. She reports no symptoms. What is the most appropriate initial management?

A. Oral ferrous sulfate 200 mg once daily
B. Oral ferrous sulfate 200 mg twice daily (Correct Answer)
C. Intravenous iron infusion
D. Blood transfusion
E. Reassurance and repeat bloods at 28 weeks

Explanation: ***Oral ferrous sulfate 200 mg twice daily*** - The patient has confirmed **iron deficiency anaemia** (IDA) in pregnancy, indicated by **Hb 105 g/L** (below 1st trimester threshold of 110 g/L) and severely low **ferritin 8 µg/L**. - Therapeutic oral iron supplementation, such as **ferrous sulfate 200 mg twice daily**, is the most appropriate initial management to replete iron stores and meet increased maternal and fetal demands. *Oral ferrous sulfate 200 mg once daily* - While **once-daily dosing** or alternate-day regimens can improve tolerance, this dose is often insufficient for treating **established iron deficiency anaemia** in pregnancy. - This lower dose is more typically recommended for **iron prophylaxis** in high-risk pregnant women rather than for correcting existing anaemia. *Intravenous iron infusion* - **Intravenous iron** is generally reserved for cases of **oral iron intolerance**, malabsorption, severe anaemia in late pregnancy, or when a rapid response is urgently required. - It is usually avoided in the **first trimester** due to limited safety data and because oral iron is typically effective and safer for initial management. *Blood transfusion* - **Blood transfusion** is an intervention reserved for **severe symptomatic anaemia** (e.g., Hb < 70 g/L or significant cardiorespiratory compromise) or active haemorrhage. - This patient is **asymptomatic** with an Hb of 105 g/L, which does not meet the criteria for emergent transfusion, and the risks outweigh the benefits. *Reassurance and repeat bloods at 28 weeks* - Failing to treat confirmed **iron deficiency anaemia** increases risks such as **preterm delivery**, **low birth weight**, and the need for peripartum blood transfusions. - Routine screening at 28 weeks does not negate the need for immediate treatment of anaemia diagnosed earlier in pregnancy.

Question 213: A 42-year-old woman presents for pre-pregnancy counselling. She has a history of severe early-onset pre-eclampsia at 28 weeks in her previous pregnancy 3 years ago, which resulted in emergency delivery and a 6-week neonatal intensive care admission. She now wishes to conceive again. Her current blood pressure is 118/72 mmHg, BMI is 27 kg/m², and she has no other medical problems. Results of investigations show: negative antiphospholipid antibodies, negative lupus anticoagulant, normal renal function with urinary albumin:creatinine ratio of 2.5 mg/mmol. Given her history, which of the following represents the most evidence-based package of preventative interventions for her next pregnancy?

A. Low-dose aspirin 75mg daily from positive pregnancy test, high-dose folic acid, and intensive monitoring from 12 weeks
B. Low-dose aspirin 150mg daily from before 16 weeks gestation, calcium supplementation 1g daily, prophylactic low molecular weight heparin, and enhanced fetal surveillance
C. Low-dose aspirin 75-150mg daily from before 16 weeks gestation, weight reduction to BMI <25, and serial growth scans from 24 weeks
D. Low-dose aspirin 75-150mg daily from before 16 weeks gestation, consideration of prophylactic labetalol from 12-16 weeks, and enhanced surveillance including serial growth scans with umbilical artery Doppler (Correct Answer)
E. Calcium supplementation 1g daily from 12 weeks, vitamin D supplementation, early serial uterine artery Doppler, and low molecular weight heparin if abnormal Doppler

Explanation: ***Low-dose aspirin 75-150mg daily from before 16 weeks gestation, consideration of prophylactic labetalol from 12-16 weeks, and enhanced surveillance including serial growth scans with umbilical artery Doppler*** - A history of **severe early-onset pre-eclampsia** (delivery before 34 weeks) is a major risk factor, and **low-dose aspirin** (75-150mg) started before 16 weeks significantly reduces recurrence. - **Prophylactic labetalol** from 12-16 weeks is a reasonable consideration for very high-risk women, and **enhanced surveillance** with serial growth scans and **umbilical artery Doppler** is crucial for monitoring fetal well-being. *Low-dose aspirin 75mg daily from positive pregnancy test, high-dose folic acid, and intensive monitoring from 12 weeks* - While aspirin is correct, commencing it *from positive pregnancy test* is less ideal than starting **before 16 weeks gestation** for maximal benefit, and 75mg might be suboptimal compared to 150mg for high-risk cases. - **High-dose folic acid** is primarily indicated for previous neural tube defects or specific comorbidities, not as a direct preventative measure for **pre-eclampsia**. *Low-dose aspirin 150mg daily from before 16 weeks gestation, calcium supplementation 1g daily, prophylactic low molecular weight heparin, and enhanced fetal surveillance* - **Prophylactic low molecular weight heparin (LMWH)** is generally not recommended for pre-eclampsia prevention in the absence of a **thrombophilia** or prior VTE, as the patient tested negative for antiphospholipid antibodies and lupus anticoagulant. - **Calcium supplementation** is primarily beneficial in populations with **low dietary calcium intake**, which is not explicitly stated or implied as a risk factor for this patient. *Low-dose aspirin 75-150mg daily from before 16 weeks gestation, weight reduction to BMI <25, and serial growth scans from 24 weeks* - **Weight reduction to BMI <25** is an important pre-conception goal, but it is not an *intervention during pregnancy* once counselling or conception has occurred. - While serial growth scans are part of surveillance, this option **lacks the consideration of prophylactic blood pressure management** (e.g., labetalol) which is critical for someone with a history of severe early-onset pre-eclampsia. *Calcium supplementation 1g daily from 12 weeks, vitamin D supplementation, early serial uterine artery Doppler, and low molecular weight heparin if abnormal Doppler* - There is **insufficient evidence** to support **vitamin D supplementation** as a primary strategy for preventing pre-eclampsia recurrence. - Relying on **uterine artery Doppler** to trigger LMWH is not a standard evidence-based approach; **aspirin** is the established primary pharmacological intervention regardless of Doppler findings in a high-risk patient.

Question 214: A 36-year-old woman is admitted at 35 weeks gestation with severe pre-eclampsia. Blood pressure is 162/108 mmHg despite intravenous labetalol. Blood tests show: platelets 142 × 10⁹/L, ALT 58 U/L, creatinine 82 μmol/L. She has been commenced on intravenous magnesium sulphate for seizure prophylaxis. After 6 hours of treatment, she becomes increasingly drowsy and difficult to rouse. Respiratory rate is 8 breaths per minute. Patellar reflexes are absent. What is the most appropriate immediate management?

A. Increase the rate of intravenous fluids
B. Administer naloxone 400 micrograms intravenously
C. Stop magnesium sulphate infusion and check serum magnesium level
D. Stop magnesium sulphate infusion and administer calcium gluconate 10ml of 10% solution intravenously (Correct Answer)
E. Arrange urgent CT head scan to exclude intracranial haemorrhage

Explanation: ***Stop magnesium sulphate infusion and administer calcium gluconate 10ml of 10% solution intravenously***- The patient exhibits core signs of **magnesium toxicity**, including **respiratory depression** (RR < 12) and **absent patellar reflexes**, requiring immediate reversal.- **Calcium gluconate** acts as a direct physiological antagonist to magnesium, effectively reversing life-threatening neuromuscular and cardiac effects.*Increase the rate of intravenous fluids*- While magnesium is renally excreted, increasing fluids is not an antidote and does nothing to stabilize the immediate **respiratory depression**.- Excessive fluids in severe pre-eclampsia can exacerbate **pulmonary edema**, a major cause of maternal morbidity.*Administer naloxone 400 micrograms intravenously*- **Naloxone** is used for opioid overdose; there is no evidence this patient received opioids, and it will not reverse **magnesium toxicity**.- Using naloxone here would inappropriately delay the administration of the life-saving antidote, **calcium gluconate**.*Stop magnesium sulphate infusion and check serum magnesium level*- While stopping the infusion and checking levels are necessary, this answer is incomplete as it lacks the **calcium gluconate** required for symptomatic toxicity.- Management of severe toxicity symptoms like **hypoventilation** must be clinical and immediate rather than waiting for laboratory confirmation.*Arrange urgent CT head scan to exclude intracranial haemorrhage*- Although drowsiness can occur in stroke, the classic triad of **magnesium infusion**, **absent reflexes**, and **respiratory depression** makes toxicity the primary diagnosis.- Clinical stabilization of the patient's airway and **cardiorespiratory status** with an antidote must precede any diagnostic imaging.

Question 215: A 34-year-old woman with pre-existing type 1 diabetes is reviewed at 16 weeks gestation. Her HbA1c has improved from 58 mmol/mol pre-conception to 42 mmol/mol currently. She is experiencing frequent hypoglycaemic episodes (3-4 per week) with blood glucose values of 2.8-3.5 mmol/L. She is asymptomatic during these episodes and treats them with oral carbohydrates. She is increasingly anxious about further reducing her insulin doses. What is the most appropriate approach to counselling this patient?

A. Reassure that hypoglycaemia is harmful to the fetus and insulin doses must be reduced immediately
B. Explain that hypoglycaemia awareness may be reduced in pregnancy and frequent hypoglycaemia increases risk of severe episodes (Correct Answer)
C. Advise that the current HbA1c is too low for pregnancy and glycaemic targets should be relaxed
D. Recommend admission for continuous glucose monitoring and intravenous glucose therapy
E. Suggest switching from insulin to metformin to reduce hypoglycaemia risk

Explanation: ***Explain that hypoglycaemia awareness may be reduced in pregnancy and frequent hypoglycaemia increases risk of severe episodes***- Pregnancy itself can **impair hypoglycaemia awareness** due to hormonal changes, and this patient's asymptomatic nature during low readings (2.8-3.5 mmol/L) demonstrates this.- Frequent mild episodes significantly elevate the risk of future **severe hypoglycaemia** requiring third-party assistance, which poses a significant safety risk to the mother.*Reassure that hypoglycaemia is harmful to the fetus and insulin doses must be reduced immediately*- Moderate **maternal hypoglycaemia** is generally not directly teratogenic or harmful to the fetus, as the fetus maintains glucose levels through placental gradients.- While education on **insulin dose reduction** is necessary given the frequent episodes, the rationale provided regarding direct fetal harm is medically inaccurate.*Advise that the current HbA1c is too low for pregnancy and glycaemic targets should be relaxed*- An **HbA1c of 42 mmol/mol** is excellent and meets the target of **<48 mmol/mol** recommended to reduce pregnancy complications in type 1 diabetes.- Glycaemic targets should not be relaxed, but the insulin regimen must be optimized to achieve these targets **without problematic hypoglycaemia**.*Recommend admission for continuous glucose monitoring and intravenous glucose therapy*- **Intravenous glucose** is reserved for acute, severe hypoglycaemic emergencies where oral intake is impossible or rapid correction is critical, not for managed asymptomatic episodes.- While **Continuous Glucose Monitoring (CGM)** is highly recommended in Type 1 Diabetes during pregnancy, it is typically initiated as an outpatient; inpatient admission is unnecessary for this presentation.*Suggest switching from insulin to metformin to reduce hypoglycaemia risk*- **Type 1 Diabetes** is characterized by absolute insulin deficiency, making insulin an essential, life-sustaining treatment that cannot be replaced by **metformin**.- Although metformin may be used as an adjunct in Type 2 or Gestational Diabetes, its use here would lead to severe hyperglycaemia and life-threatening **diabetic ketoacidosis**.

Question 216: A 27-year-old woman presents to the emergency department at 20 weeks gestation with a blood pressure of 172/115 mmHg. She reports this is her first antenatal appointment as she has just moved to the UK. She denies headache, visual disturbances, or epigastric pain. Urine dipstick shows trace protein. Her blood pressure was 145/95 mmHg when measured again 30 minutes later. Blood tests including renal function, liver function, and full blood count are normal. What is the most appropriate initial classification of her hypertension?

A. Chronic hypertension
B. Gestational hypertension
C. Pre-eclampsia
D. White coat hypertension
E. Unclassified hypertension requiring further assessment (Correct Answer)

Explanation: ***Unclassified hypertension requiring further assessment*** - This classification is appropriate when hypertension is first detected at or after **20 weeks gestation** without documented pre-pregnancy or early pregnancy blood pressure readings. - As the patient is at exactly **20 weeks** and this is her first antenatal appointment, it's impossible to differentiate between **chronic hypertension** (onset before 20 weeks) and **gestational hypertension** (new-onset after 20 weeks) without prior records. *Chronic hypertension* - Defined as hypertension (blood pressure ">" 140/90 mmHg) present **before pregnancy** or diagnosed **before 20 weeks gestation**. - The patient lacks prior blood pressure documentation, preventing confirmation of hypertension's onset before 20 weeks, making this an unsuitable definitive initial classification. *Gestational hypertension* - This diagnosis requires **new-onset hypertension** (blood pressure ">" 140/90 mmHg) occurring specifically **after 20 weeks** of pregnancy in a previously normotensive woman, without proteinuria or organ dysfunction. - Without early pregnancy blood pressure records to establish a normotensive baseline, it cannot be definitively classified as new-onset hypertension after 20 weeks. *Pre-eclampsia* - Characterized by new-onset hypertension (after 20 weeks) accompanied by **significant proteinuria** or evidence of **maternal organ dysfunction** (e.g., renal insufficiency, liver involvement, neurological symptoms). - The patient exhibits only **trace protein** on urine dipstick and has normal blood tests, failing to meet the criteria for significant proteinuria or organ dysfunction required for pre-eclampsia. *White coat hypertension* - Defined by consistently elevated blood pressure readings in a clinical setting that are **normal** when measured by **ambulatory blood pressure monitoring (ABPM)** or home blood pressure monitoring. - While the second reading was lower, the initial severe elevation (172/115 mmHg) at 20 weeks gestation requires further assessment to confirm or rule out true hypertension, rather than immediately classifying it as white coat effect.

Question 217: A 40-year-old woman in her third pregnancy presents to clinic at 32 weeks gestation. Her first pregnancy was complicated by early-onset severe pre-eclampsia requiring delivery at 30 weeks. Her current pregnancy has been uncomplicated so far. Her blood pressure today is 128/78 mmHg and urinalysis is negative for protein. She is taking aspirin 150 mg daily started at 12 weeks. What additional monitoring should be arranged for the remainder of this pregnancy?

A. Standard antenatal care with routine blood pressure checks only
B. Fortnightly ultrasound scans for fetal growth from 32 weeks
C. Serial uterine artery Doppler assessments every 2 weeks
D. Increased monitoring with blood pressure checks, urine protein assessment, and serial growth scans with umbilical artery Doppler from 32 weeks (Correct Answer)
E. Weekly blood pressure and urine protein checks from 32 weeks

Explanation: ***Increased monitoring with blood pressure checks, urine protein assessment, and serial growth scans with umbilical artery Doppler from 32 weeks*** - This patient is at high risk due to a history of **early-onset severe pre-eclampsia** (delivery before 34 weeks), requiring enhanced surveillance to detect recurrence.- **NICE guidelines** recommend frequent clinical assessment combined with **serial ultrasound scans** and **umbilical artery Doppler** to monitor for fetal growth restriction (FGR).*Standard antenatal care with routine blood pressure checks only*- Standard care is insufficient for patients with a **high-risk obstetric history**, as it fails to provide the vigilant monitoring needed for early detection of complications.- Patients with previous severe pre-eclampsia have a **recurrence risk** of up to 25-65%, necessitating more than basic screening.*Fortnightly ultrasound scans for fetal growth from 32 weeks*- While growth scans are necessary, this option is incomplete as it ignores the clinical monitoring of **maternal blood pressure** and **proteinuria**, which are essential for diagnosing pre-eclampsia.- In high-risk pregnancies, fetal and maternal surveillance must be integrated rather than focusing on **fetal growth** alone.*Serial uterine artery Doppler assessments every 2 weeks*- **Uterine artery Dopplers** are typically used as a screening tool in the first or second trimester to predict pre-eclampsia, rather than for late-third-trimester monitoring.- At 32 weeks, **umbilical artery Doppler** is the preferred modality for assessing fetal well-being and placental function in high-risk scenarios.*Weekly blood pressure and urine protein checks from 32 weeks*- This approach correctly addresses maternal monitoring but completely omits **fetal surveillance** through ultrasound and Doppler.- Since early-onset pre-eclampsia is strongly associated with **placental insufficiency**, assessing the fetus for growth restriction is a mandatory component of the care plan.

Question 218: A 38-year-old woman presents at 29 weeks gestation with sudden onset severe epigastric pain and vomiting. Her blood pressure is 145/95 mmHg and she has significant right upper quadrant tenderness. Blood tests show: haemoglobin 105 g/L, platelets 78 × 10⁹/L, white cell count 12.5 × 10⁹/L, bilirubin 35 μmol/L, ALT 420 U/L, AST 385 U/L, LDH 650 U/L, and a blood film shows schistocytes. Urine shows 2+ protein. What is the most likely diagnosis?

A. Acute fatty liver of pregnancy
B. HELLP syndrome (Correct Answer)
C. Severe pre-eclampsia without HELLP
D. Acute cholecystitis
E. Thrombotic thrombocytopenic purpura

Explanation: ***HELLP syndrome*** - This diagnosis is confirmed by the presentation of **haemolysis** (low Hb, elevated LDH and bilirubin, **schistocytes** on blood film), **elevated liver enzymes** (ALT, AST > 2x normal), and **low platelets** (<100 × 10⁹/L). - The sudden onset of **epigastric or RUQ pain** in a pregnant patient with **hypertension** (145/95 mmHg) and **proteinuria** (2+) at **29 weeks gestation** is a classic clinical manifestation. *Acute fatty liver of pregnancy* - While AFLP occurs in the third trimester and involves liver dysfunction, it typically presents with more profound **hypoglycaemia**, **coagulopathy** (prolonged PT/INR), and often more severe **hepatic encephalopathy**. - Although transaminases are elevated, the prominent **microangiopathic haemolytic anaemia** (schistocytes, low platelets, high LDH) is a hallmark of HELLP, not typically the primary feature of AFLP. *Severe pre-eclampsia without HELLP* - Although the patient meets the criteria for **severe pre-eclampsia** (hypertension and proteinuria), the specific laboratory findings of **thrombocytopenia** (<100,000/µL), **elevated liver enzymes**, and evidence of **haemolysis** (schistocytes, elevated LDH/bilirubin) explicitly define **HELLP syndrome**. - HELLP is a distinct and more severe complication; identifying it is critical as it carries a higher risk of **maternal and fetal morbidity and mortality** than pre-eclampsia alone. *Acute cholecystitis* - While **epigastric/RUQ pain** and vomiting can occur with acute cholecystitis, this diagnosis would not explain the comprehensive systemic abnormalities such as **hypertension**, **proteinuria**, **thrombocytopenia**, **elevated liver enzymes**, or the presence of **schistocytes**. - Cholecystitis is primarily a localized gallbladder inflammation, and while WBC count might be elevated, the widespread organ dysfunction points away from it. *Thrombotic thrombocytopenic purpura* - TTP is characterized by the classic pentad including **fever**, **neurological symptoms**, and **renal failure**, which are not the primary features described here. - Unlike HELLP, TTP is not fundamentally associated with **pregnancy-induced hypertension** or significant **proteinuria**; the clinical context points more strongly to HELLP.

Question 219: A 33-year-old woman with gestational diabetes diagnosed at 28 weeks is now 32 weeks pregnant. She has been following dietary advice for 2 weeks. Her home blood glucose monitoring shows: fasting values 5.0-5.8 mmol/L and 1-hour post-prandial values 7.2-8.5 mmol/L. Ultrasound scan shows fetal abdominal circumference above the 75th centile. What is the most appropriate next step in management?

A. Continue with diet and lifestyle modifications alone
B. Commence insulin therapy
C. Commence metformin therapy (Correct Answer)
D. Commence gliclazide therapy
E. Increase frequency of blood glucose monitoring to 8 times daily

Explanation: ***Commence metformin therapy*** - According to **NICE guidelines**, metformin should be offered as first-line pharmacological therapy if glucose targets are not met within **1–2 weeks** of diet and exercise. - In this case, the **fetal abdominal circumference >75th centile** indicates macrosomia risk and inadequate glycemic control, necessitating pharmacological intervention despite lifestyle changes. *Continue with diet and lifestyle modifications alone* - The patient has already attempted diet and lifestyle for **2 weeks**, yet her 1-hour post-prandial levels remain above the target of **<7.8 mmol/L**. - Continuing conservative management is inappropriate when there is ultrasound evidence of **fetal macrosomia** (abdominal circumference >75th centile). *Commence insulin therapy* - **Insulin therapy** is typically reserved as first-line if the fasting glucose is significantly high (e.g., >7.0 mmol/L) or if metformin is contraindicated or poorly tolerated. - While her targets are not met, her glucose levels are not severely elevated enough to bypass **metformin** as the initial pharmacological choice. *Commence gliclazide therapy* - **Gliclazide** (a sulfonylurea) is not the first-line oral agent in gestational diabetes and is generally considered only if metformin is not tolerated or as an adjunct. - It carries a higher risk of **fetal hypoglycemia** compared to metformin and is therefore not the preferred initial medication. *Increase frequency of blood glucose monitoring to 8 times daily* - Increasing the frequency of monitoring does not address the underlying **hyperglycemia** and evidence of fetal effects already documented. - Management must shift toward **pharmacological control** rather than more frequent observation once diagnostic thresholds for treatment are crossed.

Question 220: A 29-year-old woman attends her booking appointment at 11 weeks gestation. She is of South Asian origin with a body mass index of 28 kg/m². Her sister was diagnosed with gestational diabetes in her pregnancy. Random glucose at booking is 5.8 mmol/L. According to NICE guidelines, when should she be offered an oral glucose tolerance test?

A. Immediately at the booking visit
B. At 16 weeks and if normal, repeat at 28 weeks
C. At 24-28 weeks only (Correct Answer)
D. At 28 weeks and if normal, repeat at 32 weeks
E. Only if she develops symptoms of diabetes

Explanation: ***At 24-28 weeks only*** - According to **NICE guidelines**, pregnant women with standard risk factors such as **South Asian origin**, a BMI > 30 kg/m² (or >25 kg/m² for some ethnic groups like South Asian), or a **first-degree relative** with diabetes should be offered an **oral glucose tolerance test (OGTT) at 24-28 weeks**. - This patient satisfies multiple risk factors (South Asian origin, BMI 28, sister with GDM) but does not have a personal history of **gestational diabetes (GDM)**, which would mandate earlier testing. *Immediately at the booking visit* - Early testing is reserved for women with **previous gestational diabetes** to identify recurrence as soon as possible, or those with highly suggestive symptoms/blood tests. - A **random glucose** of 5.8 mmol/L at booking is within normal limits and does not necessitate immediate diagnostic intervention for GDM. *At 16 weeks and if normal, repeat at 28 weeks* - This specific two-step testing protocol (at 16 weeks and if normal, repeat at 28 weeks) is indicated for women who have had **gestational diabetes** in a previous pregnancy. - Since the patient's sister had GDM (family history) rather than the patient herself, the standard **24-28 week window** applies. *At 28 weeks and if normal, repeat at 32 weeks* - There is no routine recommendation in **NICE guidelines** to repeat a normal OGTT at 32 weeks based on standard risk factors alone. - Repeating the test beyond the standard window is only considered clinically if new concerns, such as **macrosomia** or **polyhydramnios**, develop later in the pregnancy. *Only if she develops symptoms of diabetes* - **Gestational diabetes** is frequently **asymptomatic**, making symptom-based screening an unreliable and dangerous strategy. - Screening is performed based on identified **risk factors** to enable early intervention and prevent maternal and fetal complications like **preeclampsia**, **macrosomia**, and **neonatal hypoglycemia**.

Question 221: A 26-year-old woman in her first pregnancy attends the emergency department at 34 weeks gestation with a severe frontal headache and visual disturbances described as 'flashing lights'. Her blood pressure is 168/112 mmHg. Urine dipstick shows 3+ protein. Bloods reveal: platelets 95 × 10⁹/L, ALT 85 U/L, creatinine 105 μmol/L. Cardiotocography shows a reassuring fetal heart rate pattern. What is the most appropriate immediate management?

A. Admit for observation and repeat blood pressure in 4 hours
B. Admit, commence intravenous magnesium sulphate and labetalol, plan delivery within 24-48 hours (Correct Answer)
C. Commence oral nifedipine and steroids, plan delivery at 37 weeks
D. Commence oral labetalol and arrange outpatient follow-up
E. Emergency caesarean section under general anaesthesia

Explanation: ***Admit, commence intravenous magnesium sulphate and labetalol, plan delivery within 24-48 hours*** - The patient presents with **severe pre-eclampsia** characterized by **severe hypertension** (168/112 mmHg), **proteinuria (3+)**, and **end-organ dysfunction** (thrombocytopenia, elevated liver enzymes, elevated creatinine), along with neurological symptoms like **severe headache** and **visual disturbances**. **Intravenous magnesium sulphate** is essential for **seizure prophylaxis** in this critical condition. - Immediate **hospital admission** for close monitoring and stabilization of **blood pressure** with intravenous antihypertensives like **labetalol** is crucial. Delivery is the definitive treatment for pre-eclampsia, and planning it within 24-48 hours allows for maternal stabilization and administration of **corticosteroids** to enhance fetal lung maturity, especially at 34 weeks gestation. *Admit for observation and repeat blood pressure in 4 hours* - This approach is dangerously insufficient for **severe pre-eclampsia** with features of **end-organ damage** and severe maternal symptoms. Delaying active intervention significantly increases the risk of complications such as **eclampsia**, **stroke**, or **HELLP syndrome**. - The patient's condition requires immediate pharmacological management, including **antihypertensives** and **magnesium sulphate**, not merely observation, due to the established diagnosis and severity. *Commence oral nifedipine and steroids, plan delivery at 37 weeks* - Planning delivery at 37 weeks is too late for a patient with **severe pre-eclampsia** and active symptoms at 34 weeks, as it poses unacceptable risks of **maternal morbidity and mortality**. Definitive management (delivery) must occur earlier. - While **corticosteroids** are given for fetal lung maturity, **oral nifedipine** may not be sufficient for initial rapid blood pressure control in severe hypertension, and delaying delivery to 37 weeks is not appropriate here. *Commence oral labetalol and arrange outpatient follow-up* - **Outpatient management** is absolutely contraindicated for severe pre-eclampsia. This is a medical emergency requiring **in-patient care** and constant monitoring due to the high risk of rapid deterioration. - Oral labetalol might be part of maintenance therapy, but it is insufficient as an immediate sole intervention, and **magnesium sulphate** for seizure prophylaxis is critically missing from this plan. *Emergency caesarean section under general anaesthesia* - While delivery is the definitive treatment, an **immediate emergency caesarean section** is generally not the first step if the fetus is **reassuring** on CTG and maternal stabilization is possible. - The mother first needs **stabilization** of blood pressure and **seizure prophylaxis** with magnesium sulphate before delivery, and usually, time is allowed for **corticosteroids** to take effect for fetal lung maturity at 34 weeks. Delivery is planned, not an immediate emergency in this specific scenario.

Question 222: A 30-year-old woman presents to the antenatal clinic at 26 weeks gestation with a random blood glucose of 11.2 mmol/L found at a routine appointment. She is asymptomatic and has no polyuria or polydipsia. Her body mass index at booking was 32 kg/m². She has no personal history of diabetes but her mother has type 2 diabetes. An oral glucose tolerance test (OGTT) is arranged. What fasting plasma glucose level would confirm a diagnosis of gestational diabetes according to current UK diagnostic criteria?

A. ≥5.1 mmol/L
B. ≥5.6 mmol/L (Correct Answer)
C. ≥6.0 mmol/L
D. ≥6.5 mmol/L
E. ≥7.0 mmol/L

Explanation: ***≥5.6 mmol/L***- According to **NICE guidelines** in the UK, a diagnosis of **gestational diabetes (GDM)** is confirmed if the **fasting plasma glucose** is **≥5.6 mmol/L** during a 75g **OGTT**.- Only one abnormal value is required for diagnosis, with the other threshold being a **2-hour plasma glucose** of **≥7.8 mmol/L**.*≥5.1 mmol/L*- This threshold is used by the **WHO (World Health Organization)** and the International Association of Diabetes and Pregnancy Study Groups (**IADPSG**).- However, it is **not used in the UK** under current **NICE (NG3)** diagnostic criteria for pregnancy.*≥6.0 mmol/L*- This is not a specific diagnostic threshold for **gestational diabetes** or impaired fasting glucose in the context of pregnancy under UK guidelines.- While higher than normal, it does not represent the specific **NICE-defined cutoff** of 5.6 mmol/L.*≥6.5 mmol/L*- This value is not used for GDM diagnosis; however, a level of **6.5% (48 mmol/mol)** is the **HbA1c threshold** for diagnosing **Type 2 Diabetes** outside of pregnancy.- Gestational diabetes screening relies on **plasma glucose levels** via OGTT rather than HbA1c due to physiological changes in blood cell turnover during pregnancy.*≥7.0 mmol/L*- A fasting plasma glucose of **≥7.0 mmol/L** is the threshold used to diagnose **pre-existing (pre-gestational) diabetes** or Type 2 Diabetes.- If this level is reached during screening, the patient is managed for **Type 2 Diabetes** manifesting in pregnancy rather than standard GDM.

Question 223: A 35-year-old woman with type 1 diabetes mellitus is planning her first pregnancy. She currently takes insulin aspart and insulin detemir, and her HbA1c is 58 mmol/mol (7.5%). She takes no other medications. According to current UK guidelines for preconception care in diabetic women, which additional medication should be commenced at an increased dose compared to the general population?

A. Folic acid 5 mg daily (Correct Answer)
B. Folic acid 400 micrograms daily
C. Vitamin D 400 IU daily
D. Aspirin 75 mg daily
E. Metformin 500 mg twice daily

Explanation: ***Folic acid 5 mg daily***- NICE and UK guidelines recommend that women with **pre-existing diabetes** take a high dose of **5 mg folic acid** daily to reduce the risk of **neural tube defects**.- This dose should be started at least **one month preconception** and continued until the **12th week of gestation**.*Folic acid 400 micrograms daily*- This is the standard dose recommended for the **general population** with low risk for neural tube defects.- Women with diabetes are at a **higher risk** of neural tube defects, necessitating the larger 5 mg pharmacological dose.*Vitamin D 400 IU daily*- Routine **Vitamin D supplementation** is recommended for all pregnant women, but this dose is not specifically increased for diabetic patients compared to the general population.- It plays a role in bone health but does not mitigate the specific diabetic-related risk of **congenital malformations**.*Aspirin 75 mg daily*- Low-dose aspirin is recommended to reduce the risk of **pre-eclampsia** in women with pre-existing diabetes.- However, it is typically commenced at **12 weeks gestation** rather than as a preconception requirement.*Metformin 500 mg twice daily*- **Metformin** may be used in Type 2 diabetes or PCOS, but this patient has **Type 1 diabetes** where insulin is the primary treatment.- While Metformin is sometimes added to insulin in T1DM, it is not a routine **preconception requirement** for all diabetic women regardless of glycemic control to prevent specific fetal anomalies.

Question 224: A 32-year-old woman attends antenatal clinic at 28 weeks gestation in her second pregnancy. She had a normal vaginal delivery in her first pregnancy. Her blood pressure today is 152/98 mmHg. A urine dipstick shows 2+ protein. Blood tests reveal: haemoglobin 118 g/L, platelets 145 × 10⁹/L, ALT 42 U/L, and creatinine 78 μmol/L. A spot urine protein:creatinine ratio is 45 mg/mmol. What is the most appropriate classification of her condition?

A. Gestational hypertension
B. Mild pre-eclampsia
C. Moderate pre-eclampsia (Correct Answer)
D. Severe pre-eclampsia
E. Chronic hypertension with superimposed pre-eclampsia

Explanation: ***Moderate pre-eclampsia*** - This patient has **new-onset hypertension** (152/98 mmHg) and significant **proteinuria** (uPCR 45 mg/mmol) developing after 20 weeks gestation, confirming **pre-eclampsia**. - The blood pressure of 152/98 mmHg falls into the **moderate hypertension** range, and there are no features indicating severe disease (e.g., BP ≥160/110 mmHg, platelets <100 × 10⁹/L, ALT >70 U/L). *Gestational hypertension* - This diagnosis is characterized by **new-onset hypertension** after 20 weeks of gestation **without significant proteinuria** or signs of end-organ damage. - The presence of a **protein:creatinine ratio (uPCR) of 45 mg/mmol** (above the 30 mg/mmol threshold) explicitly rules out gestational hypertension. *Mild pre-eclampsia* - While sometimes used, **mild pre-eclampsia** typically refers to blood pressures between 140/90 and 149/99 mmHg. - With a diastolic blood pressure of **98 mmHg** and systolic of **152 mmHg**, the patient's condition exceeds the

Question 225: A 28-year-old primigravida attends her booking appointment at 10 weeks gestation. She has no significant past medical history and takes no regular medications. Her body mass index is 24 kg/m². Blood tests reveal she is rhesus negative. According to current UK guidelines, at what gestational age should she receive her first routine dose of anti-D immunoglobulin?

A. 16 weeks
B. 20 weeks
C. 28 weeks (Correct Answer)
D. 32 weeks
E. 36 weeks

Explanation: ***28 weeks*** - In the UK, **NICE guidelines** recommend routine antenatal anti-D prophylaxis (**RAADP**) be administered at **28 weeks** gestation for Rhesus-negative women. - This timing is chosen because the risk of **sensitization** (maternal production of anti-D antibodies) increases significantly in the **third trimester**. *16 weeks* - Administration at **16 weeks** is too early for routine prophylaxis, as fetal-to-maternal **hemorrhage** sufficient to cause sensitization is rare at this stage. - Anti-D would only be given this early if a specific **sensitizing event** occurred, such as a miscarriage after 12 weeks or an invasive procedure. *20 weeks* - Although fetal blood cells are present in the maternal circulation, the **standard protocol** does not initiate routine prophylaxis at the **mid-pregnancy scan** stage. - Routine prophylaxis at this time would not provide adequate coverage through to the end of the **term pregnancy**. *32 weeks* - While some two-dose regimens include a second injection at **34 weeks**, the **initial dose** must be given earlier at 28 weeks to ensure coverage. - Waiting until **32 weeks** leaves a window of vulnerability where **silent sensitization** could occur during the start of the third trimester. *36 weeks* - Administering the first dose at **36 weeks** is far too late to be effective as **routine prophylaxis** against sensitizing events occurring earlier in the trimester. - By this stage, the woman may have already been exposed to **fetal D-positive cells**, rendering the late administration ineffective for preventing sensitization.

Practice by Chapter

Antenatal care

Practice Questions

Gestational diabetes

Practice Questions

Hypertensive disorders of pregnancy

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Pregnancy Medicine — MCQs

Pregnancy Medicine — MCQs

On this page